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xviiAbstract
The human bacterial pathogen, Streptococcus pneumoniae (the pneumococcus), has been shown to
modulate different parts of the innate immune response of its host, however its ability to modulate
the adaptive immune response remains largely uninvestigated. Furthermore, the importance of the
adaptive arm of the immune system in responding to Streptococcus pneumoniae has only recently
begun to be elucidated. I therefore investigated a potentially novel pneumococcal immunomodulatory
mechanism involving the effect of the pneumococcal toxin, pneumolysin, upon the cells at the
heart of the adaptive immune response; the CD4 T cell.
I generated purified pneumolysin and a purified pneumolysin mutant called F433 to allow me to
examine this potential effect. I found that pneumolysin inhibits in vitro antigen specific murine
CD4 T cell proliferation and cytokine production and that this effect is not observed with the F433
mutant pneumolysin. Furthermore, I demonstrated that pneumolysin accomplished this inhibitory
activity by inducing apoptosis of activated CD4 T cells and suggest that lipid rafts may be involved
in this process since we also demonstrated that pneumolysin preferentially binds to lipid rafts.
Finally I demonstrated that pneumolysin is able to inhibit the in vivo accumulation of T cells and
also inhibits in vivo antibody production.
I propose that the immunomodulatory mechanism I have described may play an important role
during pneumococcal infection and that this warrants further investigation. I propose that detailed
in vivo studies are required to demonstrate that this mechanism functions during infection and to
elucidate the effect this has upon the course of infection.
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xx1 V1 Introduction
1- 11.1 Introduction
The existence of pathogen's is all too obvious in the world today, however the reason for the
pathogenic way of life remains unclear (Granucci and Ricciardi-Castagnoli, 2003); It may result
from some disregulation from 'normal' functioning or as a result of an organism's journey to be-
coming a commensal (Rhen et al., 2003).
Regardless of the reason it is clear that central to pathogenesis is a parasitic lifestyle that involves
a complex interplay of host-parasite interactions. The effectiveness of the host's immune system is
central to the outcome of these interactions. As a result, the ability of the parasite to modulate the
host's immune response (immunomodulation) is equally influential.
In this thesis I examine the host pathogen interaction of the bacterium Streptococcus pneumoniae
(the pneumococcus) with its human host using murine models. I will be specifically investigating a
potential mechanism that S. pneumoniae uses to modulate the adaptive immune response of the
host. The reasons for these investigations are twofold; firstly, I am seeking to further understand
the pathogenic mechanisms of the pneumococcus and secondly, I am interested in the potential
therapeutic applications of 'pathogen derived' immunomodulators.
However prior to discussing my investigations it is necessary to understand the context of my work
and this is the purpose of this chapter. I will first discuss the immune system and then examine
some of the mechanisms that pathogen's use to modulate host immune systems. This discussion
will allow an understanding of the different mechanisms that the pneumococcus potentially uses to
modulate the host immune system. I will then describe some of the contexts in which
immunomodulatory molecules may be applied for therapeutic benefit. Finally I will focus on the
pneumococcus itself, specifically the immune response it provokes and some of the factors pro-
duced that allow it to colonise and infect the host.
1-21.2 Overview of the Immune System
The immune system has two parts that are distinct yet co-operate effectively. The first part is the
innate immune response and the second the adaptive immune response (Figure 1-1). The innate
immune response is relatively non specific and acts quickly upon encountering a pathogen while
the adaptive immune response is highly specific and able to recognise individual pathogen's, how-
ever the generation of the adaptive immune response takes longer than the innate response and
occurs in specific organs within the lymph tissue (Figure 1-2).
1.2.1 Innate Immune Response
Upon entering the host a pathogen encounters the innate immune response. The first component
that a pathogen encounters is one or both of the alternative or mannose binding lectin (MBL)
complement pathways which are part of a series of plasma proteins collectively termed 'comple-
ment' (Figure 1-3). The alternative complement pathway is activated by the surface of microbes
(Winkelstein and Tomasz, 1977) while MBL binds to the sugar residues on bacterial surfaces and
activates the MBL pathway (Estabrook et a!., 2004; Jack et a!., 2001). Both pathways result in a
cascade of complement proteins to interact resulting in opsonisation of the pathogen by member
iC3b which enhances phagocytic uptake due to the presence of CD2 I on phagocyte 's surface which
is the receptor for an iC3b derivative (Mosser and Edelson, 1985). Alternatively, accumulation of
further members of the complement cascade on the surface of the pathogen results in the formation
of the Membrane Attack Complex (MAC) which causes lysis of the pathogen (Tranum-Jensen  ci
a!., 1978). Although less well defined natural antibody is proposed to be an important component
of the early immune response (Lutz, 1999). Natural antibody is of the 1gM type and forms without
specific antigen stimulation (Ochsenbein and Zinkernagel, 2000). Natural 1gM is polyreactive to
conserved antigenic structures on pathogen's and in this way is able to provide a degree of imme-
diate protection to the host (Boes, 2000).
Pathogen's also encounter phagocyte's such as macrophages and neutrophils early after entry into
the host since these cells are distributed throughout the body (Djaldetti eta!., 2002). Pathogen's are
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Overview of the Immune System
The immune response to a pathogen is shown above and highlights the primary components of the immune response.
The innate immune system is first represented by anatomical barriers such as skin and cilia. The coating of the patho-
gen by alternative complement prior to macrophage phagocytosis is shown as is neutrophil phagocytosis. Release of
cytokines by macrophage that have engulfed a pathogen is illustrated; these have a multitude of effects. The adaptive
immune response begins with dendritic cell uptake of the pathogen at the site of infection, then it migrates to the lymph
node as shown in the figure. Figure 1-4 shows the interactions that occur in the lymph node but the effects are shown
here with the production of CD4 T cells that can activate macrophage, help B cells produce antibody and the produc-
tion of CD8 T cells that can kill infected cells.
1-4recognised by Pathogen Recognition Receptors (PRR) such as Toll Like Receptor (TLR) (Reis e
Sousa, 2004). PRR's recognise conserved components of pathogen's such as LPS, CpG, flagellin
and peptidoglycan (Dziarski, 2003; Hayashi et a!., 2001; Kopp and Medzhitov, 1999). Recogni-
tion results in three important events (Janeway and Medzhitov, 2002). Firstly phagocytosis (liter-
ally cell eating) of the pathogen results in the destruction of the pathogen although sometimes CD4
T cell help is required when macrophages harbour a pathogen that resists the fusion of the lyso-
some with the phagosome. CD4 T cell help enables full activation of the phagocyte. Secondly upon
ingestion of a pathogen phagocyte's also secrete cytokines which are molecules that induce a change
in another cell and in this context encourage the development of the immune response (Monton and
Tones, 1998). Finally macrophages can act as antigen presenting cells for the induction of the
secondary adaptive immune response.
Each of the cytokines, such as IL-i, IL-8, TNF-a, IL-6 and IL- 12, released by macrophages (Monton
et a!., 1999) have important effects on the developing host's immune response. IL-i and TNF-a
induce changes in the vascular endothelium characteristic of inflammation which increase the blood
flow to infected areas and decrease the flow rate in these areas (Lamping eta!., 1998). Furthermore
increased permeability is also induced which allows the influx of antibody, complement and cells
to infected areas. Locally IL-6 causes activation of lymphocytes however systemically it causes the
release of acute phase protein. Release of IL-8 causes the recruitment of neutrophils to the site of
infection (Gerber et a!., 2004) while IL-12 causes the CD4 T cell response to become skewed
towards T1 (Hsieh et a!., 1993).
The final member of the innate immune response is the acute phase proteins which includes C-
reactive protein which binds to certain bacterial and fungal lipopolysaccharide and activates the
classical complement pathway (Palaniyar et al., 2002).
1.2.2 Adaptive Immune Response
The induction of the primary adaptive immune response (Figure 1-4) begins with the encounter of
the pathogen by a dendritic cell at the site of infection which then migrates to the draining periph-
eral lymphoid organs such as the lymph nodes (Jenkins et a!., 2001). Alternatively soluble antigen
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Distribution of lymphoid tissue in humans
The red circles represent lymph nodes which are distributed at the sites indicated.
Distribution is symmetrical within the body and numbers are greater than shown.
Other lymphoid organs are also shown.
1-6may enter the peripheral lymph nodes independent of an APC but be ingested in the lymph organ
by a dendritic cell (Smith et al., 2004a). The DC processes components of the pathogen into peptides
that are presented to the TcR on T cells as part of the Major Histocompatibility Complex (MHC).
There are two MHC's; MHC I and MHC II. MHC I is present on the surface of cells throughout the
body, however MHC II are present only on the surface of APC's. The source of the proteins dic-
tates which complex they are presented on; protein present in the cytosol of the APC is presented
on MHC I while protein present in the endocytic vesicle is presented on MHC II (Morrison  et a!.,
1986). On the surface of T cells along with the TcR is either the cell surface molecule CD4 or CD8.
Cells expressing CD8 interact with MHC I while cells expressing CD4 interact with MHC II.
However, MHC:TcR with CD4 or CD8 interaction is not the only interaction required for T cell
activation. The APC must also provide costimulation through a number of receptor: ligand interac-
tions including, CD4O:CD4OL, CD8O:CD28, CD86:CD28 (Liu and Janeway, 1992). Interaction of
the APC and T cell leads to activation and proliferation of T cells which produces a population of
armed effector T cells. These armed effector T cells then function to eliminate the infection (Figure
1-4).
CD8 T cells migrate from the lymph node to the site of infection where they recognise pathogen
peptides expressed on MHC I of infected cells. They are then able to kill the infected cell by the
release of cytotoxic granules such as granzyme (Waterhouse and Trapani, 2002). When CD4 T
cells are activated they differentiate into one of two subsets. The mechanism that dictates the sub-
set is unclear however the cytokines present during activation by the APC are thought to have some
effect so that cytokines such as IL-12 cause differentiation into TH1 CD4 T cells and cytokines such
as IL-4 cause differentiation into TH2 CD4 T cells (Hsieh et al., 1993). THI CD4 T cells then
migrate from the lymph node to the site of infection where they are able to activate macrophages
(Reinhardt et a!., 2003; Stout and Bottomly, 1989) while TH2 CD4 T cells express costimulatory
molecules such as CD4O, ICOS, 0X40 that help activated B cells that have acquired antigen to
make antibody and undergo affinity maturation in the lymph node. In humans four different types
of antibody is then produced that function in different contexts (Mestas and Hughes, 2004). 1gM
antibody is produced rapidly in response to infection and performs a neutralising function in the
blood and also activates the classical complement pathway. lgG has five subtypes, of which the
production of each subtype is dictated by the TH1 / TH2 nature of the response. IgG is an effective
opsoniser and complement activator and functions primarily in the blood. The classical comple-
ment pathway is activated by antibody:antigen complexes and after activation follows the same
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Overview of the complement pathway
The schematic shows the 3 arms of the complement pathway and their convergence on the C3
convertase and the 3 subsequent outcomes.
1- 8cascade as the alternative complement pathway to produces either opsonisation of pathogen's or
the formation of the MAC on the pathogen surface (Figure 1-3). Two subtypes of IgA are produced
and line the mucosal surface of the body and neutralises pathogen's and toxins entering by these
routes. Finally IgE is found bound to mast cells which are involved in helminth immunity (Else and
Finkelman, 1998). Some of the effector cells differentiate into memory cells that persist after the
others have died and are present to enable a rapid secondary response should the same pathogen be
encountered again (Crotty and Ahmed, 2004).
Antigens that stimulate antibody production from B cells fall into three categories depending on
their requirement for T cell help (Mond eta!., 1 995b). T Dependent (TD) antigens (such a peptides)
require T cell help to induce effective antibody responses. T Independent (TI) antigens are able to
induce antibody formation in the absence of T cells; and as a result of not recruiting T cell help for
the B cells they do not induce germinal centre formation, memory generation or affinity matura-
tion. There are two types of TI's; Type 1 are mitogenic for B cells and induce antibody by crosslinking
of surface 1g. Type 2 antigens are unable to associate with the MHC and so cannot interact with the
TcR, however the response they induce is able to be influenced by T cells (Mond et a!., 1995a;
Sangster et al., 2003).
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Overview of the production of effector T cells
The schematic shows the entry of antigen on a dendritic cell and presentation via the 2-signal
model to the T cell. Subsequent effector function is displayed; CD8 T cell killing of an infected
cell, TH1 CD4 T cell macrophage activation leading to fusion of the lysosome and phagosome and
TH2 CD4 T cells providing B cell help to enable antibody production. The subsequent effects of
antibody production are shown; antibody binding to pathogens can allow MAC formation on the
surface of the pathogen or can lead to engulfment. Neutralisation of toxins by antibodies is also
important.
1-101.3 Pathogen Immunomodulation
Prior to examining some of the mechanisms that pathogen's use to modulate each part of the im-
mune system described above, it should be noted that most pathogen's target more than one of
aspect of the host immune response. African trypanosomes provide a clear example of this (Mabbott
et a!., 1998). Firstly African trypanosomes disrupt the action of the innate immune response by
interfering with the action of complement through the expression of a protease that resembles the
gp63 protease of Leishmania. Bloodstream trypanosomes activate the alternative complement path-
way and yet this does not result in trypanosome lysis; perhaps because of the presence of this
protease (El-Sayed and Donelson, 1997). Secondly the trypanosome disrupts the cell mediated
adaptive immune response by inducing CD8 T cells to produce large amounts of IFN-g (Darji  et
a!., 1996). The bloodstream trypanosome produces what has been called T lymphocyte triggering
factor (TLTF) which binds to T cells via the CD8 molecule. The resulting expression of IFN-g acts
in a beneficial manner for the trypanosome since IFN-g stimulates a MAP kinase in the trypano-
some which is suggested to enhance proliferation of the trypanosome (Olsson  et a!., 1991). The
release of IFN-g also cause a decrease in IL-2 receptor expression and IL-2 synthesis which de-
creases the T cell proliferative response (Darji et al., 1996). Thirdly by releasing a mitogenic factor
trypanosomes cause huge B cell expansion and antibody production yet the antibody produced is
not parasite specific and may even be host reactive (Reina-San-Martin et a!., 2000). Finally avoid-
ance of the humoral arm of the adaptive immune response comes via perpetual switching of the
surface glycoprotein coat. The coat is called the Variant Surface Glycoprotein (VSG) and is
sequentially expressed by each trypanosome meaning that when an immune response is mounted
against one VSG type there is another present within the population that can resist immune attack
and therefore the parasite proliferates unchecked (Schleifer eta!., 1993). From this example of the
trypanosome, my point is clear; pathogen's immunomodulatory activities are multifaceted.
It is not however my intention to focus on individual pathogen's in this chapter but rather to
sequentially examine different parts of the host immune response and examples of pathogen's that
modulate these to enhance their survival. This will allow a survey of the breadth of
immunornodulatory mechanisms that pathogen's use and will also enable recognition of conver-
gent mechanisms of imrnunomodulation.
1- 111.3.1	 Colonisation
The human host's first line of defence against pathogen's is anatomical barriers (Figure 1-1). For
example the bacterium Bordetella pert ussis must overcome the cilia' beat of the epithelial cells of
the respiratory tract to allow successful infection of the respiratory tract. Bordetella accomplishes
this by secretion of cell wall constituents that cause nitric oxide release from non-ciliated cells
which in turn inhibits the cilia beat of epithelial cells (Flak and Goldman, 1999). Furthermore,
upon reaching the site of infection a pathogen is not guaranteed successful colonisation if the niche
is already occupied by another microbial species. Thus some pathogen's have within their armoury
not only mechanisms of host manipulation but also mechanisms to allow them to remove other
organisms from the niche they are targeting. For example Pericone et a!. (Pericone et al., 2000)
demonstrated that the pneumococcus releases hydrogen peroxide which inhibits the growth of
other bacteria in the upper respiratory tract.
1.3.2 Complement
In order to overcome complement mediated lysis (Figure 1-3) that Group A streptococcus encoun-
ters upon invasion of the host, it produces an inhibitor of complement (Akesson eta!., 1996). The
Streptococcal Inhibitor of Complement (SIC) does not bind strongly to mdividual members of the
complement pathway but binds the C5b67 complex strongly, thereby preventing the formation of
the full Membrane Attack Complex.
1.3.3 Phagocytosis and Antigen presentation
Some pathogen's overcome the threat of phagocytosis by preventing uptake, such as Staphylococ-
cus aureus which generates an anti-phagocytic capsule (O'Riordan and Lee, 2004) or group A
Streptococcus which produces a bacterial homologue of CD 1 lb that inhibits phagocytosis (Lei  et
a!., 2001), however Leishmania encourages phagocytosis via the degradation of C3b to iC3b. This
1- 12enhances the ability of macrophage to phagocytose the Leishmania parasites (Mosser and Edelson,
1985). Leishmania then, at least initially, prevents fusion of the lysosome with the phagosome in
order to avoid destruction (Spath et al., 2000).
Another way to avoid phagocytosis and presentation by APC's is simply to kill these cells. While
sonie pathogen's induce necrosis of APC's the more favourable option appears to involve the in-
duction of apoptosis since it not only kills the APC but also avoids the release of pro-inflammatory
mediators. As an extracellular bacteria Yersinia prevents uptake by APC by inducing macrophage
apoptosis. Yersinia enterocolitica accomplishes this by injection of YopP (Mills eta!., 1997) via a
type III secretion system. The mechanism of apoptosis induction by YopP was not initially clear
since YopP was shown to activate NF-kóB. However recently it has been suggested that YopP
induces apoptosis when combined with the activation of the TLR system by some unknown bacte-
rial product such as LPS (Navarre and Zychlinsky, 2000).
Other pathogen's interfere with APC function by altering the intracellular processing and signal-
ling pathways to prevent presentation of their peptides by the APC. One such pathogen is the
Epstein Barr Virus (EBV). EBV expresses a protein called EBV nuclear antigen-i (EBNA- 1) which
appears to inhibit proteosome processing (Levitskaya eta!., 1997). Herpes simplex virus 1 (IISV-
1) utilises a different method based on expression of infected cell protein 47 (1CP47). 1CP47 blocks
MHC II transport (York et a!., 1994) by binding to TAP-i and TAP-2, weakening the interaction
and thereby inhibiting the transport of processed peptide fragments (Hill et a!., 1995).
Recently increasing attention has been focused upon the importance of Pattern Recognition Receptors
(PRR) for host immune functioning (Medzhitov and Janeway, 2002). Unsurprisingly there has
been the simultaneous discovery that pathogen's have developed avoidance mechanisms of these
systems. For example Salmone!la typhimurium has an LPS cell wall structure which is recognised
by TLR4. By varying the structure of the lipid A component of the LPS it is proposed that Salmo-
nella attempts a type of phase variation aimed at overcoming recognition by the PRR's (Guo et a!.,
1997; Hornefet a!., 2002).
1.3.4 Cytokines
1- 13Understanding of the complex role of cytokines within the immune system has been enhanced
through the study of the way in which different pathogen's attempt to modulate the cytokine net-
work. For example, macrophages infected with Mycobacteria tuberculosis produce the cytokines
IL-6, IL-b and TGF-b . IL-6 produced by macrophages infected with  M tuberculosis has been
shown to inhibit T cell activation (VanHeyningen et al., 1997), IL-b can inhibit macrophage pro-
duction of reactive oxygen species, can inhibit inflammatory cytokine release and can inhibit ex-
pression of costimulatory molecules and MHC (Giacomini et a!., 2001; Moore et a!., 1993). There-
fore by stimulating the release of these cytokines M tuberculosis ensures a less vigorous immune
response against it.
Rather than inducing cytokines that are advantageous to their survival, some pathogen's produce
cytokine homologues or cytokine receptor homologues. For example, the intestinal helminth Tn-
churis munis produces a protein with significant homology to IFN-g that has been demonstrated to
bind to the IFN-g receptor and effect changes similar to those observed with IFN-g (Grencis and
Entwistle, 1997). This allows Trichuris muris to establish chronic infection since IFN-g has been
demonstrated to prevent the development of an immune response that eliminates the nematode
(Else et al., 1994).
1.3.5	 T cells and B cells
Immunomodulation of T cells is the particular focus of this thesis and so I examine a number of
mechanisms used to inhibit T cells. Figure 1-4 shows the T cell activation pathway; any point on
this pathway is open to modulation.
Yersinia pseudotuberculosis is observed to inhibit both T and B cell activation when stimulated
through their antigen receptors (Yao et a!., 1999). Yersinia expresses YopH which is a tyrosine
phosphatase and subsequent work using YopH produced by Yersiniapestis demonstrated that YopH
inhibits tyrosine phosphorylation of the TcR early signalling events resulting in a decrease in IL-2
production along with decreased T cell activation (Alonso et al., 2004).
1-14Infection with Neisseria gonorrhoeae does not result in the generation of effective immunological
memory. This is in part due to the expression of Opa proteins on the bacteria which results in T cell
inhibition. Opa 52 can bind the CD4+ TcR carcinoembryonic antigen-cell adhesion molecule-i
(CEACAM-i) which contains a immuno-receptor tyrosine based inhibitory motif (ITIM). The re-
suit is the inhibition of T cell activation and proliferation (Boulton and Gray-Owen, 2002).
The filarial nematode Acanthocheilonema viteae has been demonstrated to induce T cell anergy
(Harnett et a!., 1998) and inhibits B cell activation (Deehan eta!., 1997) via a phosphorylcholine
containing glycoprotein called ES-62. ES-62 acts by modulating activation of tyrosine kinases
central to the TcR signalling cascade and as a result disrupts TcR coupling to subsequent signalling
cascades which in turn interrupts the proliferative signals following ligation of TcR and results in T
cell anergy (Harnett et a!., 1998).
I will examine in detail the mechanism of apoptosis as a T cell inhibitory mechanism later in this
chapter. However, it is worth noting at this point that some of the pathogen's use this mechanism.
Aeromonas hydrophila produces the toxin aerolysin which causes T cells apoptosis by the forma-
tion of channels in the cell membrane (Nelson et a!., 1999). Borrelia burgdorferi, when co-cultured
with T lymphocytes, induces apoptosis via a Fas dependent mechanism (Perticarari eta!., 2003) as
does H pylon (Wang eta!., 2001).
Other pathogen's indirectly suppress T cells by stimulating the production of a T cell inhibitory
factor from another cell type. For example the yeast Cryptococcus neoformans produces a capsule
component called Glucuronoxylomannan (GXM) that while it has no direct affect on T cell prolif-
eration it has been demonstrated to increase the production of IL-b which inhibits the CD4+ T cell
response (Mariano Andrade et a!., 2003).
From this examination of various mechanisms of immunomodulation it can be seen that pathogen's
modulate each part of the immune response. Apoptosis was mentioned as a mechanism of interfer-
ing with dendritic cells and T cells and a fuller examination of this will now take place. I will
consider this as a distinct topic although it will become clear as we progress that it is in fact an
integral part of the areas already examined.
1- 151.4 Apoptosis
1.4.1	 Introduction to Apoptosis
Apoptosis plays a crucial role in maintaining homeostasis within the immune system. During
lymphocyte development self reactive T and B cells are removed by apoptosis (Sohn eta!., 2003)
thus preventing potential autoimmune diseases. Apoptosis also functions subsequent to the expan-
sion phase of the lymphocyte response when the contraction phase is initiated in the expanded
population.
Apoptosis is centrally involved in the action of the immune system as a mechanism of inducing cell
death in a target cell population by cytotoxic lymphocyte killing of the target cell (Waterhouse and
Trapani, 2002). Cytotoxic T cells do this by initiating the caspase cascade within the target cell by
releasing granzyme B into the target cell. Granzyme B mimics the activity of the pro-caspase
proteases (Trapani et a!., 1998) and thereby initiates the apoptotic process. Apoptosis allows re-
moval of lymphocytes in a non inflammatory maimer which also helps to prevent autoimmune
reactions (Fadok and Chimini, 2001; Savill et a!., 1993).
There are some universal features of apoptosis observed in cells undergoing this process. These
include the classically defining morphological changes (Kerr, 1971) (including membrane disrup-
tion and formation of apoptotic bodies) in addition to chromatin condensation and cleavage (Wyllie
et a!., 1984), mitochondrial membrane potential disruption (Kluck et a!., 1997) and caspase activa-
tion (Lens et al., 1998). These changes are the result of the activation of a family of cysteine
dependent aspartine specific proteases that are called 'caspases'. These activated proteases pro-
ceed to cleave host cell structural and regulatory proteins along with nuclear DNA (Jendro  et a!.,
2002)(Figure 1-5).
1.4.2	 Apoptosis and T cells
1- 16Classically apoptosis has been described as programmed cell death (PCD) and necrosis as acciden-
tal cell death, however recent investigation (Jaattela and Tschopp, 2003) have found that necrotic
death is not as random as once thought and that necrotic and apoptotic cell death should be consid-
ered as a spectrum as opposed to two mutually exclusive alternatives (Proskuryakov et a!., 2003).
Over recent years research has increasingly pointed to the existence of a number of distinct path-
ways that lead to T cell apoptosis and that thcsc different pathways function in specific situations
(Figure 1-5). Initial discoveries had highlighted the role of death receptors such as Fas in the induc-
tion of apoptosis of activated T cells when re-stimulated by antigen through the TcR (Genestier et
a!., 1999). This gave rise to Activation Induced T Cell Death (AICD). This work had been carried
out in hybridoma cells (Ashwell eta!., 1987) however as in vivo research took place it became clear
that pathways other than death receptor induced cell death occurred in vivo (Budd, 2001; Hildeman
eta!., 2002; Lenardo eta!., 1999). This second type of T cell apoptosis was called Activated T Cell
Autonomous Death (ACAD) and was found to have distinct characteristics from AICD (Hildeman
eta!., 2003). AICD is driven by death receptors and requires repetitive or high dose stimulation via
the TcR whereas in ACAD death receptors do not have a role and a single antigen exposure is
sufficient to cause death (Hildeman et a!., 2002). Furthermore AICD is caspase dependent while
ACAD is caspase independent (Marsden and Strasser, 2003). Finally in functional terms AICD has
little involvement in T cell removal after an immune response with ACAD being important in this
role and both AICD and ACAD seem to have a role in auto-reactive T cell removal (Hildeman  et
a!., 2002).
Understanding of the signalling events involved in the apoptosis process has been increasing and
one potentially relevant development has been a proposal that suggests that lipid rafts may control
the apoptotic process since some of the proteins required for apoptotic signalling are localised to
lipid rafts (Garcia et a!., 2003). Lipid rafts have already been implicated in T cell signalling for
membrane receptors such as the TcR (Langlet et a!., 2000), CTLA-4 (Chikuma et a!., 2003), CD3
(Hiltbold et a!., 2003) and signal cascade members such as Src, Lck, Fyn (Alonso and Millan,
2001). The recent demonstration that the Death Induced Signalling Complex (DISC) is recruited to
lipid rafts (Scheel-Toellner et a!., 2002) and that lipid rafts dramatically increase in activated T
cells (Tuosto eta!., 2001) has heightened the interest in the link between apoptosis and rafts.
1- 17Some pathogen's interfere with the apoptotic pathway and I will now discuss some of the different
pathogen's that use this strategy and the mechanism by which they accomplish this.
1.4.3	 The induction of apoptosis by viruses, protozoa and
helminths
Viruses primarily subvert apoptosis in order to prolong the survival of the host cell (Spriggs, 1996).
Protozoa and helminths have been shown to induce apoptosis for example the microfilariae of the
filarial nematode Brugia malayi induce increased apoptosis of dendritic cells (Senmani et al.,2003).
However it is upon the induction of apoptosis in cells of the immune system by bacteria that I shall
focus.
1.4.4 The induction of apoptosis by Bacteria
Discoveries of bacterial infections that cause apoptosis of cells of their host has been increasing
over the past decade - for a review see (Gao and Abu Kwaik, 2000; Jendro  et al., 2002; Weinrauch
and Zychlinsky, 1999), however I will examine bacteria that specifically induce apoptosis of cells
of the immune system. Bacteria induce apoptosis via a number of different mechanisms. Many
bacteria induce apoptosis via release of a toxin. These toxins can be classified into families which
allows examination of apoptosis by the different toxin families;
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1- 191.4.4.1 Pore Forming Toxins
The pore forming toxins are further classified into three sub-groups according to the type of toxin;
cx-toxjn (from S. aureas) like toxins
Repeats in Toxin (RTX)
• Cholesterol Dependent Cytolysins (CDCs)
1.4.4.1 a-toxin like toxins
Staphylococcus aureus secretes a-toxin which has been demonstrated to induce apoptosis in T cells
(Jonas et a!., 1994). The exact mechanism is unclear however at low doses the toxin binds an
unknown receptor and forms small ion permeable pores that allow release of monovalent cations
that results in apoptosis (Hildebrand et a!., 1991). At higher concentrations a-toxin binds to the cell
membrane inducing large pores that allow Ca2 to enter and necrosis to occur.
1.4.4.2 RTX toxins
Leukotoxin from A ctino bacillus actinornycetemcomitans induces apoptosis in leukocytes (Lally el
a!., 1989; Taichman eta!., 1980), including T cells (Mangan eta!., 1991). Leukotoxin binds to cells
via LFA-1 and then forms a pore which causes apoptosis in the host cells (Yamaguchi eta!., 2004).
This group also contains the leukotoxin from Pasteurella haemolytica which causes bovine
leukocytes to undergo apoptosis (Lafleur eta!., 2001; Leite eta!., 2002; Stevens and Czuprynski,
1996; Thumbikat eta!., 2003).
1.4.4.3 CDCs
1-20The Cholesterol Dependent Cytolysins (CDCs) (Figure 1-6) are a group of around 20 toxins pro-
duced by Gram positive bacteria - for reviews see (Palmer, 2001; Tweten  et a!., 2001). The toxin
with which this thesis is concerned, pneumolysin, is a member of this group and so this group
deserves particular attention.
Eleven of the CDC's have been sequenced and one crystal structure has been released (Rossjohn el
a!., 1997) - another is in press(Polekhina eta!., 2004). Sequence comparison has demonstrated the
presence of a Trp rich conserved undecapeptide region (Figure 1-11) (Tweten, 1988) that appears
to be crucial for the hemolytic activity that the toxins all display.
While the role of each toxin within the context of its host pathogen interaction continues to be
elucidated, recent attention has focused particularly upon the mechanism of action of these toxins
(Tweten eta!., 2001). I will discuss this in more detail later in this chapter however a few key issues
centre around the role of cholesterol in the mechanism of action and the role of each of the four
domains, discovered from the crystallisation data, within the mechanism of action.
In terms of the CDC's as apoptosis inducing molecules listeriolysin produced by  Listeria
monocytogenes was discovered to induce apoptosis in DC's but not macrophages (Guzman  et a!.,
1996). The authors at the time suggested that the generation of small pores may cause apoptosis to
result rather than necrosis.
1.4.4.4 A-B toxins
Corynebacterium diphtheriae, Pseudomonas aeruginosa and Shige!!a dysenteriae all produce a
toxin with the classical structure of an A-B toxin where the B unit binds to the cell via a receptor
and enables the delivery of the active A subunit into the cytoplasm. The A subunit cleaves an
adenine residue on the 28S rRNA component of eukaryotic ribosome's, resulting in inhibition of
protein synthesis and thereby inducing apoptosis (Nakao and Takeda, 2000). Specifically cholera
toxin (Ctx) from Vibrio cholerae and its closely related relative, heat-labile enterotoxin (Etx) from
Escherichia coli have been found to induce apoptosis of CD8 T cells(Nashar eta!., 1996; Yankelevich
et a!., 1996). The mechanism by which the B subunit of heat-liable enterotoxin (EtxB) accom-
1-21pushes this has been studied and shown to involve the up-regulation of the transcription factor c-
myc (Soriani et al., 2001) which is involved in the control of cell proliferation and death and NF -
kóB (Salmond et al., 2002).
1.4.4.5 Type III Secretion systems
Salmonella lyphimurium, Yersiniapseudotuberculosis, Yersinia enterocolitica, and Shigellaflexneri
utilise a type Ill secretion system - for review see (Hueck, 1998) to induce apoptosis a variety of
cell types upon infection of their host. They form small membrane pores through which they inject
signalling molecules into the host cell. Upon invasion, Shigella Jlexneri are phagocytosed by
macrophages but escape into the cytoplasm where they induce apoptosis of the host cell (Zychlinsky
et al., 1992; Zychlinsky et a!., 1996). They accomplish this by release of IpaB which binds to and
activates caspase-1 which results in apoptosis (Chen et al., 1996).
1.4.4.6 Superantigens
Streptococcus pyogenes releases a number of superantigens that induce apoptosis of T cells by
crosslinking the TcR which has been demonstrated to induce the apoptotic pathway (Watanabe-
Ohnishi et al., 1995)and in addition can cause clonal exhaustion or anergy (Xu et al., 2004).
1.4.4.7 Other
Helicobacter pylon VacA serves as an example of a toxin released by a bacterium that induces
apoptosis but that does not fit into one of the categories outlined above. VacA inhibits IL-2 produc-
tion and prevents nuclear translocation of NFAT. It therefore inhibits the T cell response to H.
pylon (Gebert et a!., 2003).
1-22Organism	 Toxin	 Abbreviation
A rcano bacterium pyo genes
Bacillus cereus
B. anthracis
B. thuringiensis
Brevibacillus laterosporus
Clostridium bifermentans
C. botulinum
C. chauvoei
C. histolyticum
C. novvitvpeA
C. peifringens
C. septicum
C. tetani
Listeria ivanovi
L. monocytogenes
L. seeligeri
Paenibacillus alvei
Stretococcus can is
S. equisimillis
S. intermedius
S. pneumoniae
S. pyogenes
S. suis
Pyolysin
	 PLO
Cereolysin
	
CLY
Anthrolysin 0 ALO
Thuringiolysin 0
Laterosporolysin
Bifcrrnentolysin
Botulinolysin
Chauveoysin
Histolyticolysin
Oedematolysin
Perfringolysin 0 PFO
Septicolysin 0
Tetanolysin
Ivanolysin 0 ILO
Listeriolysin 0 LLO
Seeligerilysin 0 LSO
Alveolysin ALY
Streptolysin 0 SLO
Streptolysin 0 SLO
Intermedilysin ILY
Pneumolysin
	
PLY
Streptolysin 0 SLO
Suilysin	 SLY
Figure 1-6
Organisms that produce a Cholesterol Dependent Cytolysin (CDC)
Twenty three organisms have been discovered to produce a CDC. Not all have an abbreviation; a
reflection of the lack of investigation into some of the toxins.
1-23The preceding section has demonstrated the variety of mechanisms that bacteria use to induce
apoptosis and some of the molecules involved in this process. I have also identified different
immunomodulatory molecules and their function throughout this chapter and will now proceed to
discussing the potential therapeutic application context for molecules that modulate the CD4 I cell
response.
1-241.5 Therapeutic Applications
In the context of infection, the immunomodulatory properties of pathogen's are likely to be advan-
tageous to the pathogen and disadvantageous to the host, however it has been proposed that in
understanding the mechanism of action of isolated immunomodulatory components, exploitation
of these properties in a beneficial manner could occur. In particular we are interested in how
immunomodulatory molecules could be applied in the area of inappropriate immune responses
involving CD4+ T cells.
The mouse model of rheumatoid arthritis is collagen induced arthritis (CIA). Although the role of
the CD4 T cells that infiltrate the joint synovium is unclear they are suspected to have some role in
pathogenesis (Firestein, 2003). While merely killing T cells is not enough to prevent pathology
(Firestein, 2004), in conjunction with other immunomodulators this may be an effective therapy
(Moreland eta!., 1997). The B subunit of enterotoxin (EtxB) of E. coli has been used to effectively
treat this disease in mice (Williams et a!., 1997) by shifling the CD4 T cell response from TH1 to
TH2. CIA has also been effectively treated using the filarial nematode extract ES-62 (Hamett  eta!.,
2004; Mclnnes eta!., 2003) which appears to act in a similar way.
Current therapy for Crohn's disease is based upon treatment with steroids (Van Deventer, 2000)
and use of compounds that prevent T cell activation (Takazoe et a!., 2002), however recent tests
using an antibody that binds the TNF-a receptor and causes CD4 apoptosis has been identified as
being successful (ten Hove et a!., 2002; Van Deventer, 2000) as has aziathrioprine which has been
shown to induce apoptosis of CD4 T cells (Tiede eta!., 2003).
Similarly, the use of an anti-CD4 antibody was proposed to potentially have a similar effect in
multiple sclerosis (MS) however surprisingly, studies showed that inhibition of TNF-a by a block-
ing antibody exacerbates MS (Group, 1999). Furthermore, global depletion of CD4 T cells failed
(van Oosten eta!., 1997), and most antigen therapies that specifically targeted the CD4 T myelin
response were inefficient or even worsened the disease. These findings have led to a reappraisal of
the role of CD4 T cells in the pathology of MS (Hemmer et a!., 2002; Lassmann and Ransohoff,
2004).
1-25The mechanism of pathology in Guillian-Barrè syndrome remains to be elucidated however CD4 T
cells appear to be important for the production of pathology (Zhu et a!., 2002) (Hughes et a!.,
1999). It is therefore possible that an anti-CD4+ effect may reduce the development or continua-
tion of this pathology.
The chronic inflammatory disease, allergic asthma, is characterized by the presence of  TH2 cells
and eosinophils in sputum and bronchoalveolar lavage. Recently IL-12 has been shown to inhibit
allergic asthma by inducing apoptosis of TB2 cells (Kodama eta!., 2003). Therefore induction of
CD4 T cells apoptosis is, in this context, of therapeutic benefit to the host.
\Vhile it is the case that all of the components that take part in an immune response are susceptible
to modulation, some examples of the potential benefit of specifically targeting CD4 T cells has
been demonstrated here.
So far I have been concerned with modulation of the immune system by the pathogen and how this
may be utilised in a beneficial manner. Since the topic of this thesis concerns these two themes
applied to the bacterium Streptococcus pneumoniae I shall discuss this organism in more detail.
1-261.6 The pneumococcus
1.6.1	 Introduction to Streptococcus pneumoniae
The pneumococcus is a common commensal of the upper respiratory tract of humans and usually
only becomes pathogenic when the host becomes immunocompromised, a new more virulent strain
colonises the host, or nasopharyngeal inflammation occurs (Bogaert  eta!., 2004; Mizrachi-Nebenzahl
et al., 2003). Reported rates of carriage of the pneumococcus in children is above  50% yet in adults
is only 4% (Regev-Yochay et a!., 2004). Non-invasive disease is represented by otitis media, si-
nusitis and bronchitis while invasive disease is classified as pneumonia, bacteraemia and meningi-
tis and is responsible for 1 million deaths per annum in children under 5 years of age (Parsons and
Dockrell, 2002). Incidence of invasive disease in Scotland has been reported to be 10 per 100000
(Kyaw eta!., 2002).
1.6.2 The Immune Response to Streptococcus pneumoniae
Colonisation is the first and necessary step in the development of invasive disease (Bogaert  eta!,
2004). It remains unclear what factors mitigate the transition from commensal to pathogen for  S.
pneumoniae however a number of studies have attempted to dissect some of the possible factors.
While the strain of pneumococcus is known to influence to some degree the likelihood of invasive
disease (Kadioglu et a!., 2002; Sandgren et a!., 2004), other studies have suggested that the genetic
background of the host may be more influential. Studies have found that different mouse strains
recruited neutrophils to differing degrees and suggested that this may be the cellular basis underly-
ing the observed differences between host genetic backgrounds (Gingles et a!., 2001). Further
study (Kerr et a!., 2002) revealed that a susceptible mouse strain had a reduced inflammatory
response within the airways as judged by quantity and timing of TNF-a, IL-lb and IL-b produc-
1-27tion compared to a resistant strain. In addition a recently published study suggested that TLR-4
may be important in determining the level of colonisation and hence subsequent invasive disease
(Malley et al., 2003). However focus on this area has again switched to the strain of pneumococcus
since the publication of a study that agreed that the immune response of the host was influential but
suggested it is the strain ofpneumococcus that determines this the degree of this response (Mizrachi-
Nebenzahl eta!., 2003).
1.6.2.1 Antibody and Complement
Upon progressing from colonisation to invasive disease the pneumococcus faces the host's im-
mune response. In the unimmunised host natural 1gM provides the first line of defence to the
pneumococcus (Boes et a!., 1998; Briles et a!., 1981). This 1gM is naturally forming in pathogen
free mice and is poly-reactive to common pathogenic structures (Ochsenbein  et a!., 1999). The
1gM referred to here is made in mice by B-i cells (Boes eta!., 1998) which are equivalent to 1gM
memory B cells in humans (Kruetzmann et al., 2003). 1gM memory B cells are dependent on the
spleen for existence and their delayed development until around 13 months of age has been shown
to be responsible for the increased susceptibility to bacterial infections observed in neonates
(Kruetzmann et a!., 2003).
C-Reactive Protein (CRP) is another factor important for defence against the pneumococcus (Briles
et al., 1989). CRP opsonises pneumococci to enhance phagocytosis and thereby aids bacterial
removal. Both natural 1gM and CRP require complement in order for their activity to protect against
the pneumococcus (Mold et a!., 2002). Complement has been demonstrated to have a key role in
pneumococcal immunity (Winkeistein, 1981). In keeping with the paradigm that the alternative
pathway is activated directly by bacteria it was demonstrated that in the non-immune host the
alternative pathway played a crucial role in defence against the pneumococcus (Hosea et a!., 1980).
However as it was realised that the classical pathway activating factor Clq could bind to bacteria
directly or to immune complexes formed as a result of natural 1gM activity (Boes eta!., 1998) or to
CRP bound to the pneumococcus (Mold eta!., 2002) the question of which complement pathway
was the most important was examined. A recent study clarified the issue using a variety of knock-
out mice that enabled examination of the role of the classical, alternative and mannose binding
complement pathways on the innate resistance of unimmunised mice to pneumococcal infection
1-28(Brown eta!., 2002). While the MBL pathway was shown to be of minimal importance despite the
ability of MBL to bind pneumococcal surface polysaccharides (Zamze et a!., 2002), it was surpris-
ingly reported that both the classical and alternative pathways are important. Given that the classi-
cal pathway is usually associated with the adaptive immune response as a result of the dogma that
the classical pathway is activated by antibody, it seemed more likely that the alternative pathway
would be prominent in unimmunised mice. However the classical pathway was shown to be of
primary importance potentially through the mechanisms mentioned above involving natural 1gM,
CRP and also the direct binding of Clq to bacteria. Another study examined the effect of comple-
ment deficiencies on frequency of infection with different pathogen's and found that individuals
with a deficiency late in the complement pathway involving C5-9 were not more susceptible to
pneumococcal meningitis (Figueroa and Densen, 1991) which suggests that other complement
functions other than membrane lysis are important in defence against the pneumococcus.
While the crucial role of complement in the innate immune response to the pneumococcus has been
investigated and the details have begun to be worked out, the role of complement in the induction
of the adaptive immune response remained unclear until a recent investigation (I-Iaas et a!., 2002)
using complement receptor deficient mice (CD21 and CD35; present on B cells). It was demon-
strated that these mice were not any more susceptible to challenge infection with the pneumococ-
cus than wild type mice however the mice did not develop protective antibody responses upon
immunisation with the pneumococcus. The authors therefore proposed that these complement
receptors on B cells play an important role in linking the innate and adaptive immune response to
the pneumococcus.
1.6.2.2 Phagocyte's
Receptors for complement and Fc are present on the surface of macrophages and neutrophils and
are involved in the phagocytosis of pneumococci(Ali et a!., 2003; Saeland et a!., 2003). This is
reflected in the influx of neutrophils and macrophages into the lungs upon pneumococcal infection
(Kadioglu eta!., 2000). Clearance of the pneumococci from the lungs is dependent on the phagocy-
tosis of the bacteria (Gillespie, 1989; Knapp eta!., 2003). The effectors of this process are resident
macrophages (Jonsson eta!., 1985) which act immediately, however after a few hours the influx of
more effective PMNL into the alveolar space occurs (Lawrence et a!., 1996) and after 24 to 48
1-29hours an influx of monocytes occurs (Goto et a!., 2004) which differentiate into macrophages.
Subsequent to phagocytosis macrophage undergo apoptosis and this has been shown to enhance
host defence to the pneumococcus by limiting the pro-inflammatory response (Au  et a!., 2003;
DeLeo, 2004; Dockrell et a!., 2001) although the binding of inhibitory Fc receptor FcgRlIb by the
pneumococcus has also been shown to be responsible for limiting the pro-inflammatory response
(Clatworthy and Smith, 2004).
1.6.2.3 Cytokines
The myriad of cytokine interactions during pneumococcal infection are far from being elucidated
however some insight has begun. The release of pro-inflammatory cytokines has been observed in
response to the pneumococcus. For example the level of TNF-a in the blood was recorded after
pneumococcal infection and found that it increased and as a result increased the number of neutrophils
in the blood which stemmed pneumococcal growth in the blood (Takashima eta!., 1997). The role
of TNF-a in pneumococcal infection was demonstrated by comparison of the susceptibility ofBALB/
c and CBAICa mice which revealed that the more susceptible CBA/Ca mice have a reduced ability
to induced a rapid TNF-a response in the airways of the host (Kerr  et a!., 2002). TNF-a has also
been demonstrated to increase the permeability of the blood brain barrier and consequently aid the
development of pneumococcal meningitis (Tsao et al., 2002).
The effect of IL-I. was examined and found that mice defective in IL-I activity had increased lung
bacterial counts and a decreased ability to form inflammatory infiltrates (Rijneveld et al., 2001).
Furthermore they demonstrated that TNFa is more important than IL-i in pneumococcal infection
while others demonstrated that TNFa is able to compensate for IL-i during pneumococcal pneu-
monia (Rijneveld et aL, 2001) but not during meningitis where IL-I is observed to be essential
(Zwijnenburg et a!., 2003b).
IL-6 levels increased in response to pneumococcal infection (van der Poll  et a!., 1997) and in the
absence of IL-6, both IL-i and TNF-a increased. IL-6 may therefore regulate these pro-inflamma-
tory cytokines or IL-6 may function in a similar way so that upon its removal a compensatory
increase occurs. In another study while an increase in IL-6, IL-ia and TNFa occurred in the lung
1-30early in infection this was accompanied by an IL-6 increase only in the blood. Later in infection a
decrease in TNFa and IL-la occurred and then even later an increase of TNFa and IL-6 in the blood
(Bergeron eta!., 1998).
In 1996 it was demonstrated that upon pneumococcal infection of the lungs the level of IL-b
increased (van der Poll ci a!., 1996b).The role of IL-b during pncumococcal meningitis has been
addressed and while the absence of IL-b resulted in higher cytokine levels this was not observed
to alter the outcome of infection in any way (Zwijnenburg eta!., 2003c).
The role of IL- 18 and IL- 12 in pneumococcal infection was examined and it was shown that IL- 18
deficient mice had increased susceptibility to lung infection (Lauw et a!., 2002) while IL-12 defi-
cient mice had no increased susceptibility. However in pneumococcal meningitis IL-i 8 has been
observed to have a detrimental effect on the host since IL-i 8 deficient mice have prolonged sur-
vival in this context (Zwijnenburg eta!., 2003a). Examination of the role of IFN-g in pneumococ-
cal infection led to the discovery that there was no difference in mortality between a IFN-g defi-
cient strain and the wild type equivalent (Rijneveld et a!., 2002). However closer examination
revealed that IFN-g deficient mice had lower numbers of pneumoeocci in their lungs and had
decreased neutrophil influx. This suggests that IFN-g may be slightly detrimental to the host. This
contrasts with other results that have shown a protective role of IFN-g to the host in pneumococcal
infection (Rubins and Pomeroy, 1997).
The preceding paragraphs have demonstrated the importance of pro-inflammatory cytokines in the
immune response to the pneumococcus. While it has been shown that pro-inflammatory cytokines
are released from non-lymphoid cells (Khan ci a!., 2002), lymphocytes are proposed to be impor-
tant in releasing some of the pro-inflammatory cytokines observed during pneumococcal infection
(Kadioglu ci a!., 2004). Interestingly pneumococcal infection has been observed to be associated
with a simultaneous decrease in the number ofTHl cells and this decrease is not observed to occur
in the TH2 cell compartment (Kemp ci a!., 2002). Related to this the pneumococcal toxin pneumo-
lysin bias been shown to stimulate the release of IL-8 from neutrophils (Cockeran eta!., 2002b).
While the demonstration of the importance of pro-inflammatory cytokines in the innate immune
response to S. pneumoniae has been investigated, the role of cytokines in the adaptive immune
1-31response has been largely ignored. However it has been demonstrated that TNF-a is required for
the induction of the primary IgG response to pneumococcal proteins. Furthermore mice deficient
in any of the THI cytokines IL-12, IL-6 or IFN-g showed a reduced ability to form IgG to pneumo-
coccal proteins. In contrast mice deficient in IL-4 or IL-b had increased antibody titre to the same
constituents. The effect of these cytokines upon the antibody response to phosphoryicholinc (PC)
was also examined and although the same effects were noticed as for the protein response, the
effects were more modest (Khan et aL, 2002).
1.6.2.4 Pattern Recognition Receptors (PRR)
Further clarity on the role of pro and anti - inflammatory cytokines was given with the publication
of a paper which demonstrated a novel way of viewing the role of anti-inflammatory cytokines
such as IL-b in the context of pneumococcal infection (Colino and Snapper, 2003b). Previously it
had been observed that the pneumococcus induces release of anti-inflammatory cytokines which
had been interpreted as being negative to the host (van der Poll  et al., 1996a). Furthermore Bone
Marrow derived Dendritic Cells (BMDC) had been shown to undergo apoptosis (Colino and Snap-
per, 2003 a) and become activated through TLR-4 (Malley et al., 2003) in response to the pneumo-
coccus. Colino et a!. combined these two concepts by demonstrating that the release of IL-b by
DC in response to the pneumococcus provides an opposing signal to that given by TLR stimulation
which induces apoptosis. In this way the release of IL-b by Streptococcus pneumoniae is a posi-
tive event for the host since it prolongs the existence of DC which allows the development of an
adaptive immune response by enabling presentation of antigen to lymphocytes.
The elucidation of this link between the cytokine response to the pneumococcus and the PRR
response to the pneumococcus depended on prior investigations into the interactions of PRR's and
the pneumococcus. The first publication investigating the effect of Streptococcus pneumoniae on
TLR's was in 1999 by Yoshimura et a!. who found that fibroblasts expressing TLR-2 became
activated when exposed to the pneumococcus (Yoshimura et al., 1999). Following on from this
report TLR-2 was demonstrated to play a role in pneumococcal meningitis when it was found that
TLR-2 deficient mice were more susceptible to pneumococcal meningitis than wild type counter-
parts (Echchannaoui et at, 2002). Interestingly bacterial numbers in the blood were not higher in
the TLR-2 deficient mice but were higher in the brain and coincided with higher levels of 1'NF-a in
the cerebro-spinal fluid (CSF). The role of TLR-2 was examined during lung infection when it was
1-32discovered that TLR-2 is crucial for the induction of TNF-a from alveolar macrophages by the
pneumococcus (Knapp et a!., 2004). This led to the expectation that TLR-2 deficient mice would
be more susceptible to pneumococcal infection. However survival of mice was not affected by the
presence or absence of TLR-2 when infected with S.  pneumoniae. The authors went on to demon-
strate that although early inflammatory responses are decreased by the absence of TLR-2 this does
not alter the outcome since other factors appear to compensate.
The accepted paradigm within our understanding of Toll receptors was that TLR-4 was activated
by the Gram-negative bacterial product LPS while TLR-2 was activated by Gram-positive cell wall
products. This understanding was revised with the publication of a paper which showed that the
toxin pneumolysin produced by S. pneumoniae was capable of signalling through TLR-4 (Malley
et a!., 2003). Interestingly the paper also demonstrated that a complement activating and cytolytic
deficient mutant of the toxin was also able to signal through TLR-4. The authors proceeded to
examine the in vivo effect of TLR-4 deficiency. They demonstrated that mice deficient in TLR-4
had increased susceptibility to pneumococcal infection and were more likely to have invasive dis-
ease. Since TLR-4 deficient mice have a higher level of nasopharyngeal colonisation than normal
mice they proposed this discrepancy as a possible reason for the difference in invasive disease.
Furthermore when comparing the infectivity of a pneumolysin deficient strain of S. pneumoniae
with its wild type counterpart they discovered that the pneumolysin deficient strain had a compara-
ble level of mortality to a pneumolysin sufficient strain in TLR-4 deficient mice. This finding
suggests that in the absence of pneumolysin the beneficial effects to the host of the inflammation
caused by TLR-4 activation by pneumolysin are not achieved. This correlates with others who
have found that people who respond to pneumolysin and produce antibody to pneumolysin subse-
quently have more invasive disease episodes that non-responders (Cockeran eta!., 2002a). Subse-
quently a study was published which examined the effect of TLR-4 in lung infection with the
pneumococcus and suggested that TLR-4 had only a minimal role in lung infection (Branger  et a!.,
2004).
1.6.2.5 T and B cells
In 1975 Winkeistein demonstrated that T cell deficient mice had the same mean lethal dose as wild
type mice. From this it was concluded that T cells play an insignificant role in defence against the
pneumococcus and therefore the adaptive immune response was subsequently largely ignored
1-33(Winkelstein and Swift, 1975). While the innate immune response is of primary importance in
defence against the pneumococcus, the role of the adaptive arm of the immune system has recently
begun to be elucidated.
Three areas of interest have been developing as the result of investigation into the role of the
adaptive immune response to the pneumococcus. The first area actually proposes a role for T cells
in the innate immune response to the pneumococcus (Kadioglu and Andrew, 2004). Studies on the
cellular influx into the lung of mice infected with Streptococcus pneumoniae showed significant
lymphocyte accumulation at sites within the lung and that this coincided with the remission phase
of infection (Kadioglu et al., 2000). The authors suggested that the lymphocytes may be important
for cytokine secretion. In a later study, by use of a mutant pneumolysin, the same group (Jounblat
et a!., 2003) demonstrated that the complement activating properties of pneumolysin were respon-
sible for the influx of T cells into the lung observed during pneumococcal infection. To directly
assess the effect of CD4 T cells upon pneumococcal infection MHC 11-I-mice were used and were
infected with pneumococci since it was reported that the MHC II  -I- mice were deficient in CD4 T
cells but not CD8 T cells (Kadioglu et a!., 2004). The MHC II -I- mice had higher numbers of
pneumococci in the blood and lungs than normal mice. This work extended the findings of Sestini
et a!. (Sestini et a!., 1987, 1988) who had earlier demonstrated a role for CD4+ T cells in the
antibacterial activity against the pneumococcus in the lungs.
Studies from patients with AIDS have also demonstrated that T cells are important in pneumococ-
cal infection. For example Janoff et a!. (Janoffet al., 1993) studied the prevalence of pneumococ-
cal colonisation among HIV+ individuals and found no difference in colonisation levels, yet an
increased frequency of invasive disease is known to exist in HIV+ individuals (Schneider and
Rosen, 1999). Therefore it was suggested that the higher bacteraemia among HIV+ individuals
was associated with low CD4+ T cell count rather than increased exposure to the pneumococcus as
a result of increased carriage. Another study found that while HIV+ individuals may not be more
frequent carriers of S. pneumoniae, they were more likely to carry the pneumococcus for a longer
period of time (Rodriguez-Barradas eta!., 1997).
The third area of research comprises the cellular requirements of the adaptive immune response to
the pneumococcus. The protein antigens of the pneumococcus are considered to be TD antigens
1-34and have been demonstrated to require CD4 T cell help to enable antibody production. This help
requires TcR-MHC recognition and costimulation by CD4 T cells in the form of CD4O-CD4OL and
CD28-B71/2 (Wu et a!., 1999). Vaccination has demonstrated that formation of antibody to the
pneumococcus polysaccharide is possible, however the role of the T cell in producing this antibody
had not been elucidated until recently since polysaccharide was considered to be a TI-2 antigen.
Wu et a!. postulated (Wu et a!., 1999) that while purified polysaccharide does not require T cell
help for antibody production (Mond eta!., 1 995a) it may be the case that in the context of the whole
pneumococcus polysaccharide, is encountered in a protein-polysaccharide conjugate fashion that
means T cell help is involved in the antibody production from polysaccharide. They used an unen-
capsulated pneumococcal strain to examine the antibody response to the phosphoryicholine (PC)
determinant of the polysaccharide cell wall component techinoic acid. By using knockout mice
they were able to demonstrate the T cell independence of the 1gM anti-PC response and the de-
pendence of the IgG anti-PC response on alpha/beta CD4 and CD8 T cells. Their studies went on to
demonstrate that a conjugate effect was not taking place and that CD4O costimulation is required
for both the anti-PC 1gM and IgG response but that only for the IgG response does the CD4O signal
come from CD4 and CD8 T cells. Finally they demonstrated that there exists a B7 requirement for
anti-PC antibody response but that this is different to the B7 requirement of the pneumococcal
protein PspA.
These studies were followed up by examining the role of CD4OL on the antibody response to
encapsulated bacteria (Hwang et a!., 2000). It was found that CD4OL was required for IgG re-
sponses to capsular polysaccharide (caps-PS) in the context of the whole bacterium but not when
the caps-PS was administered in purified form. Furthermore their studies demonstrated that CD4OL
was not required for antibody responses to cell wall polysaccharide. Others investigated the neces-
sity of CD4O for the antibody response to different caps-PS (Jeurissen et a!., 2002). They found
that CD4O was required to differing degrees depending on the serotype of the caps-PS.
Wu et a!. (Wu et a!., 2002) further addressed the question of costimulatory requirements of the anti-
PC response and found that for both anti-PC and anti-PspA antibody B7-2 but not B7-1 was re-
quired for IgG antibody production. In addition they showed that for anti-PspA antibody CD28
costimulation is required on days 0-4 after primary immunisation, whereas anti-PC antibody CD28
costimulation is only required on day 0 after primary immunisation. They also investigated the
mechanism underlying T cell help for the immune response to PC in the context of the whole
1-35pneumococcus. Given that it was already known that polysaccharide does not associate with the
MHC (Mond et al., 1995a) the question of TcR recognition involving polysaccharide could be
precluded, however the possibility that the T cell help mechanism in the anti-PC response depends
on a protein-polysaccharide conjugate had not been fully addressed. They demonstrated, by using
TcR a- mice that have a functional TcR but are unable to recognise antigen, that the antibody
response to PC does not require simultaneous antigen recognition. Furthermore they demonstrated
that APC processing was also not required for the anti-PC antibody response. By using DC pulsed
with Streptococcus pneumoniae in vitro and then injected in vivo it was able to be shown that the
dominant antibody isotype produced to PC is 1gM and IgG3 (Colino et a!., 2002). By utilising
CD4O-/- DC the group went on to show that the anti-PC response is defective using these DC only
in terms of IgGI and that IgG3, IgG2b and 1gM were normal.
In 2004 Khan et a!. published a seminal paper in this area. In it they clarified many issues that have
surrounded the investigations outlined above. They demonstrated that the results published for the
anti-PC responses were representative of findings for capsular polysaccharide in terms of the ki-
netics of the antibody response, the necessity of the CD4 T cell and the requirement for CD4O
costimulation. However their comparisons of anti-PC to anti-PPS responses revealed one impor-
tant anomaly. Previously they had demonstrated that anti-PC IgG responses were TcR independ-
ent, however in this study while the anti-PC TcR independence was reproduced they demonstrated
that the anti-PPS response was TcR dependent although this was not due to its association with a
bacterial protein but more likely is due to the nature of the antigen or the type of B cells that
respond to this antigen (Khan et al., 2004).
In summary, in the context of the whole bacteria, pneumococcal phosphorylcholine and capsular
polysaccharide has been shown to require CD4 T cell help for antibody production. This is not the
result of conjugate presentation although this CD4 T cell help is distinct from that given to peptide
antigens since it is TcR independent (PC only), is required only for a short period of time and is
CD4O dependent.
1.6.2.6 Colonisation, antibody, T cells and pneumolysin.
1-36The previous section has focused upon the role of the T cell in antibody production to the pneumo-
coccus. However to understand the importance of the CD4+ T cell during pneumococcal infection
requires an understanding of the importance of antibody to the pneumococcus.
Antibody is not important in the defence against primary challenge in the naive host since it has
been demonstrated that the adaptive immune response has no role in host defence against this type
of infection (Haas et al., 2002; Winkeistein and Swift, 1975) and therefore antibody (other than
natural 1gM) has no role in this type of pneumococcal contact.
However most pneumococcal contacts are not of a challenge nature but rather the host becomes
colonised first and then invasive disease occurs (Bogaert et a!., 2004). Therefore the effect of
antibody in the context of colonisation is more interesting.
The effect of a normal colonisation event upon the development of antibody has been studied in
humans (Rapola et a!., 2000; Soininen et al., 2001). It was found that antibody fonnation to both
protein and polysaccharide antigens from the pneumococcus could develop as the result of carriage
although the development of antibody to polysaccharide was serotype dependent during carriage.
Potentially this means that the majority of pneumococcal contacts occur in host's that have anti-
body to the pneumococcus.
The effect of this antibody requires careful consideration. Antibody formed as a result of colonisa-
tion has been shown to prevent re-colonisation when antibody to the PspA protein is present but
antibody to the pneumococcus capsule was not protective (McCool et a!., 2002). Therefore the
normal course of infection would be to be colonised once but be unable to be recolonised.
Interestingly, the authors of the study above (McCool eta!., 2002) made the discovery that despite
carriage resulting in a rise in the titre of anti-PspA, this rise did not affect the current carriage but
only affected subsequent colonisation. They also found a serotype specificity in their studies whereby
one serotype did not cause a rise in anti-PspA antibody titre.
Other researchers have tried to elucidate the role of pneumolysin during colonisation. One group
demonstrated that an increase in antibody to pneumolysin does not occur upon experimental hu-
man carriage (McCool et a!., 2003). Furthermore production of the toxin pneumolysin was not
1-37found to differ between strains that colonise and those that cause invasive disease, suggesting that
production levels of the toxin are not responsible for the difference in invasive capacity (Spreer et
a!., 2004). Two groups have examined the colonising ability of pneumolysin deficient strain of the
pneumococcus and found conflicting results. One group found that a pneumolysin deficient strain
was no less successful in colonising the host than a pneumolysin sufficient strain (Rubins  et a!.,
1998) while another group found that a pneumolysin deficient strain was cleared rapidly from the
nasopharynx (Kadioglu eta!., 2002).
1.6.3 Virulence Factors of Streptococcus pneumoniae
The complex interaction of the pneumococcus with the host immune system is further observed in
the interaction of specific pneumococcal virulence factors with parts of the immune system. Virulence
factors are those molecules expressed by the pneumococcus that allow  in vivo growth but are not
required for in vitro growth (Hava et a!., 2003). Interestingly in relation to the discussion in the
above section a recent study demonstrated that many factors required for invasive disease were
also required for colonisation (Hava and Camilli, 2002).
1.6.3.1 CeliWall
The polysaccharide capsule (Figure 1-7) that forms the outermost layer of the pneumococcus is
crucial for virulence as evidenced by the avirulence of unencapsulated pneumococci. The anti-
phagocytic nature of the capsule has been demonstrated (Jonsson  eta!., 1985) and the formation of
antibodies to the capsule gave rise to the serotype classification system for the pneumococci. Cur-
rently around 90 capsular types have been identified.
The cell wall of the pneumococcus is composed of peptidoglycan (Figure 1-7). Attached to this are
polysaccharide chains of teichoic acid and embedded in the peptidoglycan is lipoteichoic acid
which is attached to the plasma membrane. The cell wall mediates attachment to cells of the lung
(Geelen el a!., 1993) while the phosphorylcholine binds other protein motifs to the surface (Gosink
1-38et a!., 2000). The cell wall is partly responsible for initiating the inflammatory response (Knapp el
a!., 2004).
1.6.3.2 Pneumococcal Enzymes
S. pneumoniae has been known to produce a neuraminidase for some time (Kelly et a!., 1967).
Purification of the neuraminidase has been carried out (Stahl and O'Toole, 1972), and work has
revealed that three distinct neuraminidase's are present in S. pneumoniae (Camara et a!., 1991;
Shakhnovich et a!., 2002). Recently a mutantS. pneumoniae type has been produced by insertion-
deletion that does not express the neuraminidase A gene. Upon i.p. challenge infection studies the
deletion of neuraminidase A was found to have no effect on the survival time of the mice (Berry
and Paton, 2000). However a different model involving intranasal instillation in chinchilla exam-
ined the persistence time in the nasopharynx of a wild type S. pneumoniae strain compared to that
of a neuraminidase knockout strain and found that the neuraminidase knockout was more rapidly
cleared from the nasopharynx (Tong et a!., 2000). More recently it has been shown that the neu-
raminidase produced by the pneumococcus deacylates the lipopolysaccharide of  Neisseria
meningitidis and Haemophi!us influenzae thereby aiding the pneumococcus' colonisation of the
upper respiratory tract (Shakhnovich et a!., 2002).
Streptococcus pneumoniae also produces hyaluronidase. It is proposed that hyaluronidase may be
involved in the degradation of connective tissue since hyaluronic acid is a major component of this
type of tissue (Hynes and Walton, 2000). In addition hyaluronidase was one of the genes identified
from a signature tagged mutagenesis screen for genes important for infection (ITava and Camilli,
2002). However more recently the elucidation of a new role for hyaluronan in the DC:T interaction
(Levesque and Haynes, 2001; Mummert et a!., 2002; Termeer et a!., 2003) has developed the
possibility of another role for hyaluronidase as a potential immunomodulator.
1.6.3.3 Choline binding proteins
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Overview of the pneumococcal cell wall
1-40Pneumococcal surface protein A (pspA) has been studied largely as a potential vaccine candidate
since it is protein found in all strains of S. pneumoniae (Cram et a!., 1990) and is sufficiently
conserved between strains that protective antibodies induced to PspA are protective against all
strains (McDaniel et a!., 1991). As such the focus on the function of PspA in vivo has been ne-
glected to some degree. PsaA is a metal binding component of an ABC transporter and it has also
been observed that PspA is able to inhibit complement activation (Tu et al., 1999) and can act as a
lactoferrin binding receptor (Hammerschmidt et a!., 1999).
Similar to pspA, Pneumococcal surface adhesin A (PsaA) has been studied largely as a potential
vaccine candidate and has proven to be protective for both invasive disease but also carriage
(Talkington et a!., 1996). PsaA was originally shown to be homologous to other bacterial adhesin
molecules (Sampson et al., 1994) and this function was later confirmed (Berry and Paton, 1996).
Choline binding protein A (CbpA) has been proposed to be involved in cell binding (Rosenow  et
a!., 1997) although knockout studies have not revealed a crucial role in virulence (Berry and Paton,
2000) but a crucial role in sepsis has been demonstrated (lannelli eta!., 2004). Furthermore CbpA
under the alternative name of SpsA, has been shown to bind to secretory IgA (Hanimerschmidt  et
a!., 1997). PspC (CbpA, SpsA) has also been shown to inhibit complement activation on the sur-
face of S. pneumoniae by binding complement inhibitory factor H (Dave et a!., 2004).
1.6.3.4 Others
Production of hydrogen peroxide has been shown to have a similar effect to neuraminidase in
inhibiting the colonisation of the respiratory tract by other pathogen's (Pericone et a!., 2000) al-
though its mechanism is distinct since hydrogen peroxide is directly toxic to the other organisms.
S. pneumoniae has been shown to produce an IgA protease (Male, 1979). This may degrade the
IgA that is present on mucosal surfaces and thereby aid infection by enhancing pneumococcal
attachment to the epithelium (Weiser eta!., 2003).
1-4117 Pneumolysin
1.7.1	 Introduction to Pneumolysin
Although pneumolysin is a virulence factor produced by the pneumococcus it will be considered in
a separate section. Pneumolysin was identified due to its hemolytic properties (Sutliff and Zofflito,
1968). Subsequent studies have revealed that pneumolysin is found in all virulent strains of S.
pneumoniae and that pneumolysin is a member of a group of toxins that have sequence, structural
and functional homology (Billington eta!., 2000). This group has had a variety of names through-
out its history and debate continues over the most appropriate however here they shall be referred
to as the Cholesterol Dependent Cytolysin's (CDC's) (Figure 1-8).
1.7.2 Cholesterol Dependent Cytolysins
Prior to discussing pneumolysin itself, I will give an overview of some relevant findings from
research carried out using the other CDCs. While many of the CDC's have been found to be essen-
tial for pathogenesis of their host bacterium (Berry et aL, 1989; Jost et aL, 1999; Kimoto et at,
2003; Limbago et al., 2000; Mengaud et a!., 1989; Nagamune et at, 2000), and many have been
found to have effects on host immune cells, (Bremm et at, 1984; Ito ea aL, 2003; Kimoto et a!.,
2003; Kohda et at, 2002; Macey et a!., 2001; O'Brien and Melville, 2004; Stassen et at, 2003)
some of the toxins have been studied in specific detail. One of the most studied CDC's is
perfringolysin (PFO) produced by Clostridium perfringens. Much of the research using this toxin
has focused on the structural aspects of the toxin and the mechanism of pore formation which we
will discuss later in this chapter however an area of interest to this thesis concerns the work that has
investigated the interaction of perfringolysin and cholesterol. In 1988 Ohno-Iwashita eta!. (Ohno-
Iwashita et at, 1988) demonstrated that perfnngolysin bound in two different ways to cell mem-
brane cholesterol; they found that there was high affinity and low affinity regions within the mem-
brane. In 1990 the same group showed that perfringolysin derivatives could be used as probes to
label membrane cholesterol (Ohno-Iwashita eta!., 1990) and then demonstrated that perflingolysin
1-42preferentially binds to areas of the membrane that are cholesterol rich (Ohno-Iwashita eta!., 1991).
The group went onto demonstrate that the cholesterol in these regions is sequestered to caveolae
(Fujimoto eta!., 1997) and then finally to show that perfringolysin binds preferentially to lipid raft
stmctures in cell membranes (Waheed eta!., 2001).
Related to this work is some investigation into the mechanism of action of the CDC, listeriolysin
(LLO) produced by Listeria monocytogenes. It has been shown that listeriolysin is internalised via
caveolae on host cells and this enables its action on intracellular processes (Coconnier  eta!., 2000).
Streptolysin 0 (SLO) produced by Streptococcus pyo genes, Streptococcus equisimilis  and Strepto-
coccus canis has been used as a cell permeabilising agent and much of the work on SLO reflects
this. For example the generation of pores in the membrane by SLO was shown to be a reversible
process when SLO is used at a low dose (Walev et a!., 2001; Walev eta!., 2002) and this process
was shown to be dependent on the fusion of the endomembrane with the cell membrane (McNeil et
a!., 2003). The functional relevance of the formation of these pores during infection with S.  pyogenes
was investigated after S. pyogenes was shown to manipulate keratinocyte signalling (Ruiz et a!.,
1998). Madden et a!. (Madden eta!., 2001) not only demonstrated that streptolysin 0 was found in
the detergent insoluble fraction of the cell (i.e. the lipid rafts) but also demonstrated that another
protein was introduced into the cell by streptolysin 0. This appeared to represent a Gram-positive
equivalent to the gram negative type III secretion mechanism. Upon further investigation the sec-
ond protein delivered into the cell was found to be NAD+ glycohydrolase which induced apoptosis
of the target cells (Bricker eta!., 2002) and streptolysin 0 was demonstrated to play an active role
in this process since substitution with perfringolysin abolished the translocation process (Meehl
and Caparon, 2004).
1.7.2.1 Structure and Pore Formation of CDC's
Pneumolysin was first cloned and expressed in 1986 (Paton eta!., 1986) and the gene was sequenced
in 1987 (Walker eta!., 1987). These studies revealed that pneumolysin is a 53kDa peptide. Homol-
ogy studies to other members of the CDC's have shown that pneumolysin's closest relative within
the family is Intermedilysin (See Figure 1-8). There is no crystal structure available for pneumo-
lysin and so structural insights come from comparison with others CDC's for which the structure
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1-44has been solved (Figure 1-9). These studies suggest that pneumolysin consists of four domains
(Rossjohn et a!., 1998). An area of intense speculation concerns that of the mechanism of pore
formation by the CDC's and how this relates to the structure (Figure 1-10).
Before specific investigations in the area of pore formation began, the mechanism of pore forma-
tion was not known, but was speculated to involve the binding of monomers to the cell surface,
penetration into the membrane before lateral diffusion in the membrane led to the formation of
oligomers and subsequently pores (Morgan et al., 1993). Theories on the mechanism of pore for-
mation largely were derived from analogies made with other pore forming proteins. Bhakdi  et a!.
characterised the pore forming mechanism of complement (Tranum-Jensen et a!., 1978) and of
staphylococcus alpha toxin (Fussle eta!., 1981) and suggested that streptolysin 0 used a similar
membrane damaging mechanism (Bhakdi and Tranum-Jensen, 1984; Bhakdi eta!., 1985).
In 1996 the regions of streptolysin 0 that moved into the core of the cell membrane were identified
(Palmer eta!., 1996) and were shown to be in what became known as domain 3. In 1997 the crystal
structure of perfringolysin was solved which was the first CDC to be solved (Rossjohn  et a!.,
1997). The authors showed that perfringolysin is composed of four domains, each of distinct struc-
tural features. Previous experiments had demonstrated that domain four contains the cholesterol
binding site but that the highly conserved undecapeptide is close to, but is not, the actual binding
site for cholesterol (Vazquez-Boland eta!., 1989). By examining the crystal structure ofperfringolysin
Rossjohn et a!. were able to propose a model of membrane insertion. They proposed that the Trp
residue at point 464 functioned as a hydrophobic pocket and as such would be the cholesterol
binding site. Membrane penetration was proposed to result from the ejection of the undecapeptide
Trp rich loop from the pocket upon cholesterol binding to form a hydrophobic 'dagger' which
would then penetrate the membrane and form the membrane spanning region. Previously it was
shown that cholesterol binding results in partial insertion of this region of domain four into the
membrane (Nakamura eta!., 1995) and so this mechanism of action was consistent with Nakamura's
results but inconsistent with the results of Palmer (Palmer et a!., 1996) mentioned above since the
region they had demonstrated to insert into the membrane lay within domain 3 of Rossjohns crystal
structure of perfringolysin as opposed to domain 4. However, they further justified their model via
the assertion that the conformational change that occurs during membrane insertIon was not as
much as would be required for domain 3 to enter the membrane.
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Structure of a CDC
The schematic shows a crystalisation model of a CDC and the four domains identified.
Diagram courtesy of Graeme Cowan, University of Glasgow
1-46However, it was subsequently demonstrated that significant conformational change of domain 3 of
pneumolysin does occur and that both domains 3 and 4 partially insert into the membrane(Gilbert
et al., 1999). The formation of two b-sheets in domain 3 was demonstrated (Shatursky eta!., 1999;
Shepard eta!., 1998) and these were proposed to insert into the membrane.
Based on observations of incomplete rings of oligomers in membranes (Cowell eta!., 1978) Palmer
et a!. studied the formation of pores in the membranes in an effort to differentiate the order of pore
formation and assess whither oligomerisation occurs prior to insertion (Palmer eta!., 1998). Based
on their observations that incomplete rings seen as arcs could function as pores they proposed a
different theory to that proposed by Rossjohn. Palmer proposed that monomers bind to the cell
membrane and then insert as dimers into the membrane. Oligomerisation then occurs in the mem-
brane to build full rings.
Despite elucidation of the parts of the molecules that function within the membrane it there re-
mained questions over the order of the formation of these pores. The model of Rossjohn proposed
the formation of a pre-pore complex prior to insertion and as such held that oligomerisation pre-
ceded insertion (Rossjohn eta!., 1997)while Palmer suggested that oligomerisation occurred after
membrane insertion and that pores gradually enlarged over time. This was solved when it was
shown that oligomerisation occurs at 4°C despite insertion not occurring at this temperature (Shepard
et a!., 2000) which suggested oligomerisation occurs prior to insertion however they further dem-
onstrated (Heuck et a!., 2003) that uniform pores form and that these are large and do not increase
in size over time. The authors suggest that the role of domain 4 is in binding the cell membrane and
that it remains close to the cell surface.
In summary (Figure 1-10), the current data seems to reject the 'hydrophobic dagger' hypothesis in
favour of insertion of domains 3 and 4 into the membrane. Current data also suggests that
oligomerisation occurs prior to membrane insertion.
1.7.2.2 Role of Cholesterol in CDC cell binding
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	 .In 1991 the interaction of perfringolysin with cholesterol depleted membranes was studied and by
depleting the cholesterol in membranes it was demonstrated that cholesterol was necessary for the
interaction of perfringolysin with cell membranes (Ohno-Iwashita et a!., 1991). This confirmed
data produced previously by other groups (Alving eta!., 1979; Johnson et a!., 1980) which had led
to the acceptance that cholesterol was the cell membrane receptor of the CDC's. However other
work questioned this established dogma by demonstrating that cholesterol inhibited listeriolysin
cytolysis of cells but did not inhibit cell binding (Jacobs  et a!., 1998). Furthermore it had previ-
ously been suggested that cholesterol binding was required prior to monomer interaction however
it was shown that this is not the case (Gilbert et a!., 1998). Recently it was demonstrated that the
kinetics of cholesterol binding do not fit the kinetics of pore formation (Giddings et a!., 2003) and
that cholesterol depletion in a membrane does not inhibit oligomer formation. The accumulation of
this data suggested that the role of cholesterol was not as a cell receptor. Further data by Giddings
el a!. (Giddings et a!., 2003) led them to suggest that cholesterol is essential for the transition from
pre-pore to pore rather than for initial toxin binding.
1.7.2.3 Studies on the Trp rich region of the CDC's
The sequencing of pneumolysin made it possible to carry out site directed mutagenesis upon the
toxin. This has provided valuable insight into the function of the toxin  in vivo and has given infor-
mation regarding the mechanism of action of the toxin via in vitro studies. The Trp rich undecapeptide
(Figure 1-11) has been shown to be crucial for the hemolytic activity of the toxin and in particular
that mutation of the Trp in the 433 position results in a hemolytic activity of less than 1% when
compared to the wild type toxin (Hill et a!., 1994). Regarding the mechanism of pore formation
studies reported that mutating the three tryptophan residues in the undecapeptide of pneumolysin
did not reduce cell binding (Boulnois et a!., 1990). This was collaborated by the finding that muta-
tions in the Trp residues of listeriolysin were able to bind cells (Michel  eta!., 1990). However, this
data was challenged by work that showed that mutating the Trp residues in perfringolysin did result
in a loss of hemolytic activity and that a decrease in membrane binding was responsible for this
(Sekino-Suzuki et a!., 1996). Others examined the binding capacity of the F433 in pneumolysin
and found no decrease in cell binding ability (Korchev el a!., 1998) and this was recently consoli-
dated when Imaizumi et a!. published a study on pyolysin where they mutated the tryptophans in
1-49the undecapeptide. As expected this resulted in a dramatic decrease in hemolytic activity however
they also reported that these mutant's still bound to erythrocyte membranes (Imaizumi eta!., 2003).
By use of truncated pneumolysin constructs further examination of the role of each part of the
pneumolysin molecule on cell binding has been possible. It has been demonstrated that domain 4 is
capable of binding to cclls and cholesterol independently of the rest of the molecule (Baba et a!.,
2001). Furthermore that domains 1-3 require domain 4 for cell binding was demonstrated. These
studies also suggested a role for the C terminal region of the toxin in oligomerisation since a
construct with the C terminal removed is capable of binding to cells but is unable to cause hemolysis
which may result from an inability to oligomerise.
1.7.3 Functional studies on Pneumolysin
I have reviewed the literature concerning the biophysical properties ofpneumolysin, however many
functional studies have also been carried out to understand the role of the toxin in the pathogenesis
of Streptococcus pneumoniae infection. To this end the effects of purified pneumolysin in vitro on
a variety of cell types has been studied, however most insight has come from a large number of
studies that have examined the effect on pneumococcal infection of a variety of pneumolysin mu-
tants and knockout strains.
1.7.3.1 Pneumolysin and Complement
Pneumolysin has been demonstrated to activate the classical complement pathway (Paton et a!.,
1984). This was initially proposed to be the result of sequence similarity between PLY and acute
phase protein (Mitchell eta!., 1991), however this proposal was later retracted when the structure
of pneumolysin was examined based on a homology model with PFO (Rossjohn  eta!., 1998). The
homology model demonstrated that the similarity in sequence of acute phase protein and pneumo-
lysin could not occur since the sequences were in remote domains. This model did suggest an
alternative theory for complement activation by illustrating that pneumolysin may have a similar
shape to the Fc region of antibody.
1-50Figure 1-11
The Undecapeptide region of the CDCs
Listed is an alignment to show a comparison of the most highly conserved region of all the CDCs
sequenced. This region is the 'undecapeptide'. The pneumolysin mutant 'F433' is produced by
changing the first tryptophan residue into a phenylalanine.
1-511.7.3.2 The effect of pneumolysin on cells
The effects of pneumolysin upon human PMNL at low doses included inhibition of lcukocyte
migration and chemotaxis (Johnson eta!., 1981). A similar study later observed that pneumolysin
also inhibits the respiratory burst and bacterialcidal activity of PMNL's (Paton and Ferrante, 1983).
The focus of examining the effect of pneumolysin upon cells of the immune system was continued
with the demonstration that pneumolysin was able to inhibit the  in vitro proliferation of human
lymphocytes (Ferrante et al., 1984) and then again with the demonstration that pneumolysin was
able to inhibit the respiratory burst of monocytes (Nandoskar et aL, 1986). It has been demon-
strated that S. pneumoniae is able to induce apoptosis and necrosis of neutrophils (Zysk et a!.,
2000) while more detailed studies have recently been carried out by Cockeran et a!. who have
investigated the effect of purified pneumolysin upon neutrophils. They have demonstrated that
pneumolysin causes calcium ion flux in the cell membrane which results in the activation of pro-
inflammatory signalling (Cockeran eta!., 2001b). They have identified the result of this signalling
to be the increased production of prostaglandin E(2) and leukotriene B(4) (Cockeran  eta!., 200 Ia)
and an activation and release of IL-8 (Cockeran et a!., 2002b). Pneumolysin has been shown to
induce the release of nitric oxide from macrophages (Braun eta!., 1999) while others have investi-
gated the component of pneumolysin responsible for the induction of cytokines. They used a trun-
cated pneumolysin that lacked hemolytic activity. The intact IFN-g inducing ability of the truncate
shows this activity of pneumolysin is independent from the cytolytic component of the molecule
(Baba eta!., 2002).
1.7.3.3 In vivo studies on pneumolysin
These in vitro studies have been interesting and informative up to a point, however it is in vivo
studies that have particularly given insight into the role of pneumolysin in pneumococcal
pathogenesis. In 1989 Berry et a!. made a mutant version of the type 2 wild type Streptococcus
pneumoniae that did not contain a functional pneumolysin gene (Berry et a!., 1989). When inocu-
1-52lated with a lethal dose via the intranasal or intraperitoneal route the mutant infected mice showed
an increased survival time compared to the wild type infected mice, which suggested that pneumo-
lysin may have an important role in pathogenesis. A similar experiment (Berry  et a!., 1992) was
carried out in type 3 pneumococcus with the same results which confirmed that the decreased
virulence of strains lacking pneumolysin was not strain dependent.
Following these studies the necessity of pneumolysin within each pathogenesis setting has been
examined by different researchers. The effect of the different parts of pneumolysin upon infection
via the i.p. route was examined by using pneumococci with point mutations in pneumolysin at Asp
385 to Asn which disables the complement activating properties of pneumolysin (Berry et a!.,
1995). This was found to have no effect on virulence when administered by the i.p. route. Another
mutation of Trp 433 to Phe abolished cytolytic ability of pneumolysin. This was found to increase
the survival time of mice. This experiment was repeated in 1999 but the different roles for the
cytolytic and complement activating parts had by then been elucidated for the intranasal and intrat-
racheal routes so in this experiment they elucidated whither there was a third activity of pneumo-
lysin apart from the cytolytic and complement activating activities. They demonstrated that pneu-
mococci lacking both complement activating and cytolytic activities had a virulence greater than
pneumococci deficient in pneumolysin thereby proving that pneumolysin has other activities be-
sides the cytolytic and complement activating activities (Berry et a!., 1999). The effect of pneumo-
lysin upon colonisation was examined by comparing the ability of a type 14 strain that lacked PLY
to colonise the upper respiratory tract with the wild type strain. No difference in colonising a1oility
or persistence over a four week period was noted between the two strains (Rubins  eta!., 1998).
Pneumolysin has been shown to play an important role in eye infection with S. pneumoniae (Johnson
et al., 1992) (Ng eta!., 2002) yet appears to have no role in ear infections (Sato eta!., 1996). Using
strains deficient in pneumolysin two different studies have shown that pneumolysin during men-
ingitis has a role in virulence but not a crucial one (Friedland  eta!., 1995) (Wellmer eta!., 2002). In
an attempt to understand the role of pneumolysin during bacteraemia Benton et a!. (Benton et a!.,
1995) injected a pneumolysin deficient strain of pneumococci intravenously into mice. They found
that pneumolysin played a crucial role in the development of acute sepsis instead of chronic bacter-
aemia. In an attempt to decipher which part of the pneumolysin molecule was responsible for
potentially combating the host response a pneumococcal strain that contained a construct in which
1- 53pneumolysin lacked either the hemolytic or complement activating properties was used (Benton et
a!., 1997). These studies showed that these mutated strains of the pneumococcus had a similar
virulence to the wild type strain, suggesting that another part of the pneumolysin molecule was
responsible for allowing the development of acute sepsis over chronic bacteraemia. In a further
study the key host resistance mechanism that functions to prevent pneumolysin deficient strains
progressing to acute sepsis was shown to be TNF-a (Benton et a!., 1998).
The effect of pneumolysin deficiency during pneumococcal infection of the lung was found to be
that in mice infected with pneumolysin deficient pneumococci the pneumococci grew more slowly
and did not appear in the blood as quickly (Canvin eta!., 1995). An examination of the histology of
the lung revealed that the pathology induced by pneumolysin deficient strains was delayed and less
severe compared to the wild type. Notably the neutrophil influx was less dramatic in pneumolysin
deficient infected mice. These findings were extended by utilising pneumococcal strains engi-
neered with pneumolysin that lacked either cytolytic or complement activating ability. By intratra-
cheal installation of pneumococci the development of lobar pneumonia occurred and it was dem-
onstrated that both the cytolytic and complement activating properties of pneumolysin contribute
to virulence although an additive effect was not observed for double mutants (Rubins  eta!., 1995).
Instillation of the same bacteria by the intranasal route to induce bronchopneumonia was found to
reveal that again both properties of pneumolysin were important although they are important at
different stages of infection for each type of pneumonia (Alexander et a!., 1998). In addition the
authors noticed that pneumococci possessing both cytolytic and complement deficiencies are not
avirulent which led them to suggest that pneumolysin possesses some sort of 'sub-lytic' function
that is important also. In 2000 Kadioglu et a!. published further details on the processes that occur
during the development ofpneumococcal induced bronchopneumonia (Kadioglu eta!., 2000). They
compared the cells present in the lungs after 24 hours infection with wild type S.  pneumoniae or
with a pneumolysin deficient strain. The wild type infection caused an increase in PMNL and a
decrease in macrophages with the number of lymphocytes remaining unchanged, while the pneu-
molysin deficient strain caused the same changes but to a lesser extent. While the number of lym-
phocytes remained unchanged in the tissue as a whole, immunohistochemical analysis showed that
in lungs infected with wild type pneumococci the number of T cells increased dramatically around
inflamed bronchioles with the number of B cells also increasing later in the time course and not to
the same degree. This change in lymphocyte distribution was also observed when lungs were in-
1-54fected with the pneumolysin deficient strain but changes occurred later and to a much lesser extent.
From their observation Kadioglu et a!. were able to draw some novel conclusions. They observed
that despite the influx of neutrophils into the lung during the first 12 hours of infection, this influx
does not prevent the rapid growth of wild type pneumococci observed to occur at 16 hours yet the
neutrophils do prevent the rapid growth ofpneumolysin deficient strains. This means that pneumo-
lysin is potentially responsible for the inactivation of neutrophils. Previously neutrophils had been
considered to be responsible for the cessation ofpneumococcal growth in the lungs but here Kadioglu
was able to demonstrate that it is the influx of T cells into the inflamed areas that coincides with
cessation of pneumococcal growth.
In a follow up study the group attempted to elucidate the effect of the cytolytic and complement
activating components of pneumolysin upon the cellular infiltrate into the lung (Jounblat  et a!.,
2003). While difference in bacterial growth during the early hours of infection were noted, the
differences did not persist, meaning that the most significant differences discovered by this study
came from examining the histology during infection. Pneumococci containing a pneumolysin con-
struct that lacked complement activating activities recruited neutrophils to the same degree as the
wild type infection but did not cause any alteration of the T cell distribution. In contrast pneumo-
cocci with cytolytic deficient pneumolysin did not recruit neutrophils to the same degree as the
wild type infection yet the pattern of T cell distribution was the same as the wild type.
1-551.8 Conclusion
In this chapter an overview of some of the mechanisms of immunomodulation used by pathogen's
has been given. This has allowed the recognition of the convergent mechanisms of
immunomodulation. Therefore as the pneumococcus was considered, an expectation that it may
modulate complement, phagocytosis, cytokine production, B cells and T cells had formed. Some of
these expectations were fulfilled as the immunomodulatory mechanisms of the pneumococcus were
examined. Furthermore as the immunomodulatory effect of pneumolysin upon T cells is consid-
ered an awareness of some of the potential mechanisms has been generated. In this chapter a re-
view of the immune response to the pneumococcus has also been given that has focused on the
recently elucidated adaptive immune response. Finally the toxin pneumolysin has itself been con-
sidered with particular emphasis on its role in infection and mechanism of action.
It is the aim of this thesis to determine if pneumolysin is able to exert an immunomodulatory effect
upon CD4 T cells in vitro and the mechanism of action used. Furthermore a demonstration of these
effects in vivo and an elucidation of the potential consequence of these effects for pneumococcal
pathogenesis will also be discussed.
1-561.9 Aims
The aim of this thesis is to examine a potential immunomodulatory mechanism used by the pneu-
mococcus to modulate the adaptive immune response. I will examine the in vitro immunomodulatory
ability of the toxin pneumolysin and will attempt to dissect the mechanism of action of pneumo-
lysin upon T cells. I will then procecd to examine the ability of the toxin to accomplish in vivo what
it does in vitro.
1- 572 Materials and Methods
2-I2.1 DNA preparation
Oligonucleotide primers and Polymerase Chain Reaction (PCR)
Primers used for PCR or for sequencing were obtained from Sigma Genosys. Figure 2-1 shows the
sequences and names of the primers. PCRs (Rush et al., 2002) were performed using an automated
PCR machine (Hybaid, PCR Express). The program used for all PCRs conducted, utilised a cycle
of 94°C for 30 seconds, a 55°C annealing stage for 45 seconds and finally a 90 second stage at
72°C. lOx thermopol buffer (New England Biolabs) was diluted 1:10 in the reaction. dNTP's
(Promega) were used at 10mM. Primers were used at Sopmollml. lunit of the polymerase Vent
(NEB) was used per reaction. lOOng of the F433 template plasmid was used per reaction. The
remaining volume was made up with autoclaved distilled water.
Agarose Gel
A 1% agarose gel was made by dissolving agarose (Invitrogen) in TAE (Amresco) and, after heat-
ing, Ethidium Bromide (Sigma) was added to 0.5mg/mi. The gel was cast and the samples loaded
(total volume; iOml per well) with an equal volume of DNA loading buffer (see appendix 1). A
lkb+ DNA ladder from Invitrogen was used to estimate fragment length and is suitable for sizing
linear double stranded DNA from 1 OObp - 12kb. The ladder has twenty bands, twelve of which
range from 1000 bp to 12,000 bp in 1000-bp steps and eight bands ranging in size from 100 to 1650
bp. The 1650-bp band represents 8% of the total ladder and is therefore brighter than the other
bands and so can be clearly distinguished on a gel. Electrophoresis was carried out in TAE buffer at
80 volts until the ladder was sufficiently spread over the length of the gel. Gels were photographed
using UV light.
Purification, digestion and amplification of DNA
2-2Primer name	 Primer sequence
4T	 GTT GAT CGT GCT CCG ATG AC
4U	 TAT ACA GTC AGC GTA GAC GC
4V	 CAA TAC AGA AGT GAA GGC GG
9Y	 CGG GAT CCG GCA AAT AAA GCA
________________________ GTA AAT GAC TTT
9Z	 GAC GGA OCT CGA CTA GTC ATT
__________________________ TTC TAC CTT ATC
Figure 2-1
Primers used for FCR and sequencing
2-3In order to isolate PCR or digestion products from the contaminants and from the gel itself the
required band was cut from the Agarose gel under ultraviolet light and purified using a Qiagen
QlAquick Gel Extraction Kit following the manufacturers instructions.
Digestions of PCR products and plasmid vectors were carried out using BAM Hi/Sac I restriction
enzymes (Promega) at 0.5 units/mi. Multicore buffer (Promega) was used to buffer the reaction and
distilled autoclaved water was used to make up the remaining volume.
Small scale plasmid DNA amplification was carried out using the Qiagen QlAprep Miniprep Kit.
Manufacturers instructions were followed throughout.
Large scale plasmid DNA amplification was carried out using the Qiagen Maxiprep Kit. Manufac-
turers instructions were followed throughout.
Ligation and Transformation
When ligating into the pCR 4 TOPO plasmid (Invitrogen), addition of 3' A-Overhangs to the PCR
products was necessary since Vent polymerase was used in the PCR does not leave these present. 3'
A-Overhang addition was carried out on PCR products following the procedure of the TOPO TA
Cloning Kit. This involves incubating the PCR products with Taq for 15 minutes at 72°C along
with Taq buffer.
For ligations of both pCR 4 TOPO and pET33b+ (Novagen), ligating incubations were performed
at room temperature for 6 hours. The ligation mixture consisted of a vector to insert molar ratio of
1:3 using SOng of vector per ligation. lOx ligation buffer was diluted 1:10 and 3 units of DNA
ligase (Promega) was used per reaction. The remaining volume was made up with autoclaved
distilled water.
When transforming TOP 10 E. coli, 1-SOng of ligation was transformed into TOP 10 (DH5a) E. coil
using the standard protocol of the TOPO TA Cloning Kit. After addition of the ligation, E.coii were
incubated on ice for 5-30 minutes and then heat shocked at 42°C for 30 seconds. SOC medium (see
2-4appendix 1) was added and the cells were left shaking for 1 hour at 3 7°C. The transformation was
then plated on ampicillin or kanamycin agar plates and incubated overnight at 3 7°C.
When transforming BL21 E. coli (Stratagene), 1-5Ong of plasmid was added to E. coli prepared
with 13-ME (Sigma). This was left on ice for 30 minutes before heat shocking the cells at 42°C for
45 seconds. The cells were added to ice for 2 minutes prior to receiving O.9m1 of SOC medium (see
appendix 1) and being incubated shaking for 1 hour at 37°C. The transformation was then plated on
kanamycin agar plates and incubated overnight at 37°C.
Luria Broth (LB) Agar Plates
LB (Sigma) was made according to the manufacturers instructions. 1% Agar (Duchefa) was added
to this prior to autoclaving. Upon reheating kanamycin (Sigma) was added to 30mg/mi or ampicil-
lin (Sigma) to lOOmg/ml. Using aseptic technique the medium was then poured into sterile petri
dishes (Bibby Sterelin) and left to set. When preparing overnight cultures a single colony was
selected and grown in LB with kanamycin overnight and then purified on a small or large scale.
2-52.2 Protein Preparation
Growth and induction of E. coil
BL2 1 E. coli were streaked onto an LB agar plate containing kanamycin and incubated overnight at
37°C. A single colony was picked and grown overnight at 37°C in LB with kanamycin to ensure
vector pressure was applied. A small amount (lOml) of the overnight culture was inoculated into 1
litre of LB with kanamycin which was grown at 37°C to mid log phase (Optical Density 600nm of
0.6 m, measured using a UV/Vis Spectrophotometer UV/2 [Unicam]) before being induced with
1mM isopropyl-b-d-thiogalactopyranoside (IPTG) (Melford Laboratories Ltd) for 1.5 hours. The
bacteria were then harvested by centrifugation at 4°C and 5000G for 7 minutes in a Sigma Labora-
toly Centrifuge 4K1 5 centrifuge. The bacteria were resuspended at 5mIIg of bacteria in 'bugbuster'
(Novagen) and lyzozyme (Sigma) added to lmg/ml and lml of benzonase (Novagen) per ml of
suspension. This was then put on ice for 30 minutes prior to shaking on a desktop shaker for 20
minutes at room temperature. The supematant was harvested by centrifugation at 4°C for 30 min-
utes at 14000 RCF and then 0.2mm filtered using a syringe tip filter (Satonus).
XL! 0 E. coli were streaked onto an LB agar plate containing ampicillin and inoculated overnight at
37°C. A single colony was picked and grown overnight at 37°C in LB broth with ampicillin. A
small amount (1 OmI) of the overnight culture was inoculated into 1 litre of LB with ampicillin
which was grown at 37°C to mid log phase (OD600nm of 0.6) before being induced with 1mM
IPTG for 1.5 hours. The bacteria were then harvested by centrifugation at 4°C at a speed of 5000G
for 7 minutes in a Sigma Laboratory Centrifuge 4K15 centrifuge. The bacteria were resuspended in
20m1 PBS (see Appendix 1) for every litre of original culture before being disrupted in a Constant
Systems cell disrupter at a pressure of l2Kpsi. The supernatant was harvested by centrifugation at
4°C for 30 minutes at 14000 RCF.
2.2.1 Chromatography
2-6To perform Metal Chelate Chromatography (MCC), the BioCAD 700E perfusion chromatography
workstation (Perseptive Systems) was equipped with a metal chelate co1unm to enable the extrac-
tion of the proteins tagged with six histidine residues.
The column used was 100mm in length with a diameter of 4.6mm and a volume of 1 .662ml. The
flow rate was set at 4mllmin throughout. The column was charged with nickel sulphate initially by
the following protocol; 30 column volumes (CV) of 10% 500mM EDTA was run through the
column to clean it then 2OCV of 100% 1120 to wash it. The column was then charged with 1 OCV of
100% 100mM nickel sulphate and washed with 1OCV 6.6% 3M NaC1.
The column was then equilibrated using a blend of 90% 50mM Hepes and 10% 3M NaC1 for 10
CV then 5 CV of 25% 2M Imidazole, 10% 50mM Hepes and 3M NaC1. Finally the blend was
reduced to 10 CV 0.1% 2M Imidazole, 89.9% Hepes, 10% 3MNaCI.
The crude preparation of sample was loaded on in 5m1 amounts. A minimum of 5m1 and maximum
of lOml of crude preparation was loaded at any point.
The column was then washed first with 5 CV of a blend of 0.5% 2M Imidazole, 83% 50mM Hepes,
16.5% 3M NaCl followed by 10 CV of 1.0% 2M Imidazole, 68% 50mM Hepes, 15% 3M NaCI,
15% 100% EtOH and finally with 10 CV of 2.5% 2M Imidazole, 66.5% 50mM Hepes, 15% 3M
NaCI, 15% 100% EtOH.
The bound protein was then eluted by increasing concentrations of imidazole. The starting concen-
tration was 100mM which corresponds to 5% 2M Imidazole 95% 1120. 5 CV were run of each
concentration and 50mM increments were used up to 300mM before a final wash with 500mM
imidazole.
To perform Hydrophobic Interaction chromatography (HIC), the BioCAD 700E perfusion chroma-
tography workstation was equipped with a column containing POROS 2OPE (Phenyl Ether) from
Applied Biosystems that enable the extraction of the proteins according to their surface exposed
hydrophobic groups.
2-7The column used was 100mm in length with a diameter of 4.6mm and a volume of l.66m1. The
flow rate was set at 4ml/ml throughout.
The column was then equilibrated using a blend of 50% PBS-NaCl and  50% 1M NaC1 for 14 CV.
The crude preparation of sample was loaded on in 5ml amounts. A minimum of 5m1 and maximum
of 1 Oml of crude preparation was loaded at any point. The column was then washed and the protein
eluted with a starting concentration of a blend of 50% PBS-NaC1 and 50% IM NaCl rising to 100%
PBS-NaC1 over 9 CV then 1OCV of 100% 1120.
To perform Anion Exchange Chromatography, the BioCAD 700E perfusion chromatography
workstation was equipped with a HQ non porous column to enable the extraction of the proteins
according to their surface charge.
The column used was 4.6mm in length with a diameter of 50mm and a volume of 0.83 imi. The
flow rate was set at 5mllml throughout.
The column was equilibrated with 3 CV of 1120, then 3 CV of PBS-NaC1, then 3 CV of 50% PBS-
NaC1 and 50% 3M NaC1, then S3 CV ofPBS-NaCl. The sample received from HIC was loaded on
in Sml amounts. The column was then washed with 10 CV of PBS-NaC1. Finally the protein was
eluted with a gradient starting at 100% PBS-NaCl and rising to 50% PBS-NaG! and 50% 3M NaC!
over 30 C V.
Where required samples were concentrated using minicom sample concentrators (Amicon,
Millipore).
2-82.2.2 Quality Control
SDS-PAGE
To assess the purity of proteins Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) was carried out. Apparatus to cast the gel was from Biorad. The separating gel (see Appen-
dix 1) was poured to fill 3/4 of the gel space and left to set. After 1 hour the stacking gel (see
Appendix 1) was carefully layered on top of the separating gel and a comb was inserted. This was
left to set for 1 hour before filling the tank with running buffer (see Appendix 1). Samples were
prepared by boiling an equal amount of sample and sample buffer (see Appendix 1) in an eppendorf
tube for 5 minutes immediately before addition of 1 5m1 of each sample to different wells of the gel.
For every gel 6m1 of Biorad Kaleidoscope marker was added to one well of every gel. The gel was
run at 100V for 2 hours.
The gel was then carefully removed and left gently shaking in Coomassie stain (see Appendix 1)
for 3/4 hour and then left in destain (see Appendix 1) until it was clear.
Biorad Kaleidoscope Prestained standards were used in all SDS PAGE gels. These standards have
a range of 200kDa - 6.5kDa.
Western Blotting
SDS PAGE gels were equilibrated in transfer buffer (see Appendix 1). Protein was transferred from
the gel, using a Bio Rad transfer tank, to Hybond-C super membrane (Amersham Life Sciences).
The gel was sandwiched between filter paper and fibre pads and put into the transfer tank with
transfer buffer. A magnetic stirrer and ice pack in the tank ensured the temperature remained con-
stant within the tank during the transfer which was conducted at 80 V for 2 hours.
After transfer the membrane was stained with the protein stain Ponceu S (Amersham Bioscience)
to check the transfer had been successful. The membrane was then blocked in 3% skimmed milk
(Marvel, Premier Brands, UK) in Tris NaCL (see Appendix 1) for 1 hour or overnight at room
2-9temperature. The membrane was then incubated for 2-3 hours at 37°C or overnight at room tem-
perature in 1:1000 dilution of anti-pneumolysin antibody (made in rabbits and purified by Tim
Mitchell) in 3% skimmed milk Tris NaC1. After washing the membrane four times in Tris NaC1 the
membrane was blotted with the secondary antibody (1:1000 dilution in 3% skimmed milk Tn
NaCl; anti rabbit Ig I-IRP-linked whole antibody from donkey[Amersham]) for 1 hour at 37°C.
After washing a further 4 times with Tris NaC1 the membrane was transferred to developer solution
(see Appendix 1) for 15 minutes and then washed in water and left to dry.
Absorbance Assay
To assess the nucleic acid and protein content of each fraction an absorbance assay was carried out
on each sample. An aliquot of each fraction was scanned on the spectrophotometer to give the 260,
280 and 320 nm reading. If the sample contained aggregates then this would be noticed in the 320
reading. Fractions suitable for pooling for further examination are those with a 280 value larger
than the 260 value and with a 320 value close to 0.
Prior to use quartz cuvettes (Helima) were cleaned using 5% Decon (Decon) and 5% Acetic acid
(BDH) and then rinsed with PBS (see Appendix 1). A UV/Vis Spectrophotometer UV/2 (Unicam)
was programmed to asses the sample absorbance at intervals from 220nm - 320nm. The baseline
was set using PBS. lOOml of sample was added to one cuvette and the scan was carried out on this
sample. The concentration of pneumolysin in the sample if it is pure pneumolysin can be deter-
mined using the extinction co-efficient which for pneumolysin is  0.75.
Hemolytic Assay
To assess the hemolytic activity of pneumolysin red blood cells were prepared by centrifuging imi
of defibrinated sheep blood (E&O Laboratories) at 13000 RPM for 4 minutes. 200m1 of the re-
maining blood pellet is resuspended in lOmi of PBS to make a 2% solution. 50m1 PBS (see Appen-
dix 1) was aliquoted into every well of a 96 well round bottomed plate (Nunc). 50m1 of the sample
2 - 10is added to the first well and doubly diluted across the row using new pipette tips for each dilution.
50m1 of the blood cell suspension was added to each well and incubated at 37°C for 30 minutes and
then left at room temperature until the PBS control wells become pelleted in the base of the well.
The hemolytic activity of the sample was determined by recording the well in which the pellet
formed was half the size of the PBS/control pellet. Hemolytic activity was then calculated accord-
ing to a predefined chart (see Figure 2-2).
Bradford Assay
This assay detects the quantity of protein in a sample based on the change in absorbance that occurs
when protein binds to the reagent Coomassie Brilliant Blue (Sigma). Absorbance shifts from 465
to 595nm.
Standards were made using ovalbumin protein (grade V - Sigma) from 200ug/ml to l500ug/ml.
1 Oul of standard was added in triplicate to selected wells of a 96 well flat bottomed plate. 1 Oul of
sample was also added in triplicate to the first well of the 96 well plate and doubly diluted in PBS
down the plate. Absorbance was measured at 595nm using a Dynex plate reader and the concentra-
tion of protein in the samples calculated relative to the standards.
Endotoxin Assay
Endotoxin levels were measured using the Limulus Amebocyte Lysate (LAL) Kinetic QCL kit
from BioWhittaker. Throughout this assay endotoxin free tubes and tips were used. Endotoxin
standard (Bio Whittaker) was reconstituted in endotoxin free water and then vortexed for 15 min-
utes. To make the standard curve, the endotoxin standard was diluted in water to give standards of
50, 5, 0.5, 0.05, 0.005 IU/ml (international units). Vortexing for 1 minute was necessary between
each dilution. Samples were diluted in a similar manner to give a range of concentrations between
1:100 and 1:1000000 dilution. Standards and samples are loaded onto a 96 well plate in duplicate
and appropriate 'spikes' of 51U/ml added to determine assay interference levels. Finally the lysate
2-11Well Number	 Titre (HU/mi)	 Well Number	 Titre HU/ml
1	 40	 13	 1.6x 10
2	 80	 14	 3.2x 10
3	 160	 15	 6.4x 10
4	 320	 16	 1.3x 106
5	 640	 17	 2.6x 10
6	 1280	 18	 5.2x 10
7	 2560	 19	 lx 1O
8	 5120	 20	 2x108
9	 lx 10	 21	 4x 108
10	 2x 10	 22	 8x 108
11	 4x104	 23	 I.6x 10
12	 8x 10	 14	 3.2x 10
Figure 2-2
Calculation table for hemolytic assay
2 - 12is added to the plate and the OD 405nm reading at 37°C was taken every 2 minutes for 1.5 hours
using an Ultra Microplate Reader from Biotek Instruments.
2 - 132.3 Tissue Culture
Mice
Mice homozygous for the cOVA peptide 323-339/I-Ad-specific DO 11.10 TcR transgenes (detected
using the clonotypic mAb KJ1.26) on the BALB/c background (Murphy et a!., 1990) were used
throughout when reference is given to DO 11.10 mice. On average the percentage transgenic T cells
in a lymph node preparation from these mice is 40% as measured by flow cytometry (see Figure 2-
3). BALB/c mice were purchased from Harlan-Olac. All animals were specified pathogen free and
were maintained under standard animal house conditions with free access to both water and stand-
ard rodent pellets at the University of Glasgow CRF in accordance with local and Home Office
regulations.
Pneumococcal strains
The wild-type S. pneumoniae strain used was serotype 2 strain D39, NCTC 7466 (National Collec-
tion of Type Cultures, London, UK). The pneumolysin negative mutant used, PLY-, was made in
the lab of Tim Mitchell (University of Glasgow). Pneumococci were grown in Brain Heart Infusion
Broth (BHI - made to manufacturers specification - [Oxoid]) to log phase and then frozen at —70°C
in 20% glycerol. 'Where required, eiythromycin selection was used at lug/mI.
Viable counts were carried out by diluting the stock pneumococci in PBS (see Appendix 1) using
ten fold dilutions and plating three 20tl aliquots of each dilution onto a sector of a blood agar plate
that was divided into 6. The plates were incubated at 37°C overnight and colonies counted in each
sector where the spot had between 40-250 colonies. CFU was calculated as the number of colonies
multiplied by the dilution factor. The bacteria were used directly from the frozen stocks by washing
them with PBS and then diluting to the required CFU/ml in PBS.
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Figure 2-3
The percentage of transgenic CD4 T cells in a DO11.1O donor
The plots are of a lymph node preparation from a niave DO 11.10 mouse. Gate 1 is set around the
population of lymphocytes that represent 82%. Gate 2 is set around transgenic T cells (CD4^, KJ+)
and represents 40% of total cells. Gate 3 is set around CD4+ T cells and represents 55% of cells.
2-15Lymph node single cell suspension
The inguinal, mesenteric, superficial cervical, brachial and popliteal lymph nodes were removed
from mice and pooled. They were made into a single cell suspension by mashing with the rubber
end of a syringe and then passing through Nitex mesh (Cadisch Precision Meshes) and centrifuging
at 450G for 5 minutes before resuspending in complete RPMI (see Appendix 1).
Pneumococci: lymph node suspension co-culture
Co-culture of lymph node cell suspensions and pneumococci was carried out in 6 or 24 well plates
(Costar) depending upon the volume of cells required. If a proliferation assay was subsequently to
be set up then 6 well plates were used. 1 ml cultures of 1 x 106 lymphocytes were set up in 24 plates
or 5m1 cultures containing 5 x 106 lymphocytes when 6 well plates were used. Single cell lymph
node suspensions were made in complete RPMI without penlstrep (Gibco). Pneumococci were
inoculated into the cultures at 0 hours and incubated at 37°C,  5% Co2.
In some experiments bacteria were killed by addition of penicillin (Gibco) to 100U/ml, streptomy-
cm (Sigma) to 100mg/mi and gentamicin (Sigma) to 200ug/mi. At some points catalase (Sigma
C3155) was used at 2000 units/mi and Hepes (Gibco) at 25mM.
Thymidine Incorporation Assay
To measure the amount of DNA replication in a cell population, 200ml of cell suspension contain-
ing 2x 10 lymphocytes was plated into each well of a 96 well plate (Costar) (Garside eta!., 1995).
Cultures were incubated at 37°C , 5% CO2. 24 hours prior to harvesting, the cultures were pulsed
with lmCi/well 3F1-thymidine (Radionucleotide Dispensary, Western Infirmary, Glasgow). Plates
were harvested using a Tomtec cell harvester onto filter mats (Wallac) and 3H-thymidine incorpo-
ration measured on a Trilux liquid scintillation and luminescence counter (Perkin Elmer Life Sci-
ence).
2-16Cytokine Assay and ELISA
To measure the amount of specific cytokines produced by a cell population, imi of cell suspension
containing lx 106 lymphocytes was plated into a 24 well cell culture cluster plate (Costar). Cultures
were incubated at 37°C, 5% CO2. To harvest the medium for cytokine ELISA the medium was
removed from the culture cluster and centrifuged at 450G for 5 minutes in an eppendorf to allow
the supernatant to be removed. Supernatant was frozen at -20°C until further analysis.
ELISAs (Eaton et aL, 2003) were carried out using 96 well plates (Immunolon 4 HBX, Dynex)
which were coated with 50m1 of anti-IL-2 (1mg/mi) or anti-IFNg (1.5mg/mi) binding antibodies
(all Pharmingen) overnight at 4°C. Plates were washed with PBS/0.05% Tween, blocked with
PBS/10% FCS for lhr at 37°C, then washed and incubated with samples (50m1) and cytokine
standards (R&D Systems)(5Oml per well of 5ng/ml IL-2 or SOml of 8Ong/ml doubly diluted down
the plate in triplicate) at 4°C overnight. Plates were washed again, incubated with SOml biotinylated
anti-IL-2 (0.5mg/mi) or anti-IFNg (lug/mi) detection antibodies (all Pharmingen) for lhr at 37°C,
then washed and incubated with streptavidin peroxidase (1/1000) (Sigma) for lhr at 37°C. Plates
were then washed and TMB Microwell Peroxidase Substrate (Kirkegaard and Perry Laboratories)
was added. Enzymatic colour changes were analysed on a Dynex plate reader at 630nm.
Ovalbumin
Whole chicken ovalbumin protein (OVA - Fraction V) was obtained from Sigma and made to the
required stock concentration by dissolving in PBS (see Appendix 1) and was then 0.2mm filter
sterilised (Sartorius). Ovalbumin peptide of the fragment 323-339 was obtained from Genosys.
CFSE staining
To allow detection of cell division using the flow cytometer cells were stained using CFSE dye
(Lyons and Parish, 1994). Lymph node single cell suspensions were resuspended to 5 x l0 cells/mi
2 - 17in HBSS. 5-(and-6-) carboxyfluorescein diacetate, succinimidyl ester (5(6)-CFDA, or CFSE) (Mo-
lecular Probes) was added to give a concentration of 0.5mm CFDA. The CFDA was from a CFDA
SE Cell Tracer kit from Molecular Probes. The cells were incubated in the CFDA for 10 minutes at
37°C and then washed three times in HBSS.
Bone Marrow Derived Dendritic Cells (BMDC)
GMCSF was made by growing the x63-GMCSF myeloma cell line for 2-3 days in complete IMDM
(see Appendix 1) supplemented with lmg/ml G418 (Sigma) and then harvesting the supernatant.
Dendritic cells were cultured from bone marrow by a method adapted from Lutz et a!. (Lutz et al.,
1999). The femur and tibia were removed aseptically from BALB/c mice and sterilised with etha-
nol. The end of each bone were removed and the bone marrow flushed out using a 26 gauge needle
(BDH Microlance) and syringe filled with RPM! 1640. After washing twice the cells were
resuspended in complete RPMI (see Appendix 1) containing 5% GMCSF at 4x 10 cells/mi. 2m1
of this was added to each well of a 6 well culture cluster (Coming Costar) and the cultures were
incubated at 37°C , 5% CO2. 3 days after setting up the cultures 2m1 more of 5% GMCSF was
added to each well. 5 days after setting up the cultures 2ml of medium was removed from each well
and a fresh 2ml was added.
T cell purification
Lymph node single cell suspensions were resuspended to 2x 10 lymphocyte/mi in MACS buffer
(see Appendix 1). To remove unwanted cell populations, 25m1 rat anti mouse-CD8, 7Oml rat anti
mouse-CD 19 and SOml rat anti mouse-CDllb (all Serotec) were added per ml of the lymphocyte
suspension. 60m1 rat anti mouse-CD 16/32 (Pharmingen) was also added (for antibody details see
Appendix 1). This was placed on ice for 10 minutes before washing twice in MACS buffer and
resuspending in MACS buffer at 2x 10 lymphocyte/mi. 200ml of goat anti rat IgG beads (Miltenyi
Biotec) was added for every ml of cell suspension and placed on ice for 10 minutes. The cells were
washed twice before being applied to a CS column (Miltenyi Biotec) fitted with a 23 gauge needle
as a flow regulator. The T cells came off in the flow through which was collected while the other
2 - 18cell types remained bound to the column. A purity of 95% or greater was routinely achieved as
determined by CD4 staining and flow cytometric analysis (Smith et a!., 2000).
DOl 1-GFP Hybridoma
D011-GFP T hybridoma cells ((Underhill et al., 1999)) are based on the conventional D011-b T
hybridoma that recognises amino acids 323-3 39 of OVA independent of co-stimulation. The DO IL-
GFP hybridoma had a plasmid introduced that contained the gene encoding GFP. This GFP gene is
regulated by an IL-2 promoter, which is activated by the binding of nuclear factor of activated T
cells (NFAT).
2 - 192.4 Cell Viability/Apoptosis Assays and Lipid Raft
detection
Trypan Blue Exclusion Assay
To test for cell viability the trypan blue exclusion assay was used since trypan blue is excluded
from viable cells. 30m1 of cell suspension was incubated with 3Oml of 0.4% trypan blue (Sigma).
The number of lymphocytes excluding trypan blue was assessed using an Improved Neubauer
Hemocytometer (Hawksley & Sons)
Annexin V/PT Assay
The Annexin V / Propidium Iodide assay was used to detect cell death and apoptosis. Annexin V
binds to phosphatidylserine which is exposed to the outer membrane of the cell as one of the early
signs of apoptosis. Viable cells exclude propidium iodide. An Annexin V-FITC apoptosis detec-
tion kit was purchased from Pharmingen and used as directed in the manufacturer's instructions.
After culturing cells were washed twice with cold PBS prior to resuspending at lx 106 cells/mI in
'binding buffer'. lx 1 0 of these cells were then incubated with 5ml of both Annexin V and Propidium
Iodide at room temperature for 15 minutes prior to analysis by flow cytometry.
Lactate Dehydrogenase (LDH)
The LDH assay was used to detect loss of cell membrane integrity and therefore viability. A 'Cytotox
96 non radioactive cytotoxicity Assay' kit was purchased from Promega and used according to the
manufacturers instructions. The 'Cytotox 96' kit measures lactate dehydrogenase (LDH) presence
in medium by utilising the ability of LDH to catalyse the transformation of a tetrazolium salt into a
red formazan material that can be detected using a plate reader set to detect at 490nm.
2 - 20Lipid rafts
To detect lipid rails on the surface of cells, 13mm round cover slips (I3DH) were coated with
polylysine and placed into a 24 well tissue culture cluster (Coming Costar). Cells were cultured on
top of the cover-slips in the cluster for 24 hours at 37°C, 5% CO2 prior to the addition of CtxB-
AF647 (Molecular Probes) to a final concentration of  0.5mg/mi. After 20 minutes incubation at
37°C the medium was removed and replaced with fresh medium. The cover slip was then removed
and washed in PBS and then sealed onto a microscope slide with nail varnish (Rimmel). The cells
were viewed and photographed on a Zeiss Axiovert 200 microscope with the appropriate filter set.
2 - 212.5 Flow Cytometry
A Becton Dickinson FACSCalibur Flow Cytometer equipped with CeliQuest software was used
for all flow cytometry applications.
Where staining was required it was carried out by taking Ix  106 of the cells to be stained and
washing them with FACS buffer (see Appendix 1) and resuspending them in lOOmi Fc block (see
Appendix 1) before incubating at 4°C for 10 minutes prior to addition of the primary antibodies.
lml of primary antibody was added and incubated at 4°C for 20 minutes. Cells were washed with
FACS buffer and resuspended in a 1:50 dilution of secondary antibody in FACS buffer and incu-
bated for 10 minutes at 4°C before washing in FACS buffer and resuspending in SOOml FACS flow
(Smith eta!., 2002a). For antibody details see appendix 1.
Prior to analysing stained cells, forward scatter and side scatter were adjusted so the cells of inter-
est could be gated on the screen. Unstained samples were used as auto-fluorescence controls allow-
ing settings to be adjusted so that auto-fluorescence background was within the first decade of the
log scale of the fluorescence intensity histogram. Unstained samples were compared with isotype
and positively stained controls to confirm the correct scale. Compensation settings were set such
that on an FL1 vs. FL2 dot plot, an FLI positive population was vertically aligned with negative
population, and an FL2 positive population was horizontally aligned with the FL2 negative popu-
lation. A similar process was used to compensate FL2 vs. FL3.
2 - 222.6 Laser Scanning Cytometer (LSC)
A Laser Scanning Cytometer from Compucyte was used for all LSC applications. To stain the
cells, lx 1 05 cells were cyto spun at 600RPM for 4 minutes using a Shandon Cytospm 3 onto Super
Frost Plus microscope slides (Menzel Glaser) using Thermoshandon filter cards, cytofunnels and
sample chambers. Cells were then fixed for 15 minutes at room temperature in 1% paraformaldehyde
before being washed twice with PBS. lOOml TNB (see Appendix 1) was applied for 10 minutes
prior to the addition of 1 OOml of the primary antibody biotinylated KJ1 .26 at a 1:250 dilution in
TNB (see Appendix 1) for 40 minutes. The slide was washed three times with TNT (see Appendix
1) prior to incubating with 50m1 of streptavidin-HRP (Sigma) at a 1:100 dilution for 3Omins. The
slide was washed three times in TNT (see Appendix 1) before biotinylated tyrimide (Perkin Elmer)
at a 1:50 dilution was added to the cells for 10 minutes. The slide was washed again three time in
TNT (see Appendix 1) and 1 OOml of streptavidin AF647 (Molecular Probes) diluted 1:500 in TNB
(see Appendix 1) was added for 30 minutes. The slide was then washed three times in TNT (see
Appendix 1) and left to dry before mounting in vectasheild mounting medium containing DAPI
(Vector Laboratories) and a cover slip (Adams et al., 2004a).
2 - 232.7 In vivo
Adoptive Transfer
A lymph node single cell suspension was prepared from naive DO 11.10 mouse lymph nodes (in-
guinal, popliteal, brachial, superficial cervical, mesenteric) and spleen (Smith  et a!., 2002b). The
proportion of CD4+ KJ+ T cells was assessed by staining for CD4 and using the clonotypic anti-
body KJ1.26 in flow cytometry. Cells were then resuspended in RPMI to either 1 x 10 KJ+ cells!
ml or 1.5 x 10 KJ+ cells/mi. Using a 26 gauge needle (BDH) and Imi syringe 200ml was injected
via the tail vein into 6-8 week old age and sex matched BALB/c recipients.
Injections
lOOmi PBS (Gibco) or Pneumolysin was injected intraperitonealy into mice using a 26 gauge nee-
die (BDI{). The pneumolysin used in vivo was made using the hydrophobic interaction column and
gel filtration column.
Ovalbumin (Sigma) was dissolved in PBS to 2mg/mi and filter steriiised. This was then made into
an emulsion by combining it with an equal quantity of Complete Freunds Adjuvant (CFA) (Sigma)
and vortexing the mixture until it remained aggregated when placed on water. 1 OOml (100mg) was
injected subcutaneously into the back using a 21 gauge needle and imi syringe.
Antibody ELISA
ELISA's (Eaton et al., 2003) were carried out using 96 wcli plates (Iminunolon 2 HBX, Dynex)
which were coated with 20mg/mi Ovalbumin (Sigma) overnight at 4°C. Plates were washed with
PBS/0.05% Tween, blocked with 200mi PBS/10% FCS for lhr at 37°C, then washed and incubated
with samples at 4°C overnight. Samples were diluted according to this procedure; IgGI diluted 1/
2 - 24200 (unimmunised) or 1/3 000 (immunised). Plates were washed again, incubated with biotinylated
anti-IgGi (0.25mg/mi - A85-1)) detection antibody (all Pharmingen) for lhr at 3 7°C, then washed
and incubated with streptavidin peroxidase (1/1000) (Sigma) for lhr at 37°C. Plates were then
washed and TMB Microwell Peroxidase Substrate (Kirkegaard and Perry Laboratories) was added.
Enzymatic colour changes were analysed on a Dynex plate reader at 630nm.
Immunohistochemistry
An inguinal lymph node was removed from the mouse and embedded in OCT embedding medium
(Sakura) and a cryomould (Sakura). This was snap frozen in liquid nitrogen before further freezing
at -20°C until further use. Tissue sections were cut 6mm thick on a cryostat microtome
(ThermoShandon) and then fixed with acetone and left to dry. Tg T and B cells were detected on
sections (Smith et a!., 2002b) by blocking in 2% goats serum/PBS for 15 minutes before being
incubated with lOOmi of biotinylated KJI .26 (at 1:500 dilution in 2% Goats serum) for 30 minutes.
Sections were washed with PBS and then incubated for 30 minutes in lOOmi ABC-AP (Vector
Labs) and then washed again in PBS prior to incubating in the alkaline phosphatase substrate
BCIP/NBT/Tris-HC1 pH 9.5 for 45 minutes in the dark. After PBS washing, lOOmI of B220 (at
1:400 dilution in 2% Goats serum) was added for 30 minutes and then sections were washed again
with PBS. Section were then incubated with ABC-HRP (Vector) for 30 minutes. After further PBS
washing, the HRP substrate 3,3' -diamminobenzidine was added for 10 minutes before washing in
H20. Subsequent exposure to acetone/2% acetic acid, 70% ethanol, 95% ethanol, 95% ethanol then
100% ethanol dehydrated the tissues, before clearing in Histoclear and immediate mounting in
Histomount.
Statistics
Results are expressed as mean ± SEM. To test significance Student's unpaired t-tests were per-
formed. A p value of< 0.05 was regarded as significant.
2 - 253 Production of pneumolysin
3-13.1 Introduction
To allow the investigation of the immunomodulatory properties of pneumolysin with a high degree
of accuracy and also to allow the utilisation of a variety of experimental systems, I purified pneu-
molysin. I used a pneumolysin mutant called F433 which has a Tryptophan (TGG) changed to a
phenylalanine (TTC) at position 433 and as a result is not hemolytic.
The purification process is essentially biomolecule separation and depends on recognition of some
unique, and therefore identifiable property, of the target molecule that enables it to be isolated from
the contaminating material. Features such as molecular weight, charge, hydrophobicity and solu-
bility may be used, however particular affinity properties such as binding specificity for a substrate
can be exploited to allow extraction of the target molecule. Furthermore, if the molecule of interest
can be cloned then it can be engineered to contain a tag of some sort that allows the target molecule
to be purified using the affinity of the adjoining tag. The most common example of this is the His-
tag system.
Pneumolysin was first purified in 1971 by Shumway et a!. (Shumway and Kiebanoff, 1971) by
isolating the toxin from the whole pneumococcus. This was the practice, albeit with modifications,
until 1986 when Paton et a!. (Paton et a!., 1986) cloned the pneumolysin gene into E. coli and
purified the toxin from the supernatant of crude extracts. Since then E. coli has become the stand-
ard expression vector for preparation of purified pneumolysin.
For my studies I chose to use two different methods to isolate pneumolysin. Both methods have
been used previously and both utilise pneumolysin expression in an E. coil vector. The first method
used a His tag purification method for obtaining both wild type and F433 type pneumolysin for use
in vitro. The second method purified pneumolysin based on its hydrophobicity and charge. Both
these methods require the pneumolysin gene to be in a suitable expression vector. The wild type
pneumolysin gene was available in the pET33b+ expression vector which is suitable for use with
the His tag / Metal Chelate (MC) purification method since pET33b+ adds 6 histidines to the
peptide thereby allowing the protein to bind to the nickel ions. The F433 pneurnolysin mutant was
not available in pET33b+ and therefore was transferred into this expression vector system to make
it compatible with the MC purification method. The wild type pneumolysin gene had previously
3-2been cloned into the pKK expression vector which was suitable for use with the hydrophobic
interaction and anion exchange purification method.
3-33.2 Results
3.2.1 Cloning of F433 pneumolysin into pET33b+
PCR amplification of F433 gene from template
I amplified the F433 pneumolysin gene from a template plasmid using primer 9Z and 9Y. The
products were analysed on a gel. The pneumolysin gene is 1416bp (Walker et a!., 1987) and
therefore would be expected to show up as a 1.4kb fragment when run on a gel. A 1.4kb fragment
was evident and no contaminants were present.
Cloning of F433 into TOPO
To allow me to further amplify the F433 gene I ligated the PCR product into the PCR4 TOPO
plasmid and transformed it into TOP 10 cells which were grown with antibiotic selection. To check
if this had been successful I then extracted and digested the plasmid (with BAM Hi and SAC I)
containing the PCR product before running it on a gel. Two bands were observed at the correct
sizes (4kb [TOPO is 3.9kb] and 1.4kb).
Ligation into pET33b+ and transformation into TOP 10
My data suggested that I had successfully cloned the F433 gene into pCR4 TOPO plasmid. To
allow me to purify pneumolysin using metal chelate chromatography I had to transfer the F433
gene from the pCR4 TOPO plasmid to the pET33b+ plasmid. I therefore prepared a large amount
of the pCR4 TOPO plasmid containing the F433 gene by large scale DNA preparation and then
extracted the F433 gene by restriction digestion. I prepared the pET33b+ plasmid in a similar way
then carried out a digestion on it. Prior to ligation I wanted to confirm that the fragments of vector
and insert I had prepared were correct. I therefore ran a sample of each on a gel (Figure 3-1). In
Figure 3-3 the I kb+ ladder is shown in lane 1. In lane 3 the F433 insert was run and a band appears
3-4Figure 3-1
pET33b+ Plasmid and F433 Insert
The TOP 10 strain containing the pCR4 TOPO plasmid with the F433 gene insert was maxipreped.
A maxiprep of the strain containing the empty pET33b+ plasmid was also carried out. Both maxipreps
were carried out by isolating a single colony of each strain and growing an overnight culture. Both
preparations was subsequently digested using BAM and SAC restriction enzymes. The digested
F433 gene was run on an agarose gel and then gel purified. We also ran a sample of each prepara-
tion on the agarose gel shown above.
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0at 1.4kb which is the expected size of the F433 gene. In lane  5 a band is evident that correlates to
between the 5 and 6 kb markers on the ladder. The pET vector is known to be 5.4kb. This gel
confirmed that I had isolated the correct fragments so I ligated the pET33b+ vector and the F433
insert and then transformed them into TOP 10 cells. To check the correct vector and insert had been
ligated a digestion of the ligation was analysed on a gel and found to contain the correct size of
products (pET33b+ at 5.4kb plus F433 at 1.4kb gives an expected size of 6.8kb).
Transformation of BL2 I E. coli
From the results above it seemed highly probable that I had cloned the F433 gene into pET33b+ in
TOP 10 cells. I therefore transferred some of the plasmid from the miniprep of the TOP 10 cells into
BL21 cells for protein expression (see next section) and used some of the plasmid for sequencing
(carried out by MBSU, University of Glasgow). The sequence data confirmed that I had correctly
cloned the F433 gene into the pET33b+ plasmid. Figure 3-2 illustrates the alignment of the F433
pneumolysin and wild type pneumolysin. Figure 3-3 contains a schematic representation of the
pET33b+ plasmid containing the F433 pneumolysin gene.
3.2.2 Production and purification of wild and F433 pneumolysin
using Metal Chelate Chromatography
3.2.2.1 Process Optimisation
I used the pET33b+ plasmid containing the wild pneumolysin gene (previously prepared) and the
F433 pneumolysin gene (prepared in the above section) in the BL2 1 host to generate pneumolysin
protein. During expression in this system some aggregates of pneumolysin can form and so in order
to obtain the maximum amount of pneumolysin in the soluble fraction, I determined the optimum
time of protein induction.
3-7BamHI(16o9)
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Figure 3-3
pET33b+ with F433 pneumolysin gene
The schematic shows the pET33b+ plasmid containing the F433 pneumolysin gene in-
serted between the Barn and Sac restriction sites. The ampicillin and kanarnycin resist-
ance genes are also shown.
Diagram courtesy of Graeme Cowan, University of Glasgow
3-8I measured the amount of pneumolysin in each fraction over a 4 hour induction period. Figure 3-4
shows the gel produced from the soluble fraction of wild type expression and in lane 1 is the ladder.
Pneumolysin is 53kDa in size and so would be expected to correlate with a position between the
violet band at 4lkDa and the green band at 8SkDa on the ladder.
In lane 2 the soluble fraction from the 0 minutes sample is present. There is no band where pneu-
molysin would be expected to be observed in this lane indicating that production of pneumolysin
occurs only when the bacteria are induced with IPTG.  In lane 3 the soluble 30 minute sample is
present and a band is evident where pneumolysin would be expected. After 60 minutes lane 4
shows us that the amount of pneumolysin has increased and by 90mins lane 5 demonstrates that
this has reached a maximum. Subsequently in lanes 6 to lithe amount of pneumolysin remains the
same or decreases.
Insoluble samples from the wild type expression are shown in Figure  3-5. By 90 minutes the in-
soluble amount is at a maximum as seen in lane 4 and although the amount fluctuates in subsequent
samples (Gel I - lanes 5 and 6 and Gel 2 - lanes 2-5) the amount of insoluble pneumolysin remains
high.
The gel of the soluble production for F433 mutant type pneumolysin in BL21 is shown in Figure 3-
6. The fractions show similar expression levels over the same time course as the wild type pneumo-
lysin containing 821 E. coil. Lane 9 (gel 1) contains previously purified pneumolysin to act as a
positive control. As shown in lane 5, peak pneumolysin production appears to occur 90 minutes
after induction.
From this data I concluded that 90 minutes was the optimum induction period that would yield the
highest amount of soluble wild and F433 type pneumolysin.
3.2.2.2 Metal Chelate Chromatography
After identifying the optimal induction period I proceeded to produce purified pneumolysin from
crude extracts using perfusion chromatography. The results of the perfusion chromatography are
3-9Lane 1; kaledioscope ladder
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Figure 3-4
Soluble fractions of wild type pneumolysin
The pET33b+ containing wild or F433 pneumolysin in BL21 E. coli were grown and
induced. For 4 hours after induction with IPTG, a sample of the culture was taken every
30 minutes. After disrupting with bug buster and centrifugation, the proportion of pneu-
molysin in the soluble and insoluble fractions was determined by running SDS PAGE
gels of the samples. Figure 3-4, 3-5 and 3-6 show the results. We used the kaleidoscope
ladder as the standard for each gel.
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Figure 3-5
Insoluble fractions of wild type pneumolysin
Samples were prepared as described in Figure 3-4 and separated over two gels and have
been aligned here.
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Figure 3-6
Soluble F433 pneumolysin fractions
Samples were prepared as described in Figure 3-4. The fractions were separated over
two gels and have been aligned.
3 - 12shown in Figure 3-7 and 3-8. The plots for both wild and F433 pneumolysin are very similar. In
fraction 1 and 2 the increase and then decrease in 280 and 260 nm reading are the result of the
column being loaded with sample and then being washed to remove any non binding debris. In
fraction 4 the concentration of salt increases in the column. This causes the release of some mate-
rial which results in the rise in 280 and 260 nm value. In fraction 6-9 5OniM imidazole is intro-
duced to the column aiid this results in more material being removed from the colunm and a distinct
peak resulting. Infractions 10 and lithe imidazole concentration is increased to 100mM and this
results in more protein being released from the column. The remaining fractions do not yield any
further material despite the increasing concentration of imidazole.
While some pneumolysin is likely to be present in all fractions, this data suggested that purified
pneumolysin would be present in fractions 8-il. I proposed that pooling these fractions would
yield a highly purified preparation of pneumolysin, however prior to pooling these fractions I
conducted a number of test to confirm this hypothesis.
3.2.2.3 Quality Controls
Absorbance assay
One of the key indications of a purified fraction is the presence of a higher level of protein than
nucleic acid. An absorbance assay showed that only in fractions 8-11 was the 260 reading was
lower than the 280 reading and there were no aggregates as indicated by the low 320nm reading.
This data confirmed what I had suggested from the chromatography plot; that for both wild and
F43 3 fractions 8-11 were potential candidates for further examination since fractions 1-7 contained
too much nucleic acid contaminants and fractions 12-15 contained aggregates.
Flemolytic activity
Since pneumolysin is a hemolytic protein, the amount of pneumolysin present in any sample can be
estimated by the amount of hemolysis it causes. I therefore carried out a hemolytic assay on each
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Figure 3-7
Purification of wild type pneumolysin using the BioCAD workstation and Metal
Chelate Chromatography
BL21 E. coli containing the wild or F433 pneumolysin gene in pET33b+ were sepa-
rately grown and induced. After induction the bacteria were resuspended in bugbuster
and then centrifuged and the supernatant collected and loaded onto the metal chelate
column on the BioCAD workstation. The plot above and in Figure 3-8 graphically
displays the purification process. The red line correlates with the right hand axis
and represents the 280nm reading which is representative of the amount of protein
in the sample. The green line correlates with the left hand axis and represents the
260nm reading which is representative of the amount of nucleic acid in the sample.
The plot is divided into 27 sections, each one correlating to a fraction from the
BioCAD column.
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Figure 3-8
Purification of F433 pneumolysin using the BioCAD workstation and Metal
Chelate Chromatography
Chromatography was carried out as described in Figure 3-7
3 - 15fraction as a second test. Fractions 7-11 contained a significant amount of hemolytic activity of
1000-20 000 HU/mi.
Although the P433 mutant has greatly reduced hemolytic ability, the presence of pneumolysin can
still be detected using this assay. The results are similar to those for the wild type.
This data, for both the wild and F433 type pneumolysin, confirmed the data obtained from the
absorbance assay; that fractions 8-11 contained pneumolysin and were the fractions of highest
purity of pneumolysin to be included when pooling the fractions.
SDS PAGE
It was important to determine if the fractions to be pooled were pure and so as a third test I meas-
ured the purity of each fraction by SDS PAGE. My data from the previous two tests indicated that
fractions 1-7 and 12-15 would be unsuitable for inclusion in the fmal pooling and so I ran only
fractions 8-11 from both wild and F433 on SDS PAGE. In figures 3-9 and 3-10 the ladder is present
in lane 1. In Figure 3-12 lanes 2-5 contain fractions 8-11 from the wild type preparation and in
Figure 3-13 lanes 2-5 contain fractions 8-11 from the F433 type preparation. Each lane contains a
single band at the expected size of 53kDa and no other bands are observed indicating that all
fractions are free of contaminants. As a result of observing that all fractions contain a highly puri-
fied single protein I concluded that all of the fractions were suitable for pooling.
Western Blot
I carried out a fourth and final test to confirm that the protein we had expressed and found to be
hemolytic and highly purified was in fact pneumolysin. To do this I carried out a Western blot for
pneuiuolysin. In Figure 3-11 and 3-12 the ladder is clearly visible in lane 1. In lane 2-6 fractions 8-
11 are present respectively. In every lane a single band is observed which indicates that each frac-
tion contains pneumolysin
3 - 16Lane 1; kaledioscope ladder
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Figure 3-9
SDS PAGE gel of fractions 8-11 from wild pneumolysin purification
3 - 17I 
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Figure 3-10
SDS PAGE gel of fractions 8-11 from F433 pneumolysin purification
3 - 183.2.2.4 Pooling and subsequent analysis
In the previous four tests I had concluded that fractions 8-11 contained less nucleic acid than
protein and had significant hemolytic activity which indicated not only the presence of protein but
that the protein is functionally active. Furthermore I had observed that fractions 8-11 contained no
contaminants and confirmed the protein present was pneumolysin. Fractions 1-7 and 12-15 had
been shown to be unsuitable based on the same tests. I therefore concluded that each of the frac-
tions 8-11 of both wild and F433 type pneumolysin were suitable for pooling into the final prepa-
ration. I then performed some further quality controls on both stock pneumolysin types.
Absorbance assay
To confirm that the pooled fractions continued to have a higher 280 reading than 260 and that the
protein had not aggregated upon pooling a further wavelength scan was conducted. The 260 value
remained lower than the 280 value for both types of pneumolysin and the 320 reading remained
negligible.
In order to determine the final concentration ofpneumolysin in each sample the 280nm reading can
also be used to estimate the concentration of pneumolysin by using the extinction co-efficient.
Using this method wild type pneumolysin was estimated to be at a concentration of 0.129mg/mi
and F433 type pneumolysin at 0.054mg/mi.
Bradford Assay
To confirm the estimated concentration obtained by using the extinction co-efficient, a Bradford
assay was conducted on each sample. Wild type pneumolysin was found to have a concentration of
0.1 37mg/mi by this method while F433 pneumolysin was found to have a concentration of 0.06 5mg/
ml. By averaging the concentration value obtained from the extinction coefficient with that from
the bradford assay, I concluded that wild type pneumoiysin had a concentration of 0.133mg/mi
while the F433 pneumolysin had a concentration of 0.059mg/mi.
3 - 19Lane I
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Figure 3-11
Western blot of gel of figure 3-9 (wild type pneumolysin)
3 - 20Lane 1
I	 Lane 2; fraction
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Figure 3-12
Western blot of gel of figure 3-10 (F433 pneumolysin)
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Figure 3-13
LPS levels in pneumolysin
The amount of endotoxin in each sample was measured using the LAL assay. The
table above presents the average of three measurements using the LAL assay.
3 - 22Hemolytic assay
In order to determine the hemolytic activity of the final pneumolysin preparations, hemolytic
assays were performed. Wild type pneumolysin caused hemolysis to well 8 which corresponds to a
hemolytic activity of5 120 HU/ml and correlates to an activity of 3.8x 10 HU/mg of protein. The
F433 type pneumolysin was found to cause hemolysis up to well 2 which corresponds to an activity
of 80 HU/ml and correlates to an activity of l.3x 10 IIU/mg.
Endotoxin Assay
Endotoxin levels were measured in pneumolysin samples. Figure 3-13 shows that wild type pneu-
molysin was found to have 237 EU/ml which corresponds to l7pg LPS per lOOng of pneumolysin.
F433 pneumolysin had 419 EU/ml which corresponds to 7lpg LPS per lOOng of pneumolysin.
3.2.3 Production and purification of wild type pneumolysin by
Hydrophobic Interaction and Anion Exchange Chromatography
3.2.3.1 Chromatography
Hydrophobic Interaction Chromatography
In order to obtain purified wild type pneumolysin using the fTC and Anion Exchange system I
prepared crude extracts of cells containing the pneumolysin protein. The optimal induction period
had previously been ascertained in our laboratory and so I was not required to determine this. The
results of the perfusion chromatography are shown in Figure 3-14. Fractions 1-4 contain the initial
washes from the column as evidenced by the high 280 and 260 readings in these fractions. Fraction
3 - 235-8 contain a 'shoulder' of these washes and produce lower 280 and 260 readings. I selected frac-
tions 5-8 for further purification.
Anion Exchange Chromatography
In order to remove the salt present in fraction 5-8 obtained from the HIC we dialysed the fractions
overnight against PBS-NaC1 prior to loading onto the anion exchange column for purification. The
process of purification is displayed graphically in Figure 3-15. Fraction 9 clearly contains the only
peak of protein. Previous work in my lab had demonstrated the reliability and predictability that
this fraction would contain pneumolysin. The ninth fraction from each run of the BioCAD was
pooled and concentrated using the minicom concentrators.
3.2.3.2 Quality controls
Wavelength Scan
In order to ensure that the 280nm reading was higher than the 260nm reading and that aggregates
were minimal, a wavelength scan was performed upon the pneumolysin from the Anion Exchange
column. The 260 reading was 0.16 1 while the 280 reading was 0.162. The 320 reading 0.067.
Using the 280 reading I was able to calculate the concentration of pneumolysin to be 1.23mg/mi.
SDS PAGE
To assess the purity of the preparation Iran a sample on an SDS PAGE gel. Figure 3-16 shows this
gel and the previously prepared pneumolysin which acts as a positive control value and can be seen
to run at a value of approximately 53kDa in lane 1 as judged by the purple (4IkDa) and green bands
(85kDa) of the ladder in lane 3. Within lanes 4 and 5 a single band is clearly visible that correlates
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Purification of wild type pneumolysin using a Hydrophobic Interaction Column
(HIC)
The E. coli strain XL1O containing the plasmid pKK2332 with the wild type pneumo-
lysin gene was grown, induced and resuspended in PBS prior to disrupting with the
cell disrupter. After centrifugation, the supernatant was loaded onto the hydrophobic
interaction column on the BioCAD workstation. The process of purification is graphi-
cally displayed above; The red line correlates with the right hand axis and represents
the 280nm reading which is representative of the amount of protein in the sample. The
green line correlates with the left hand axis and represents the 260nm reading which
is representative of the amount of nucleic acid in the sample. The plot is divided into
16 sections, each one correlating to a fraction from the BioCAD column.
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Purification of wild type pneumolysin using Anion Exchange Chromatography
Fraction 5-8 from the HIC purification were dialysed overnight at 4oC against PB-S and then
loaded onto the Anion Exchange column on the BioCAD workstation. The process of purification
is graphically displayed above; The red line correlates with the right hand axis and represents the
280nm reading which is representative of the amount of protein in the sample. The green line
correlates with the left hand axis and represents the 260nm reading which is representative of the
amount of nucleic acid in the sample. The plot is divided into 14 sections, each one correlating to a
fraction from the BioCAD column.
3 - 26with the position of a 53kDa protein on the ladder and is in exactly the same position as the pneu-
molysin control. This confirms the purity and identity of the protein prepared.
Hemolytic Assay
In order to determine the hemolytic activity of the final pneumolysin preparation a hemolytic assay
was performed. Wild type pneumolysin caused hemolysis up to well 14 which correlates with an
activity of 3.2x 1O HU/mi which is equivalent to an activity of 2.6x 1O HU/mg of protein.
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Figure 3-16
SDS PAGE gel of fraction 9 from Anion Exchange column
Lane 1 contains a positive control of pneumolysin. Lane 2 is blank. Lane 3 contains the ladder
(kaleidoscope). Lanes 4 and 5 contain a different amount of the pneumolysin sample.
3 - 283.3 Discussion
In this chapter I cloned the F433 pneumolysin gene into the pET33b+ vector. I then expressed and
purified wild and F433 type pneumolysin protein using the pET33b+ vector and metal chelate
chromatography for use in vitro. Finally I used a pKK232 expression vector containing the wild
type pneumolysin gene in conjunction with hydrophobic interaction and anion exchange chroma-
tography to produce purified wild type pneumolysin for use in vivo.
The PCR reaction used to amplify the F433 gene from the plasmid stock utilised the primers 9Z and
9Y (see Figure 2-1). These primers were designed to include the BamEll restriction site on the
forward primer and the Sad restriction site on the reverse primer. The primers therefore added a
BamHl site to the beginning of the cloned gene and a Sad site to the end of the gene during PCR
amplification and so BanilSac digestion was used throughout the cloning work. When I was clon-
ing the F433 gene into pET33b+ I used the TOPO plasmid as an intermediate transfer plasmid to
allow me to increase the success of cloning the PCR product. Insertion into the TOPO plasmid
avoids the use of restriction sites and so I could insert blunt ended PCR product which increased
the efficiency of the TOPO plasmid in taking up PCR product made it an attractive intermediate in
this situation where limited PCR product was available.
When deciding which purification method to use to purify pneumolysin I examined the traditional
method of producing pneumolysin directly from the whole pneumococcus by the method of Shumway
et a!. (Shumway and Klebanoff, 1971) who used an anion exchange purification column. This
method has been modified including successful attempts to increase the yield (Kanclerski and
MolIby, 1987). However production of pneumolysin by plasmid expression in  E. coil has become
the standard procedure due to the high yield this method affords. Purification of pneumolysin from
E. coli was first carried out in 1986 by Paton et al. (Paton et al., 1986) who continued to use a anion
exchange colunm to purify the crude extract. In 1989 Mitchell  et a!. (Mitchell et a!., 1989)in-
creased the yield and speed of the purification process by bringing a hydrophobic interaction col-
umn into the purification process. Purification ofpneumolysin from Bacillus subtilis was attempted
by Taira eta!. (Taira et a!., 1989) however this method has not been developed further.
3-29Furthermore, previous studies in my laboratory (J. Search, PhD Thesis, University of Glasgow,
2000) which had demonstrated that purification methods using a standard  E. coli expression sys-
tem and hydrophobic interaction and anion exchange purification columns yielded pneumolysin
that had considerable endotoxin contamination. Therefore in light of all these previous studies, and
given that my in vitro studies were potentially highly sensitive to endotoxin (due to the sensitivity
of BMDC to LPS), it was necessary to identify a more rigorous purification method. I chose the
His-tag purification method for purifying pneumolysin since we considered it to be the most appro-
priate to enable me to produce highly purified pneumolysin. Braun et a!. (Braun et a!., 1999) had
previously used the His tag purification method to purify pneumolysin and had demonstrated that
the method yields pneumolysin of high purity. These authors used a similar pET vector to the one
we used but they purified pneumolysin under denaturing conditions to avoid the problems of the
formation of insoluble fractions. I chose not to use denaturing conditions with the pET vector since
I considered ample protein to be present in the soluble phase. Braun eta!. (Braun eta!., 1999)dem-
onstrated that the pET purification method results in low endotoxin contamination.
After successfully cloning the F433 pneumolysin gene into the pET33b+ plasmid I carried out an
optimisation experiment to determine the induction period that would utilise the maximum amount
of pneumolysin in the soluble fraction. My data shows that the amount of pneumolysin in solution
does reach a plateau (Figures 3-4 and 3-6) and my data also shows an increasing amount of pneu-
molysin in the insoluble fraction however the gels for the insoluble fractions do not portray a
consistent amount of pneumolysin indicating that the boiling procedure used to liberate the insolu-
ble pneumolysin into solution may not have been entirely successful for all fractions.
After determining the optimal conditions for inducing pneumolysin production I proceeded to pu-
rifying pneumolysin. The clear peak on the anion exchange chromatogram indicate the presence of
the pneumolysin as expected. I chose fractions that had a higher protein content than nucleic acid
content since fractions with high nucleic acid content may interfere with future in vitro studies. The
western blots (see Figure 3-11 and 3-12) appeared to have a faint band below the main band of
protein. The degradation is minimal and may be caused by enzymatic digestion of the crude prepa-
ration prior to purification by E. coli enzymes.
After pooling the fractions I analysed the final preparation. The differing concentrations of the
final preparations of wild and F433 pneumolysin are the results of differing concentration of crude
3-30protein loaded onto the colunm. The hemolytic activity of the fmal preparation of wild type pneu-
molysin is 3.8x l0 HU/mg. This is a surprisingly low value for the wild type toxin compared to
other reports in the literature which range from 4x l0 HU/mg to 2x 106 HU/mg (Baba eta!., 2001;
Kelly and Jedrzejas, 2000; Mitchell et a!., 1989; Paton and Ferrante, 1983). While it may be the
case that the toxin prepared here does have a low hemolytic activity, I am also aware that the blood
used within my lab may have some effect on the low hemolytic activity reported here since other
results from my lab have yielded surprisingly low hemolytic activities. In addition the only other
reported hemolytic activity of His tagged pneumolysin in the literature had a low hemolytic activ-
ity of 4x l0 HU/mg (Baba et al., 2001).
Previous results in my laboratory (J. Search, PhD Thesis, University of Glasgow, 2000) had dem-
onstrated that pneumolysin produced by isolation from E. coli and purification using HIC chroma-
tography gave endotoxin levels of 200pg endotoxin per bOng PLY. The endotoxin levels within
my samples using metal chelate chromatography are lower than these. The difference in endotoxin
levels present in the wild and F433 preparations is possibly the result of differing concentration of
toxin. Two previous reports of purif'ing a CDC using metal chelate chromatography and measur-
ing endotoxin contamination yielded endotoxin levels lower than mine. Braun et a!. (Braun et a!.,
1999) produced pneumolysin with 0.2pg endotoxiri/lOOng pneumolysin. Ito et a!. (Ito eta!., 2003)
produced seeligerilysin 0 (LSO) with endotoxin contamination of 0.Olpg endotoxin/lOOng ofLSO.
Both experimenters used subsequent purification procedures after metal chelate chromatography
and this may account for the significantly lower endotoxin levels obtained compared to my values.
Ito et a!. (Ito et a!., 2003) used a Detoxi-Gel Endotoxin removing column and this would be a
possible additional purification step to add to my procedure. Pneumolysin purified using the HIC
and Anion Exchange column was found to have a hemolytic activity of 2.6x 10 HU/mg. This is ten
fold higher than that obtained for the his-tagged toxin and compares with previous findings al-
though remains lower than expected and further suggests a problem with the blood used in the
hemolytic assay.
In this chapter the preparation of pneumolysin for use in future experiments was successful.
3 -314 Assessing the T cell inhibitory ability of
pneumolysin in vitro.
4-14.1 Introduction
Streptococcus pneumoniae is a pathogen which can cause a number of important diseases includ-
ing pneumonia and meningitis. Like other pathogens (Banks and Rouse, 1992; Donelson et a!.,
1998; Gebert et a!., 2003; Harnett and Harnett, 2001), S. pneumoniae may attempt to inhibit the
immune response against it in order to allow colonisation of its host, to prolong host colonisation,
or to enhance dissemination within the host. In the introduction I discussed the ways in which
different pathogens manipulate aspects of the host response and the evidence that  S. pneumoniae
affects the innate immune response. Natural antibody, complement and CRP were all observed to
be important in the defence against the pneumococcus (Boes  eta!., 1998; Mold eta!., 2002). Fur-
thermore, it was observed that S. pneuinoniae was able to modulate components of the innate
immune response such as complement, neutrophils and macrophages(Braun  et a!., 1999; Cockeran
et a!., 2002b).
The role of the adaptive immune response in defence against the pneumococcus was also discussed
in the introduction. There the antibody produced by memoty B cells (natural antibody) was shown
to be important in initial defence against the pneumococcus and that this antibody was produced in
a T cell independent manner (Kruetzmann eta!., 2003; Wu et a!., 2002). It was also observed that
specific antibody is made to both pcilysaccharide and protein elements o the pneumococcus anO.is
produced as a result of both colonisation and invasive disease (Rapola et a!., 2000). While this
antibody does not apparently aid the resolution of current colonisation, it is observed to prevent re-
infection (McCool et a!., 2002). Production of antibody to both polysaccharide and protein ele-
ments of the pneumococcus was shown to be T cell dependent (Khan  eta!., 2004). Studies in nude
mice demonstrated that the T cell has no role in defence against high dose pneumococcal infections
(Winkeistein and Swift, 1975), however this model is potentially misleading since colonisation
generally precedes infection.
Studies by Darji et a!. (Darji et a!., 1997) had demonstrated that the pneumolysin related toxin,
listeriolysin, was able to induce T cell anergy. Additionally, the study of Ferrante eta!. (Ferrante et
a!., 1984) demonstrated that pneumolysin was able to inhibit mitogen induced proliferation of
human B and T cells. I therefore decided to further examine the effects of pneumolysin upon the
4-2prime controller of the adaptive immune response, the CD4 T cell. I was interested to investigate
the effect of pneumolysin upon antigen specific proliferation of murine T cells.
4-34.2 Results
4.2.1	 The role of pneumolysin in inhibiting T cell proliferation
in the context of the whole pneumococcus.
Examination of the in vitro effect of pneumolysin upon T cells in the context of the whole bacte-
rium is a physiologically relevant model of T cell exposure to the pneumococcus. Given the re-
cruitment of lymphocytes to the lung observed during pneumococcal infection (Kadioglu et al.,
2000), it is likely that the whole pneumococcus potentially encounters lymphocytes within the
spleen and within the lung. I started to address the question of the effect of pneumolysin upon
lymphocytes during pneumococcal infection by co-culturing S. pneumoniae expressing wild type
pneumolysin, or an S. pneumoniae mutant that does not express pneumolysin (called PLY-), with
lymphocytes. Initially it was necessary to optimise the culture conditions.
4.2.1.1 Optimisation of culture conditions
In co-culture systems, the lymphocytes may be exposed to a variety of toxic bacterial derived
immunomodulatory factors. I therefore wanted to determine a ratio of bacteria to lymphocytes, and
culture period, which would allow me to compare the differential effect of the presence or absence
of pneumolysin in the bacteria.
Optimising the concentration of bacteria and duration of culture.
I cultured D39 and PLY- S. pneumoniae with lymphocytes for 24 hours and measured lymphocyte
viability in order to determine if a 24 hour incubation time resulted in an effect on lymphocyte
viability. I found that after 24 hours bacterial cultures were in decline for both D39 and PLY- as
evidenced by declining numbers of bacteria (Figure 4-1 & 4-2). At 24 hours lymphocyte viability
was assessed by trypan blue exclusion (Figure 4-3). Lymphocytes that had not been incubated with
bacteria were the positive control and the number of viable lymphocytes in these cultures after 24
hours was taken as 100% viability. Lymphocytes incubated with any of the three concentrations of
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Growth of D39 when incubated with lymphocytes.
At 0 hours D39 S. pneumoniae was inoculated at a final concentration of 2.5 x 10
(blue line - d39 1), 1 x 106 (pink line - d39 2) and 1 x 10 (yellow line - d39 3) CFU/
ml into DO11.10 lymph node single cell suspension cultures. Bacteria viability was
measured by viability counting at 24 and 48 hours.
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Figure 4-2
Growth of PLY- when incubated with lymphocytes.
At 0 hours the S. pneumoniae, pneumolysin knockout, PLY-, was inoculated at a
final concentration of 2.5 x 10 (blue line - ply- 1), 1 x 106 (pink line - ply- 2) and 1 x
10 (yellow line - ply- 3) CFU/ml into DO11.10 lymph node single cell suspension
cultures. Bacteria viability was measured by viability counting at 24 and 48 hours.
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Figure 4-3
Viability of lymphocytes incubated with S. pneumoniae for 24 hours
Lymph node single cell suspensions from DO11.10 mice were incubated
with D39 and PLY- S. pneumoniae as outlined in Figure 4-1 & 4-2. Lym-
phocyte viability was measured by Irypan blueS	 ic,n 'ftv.r 24
The control of cells that were incubated without bacteria were taken to be
100% viable and the cells incubated with bacteria were compared with this.
Cultures initially inoculated with 2.5 x 10 CFU/ml bacteria are given the
suffix '1' in the chart above. Cultures initially inoculated with I x  106 CFU/
ml bacteria are given the suffix '2' in the chart above. Cultures initially
inoculated with 1 x l0 CFU/ml bacteria are given the suffix '3' in the chart
above.
4-6D39 were found to be dead while lymphocytes incubated with the lower two inoculums of the PLY-
were found to be 80% viable however the higher concentration of PLY- bacteria had killed 100% of
the lymphocytes.
I therefore concluded that 24 hours is too long a period of time to incubate live S.  pneumoniae with
lymphocytes since the lymphocyte viability decreases dramatically within this period even with
bacteria which do not express pneumolysin.
In order to determine a suitable length of time for bacterial growth that did not alter lymphocyte
viability, I measured the effect of growing S. pneumoniae on lymphocyte viability over a 24 hour
period. (Figures 4-4, 4-5, 4-6). I measured bacteria numbers by viability counting at each time
point and found that the growth curves of D39 and PLY- were very similar as demonstrated in
Figures 4-4 and 4-5. The lower starting concentration of bacteria for both D39 and PLY- (starting
at 5 x l0 CFU/ml) peaked after 8 hours at a value of-i x 108 CFU/ml (Figure 4-4). The higher
starting concentrations of bacteria (starting at 1 x 106 CFU/ml) peaked after 4 hours at 1 x 10 CFUI
ml and then rapidly declined (Figure 4-5).
Figure 4-6(A) demonstrates that after four hours, lymphocytes incubated with the lowest concen-
tration of either D39 or PLY- had not decreased in viability compared to the control lymphocytes in
medium alone. After the same four hour period, however, the lymphocytes incubated with the
higher concentration of D39 or PLY- had decreased dramatically in viability with almost 100%
dead. By the eight hour time point (Figure 4-6B) a 50% decrease in lymphocyte viability was
evident relative to the control for the lymphocytes incubated with the lower concentration of D39.
A similar decrease was not observed for the lymphocytes incubated with the lower PLY- concen-
tration of bacteria which maintained nearly 100% viable cells. Unsurprisingly, the higher concen-
tration of both bacteria strains still had 100% dead cells. As shown in Figure 4-6(C) and 4-6(D) at
the later time points of 18 and 24 hours the trend of decreasing lymphocyte viability continues for
all the cell cultures where bacteria are present. These results suggested that the higher initial con-
centration of bacteria was not useflul for further studies since lymphocytes die within the first four
hours of being cultured with bacteria at this initial concentration. After 4 hours lymphocytes incu-
bated with the lower concentration of either bacteria are still alive yet, after 8 hours lymphocyte
viability decreases. I concluded that 4 hours was the optimal time for bacterial co-culture with the
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Growth of S. pneumoniae strains in the presence of lymph node cells
At 0 hours D39 S. pneumoniae and the S. pneumoniae mutant PLY- were inocu-
lated at a final concentration of 5 x 1 04 CFU/ml into DO 11.10 lymph node single
cell suspension cultures. At 0, 4, 8, 18 and 24 hours the number of bacteria were
measured by bacteria viable counting. The blue line represents the growth curve
of D39 while the pink line illustrates the growth of PLY-.
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Figure 4- 5
Growth of S. pneumoniae strains in the presence of lymph node cells
At 0 hours D39 S. pneumoniae and the S. pneumoniae mutant PLY- were inocu-
lated at a final concentration of 1 x 106 CFU/ml into D011.l0 lymph node single
cell suspension cultures. At 0, 4, 8, 18 and 24 hours the number of bacteria were
measured by bacteria viable counting. The blue line represents the growth curve
of D39 while the pink line illustrates the growth of PLY-.
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Figure 4-6
Viability of lymphocytes cultured with S. pneumoniae
At 0 hours D39 S. pneumoniae and the S. pneumoniae mutant PLY- were in-
oculated into D011 .10 lymph node single cell suspension cultures. At 4 (A), 8
(B), 18 (C) and 24 (D) hours the viability of the lymphocytes was assessed by
trypan blue exclusion. Cultures initially inoculated with 5 x 10 CFU/ml bacte-
ria are given the suffix '1' in the charts i.e. "D39 1" indicates inoculation with
5 x 10 CFU/ml. Cultures initially inoculated with 1 x 106 CFU/ml bacteria are
given the suffix '2' in the charts.
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4-11lymphocytes before lymphocyte viability began to decrease as a result of non-pneumolysin medi-
ated effects.
4.2.1.2 Determining the effect of pneumolysin upon lymphocyte
proliferation in the context of the whole pneumococcus
Having established that an initial inoculum of 5 x 1 0 CFU/ml of S. pneumoniae, incubated for 4
hours in cultures of lymph node cells did not decrease lymphocyte viability I was able to proceed in
testing the effect of the presence or absence ofpneumolysin in this context upon the proliferation of
antigen specific T cells. I did this by utilising the Tg mouse strain DOl 1.10 (for details see Material
and Methods) in conjunction with the wild type D39 S. pneumoniae and the pneumolysin knockout
mutant of S. pneumoniae, PLY-.
S. pneumoniae does not affect T cell proliferation.
I inoculated lymph node cultures prepared from the DO 11.10 mice with D3 9 and PLY-. After 4
hours growth, bacteria were killed using antibiotics (see Material and Methods for details). This
prevented any further bacterial growth, and thereby prevented the toxic effects associated with
bacterial growth beyond 4 hours. Bacteria had reathed a  CFU!m f x ^3 a th time
antibiotics (data not shown). The cultures were incubatei for a furnet € crs prior o  1'jmvye
viability being assessed by trypan blue exclusion immediately prior to setting up proliferation
assays. As can be seen from Figure 4-7 at the end of the incubation period there is little appreciable
difference in viability between the lymphocytes cultured with bacteria and those that were nOt. The
proliferation assay (Figure 4-8) illustrates that there was no significant difference in the degree of
thymidine incorporation between the control of untreated lymph node cells stimulated with oval-
bumin compared to lymph node cells that had been incubated with D39 or PLY- strains of S.
pneumoniae and then stimulated with ovalbumin. Therefore pre-incubation with or without pneu-
molysin in the context of the whole bacteria, in these cultures, did not affect the ability of T cells to
proliferate in response to subsequent antigen stimulation. The results presented are representative
of three experiments.
4 - 12Viability of lymphocytes 6 hour after adding antibiotics
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Figure 4-7
The viability of lymphocytes immediately before setting up proliferation assay
Lymph node single cell suspensions were prepared from DO11.10 mice and were
inoculated with 1 x 10 CFU/ml ofD39 or PLY-. After four hours incubation antibiotics
were added to the cultures to kill the bacteria. After a further 6 hours the viability of the
lymphocytes was assessed by trypan blue exclusion. The results are shown in the chart
above. Lymphocytes that were cultured without bacteria are labelled as 'lymphocytes'.
Lymphocytes that were cultured with D39 or PLY- are labelled accordingly. Lymphocytes
alone were taken as 100% viable and used as the baseline to compare the other culture
conditions to.
4-13Proliferation of lymphocytes incubated with whole S. pneumoniae
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Figure 4-8
Proliferation of lymphocytes cultured with S. pneumoniae
After incubation with S. pneumoniae (see Figure 4-7), lymphocytes were
washed and put into thymidine incorporation assays with 1mg/mi ovalbumin
and thymidine incorporation was measured at 72 hours. Lymphocytes that
had not been exposed to bacteria are labelled as 'lymphocytes' or 'lymphocytes
+ OVA' and act as controls. Lymphocytes cultured with D39 prior to the
proliferation assay are labelled 'lymphocytes + OVA + D39'. Lymphocytes
cultured with PLY- prior to the proliferation assay are labelled 'lymphocytes
+ OVA + PLY-'.
4 - 14Hydrogen peroxide is released by S. pneumoniae and is responsible for lymphocyte
death.
There remained the possibility that pneumolysin was not present at a high enough concentration in
the above system and therefore did not exert any effect. Therefore, to allow an increase in the
pneumolysin concentration without affecting lymphocyte viability, I attempted to neutralise any
other toxic components that kill lymphocytes when the bacteria were used at higher concentrations
or longer culture periods. I had observed a change in pH of the medium when bacteria were grown
with lymphocytes and I therefore supplemented the medium with hepes buffer. Furthermore, I
proposed that hydrogen peroxide may be being released by S. pneumoniae which may adversely
affect lymphocyte viability. In order to assess the effects of pH change and hydrogen peroxide
release upon lymphocyte viability, I cultured lymphocytes in medium supplemented with hepes
buffer, catalase, or both. I used catalase to neutralise hydrogen peroxide.
In this experiment I used a starting concentration of bacteria of 3x lO CFU/ml of D39 and 5x l0
CFU/ml for PLY-. After 4 hours both D39 and PLY- recorded a CFUImI of 5x 10 CFU/ml. Clearly
this was a surprising result given the difference in initial bacterial concentrations between D39 and
PLY-. Bacteria were killed at this 4 hour time point and after a further 12 hours lymphocyte tiypan
blue exclusion (Figure 4-9) indicated that in cultures of medium alone, 80% of lymphocytes were
viable. Lymphocytes exposed to D39 or PLY- in un-supplemented medium had no viable cells. In
cultures supplemented with catalase, lymphocytes alone did not show any decrease in viability
compared to the control of medium alone. For lymphocytes exposed to D39 in medium supple-
mented with catalase 30% of cells were viable. For lymphocytes exposed to PLY- in medium
supplemented with catalase 60% of cells were viable. Therefore catalase is able to neutralise some,
but not all, of the toxic products from S. pneumoniae produced in co-culture. In cultures exposed to
D39 or PLY- in medium supplemented with catalase and hepes, 80% of cells were viable. There-
fore catalase and hepes used in combination are able to fully neutralise all of the toxic components
released upon co—culture of lymphocytes and S. pneumoniae.
To confirm the results from trypan blue exclusion and to utilise a more rapid method for assessing
lymphocyte viability I used annexinV / propidium iodide staining and flow cytometry. I used this
on the samples from the experiment above (Figure 4-10). The data obtained by this method was
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Figure 4-9
The effect of hydrogen peroxide on lymphocytes cultured with S.
pneumoniae
Cultures of lymph node cells prepared from BALB/c mice in complete RPMI
were inoculated with 3 x 1O CFU/ml D39 or 5 x 1O CFU/ml PLY-. Into
additional identical cultures, catalase alone, or catalase and hepes, was added.
The bacteria were incubated for 4 hours then antibiotics were added to kill the
bacteria. After a further 12 hours lymphocyte viability was measured by trypan
blue exclusion and the results are shown above.
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Figure 4-10
The effect of hydrogen peroxide on lymphocytes cultured with £ pneuinoniae
Cultures of lymph node cells prepared from BALB/c mice in complete RPMI were
inoculated with 3 x 1O CFU/ml D39 or 5 x 10 CFU/ml PLY-. Into additional identical
cultures catalase alone, or catalase and hepes, was added. The bacteria were incubated
for 4 hours then antibiotics were added to kill the bacteria. After a further 12 hours
lymphocyte viability was measured by anncxinV/PI.
4-17identical in pattern compared to the trypan blue data although the actual percentage of live cells in
each sample was generally 20% less than when using trypan blue.
The results above indicated that hydrogen peroxide was being released by the bacteria and was
toxic to the lymphocytes. The results also demonstrated that the p11 change in the medium was
toxic to the lymphocytes. By neutralising the hydrogen peroxide and buffering the medium, a
higher concentration of S. pneumoniae could be used before any decrease in lymphocyte viability
occurred. Increasing the bacteria concentration may increase the concentration of pneumolysin.
The results of these experiments are representative of two experiments
Pneumolysin does not appear to affect T cell proliferation when present as a component
of the whole pneumococcus and examined within these experimental systems.
As my previous data demonstrated that bacterially derived hydrogen peroxide was toxic for lym-
phocytes but that catalase in the medium could neutralise this, I again examined the effect of pneu-
molysin upon T cell proliferation. I utilised a higher concentration of bacteria than had been used in
the experiment of Figure 4-7 and 4-8.
I cultured lymph node cells in the presence of S. pneumoniae and measured the growth of the
bacteria. After 4 hours bacteria were counted and found to be at a CFU/ml of 5x 10. Lymphocyte
viability was then assessed (Figure 4-11). In medium alone lymph node cultures, viability was
55%. Culturing lymphocytes with bacteria did not decrease lymphocyte viability since 55% of
lymphocytes were alive in cultures containing bacteria.
I then used the treated lymphocytes in a proliferation assay to compare the effects of pretreating the
lymphocytes with bacteria that contained or lacked pneumolysin (Figure 4-12). As expected, the
unstimulated cells did not proliferate throughout the 72 hour time period examined. Untreated cells
stimulated with ovalbumin proliferated to 4 x 10 cpm within the first 48 hours rising to 2 x l0 cpm
after 72 hours. Cells pre-treated with D39 proliferated to 1.7 x 10 over 72 hours while those pre-
treated with PLY- proliferated to 1.8 x 10g . There is little difference between treated and untreated
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Figure 4-11
The effect on lymphocyte viability of growingS.pneumoniae with lymphocytes
in the presence of catalase and hepes.
D39 and PLY— were inoculated to a CFU/ml of 5 x 1O in cultures of single cell
suspensions made from DOl1.1O lymph nodes containing catalase and hepes. Af-
ter 4 hours bacteria were killed using antibiotics and after a further 12 hours the
viability of the lymphocytes was assessed using the Annexin V/PI assay.
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Figure 4-12
Proliferation of lymphocytes cultured with S. pneumoniae.
Lymph node cultures from DO 11.10 mice were set up and treated as outlined in
figure 4-11. After washing the cells in RPMI, they were set up in a proliferation
assay and stimulated with 1mg/mi ovalbumin and proliferation monitored over 24,
48 and 72 hours by thymidine incorporation. Unstimulated cultures are marked as
'cells' and are represented by a blue line. Cultures stimulated with ovalbumin are
marked as 'cells ova' and are represented by a pink line. Cultures of cells previously
treated with D39 and now stimulated with ovalbumin are denoted as 'D39 ova' and
represented as a yellow line. Cultures of cells previously treated with PLY- and now
stimulated with ovalbumin are denoted as 'PLY- ova' and represented as a turquoise
line.
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4-20lymphocytes upon stimulation and certainly very little difference between the lymphocytes pre-
treated with D39 and those pre-treated with PLY-. The results presented are representative of two
experiments.
Therefore, despite the increased concentration of bacteria present in the cultures, no observable
effect upon proliferation, resulting from the presence of pneumolysin, was obscrvcd using this
system. This is potentially due to the experimental system used however this point will be dis-
cussed further later.
4.2.2 The effect of purified pneumolysin on the T cell response
Although pneumolysin had not been observed to inhibit lymphocyte proliferation in the context of
the whole bacterium, I had concluded that the intrinsic difficulties involved m conducting these
assays meant that, while my results were accurate in terms of the experiments conducted they had
not yielded a conclusive result regarding the effect of pneumolysin upon murine T cell prolifera-
tion. Ferrante et a!. (Ferrante et a!., 1984) had utilised purified pneumolysin toxin to investigate the
effects of pneumolysin on lymphocytes and so I decided to pursue this line of enquiry.
4.2.2.1 The effect of pneumolysin upon T cell proliferation and cytokine
production.
As outlined in the introduction, proliferation and cytokine production are useful indicators of T cell
function.
Purified wild type pneumolysin inhibits antigen driven proliferation and F433 mutant
pneuniolysin does not.
I first of all measured the effect of purified wild type pneumolysin and the non lytic mutant F433
pneumolysin upon murine derived antigen specific T cell proliferation using lymph node single
cell suspensions from naive DO 11.10 mice.
4-21Lymph node cells that did not receive antigen did not proliferate throughout the 72 hour period.
Figure 4-13A illustrates that lymph node cells that were stimulated with ovalbumin had a detect-
able increase in the level of thymidine incorporation relative to unstimulated cells by 24 hours
however this difference becomes more evident by 48 hours when the stimulated cells have a cpm
value of 3.7 x 10 while the unstimulated cells have a cpm under 1000. By 72 hours the stimulated
cells have a cpm of 1.3 x 10 while the unstimulated cells remain under 1000 cpm. It is therefore
clear that antigen driven proliferation of the lymphocytes is taking place.
As can be clearly seen in Figure 4-13A pneumolysin inhibited antigen driven proliferation. Inhibi-
tion of proliferation was achieved most effectively with the highest dose of wild type pneumolysin
and was first evident after 48 hours when lymph node cells stimulated with ovalbumin and treated
with lOOng/mi of wild type pneumolysin have a cpm of 4000 compared to control cells stimulated
with ovalbumin alone that have a cpm of 3.7 x lO4at the same time point. However, the inhibitory
effect of bOng/mi wild type pneumolysin was most evident after 72 hours when the pneumolysin
treated cells stimulated with ovalbumin have a cpm of 6000 while the untreated cells stimulated
with ovalbumin have a value of 1.3 x l0 cpm; this represents a  95% inhibition. 7Ong!ml and 4OngI
ml wild type pneumolysin had a similar, but not quite as dramatic, inhibitory effect as lOOng/mi
resulting in values of 1.4 x 10 and 2.5 x l0 cpm after 72 hours respectively. lOng/mi was the
lowest concentration of pneumolysin used and resulted in the least inhibition; after 72 hours lymph
node cells stimulated with ovalbumin in the presence of lOng/mi pneumolysin proliferated to a
cpm of 1 x 10 cpm.
From this data it can be observed that wild type pneumolysin inhibits the proliferation of antigen
driven T cell proliferation in a dose dependent manner.
I also tested the effect of the pneumoiysin mutant 'F433' upon T cell proliferation within the same
assay. Therefore the stimulated and unstimulated controls were the same as outlined above. Figure
4-13B shows that in the presence of 100, 70, 40 and 10 ng/ml F433 pneumolysin ovalbumin stimu-
lated lymph node cells proliferated to a similar level as the stimulated control cells.
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Figure 4-13
Proliferation of murine antigen specific T cells in the presence of pneumolysin
Cultures of single cell suspensions from DO 11.10 mice were set up in a proliferation
assay and were stimulated with 1mg/mi ovalbumin. Pneumolysin was added
simultaneously with the ovalbumin at a final concentration of 10 (brown line), 40
(purple line), 70 (turquoise line) or 100 (yellow line) ng/mI. Proliferation was measured
by thymidine incorporation at 24, 48, and 72. Unstimulated cells are indicated by a
blue line. Stimulated but untreated cells are indicated by a pink line. Graph A represents
the proliferation of lymphocytes in the presence of wild type pneumolysin. Graph B
represents the proliferation of lymphocytes in the presence of F433 pneumolysin.
A - proliferation of lymphocytes in the presence of wild type
pneumolysin
time (hours)
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4-24This data shows that the F433 mutant pneumolysin does not inhibit antigen specific T cell prolif-
eration.
Cells that did not receive antigen did not proliferate in the presence of any dose of either wild type
or f433 pneumolysin and therefore I could conclude that pneumolysin was not exhibiting a mi-
togenic effect within these experiments. Furthermore upon repetition of this experiment 3 times,
similar results were obtained every time.
From all the data presented above we were able to conclude that wild type pneumolysin inhibits
murine antigen driven T cell proliferation and F433 pneumolysin does not.
Pneumolysin inhibits cytokine production by T cells.
Having observed that pneumo!ysin was ab'e to inhibit  T cell proifferation was interested to dis-
cover whither pneumolysin was able to inhibit the production of cytokines from T cells. I measured
the production of a variety of T cell cytokines from antigen specific lymphocytes stimulated with
ovalbumin in the presence or absence of pneumolysin. IL-2 is the major T cell growth factor and so
we measured it to allow me to determine if there was a correlation between inhibition of prolifera-
tion and IL-2 production. As further indicators of CD4 T cell function I also measured IFN-g since
this is produced as part of the T cell response to antigen.
Pneumolysin inhibits IL-2 production
Figure 4-14 shows the effects of pneumolysin upon IL-2 production. Unstimulated lymph node
cells did not produce any IL-2 over the 72 hour time period examined. After 24 hours cells stimu-
lated with ovalbumin produced a detectable level of IL-2 of O.3ng/ml. By 48 hours this has in-
creased to I .2ngIml and by 72 hours it is at 3 .8ng/ml. Inhibition of IL-2 production is most evident
using the highest concentration of wild type pneumolysin and is first detected after 24 hours when
cells stimulated with ovalbumin in the presence of 1 OOng/ml of wild type pneumolysin have no
detectable IL-2 in the medium. After 48 hours there is a small amount of IL-2 detectable at O.O6ng/
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Figure 4-14
The effect of pneumolysin on IL-2 production by lymphocytes
Lymph node single cell suspensions were made from naive DO 11.10 mice and were
set up in a cytokine assay. Where appropriate 1mg/mi ovalbumin was used and doses
of wild and F433 pneumolysin at 100 (yellow line), 70 (turquoise line), 40 (purple
line), 10 (brown line) ng/ml. At 24,48 and 72 hours the supernatants were harvested
and ELISA' s were carned out to detect IL-2. The effect of wild type pneumolysin is
displayed in A and the effect of F433 type pneumolysin is displayed in B. Unstimulated
controls are shown as a blue line and stimulated controls as a pink line.
A - IL-2 production by lymphocytes in the presence of wild type
pneumolysin
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4 - 26ml. By 72 hours 0.3ng/ml IL-2 is present, compared with the stimulated control which has 3.8ng/
ml by the same time. This represents a 92% inhibition. This pattern is repeated with 70 and 40 ng/
ml pneumolysin although the degree of inhibition is not quite as large since  0.6ngIml of IL-2 is
produced by 72 hours in both cases. lOng/mi pneumoiysin inhibits IL-2 production to a lesser
degree than the higher concentrations of pneumolysin since after 72 hours 3 .4ng/ml IL-2 is found
in the medium which is not significantly less than the 3.8ng/nl produced by the stimulated cells
alone.
I concluded that pneumolysin was inhibiting the antigen driven production of IL-2 by T cells in a
dose dependent manner within this system.
I was also interested to note whether F433 pneumolysin exerted any effect upon IL-2 production.
The same controls were used for this part of the assay as those used for the wild type so the
unstimulated cells produced no IL-2 over the 72 hour time course but the stimulated cells produced
IL-2 detectable after 24 hours and rising to a final level of 3.8ng/ml in the medium after 72 hours.
Stimulating the cells with ovaibumin in the presence of 100, 70, 40 or 10 ng/ml F433 pneumolysin
did not alter the amount of IL-2 produced relative to the untreated stimulated control.
I concluded that F433 pneumolysin did not inhibit the production of IL-2 by antigen stimulated T
cells.
Pneumolysin inhibits IFN-g production
Figure 4-15 shows the results of the ELISA carried out to determine the effect of pneumolysin
upon lymphocyte production of IFN-g. After 24 hours unstimulated lymph node cells had pro-
duced IFN-g to a level of lng/ml in the medium. In the following 48 hours this decreased so that by
72 hours there was no detectable amount of IFN-g in the lymph node culture. After 24 hours the
lymph node cultures stimulated with ovaibumin had produced IFN-g to a level in the medium of
4.8ng/ml, rising to 3Ong/mi by 48 hours and finally 4Ong/ni after 72 hours.
Lymph node cells stimulated with ovalbumin in the presence of 4Ong/mi wild type pneumolysin
produced less IFN-g over the 72 hour time period examined compared with the untreated stimu-
lated control. This was first detected after 24 louwhen pneumolysin treated cells had produced4
3.5
2.5
c'J
-J
1.5
0.5
0
B - IL-2 production by lymphocytes in the presence of F433 pneumolysin
5
4.5	
S
24hr	 48hr	 72hr
time (hours)
-4-- cells
cells + ova
cells + ova + f 433 ply 100
cells + ova + f 433 ply 70
-*- cells + ova + f 433 ply 40
—.--cefls^ova+f433plylO
4 - 2845
40
35
Effect of pneumolysin on IFN-gamma production
30
E
c25
S	 /
z
LL	 I
-	 / I.t
24	 48	 72
time (hours)
—a—cells
- -- cells ova
cells ova wild
cells ova f 433
Figure 4-15
The effect of pneumolysin on IFN-gamma production by lymphocytes
Lymph node single cell suspensions made from naive DO 11.10 mice and were set up in
a cytokine assay. Where appropriate 1mg/mi ovalbumin was used and doses of wild
(yellow line) and F433 (turquoise line) pneumolysin at 40 ng/ml. At 24, 48 and 72
hours the supernatants were harvested and ELISA' s were carried out to detect IFN-
gamma. Stimulated controls are shown as a pink line. Unstimulated controls are shown
as a blue line.
4-29IFN-g to 1 .9ng/ml compared to 4.8nglml by the untreated control. This difference was more notice-
able at 48 and 72 hours when the pneumolysin treated cells produced IFN-g to 4.4 and 5.9ng/ml,
respectively, compared to the stimulated control of 30 and 4Ong/ml at the same time points.
These results mean that pneumolysin markedly inhibits IFN-g production by antigen stimulated T
cells.
Lymph node cells stimulated with ovalbumin in the presence of 4Ong/ml F433 pneumolysin pro-
duced IFN-g to a higher level over the first 24 hours than the cells stimulated with ovalbumin
alone; 14.1 nglml compared to 4. 8ng/ml for the ovalbumin alone. However, by 72 hours the cells
stimulated with ovalbumin in the presence of the F433 pneumolysin had produced an equivalent
amount of IFN-g compared to cells stimulated with ovalbumin alone of 4Ong/ml. From this I con-
cluded that the F433 mutant pneumolysin does not alter IFN-g production
These findings led me to conclude that wild type pneumolysin inhibits CD4 T cell cytokine pro-
duction and that F433 pneumolysin does not. I had not, however measured cytokine production on
a 'per cell' basis and so we could not conclude that pneumolysin actually prevented individual cell
cytokine production. It therefore remained unclear if the inhibition in cytokine production was the
function of inhibition of proliferation or if it was a separate inhibitory mechanism. Taken together
the above data demonstrates that wild type pneumolysin is able to inhibit T cell function.
4.2.2.2 The effect of pneumolysin on resting lymphocyte viability
There remained the possibility that wild type pneumolysin was causing the inhibitory effects out-
lined above by simply lysing the resting lymphocytes. I therefore wanted to confirm that the effects
I was observing were not the result of resting cell lysis but were due to some other mechanism and
that the concentration of toxin we were using was non-lytic.
Ann exin V/Fl
I measured the effect of pneumolysin upon resting lymphocyte viability by assessing their viability
after 12 and 24 hours using the AnnexinV/PI assay. Figure 4-16 illustrates that after 12 hours 75%
of untreated cells are alive. Comparably only 40% of cells treated with l000ng/ml wild type pneu-
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The effect of pneumolysin on lymphocyte viability as assessed using Annexin VIP!
Lymph node single cell preparations were made from BALB/c mice and treated with
1000, 100 or 40 ng/ml of wild or F433 type pneumolysin. Cell death was measured
using the Annexin V/PI assay at 12 (A) and 24 (B) hours. Cells were classified as being
either apoptotic, nucleated (nuc), dead or alive depending on their AnnexinV/PI char-
acteristics; An+ P1+ = dead. An+ P1- = apoptotic. An- P1+ = nucleated. An- P1- = live.
4-31Effect of pneumolysin upon lymphocyte viability after 12 hours as measured
by LDH release
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Figure 4-17
The effect of pneumolysin on lymphocyte viability as assessed using AnnexinV/PI
Lymph node single cell preparations were made from BALB/c mice and treated with
1000, 100 or 40 ng/ml of wild or F43 3 type pneumolysin. Cell death was measured using
the LDH assay at 12 (A) and 24 (B) hours. Cells treated with lysis solution were taken to
be 100% lysed and used as the baseline to calculate the other data.
4-32molysin are alive while 68% of cells treated with bOng/mi of wild pneumolysin are alive.  75% of
cells treated with 4Ong/ml of wild type pneumolysin are alive after 12 hours. After 24 hours the
number of live cells within the untreated group of lymph node cells had decreased to 65%. The
same pattern as that observed at 12 hours was evident; l000ng/ml wild type pneumolysin induced
50% decrease in viability while lOOng/mi wild type pneumolysin caused a small decrease in viabil-
ity and 4Ong/ml wild type pneumolysin did not cause any decrease in viability compared with the
untreated control group.
Throughout the two time points examined treating the cells with F433 pneumolysin of any concen-
tration did not alter the viability of the resting cells when compared with the untreated control
group. Also of note is that there was no changes in the way cells were dying between groups in that
the proportions of apoptotic or nucleated cells did not increase within any group.
From this I can conclude that 4Ong/ml of wild type pneumolysin does not cause lysis of the resting
lymphocytes whereas it does cause significant inhibition of proliferation, and IL-2 and IFN-g pro-
duction.
LDH
In order to confirm the data reported in Figure 4-16, I used the LDH assay as a further measure of
cell lysis. The results (Figure 4-17) demonstrate that 4Ongfml of wild type pneumolysin does not
cause lysis of resting lymphocytes.
Taking both the Annexin V /PI data and the LDH data together I concluded that 4Ong/ml pneumo-
lysin was a non lytic dose of pneumolysin. Therefore experiments where pneumolysin was ob-
served to inhibit T cell function was not due to cell lysis but must represent another mechanism.
Both experiments were repeated twice and the results presented above are representative of all the
experiments
4.2.2.3 Pneumolysin appears to inhibit T cell division
4 - 33It seemed most likely that pneumolysin was inhibiting the proliferation of ovalbumin specific T
cells in Figure 4-13 since the antigen used was specific for the T cells. There remained the possibil-
ity, however, that thymidine incorporation was recording the proliferation of both antigen specific
T cells and other cell types present in the lymph node preparation such as B cells. This then opened
the possibility that pneumolysin was not acting upon the T cells but upon another cell type. In
addition thymidine incorporation used in Figure 4-13 does not necessarily measure cell division,
but rather measures DNA replication. To clarify and confirm that my conclusions from Figure 4-13
were correct; i.e. that pneumolysin was inhibiting the proliferation of antigen specific T cells I
wanted to measure directly the effect of pneumolysin upon the T cell and upon cell division. The
fluorescent cell dye CFSE in conjunction with flow cytometric analysis allowed us to do this.
I measured the fluorescence intensity of transgenic T cells stained with CFSE over a period of 144
hours in order to assess the number of cell divisions that had taken place. I also assessed the effect
of pneumolysin upon the number of cell divisions. Figure 4-18 shows that unstimulated cultures
did not divide throughout the time period examined. Figure 4-18 also demonstrates that in cultures
that received ovalbumin only a small amount of cell division took place during the first 72 hours
since 95% of cells remain undivided (CFSE high) while only 1% of cells have divided once. How-
ever in the succeeding 24 hours from the 72 hour time point, cell division of the stimulated cells
begins to occur. After 96 hours only 32% of cells stimulated with ovalbumin remain undivided. A
further 4% have made one division while 52% have divided up to 7 times or more. Stimulating with
ovalbumin and treating the cells with wild type pneumolysin alters the cell division cycle com-
pared to untreated cells since after 96 hours 73% remain undivided while 11% have divided 7 times
or more. Treating the cells with F433 pneumolysin and ovalbumin does not affect the cells since
after 96hrs, 19% of the cells remain undivided and 66% are divided 7 times or more. The inhibitory
effects of wild type pneumolysin are observed at 120 hours and 144 hours also. Of the cells stimu-
lated with ovalbumin alone, 9% remain undivided after 120 hours and 82% have divided 7 times or
more. At the same time point 34% of cells treated with wild type pneumolysin remain undivided
and 46% have divided 7 times or more. After 144 hours 7% of cells stimulated with ovalbumin
alone remain undivided compared to the wild type pneumolysin treated cells for which 18% are
undivided. 83% have divided 7 times or more when stimulated with ovalbumin compared to 66%
for those treated with pneumolysin. At both time points T cells treated with F433 pneumolysin had
a comparable number of divided cells to the T cell stimulated with ovalbumin alone.
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Figure 4-18
The effect of pneumolysin upon lymphocyte cell division as assessed by CFSE
staining
Lymph node cell suspensions were prepared from DOl1.10 mice and stained with
CFSE. These cells were then cultured with 1mg/mi ovalbumin and 40 ng/ml of wild or
F433 type pneumolysin over a 144 hr time period. By staining for CD4-PerCP and
biotynilated KJ1.26 conjugated to Streptavidin-PE we were able to measure the
fluorescence intensity of the transgenic T cells using the flow cytometer. The cell
division status of each group we measured at 48 (A), 72(B), 96(C), 120 (D), and 144
(E) hours. Unstimulated cells are presented as blue bars. Stimulated cells are red bars.
Cells stimulated in the presence of wild type pneumolysin are presented as yellow bars
and those stimulated in the presence of f433 pneumolysin are turquoise bars
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Data obtained from Figure 4-18
Some of the histograms obtained from the flow cytometry carried out in Figure 4-18 are shown. (A)
shows the data obtained at 72 hours from cells stimulated with ovalbumin. (B) and (C) show the
same group at 96 and 120 hours respectively.
4 - 37From these observations I concluded that our presumptions based on our observations in Figure 4-
13 were correct and that pneumolysin was inhibiting antigen specific T cell division. Furthermore,
repetition of this experiment confirmed these results to be accurate and repeatable.
4-384.3 Discussion
In this chapter I have demonstrated that the toxin pneumolysin produced by  Streptococcus
pneumoniae is able to inhibit the proliferation and cytokine production of murine T cells. This
occurs by a mechanism distinct from direct cell lysis by the toxin. In the context of the whole
bacteria pneumolysin was not observed to have the same ability.
In this chapter I used ex vivo DO 11.10 cells to study the effect of a potential immunomodulator on
the T cell response to bystander antigen. This is a system that has been used before (Matsue et a!.,
2002) to assess the impact of immunomodulators upon the T cell response.
The discrepancy between my findings using the whole bacteria (Figure 4-12) and those using the
purified toxin (Figure 4-13) has a number of explanations. Other researchers have found the toxic-
ity of the whole bacteria problematic in these sorts of systems and have resorted to using heat killed
bacteria (e.g. (Madsen eta!., 2000) (Arva and Andersson, 1999a, b; Colino and Snapper, 2003 a)).
I chose to use live bacteria to enable pneumolysin production and release however this introduced
unknown variables that were difficult to control for. The variables included; variance of the inocu-
lum dose between strains within an experiment and also inoculuin variance between experiments.
Related to this, but distinct, is the potential variation in strain growth rate  in vitro. Any factor
released or produced by the pneumococcus may affect the experiment and thereby introduce an
unknown variable that cannot be controlled for. Furthermore the synergy or compensation of re-
leased factors with each other could introduce further variables into the experiments. Finally, within
my experiments the concentration of pneumolysin was unknown. I attempted to address some of
these variables within our experiments. I tried to ensure inoculum consistency at all points. I ad-
dressed the releases of hydrogen peroxide by the pneumococcus. I also tried to address the concen-
tration of pneumolysin.
I succeeded in ensuring inoculum consistency between strains in all experiments except one (Fig-
ure 4-9) however the difference in this experiment between D39 and PLY- seems likely to be the
result of an error of measuring the initial inoculams considering the consistency later in the experi-
ment. There is more variation when considering inoculum consistency between experiments. For
example in Figure 4-7 we had hoped to add Sx 10 CFU/ml but the resulting CFU/ml was lx 10,
4-39however all of this variation was recorded and none of it would have had significant impact upon
the experiments. Previous work has demonstrated that the PLY- mutant shows no in vitro growth
defect when compared to the wild type pneumococcus ((Berry eta!., 1989))and so I could reason-
ably assume that this potential variable could be dismissed.
In identifying hydrogen peroxide as a toxic factor I succeeded in removing the toxic effect of
released factors from the pneumococcus. This however does not exclude the possibility that an-
other non toxic released factor may act in these experiments. My identification of hydrogen perox-
ide as a toxic factor is in keeping with studies carried out on the pneumococcus that show that
hydrogen peroxide is produced by the bacteria and in quantities sufficient enough to exert a toxic
effect on other bacteria (Pericone et a!., 2000).
I succeeded in my attempt to increase the final concentration of bacteria despite the similarity in
starting inoculum between the experiments of Figure 4-7 and Figure 4-11 (starting inoculum of lx
10 CFU/ml and 5x 10 CFU/ml respectively). In Figure 4-7 the final concentration was lx 106
CFU/ml while in Figure 4-11 the final concentration of bacteria is 5x 10 CFU/ml. At the time of
conducting these experiments I was unaware of the concentration ofpneumolysin required to exert
an inhibitory effect of lymphocytes and I therefore did not measure the concentration of pneumo-
lysin. In retrospect this would have been a good idea as it would have allowed me to compare my
data more directly with the work done using the purified toxin and thereby assess whether inhibi-
tory concentrations ofpneumolysin in the medium were reached using the co-culture system. There-
fore despite my attempts to increase the concentration ofpneumolysin there remains the possibility
that concentrations within my experiments was insufficient. The only indication on this matter
comes from the data of Houldsworth eta!. (Houldsworth eta!., 1994) who estimated lx 10 pneu-
mococci to be equivalent to 1 Opg of pneumolysin. I would estimate therefore that in our experi-
ments a fmal concentration of 5x 10 CFU/ml pneumococci would give 500ng/ml of pneumolysin.
From retrospective data using the purified toxin I can suggest that this is a more than adequate
concentration of toxin to observe an inhibitory effect.
Despite the recent studies by Balachandran eta!. (Balachandran eta!., 2001) which demonstrated
that the release ofpneumolysin is not dependent on the production of autolysin for the strain WU2,
the data for other strains seems to indicate that pneumolysin release is autolysin dependent (Lock
et a!., 1992). It is therefore a possibility that in my cell culture experiments, the conditions present
4 - 40did not meet the requirements for the release ofpneumolysin into the medium. Recently it has been
demonstrated that release of pneumolysin is inhibited by the presence of erthromycin and this may
also be a factor in our experiments (Lagrou et a!., 2000). Furthermore despite another demonstra-
tion that penicillin enhances the release of pro-inflammatory products from the pneumococcus
(Moore et a!., 2003), this effect was autolysin dependent.
I considered the possibility that the experimental procedure may also be responsible for the lack of
inhibitory effect observed using the whole bacteria. Walev et al. (Walev et a!., 2002)found that
pores formed in the membrane by streptolysin 0 were resealable. Furthermore Walev et a!. (Walev
et a!., 1 995)found that streptolysin is shed from the membrane over time. The experimental proce-
dure involving washing cells after exposure to the toxin may allow resealing or increased shedding
of toxin from the membrane which may result in lack of inhibitory effect. In conflict with this
proposal is the data of Ferrante et a!. (Ferrante et a!., 1984) who washed the cells after toxin
exposure yet still observed toxin activity. Another possibility is that of thiol activation. For many
years thiol activation was thought to be required for the function of the CDC's, hence the reason for
them being called the Thiol Activated Cytolysins, however it was repeatedly demonstrated that
thiol activation is not a requirement for toxin activity (Pinkney eta!., 1989; Saunders eta!., 1989)
when the toxin is purified. However thiol activation may be required when the toxin is not in a
purified form and this could be a reason for the lack of effect since the toxin is not purified.
Further investigation is required to elucidate which of the variables outlined is finally responsible
for the discrepancy between the effect of pneumolysin in the context of the whole pneumococcus
and in purified form. My data suggests that inoculum and growth variance is not responsible as
does previous work on the growth rate of PLY-. My data also excludes the possibility of a toxic
factor being the responsible variable. My work on the concentration and release of pneumolysin is
inconclusive and therefore these remain potential variables responsible for the difference between
results using the whole bacteria and the purified toxin. Further work is required in this area.
As observed in the introduction to this thesis, studies using pneumolysin strains in which the gene
has been deleted have yielded much information regarding the role of pneumolysin in the patho-
genicity of the pneumococcus. To a much lesser degree pneumolysin deficient strains of the pneu-
mococcus have also been used in vitro to study the effect of pneumolysin. The effect of pneumo-
lysin upon brain cells has been examined in this way (Hirst eta!., 2000; Zysk eta!., 2001), as has
4-41the effect on endothelial cells (Rubins et a!., 1992). Perhaps most relevantly, Zysk et a!. (Zysk et
a!., 2000) used a pneumolysin deficient strain to examine the effect of pneumolysin upon the in-
duction of apoptosis of neutrophils.
My results (Figure 4-13), showing the inhibitory effect of purified wild type pneumolysin upon
lymphocytes are consistent with the data of Ferrante et a!., (Ferrante et a!., 1984), however my
results extend these findings. These studies demonstrated that pneumolysin could inhibit the mi-
togenic induced proliferation of human lymphocytes; here I have demonstrated that antigen spe-
cific proliferation can be inhibited and that murine T cells are susceptible. The human specificity of
a member of the CDC's (e.g. Intermedilysin (Nagamune  eta!., 1996)) is currently attracting inter-
est and it is therefore pertinent that this ability of pneumolysin to inhibit lymphocyte proliferation
is not confined to human lymphocytes but reflects the species non-specificity of its other functions.
I had hoped that the use of the F433 mutant pneumolysin would give me insight into the mecha-
nism of pneumolysins inhibitory activity. The controversial nature of the effects of mutations in the
Trp rich region of the CDC's was outlined in the introduction to this thesis. Here the work of
Boulnois eta!. was examined (Boulnois eta!., 1990) and others (Imaizumi eta!., 2003; Korchev et
a!., 1998; Michel eta!., 1990) who produced data that showed that the F433 mutant or the equiva-
lent in other CDC's still bound to cells but was dysfunctional in pore formation. This data was
challenged by Sekino-Suzuki et a!. (Sekino-Suzuki eta!., 1996) who showed that in perfringolysin
mutations of the Trp 's in the undecapeptide region resulted in decreased cell binding. I have not
examined cell binding and so my data does not enlighten this controversy however the interpreta-
tion of my studies using the F433 pneumolysin mutant is clearly dependent on the work mentioned
above. If the work of Boulnois eta!. (Boulnois eta!., 1990) and others, who have suggested that the
F433 mutant retains full binding capacity is correct, then I would conclude that the lymphocyte
inhibitory activity of pneumolysin that I have observed is dependent on the ability to form func-
tional membrane pores. In contrast, if the work of Sekino-Suzuki et a!. is accurate then I would
simply conclude that cell binding is required for this activity of pneumolysin. As discussed in the
introduction a mutant strain of S. pneumoniae containing the F433 mutant pneumolysin has been
made and was shown to cause reduced virulence in vivo compared to the wild type strain but its
virulence was intermediate when comparing the wild type and PLY- strains (Berry  et a!., 1995).
4 - 42In Figures 4-14 and 4-15 data is displayed regarding the effect of wild type pneumolysin upon the
production of cytokines by antigen driven T cells. I demonstrated that wild type pneumolysin is
able to inhibit T cell cytokine production as evidenced by the decreased production of IL-2 and
IFN-g. My method did not measure the absolute production of cytokines per cell but rather as a
population of cells, therefore I cannot conclude from our data that pneumolysin inhibits the pro-
duction of cytokines from each cell but rather that pneumolysin inhibits the production of cytokines
from the whole population. This represents a distinct difference in mechanism since the former
would represent a direct activity of pneumolysin upon cytokine production whereas the latter would
mean that decreased cytokine production was simply a function of the effect on proliferation.
My data in Figure 4-16 and 4-17 showing that pneumolysin is not lytic for lymphocytes at 4Ong/ml
is consistent with the data of Walev et al (Walev et al., 2001). These researchers found that treating
the THP cell line with concentrations of 100 - 2Ong of streptolysin 0 resulted in cells remaining
viable. They made the interesting observation simultaneously that at these concentration pore for-
mation occurs yet does not alter cell viability. 4Onglml pneumolysin may therefore be forming
membrane pores despite there being no change in cell viability. This may be pertinent to the mecha-
nism of action
In the introduction to this thesis it was observed that pneumolysin affects different cell types to a
differing degree. Each cell type has a different sensitivity to pneumolysin (Hirst et a!., 2002). For
example, while we found lymphocytes to be sensitive to lOOng/ml pneumolysin, it was discovered
that the effect of pneumolysin upon alveolar epithelial cells (Rubins  et a!., 1993) and found that
lSOng/ml was toxic to these cells. Studies on the effect ofpneumolysin on human neutrophils have
found that in calcium free medium, cell lysis measured by LDH, was 40% when pneumolysin was
present at 4OngImI (Cockeran et a!., 2001b). Comparing this data with my data where I observed
concentrations of pneumolysin greater than 4Ong/ml to affect lymphocyte viability, I can conclude
that neutrophils are more sensitive than lymphocytes to lysis by pneumolysin.
Some have used the LDH assay to measure the lytic effects of pneumolysin upon spleen cells
(Baba et a!., 2002). They found that around 300ng/ml of pneumolysin caused 35% lysis of spleen
cells while 2600ng/ml of pneumolysin caused 75% lysis. This would suggest that spleen cells are
4 - 43not as sensitive to pneumolysin as lymph node cells when taking our data into comparison. Others
found that 0.1mg - 10mg/mI of pneumolysin induced microgilial cell apoptosis but did not make a
study of the lytic ability in this situation (Braun et al., 2002). The ability to induce lysis of mono-
cyte and epithelial cell lines was studied and it was found that concentrations of around 7-7Ong/ml
ofpneumolysin induced significant lysis of both cell lines (Hirst eta!., 2002). Feldman eta!. found
that bOng/ni pneumolysin caused significant damage to epithelial cells  in vitro (Feldman et a!.,
2002) while Johnson et a!. found that at around 9Ong/ml pneumolysin, 50% ofpolymorphonuclear
leukocytes are lysed. (Johnson eta!., 1981) .My results add to the data on the differing sensitivity
of cells to pneumolysin. I note the differing hemolytic activity per mg of pneumolysin between
researchers and therefore suggest that only when using the same preparation of toxin can a true
comparison be made.
The data I have obtained using in vitro CFSE analysis shows few intermediate cell divisions. For
example in Figure 4-19 C around 30% of stimulated cells are in ml and 50% in m7 yet only around
5% are in m2-6. The reason for this may be due to the nature of in vitro cell division which has been
noticed to be asynchronous. The asynchrony is the result of different entry times into the cell
division cycle as opposed to differences in the length of the cell division cycle (Hasbold et a!.,
1999; Lyons, 2000). It is therefore possible that the lack of intermediate divisions observed in my
data results from asynchronous entry into cell division but rapid progress through the cell division
cycle once it has been initiated. Furthermore my data shows that not all of the percentages within
each group add up to 100%. This is because some death occurs with each round of cell division
(Usherwood et a!., 1999) but they clump together to form CFSE "high" particles that remain within
the gated areas.
My data in this chapter has clearly demonstrated that pneumoiysin is able to inhibit lymphocyte
function however the mechanism by which pneumolysin acts remains unclear. As I saw in intro-
duction to this thesis, the inhibition of lymphocyte function is a common pathogen
immunomodulatory mechanism. I noted that Yersinia pseudotuberculosis, Nesseria gonorrhoeae,
Acanthochei!onema viteae and Staphylococcus aureus are all examples of pathogens that target T
cell function. I also examined the different mechanism by which pathogens accomplish this altera-
tion of T cell function. I noticed that some pathogens alter cell signalling to cause decreased T cell
activation, while others induce T cell anergy or apoptosis. Of particular interest at this point in my
4 - 44investigation into the inhibitory effect of pneumolysin is the studies carried out by Darji et a!.
(Darji et a!., 1997) who observed that listeriolysin induced T cell anergy via alteration of DC's. I
therefore went on to investigate the mechanism by which pneumolysin may be accomplishing the
inhibitory effect on T cell function observed in this chapter.
4-455 Dissecting the T cell inhibitory mechanism
of pneumolysin in vitro.
5-i5.1 Introduction
Pathogens have been observed to utilise a number of distinct mechanisms to inhibit T cells. Pneu-
molysin, produccd by Streptococcus pneumoniae, modulates T cell function. The mechanism pneu-
molysin uses to accomplish this remains unclear and there exists a number of possible options.
From my studies presented so far it is not clear if pneumolysin acts directly upon the T cell or in an
indirect way. Acting in an indirect manner, pneumolysin may affect accessory cells found in the
lymph node preparation which may then act upon the T cell or the accessory cells may release a
factor which acts on the T cell. Alternatively pneumolysin may act directly upon the T cell to cause
the inhibitory mechanism. The points on the T cell activation pathway upon which pneumolysin
could act are shown in Figure 5-1.
The effects of pneumolysin upon cells such as macrophages and neutrophils have been outlined
earlier in this thesis. These cell types are contained within a lymph node preparation such as that
used in Figure 4-13. It is possible that pneumolysin could stimulate the release of a factor from one
of these cells that subsequently acts on the T cell. For example nitric oxide could be released by
macrophages (Braun et a!., 1999) which could result in T cell inhibition. A similar situation was
observed with the nematode worm Brugia malayi which inhibits the T cell response in vitro (Jenson
et a!., 2002) through stimulation of nitric oxide from macrophages which in turn inhibits T cell
proliferation.
Acting on the APC, pneumolysin could alter antigen uptake, antigen processing, antigen presenta-
tion or costimulatory molecule upregulation. An effect on any one of these could cause an inhibi-
tory effect on the T cell. Listeria monocytogenes releases the CDC, listeriolysin, which indirectly
inhibits I cell proliferation by acting upon the APC (Darji et a!., 1997).
Finally, pneumolysin may act directly upon the T cell and may alter T cell upregulation of activa-
tion markers such as CD25, which is part of the IL-2 receptor, or may inhibit cytokine release or
finally may induce anergy or apoptosis of the T cell. Vac A toxin from Helicobacterpylori inhibits
the T cell response by inhibiting the production of IL-2 by preventing the translocation of NFAT
within the T cell (Gebert et aL, 2003). Also, the introduction the effect of the filarial nematode
5-2product ES-62 upon T cells is to induce T cell anergy (Hamett  eta!., 1998). Furthermore aerolysin
causes the induction of T cell apoptosis (Nelson eta!., 1999).
The examples given for each mechanism serve to highlight the fact that all of the possible inhibi-
tory mechanisms are used by at least one pathogen and therefore could be used by pneumolysin.
Given the range of potential mechanism by which pneumolysin may be acting, I decided to
sequentially analyse each possibility (see Figure 5-1).
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Figure 5-1
The T cell activation pathway.
The points at which an immunomodulator could act on the T cell activation pathway are mdi-
cated by a pink arrow.
5-45.2 Results
5.2.1 The role of accessory cells in the inhibitory activity of
pneumolysin
Inhibition of T cell proliferation had been observed in experiments using mixed cell populations
(Figure 4-13) where dendritic cells, macrophage, T cells and B cells are all present. The possibility
remained that pneumolysin's inhibitory effect upon the T cell was via an indirect mechanism in-
volving another cell type such as the macrophage. To address this problem I purified T cells and
thereby removed all other cell types.
5.2.1.1 The requirement of accessory cells for the T cell inhibitory activity
of pneumolysin
The first step in examining the inhibitory mechanism of pneumolysin was to remove accessory
cells from the environment where T cell inhibition by pneumolysin had previously been observed.
I selected the proliferation assay of Figure 4-13 as the assay to mimic. By purifying the T cells and
culturing them with BMDC, I addressed the question of the necessity of accessory cells.
Accessory cells other than DC's are not required for inhibition
I measured the effect of accessory cells upon pneumolysin's inhibitory activity by using purified
BMDC and purified Tg T cells within a proliferation assay. Figure  5-2 demonstrates that in cul-
tures containing DC and T cells alone, T cells did not proliferate throughout the 72 hour period
examined. Cultures of DC and T cells with ovalbumin had minimal thymidine uptake within the
first 24 hours, however by 48 hours thymidine incorporation had increased to give a cpm of 6 x lO
and by 72 hours, 1.8 x I O cpm. In comparison, cultures of DC and T cells with ovalbumin and
wild type pneumolysin had a cpm at 48 hours of 1.5 x 1O and 5 x lO at 72 hours. This represents
5-5Proliferation of D011 .10 1 cells in the presence of pneumolysin
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Figure 5 - 2
The effect of pneumolysin upon T cell proliferation in the absence of
accessory cells
BMDC were used on day 7 of culture as APC and T cells were isolated from
DO1l.l0 transgenic mice and purified. A proliferation assay was set up us-
ing 1mg/mi ovalbumin and 4Ong/ml of wild or F433 pneumolysin where
appropriate. The ratio of DC to T cells was 1:40 to give a final number of
cells per well of a standard 96 well proliferation plate of 2x 1 0. Proliferation
was measured by thymidine incorporation at 24,48,72 hours. Cultures con-
taming no antigen but both cell types are represented as a blue line. Cultures
stimulated with ovalbumin are presented as a pink line. Cultures stimulated
with ovalbumin in the presence of wild or f433 pneumolysin are presented as
a yellow and turquoise line respectively. Unstimulated cultures with wild or
f433 type pneumolysin are presented as a purple and brown line respectively.
5-6a 75% inhibition of the control when wild type pneumolysin is present. In this system F433 pneu-
molysin did not alter T cell proliferation compared to the control. The data presented in Figure 5-2
are representative of at least 3 experiments. (Purified T cells alone did not proliferate with antigen.
Data not shown.) I also measured the effect of pneumolysin on the viability of BMDC and ob-
served no effect of pneumolysin upon BMDC (data not shown). This ensured that in this system
pneumolysin was not acting by killing the BMDC and thereby reducing proliferation.
Overall, the data demonstrated that pneumolysin must be acting directly upon the APC or the T cell
and was not causing the release of an accessory cell factor that was subsequently causing T cell
inhibition.
5.2.1.2 The effect of pneumolysin upon APC independent proliferation
There remained the possibility that pneumolysin could be inducing the release of a factor by the
BMDC that caused T cell inhibition. I therefore measured the effect of pneumolysin upon APC
independent proliferation by stimulating purified T cells with lonomycin and PMA.
The data in Figure 5-3 shows that only in the presence of both lonomycin and PMA do T cells
proliferate. T cells stimulated with Jonomycin and PMA proliferated by 48 hours to give a cpm of
1.2x lO cpm and by 72 hours, 2x 1O cpm. In comparison T cells stimulated with lonomycin and
PMA in the presence of wild type pneumolysin proliferate to 9x 1O cpm after 48 hours and 1.5x
lO cpm after 72 hours. This represents a 25% inhibition of proliferation which clearly illustrates
that pneumolysin is inhibiting the APC independent proliferation of T cells. This data is repre-
sentative of at least two experiments.
The data from the above two experiments (Figure 5-2 and 5-3) led me to deduce that pneumolysin
was able to inhibit T cell proliferation directly and did not require the presence of any accessory
cells and therefore was not acting by inducing the release of a factor from an accessory cell. In
addition I was able to conclude that pneumolysin did not require the presence of the APC's for T
cell inhibition to be observed. However the data presented in Figure 5-3 was not as convincing as
that which was presented in Figure 5-2 and so I examined some of the factors associated with
antigen presentation that pneumolysin may interfere with.
5-7The effect of pneumolysin upon the proliferation of purified
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Figure 5-3
The effect of pneumolysin upon APC independent proliferation
Purified T cells were isolated from BALBIc mice. A proliferation assay was set up
using 5OngIml PMA and luM lonomycin along with 4Ong/ml of wild pneumolysin
where appropriate. lx 1O T cells per well were used. Proliferation was measured by
thymidine incorporation at 24, 48, 72 hours. Cells stimulated with only one of
lonomycin or PMA are represented by turquoise and blue lines respectively. Stimulated
cells are represented by the pink line while cells stimulated in the presence of wild
type pneumolysin are represented as a yellow line.
5-85.2.1.3 Pneumolysin does not affect the antigen processing ability of the
APC.
Although my work using the APC independent system had demonstrated that pneumolysin was
capable of acting directly upon the T cell I wanted to assess whether in this system pneumolysin
was acting exclusively on the T cell or was exerting a synergistic effect by acting on the T cell and
APC. In order to address the question of whether pneumolysin was acting on the APC and how
pneumolysin may be acting upon the T cell, I began to investigate the sequential steps in the T cell
activation pathway.
Figure 5-1 illustrates the T cell activation pathway. The first step in the pathway is antigen process-
ing. By using peptide fragments as antigen, the requirement for antigen processing prior to presen-
tation was avoided. I used ovalbumin peptide as antigen within whole DO 11.10 lymph node prepa-
ration cultures since I had demonstrated the irrelevance of other cells present within the whole
lymph node preparation.
Figure 5-4 shows that unstimulated cells did not proliferate throughout the time period examined
however cells stimulated with ovalbumin peptide began to proliferate within the first 24 hours to
record a cpm of 6 x 10g. By 48 hours this had increased to 3 x 10 cpm and by 72 hours, 7 x l0 cpm.
Stimulated cells incubated with wild type pneumolysin proliferated less than the control; At 48
hours the cpm was 1.7 x 10 compared to the untreated value of 3 x 1O, and after 72 hours cells
incubated with wild type pneumolysin record a cpm of 3 x I 05 compared to the untreated control
value of 7 x 10 cpm. This means that, where present, wild type pneumolysin is causing a 42%
inhibition of peptide stimulated proliferation. Cells stimulated with ovalbumin peptide and treated
with F433 pneumolysin recorded similar values compared to the control of cells and peptide alone.
The data in Figure 5-4 is representative of at least 3 experiments.
From this data I were able to conclude that pneumolysin does not act by interfering with antigen
processing since it is still able to exert an inhibitory effect even when antigen processing is re-
quired.
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Figure 5 - 4
The effect of pneumolysin upon antigen processing by APC
Lymph node single cell suspensions were prepared from DO11.1O mice.
Proliferation assays were set up using 0.5 1g/m1 ovalbumin peptide and
4Ong/ml wild or F433 pneumolysin. Proliferation was measured by 3H
thymidine incorporation 24, 48 and 72 hours. Unstimulated cells are
represented by a blue line and stimulated cells by a pink line. Cells stimulated
in the presence of wild or f433 pneumolysin are represented by a yellow or
turquoise line respectively
5 - 105.2.1.4 Pneumolysin does not alter antigen presentation
The next step in the T cell activation pathway after antigen processing is antigen presentation. I
therefore wanted to examine if pneumolysin was inhibiting the T cell response by decreasing the
amount of antigen being presented by the APC to the I cell.
Antigen presentation measured by DO11.1O GFP T cell hybridoma
The DO 11.10 GFP T cell hybridoma can be used to measure antigen presentation. GFP expression
is under the control of the NFAT promoter within the hybridoma T cell. The hybridoma T cell is
activated when ovalbumin is presented to it and the resultant GFP expression can be detected and
quantified by measuring fluorescence. The fluorescence produced is proportionate to the amount
of GFP which is in turn proportionate to the amount of T cell activation which is proportionate to
the amount of antigen presentation. I measured fluorescence using flow cytometry (see Figure  5-5)
and found that after 24 hours, cultures containing DC and GFP only had a MFI of 4. With ovalbu-
mm present the MFI increased to a value of 13. When wild type pneumolysin was present (along
with ovalbumin, DC's and T cells), the MFI decreased to a value of 9 while F433 type pneumolysin
did not alter the MFI relative to the positive control. After 48 hours the stimulated cells have an
MFI of 12 and the cell incubated with wild type pneumolysin having a MFI of 10. The difference in
MFI between cells stimulated with ovalbumin and those stimulated in the presence of wild type
pneumolysin persists to 48 hours. By 72 hours the difference between the stimulated groups is
minimal. Only when each of, DC's, T cell hybridoma and ovalbumin were present did GFP expres-
sion increase. This experement is representative of two experiments.
From this data it appears as though the presence of wild type pneumolysin is inhibiting the presen-
tation of antigen by the DC since the MFI of GFP T cells in cultures with wild type pneumolysin is
lower than in cultures lacking wild type pneumolysin. However, this not the only interpretation;
the GFP T cells are not an inert readout. Wild type pneumolysin may be acting on the T cells to
alter the readout. It is possible therefore that equal amounts of presentation by the APC could be
occurring yet a difference in fluorescence is observed. This result therefore required further inves-
tigation prior to drawing definitive conclusions.
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Figure 5 - 5
The effect of pneumolysin upon antigen presentation
BMDC were used on day 7 of culture as APC to the DO! 1.!0 GFP T cell hybridoma at a
ratio of 9:1. Ovalbumin was used to stimulate the cultures at 1mg/mi and 4Ong/ml pneumo-
lysin was used where appropriate. At 24, 48 and 72 hours the cultures were harvested and
the mean fluorescence intensity (MFI) of the GFP T cells was measured by flow cytometry.
DO 11.10 GFP T cells that received only ovalbumin are marked as 'gfp OVA' and are pre-
sented as a dark blue bar. Where DC's were incubated with DO1!.10 GFP T cells and
ovalbumin only they are marked as 'DC gfp OVA' and are presented as a pink bar. Where
DC's were incubated with DO!1.!0 GFP T cells, ovalbumin and wild type pneumolysin
they are marked as 'DC gfp OVA wild ply' and are presented as a yellow bar. Where DC's
were incubated with DO 11.10 GFP T cells, ovalbumin and  f433 type pneumolysin they are
marked as 'DC gfp OVA f433 ply' and are presented as a turquoise bar. Where DC's were
incubated with DO1 1.10 GFP T cells only they are marked as 'DC gfp' and are presented as
a brown bar.
5 - 12Pneumolysin does not alter T cell activation
The next step after antigen presentation in the T cell activation pathway is the upregulation of
activation markers on the surface of the T cell. I wanted to determine ifpneumolysin was inhibiting
upregulation of these markers and thereby inhibiting T cell activation. Furthermore, this experi-
ment served as a supplementary experiment to the GFP hybridoma presentation assay since the
amount of T cell activation in a population is dependent on the amount of antigen being presented
by the APC. I measured the level ofT cell activation (by assessing CD69 and CD2S expression)
occurring within the lymph node culture to both inform as to the interpretation of the above data
but also as an assessment of the next step in the T cell activation pathway.
Figure 5-6 (A) shows that cells that did not receive antigen were considered unactivated and there-
fore CD69 'low'. Using this to set the gating on the flow cytometer, I was able to measure the
percentage of CD69 'high' cells in cultures that had received antigen. After 24 hours 10% of KJ+
CD4+ T cells incubated with ovalbumin had become CD69 positive. Cells incubated with wild or
F433 type pneumolysin and ovalbumin had a similar value. By 48 hours the number of activated
cells had increased as evidenced by the increase in the percent of CD69 positive CD4+ KJ+ T cells
to 17%. Cells incubated with either type of pneumolysin had a similar value. After 72 hours the
highest amount of activation is observed; 30% of KJ+ CD4+ T cells are CD69 positive when
incubated with ovalbumin alone. Cells incubated with either type of pneumolysin and ovalbumin
had a similar value.
Simultaneous to the measurements above of CD69 expression I measured CD25 expression (see
Figure 5-6[B]). T cells from cultures without antigen did not upregulate CD25 over the 72 hour
time period. In cultures stimulated with ovalbumin 8% of CD4+ KJ+ T cells had become CD25
positive by 24 hours. Cells incubated with wild type or F433 pneumolysin and ovalbumin had the
same value. After 48 hours the percentage of positive CD4+ KJ+ cells had doubled to 15% and by
72 hours the percentage of CD25 positive CD4+ KJ+ cells had doubled again to 30%. At both time
points wild or F433 type pneumolysin did not alter the level of CD25 surface expression on the
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The effect of pneumolysin upon T cell upregulation of activation markers
Lymph node single cell suspensions were prepared from DO 11.10 mice and set up as for
a cytokine assay with wild or F433 type pneumolysin at 4Ong/ml where appropriate and
1mg/mi ovalbumin. At 24, 48 and 72 hours the expression level of CD25 and CD69 on
transgenic T cells was measured by flow cytometry using CD4-PerCP, biotynilated KJ 1.26,
streptavidin-PE, and CD25-FITC or CD69-FITC. The data is presented as percent posi-
tive cells, however the Mean Fluorescence Intensity data is identical when compared.
Isotype controls were used; Rat 1gM FITC and Hamster IgG FITC. Unstimulated cells are
represented by a blue line and stimulated cells by a pink line. Cells stimulated in the
presence of wild or f433 pneumolysin are represented by a yellow or turquoise line re-
spectively. The data obtained from flow cytometry is shown in C-N. The similarity be-
tween stimulated and stimulated in the presence of Wild type pneumolysin is evident.
A - The effect of pneumolysin upon the expression of CD 69 on T cells
35
30
25
-4--- cefls
cells a
-	 cells+ova+ptywikl
cells +ova+p4yf433
5
0
24
	
48
	
72
time (houre)
5 - 14-.-- cells
cells ^ova
cells + ova + ply w dd
cells + ova ^ ply f 433
20
15
10
5j
0-
25
B - The effect of pneumolysin upon the expissicn of CD 25 on Tcefls
35
30
24
	
48
	
72
time (hours)
5 - 15C - CD25 - 24hrs -Unstimulated
M2
Ml
	
I
	
I
1 
1J
	
10'
	
10'
	
1 0'
cd25
D - CD25 - 24hrs -Stimulated
M2
Ml
___ I
:z
cd25
E - CD25 - 24hrs —Stimulated + Wild PLY
U-,	
M2
C
	 Ml
C
C
0
C
C
	 J
lou	
10'
	
10'
	
1 0'
	 1
cd25
5 - 16
C)
0
Q.j10' lou
Ml
F - CD69 - 24hrs -Unstimulated
Ii•)	
M2
MI
V
lou	
10'
	
1 0
	
10"
	
1
cd69
G - CD69 - 24hrs -Stimulated
M2
MI
C)	 I
ill
o	 LII'	
I
ocsJ 1 r	 I
-
100	iol	 10
cdô9
H - CD69 - 24hrs —Stimulated + Wild PLY
M2
V
(A C')
C
o
oc'J
1 0
	
10"
cd69
5 - 17I
I - CD25 - 48brs -Unstimulated
Ii,	
M2
Ml
0
lOu	 10'	 1O	 10"
	
1
cd25
J - CD25 - 48hrs -Stimulated
U,	
M2
MI
C)	 I
100	 1
	 14
cd25
K - CD25 - 48hrs —Stimulated + Wild PLY
U,	
M2
Ml
(A C)
C
1;4
cd25
5-18L - CD69 - 48hrs -Unstimulated
I1	
M2
Ml
i C)
Pc
4
lou	
10'	 1O	 1O,
	 14
cd69
M - CD69 - 48brs -Stimulated
M2
Ml
•
100	lol	 io	 10
cd69
Id,.
Ml
( c)
C
o - _______
OCSJI
1I
100
N - CD69 - 48hrs —Stimulated + Wild PLY
M2
101
	
1 o2
	
1
cd6Q
5 - 19transgenic T cells. The data presented above is representative of at least three experiments. Isotype
controls showed no increased staining (data not shown).
From this data I observed that the Tg T cells all become activated to the same degree regardless of
the presence or absence of pneumolysin. I concluded that pneumolysin's inhibitory activity was
not the result of its interference with the T cell upregulation of activation markers. This data also
allowed me to interpret the previous data from the GFP presentation assay. I now suggest that the
most consistent interpretation of the presentation data is that pneumolysin is causing some altera-
tion in the nature of the GFP T cell as opposed to inhibiting the presentation of antigen since if the
latter were the case then I would expect to see a difference in the number of T cells becoming
activated within this experiment.
5.2.2	 The induction of T cell anergy, apoptosis and death by
pneumolysin.
My data up to this point led me to conclude that pneumolysin was acting directly on the T cell and
was acting later in the pathway of T cell activation to cause inhibition of proliferation. Given that
the T cells are becoming fully activated yet are not proliferating I proposed two alternatives; either
pneumolysin was inducing T cell anergy or pneumolysin was inducing T cell apoptosis subsequent
to activation.
5.2.2.1 Pneumolysin does not induce T cell anergy.
My results indicated that T cells incubated with wild type pneumolysin and ovalbumin shared
characteristics with anergic cells; both become activated and divide a few times then stop dividing
and become unresponsive to antigenic stimulation. The unresponsiveness of anergic cells is broken
by the addition of exogenous IL-2 which restores responsiveness, enabling them to proliferate.
While I had not demonstrated the unresponsiveness of the T cells treated with pneumolysin I had
observed that the cells become activated yet do not proliferate to the same degree as untreated cells.
5 - 20I had also demonstrated that APC's treated with pneumolysin process and present antigen to the
same degree. Yet studies using LLO had found that LLO inhibits the T cell response not by altering
the APC quantitatively by altering processing or presentation but rather by altering antigen presen-
tation in such a way as to induce T cell anergy rather than proliferation (Darji  et al., 1997).
Exogenous IL-2 does not break the inhibitory effect of pneumolysin
I added exogenous IL-2 to stimulated whole lymph node cultures containing wild type pneumo-
lysin and measured proliferation by thymidine incorporation to test the hypothesis that pneumo-
lysin was inducing T cell anergy.
Figure 5-7 shows that in cultures without antigen cells proliferated little throughout the time period
examined even with 1, 5 or 10 ng/ml of IL-2 present. Cells stimulated with ovalbumin proliferated
above the unstimulated level by 48 hours reaching a cpm of 1 x 10 and by 72 hours 5.5 x 10 cpm.
In comparison cells stimulated with ovalbumin in the presence of wild type pneumolysin while
having similar cpm values at 24 and 48 hours to the untreated cells, by 72 hours had a cpm of  3.5 x
1 0. Therefore pneumolysin is inhibiting proliferation in this system as would be expected.
Cells stimulated with ovalbumin in the presence of 1 ng of IL-2 gave a cpm of 5.6 x 10 which is
slightly greater than that observed for cells with ovalbumin alone. SngIml of IL-2 gave a cpm of
6.8 x 10 after 72 hours however 10 ng/ml IL-2 recorded the highest cpm of 7.5 x 10g. This data
shows that addition of IL-2 to cultures stimulated with ovalbumin caused an increase in prolifera-
tion as the concentration of exogenous IL-2 increased.
Cells stimulated with ovalbumin and incubated with wild type pneumolysin in the presence of 1 or
5ng/ml of IL-2 did not differ at any time point in the amount of thymidine incorporated compared
to cells stimulated with ovalbumin in the presence of wild type pneumolysin that lacked exogenous
IL-2; all groups proliferated to give a cpm of 3.5 x 10 after 72 hours. In comparison, stimulated
cells incubated with wild type pneumolysin in the presence of lOng/mi of IL-2 proliferated slightly
more so that after 72 hours they recorded a cpm of 4 x l0. The data from this experiment is
representative of three experiments.
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Figure 5 - 7
The effect of exogenous IL-2 upon the inhibitory ability of pneumolysin
Proliferation assays were set up using lymph node single cell suspension made from
DO 11.10 mice. 1 mg/nil ovalbumin was added and 4Ong/ml wild or F433 pneumolysin
where necessary. IL-2 was added exogenously to some of the cultures during the set
up procedure at concentrations of 1,5 and 10 ng/ml. These concentrations were chosen
in light of the amount of IL-2 detected in a standard cytokine assay. Proliferation was
measured by 3H thymidine incorporation at 24, 48 and 72 hours. Unstimulated cells
are represented by a blue line and stimulated cells by a pink line. Cells stimulated in
the presence of wild type pneumolysin are shown as a yellow line. Stimulated cells
with exogenous IL-2 are denoted by a turquoise line. Stimulated cells with exogenous
IL-2 and wild type pneumolysin are shown as a purple line.
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5 - 23This data produced clear findings. Firstly, pneumolysin caused inhibition within this system. Sec-
ondly exogenous IL-2 clearly caused cells stimulated with ovalbumin alone to proliferate more
than when exogenous IL-2 is not added. Thirdly, exogenous IL-2 does not break the inhibitory
effect of pneumolysin and therefore pneumolysin does not induce T cell anergy.
5.2.2.2 Pneumolysin treated cells do not arrest in GO/GI but progress to
apoptosis.
Anergic cells arrest in the cell cycle at GO/Gi. Therefore I would expect to observe an accumula-
tion of cells at this stage of the cycle if anergy was induced within a population. In order to confirm
the results above about anergy and begin to examine the question of apoptosis, I measured the cell
cycle stages within a population of T cells stimulated with ovalbumin and incubated with pneumo-
lysin. In order to assess individual cells rather than looking at a whole population I used laser
scanning cytometry (LSC)
Figure 5-8 demonstrates that, after 24 hours, 85% of unstimulated cells are within either the GO or
G1-S gate as would be expected of resting cells. Some cells are found in the daughter cell gate
however these are most likely to be pre-apoptotic rather than newly divided. By 48 hours 35% of
unstimulated cells are apoptotic and 10% are in GO with a further 20% in each of the G1-S and
daughter gates. Cell cycle stages are similarly distributed at 72 hours. Thus, unstimulated cells,
over the 72 hour time period, have the characteristics of a population progressing from resting to
dying.
Cells stimulated with whole ovalbumin show the expected pattern of a proliferating cell culture
where the cells move from being in GO and G1-S at 24 hours through to being predominantly in
GI- S or newly divided after 72 hours. Thus I observe that 90% of cells for the first 48 hours are in
GO or G1-S and then after 72 hours only 10% are in GO, 60% are in G1-S and 20% are newly
divided daughter cells.
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The effect of pneumolysin upon Tg T cell cycle progression
Single cell suspensions were prepared from DO11.1O mice and assays set up as for cytokine
assays with 1mg/mi ovalbumin and 4Ong/ml wild pneumolysin where appropriate. At 24, 48
and 72 hours cultures were harvested and prepared for analysis on the LSC by staining with
KJ1.26 and DAPI. Cell cycle analysis of transgenic T cells was then carried out.
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Figure 5-9
Proliferation of murine antigen specific T cells in the presence of pneumolysin
Cultures of single cell suspensions from DO11.1O mice were set up to measure
proliferation and were stimulated with 1mg/mi ovalbumin. Pneumolysin was added
simultaneously with the ovalbumin at a final concentration 40 ng/ml (yellow line).
Proliferation was measured by thymidine incorporation at 24,48, and 72. Unstimulated
cells are indicated by a blue line. Stimulated but untreated cells are indicated by a pink
line.
5 - 26Stimulated cells treated with wild type pneumolysin while having 60% of cells in GO or G1-S after
24 hours also have 30% of cells in the daughter cell gate. Those cells in the 'daughter cell' gate at
24 hours possibly progress by 48 hours to become apoptotic so that at 48 hours 30% of cells are
apoptotic. There remains 60% of cells in either GO orGl-S after 48 and 72 hours with the apoptotic
group increasing to 35% of cells by 72 hours. The data for this experiment is representative of two
experiments.
From this I can observe that pneumolysin does not cause an accumulation of cells in the GO gate
but rather appears to induce apoptosis of stimulated cells.
Figure 5-9 shows the proliferation data obtained from the same cells used for the LSC work pre-
sented above. This data shows that pneumolysin was acting in an inhibitory way as I had demon-
strated previously and that the work using the LSC was representative of and relevant to earlier
work such as Figure 4-13.
Pneumolysin induces apoptosis of activated T cells
In order to confirm the observations of the data presented above that pneumolysin induces apoptosis
of activated T cells, I measured the level of apoptosis occurring in cultures of cells stimulated with
ovalbumin in the presence of pneumolysin. I used the Annexin V / P1 assay that utilises flow
cytometry to measure apoptosis (see Figure 5-10).
Ann exin VIP!
As would be expected of unstimulated cells, after 72 hours 80% are dead or dying and 20% remain
alive. After 96 hours the dead cells increase further to 85% and the live cells decrease to 15%. In
comparison, after 72 hours 35% of cells stimulated with ovalbumin are alive and 65% dead and
after 96 hours 50% of stimulated cells are alive and 50% dead. 25% of cells stimulated with oval-
bumin in the presence of wild type pneumolysin are alive after 72 hours and after 96 hours 40% of
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Pneumolysin induces apoptosis of activated T cells	 uP 101	 io	 io
Single cell suspensions were prepared from DO11.1O mice and were set up as for cytokine assays
with 1mg/mi ovalbumin and 4Ong/ml wild pneumolysin where appropriate. At 72 and 96 hours we
measured the percentage of apoptotic cells within each culture condition using the AnnexinVfPl
assay. Some of the flow cytometric data is shown. Quadrants; LL=Live cells, UL=Apoptotic,
UR=Dead, LR=Nucleated.
5 - 28cells are alive. This represents 10% less live cells at each time point for the cells stimulated with
ovalbumin in the presence of pneumolysin compared to stimulated cells not exposed to pneumo-
lysin. In terms of the actual number of apoptotic cells, at 72 hours there is no difference between
cells stimulated with ovalbumin and those stimulated in the presence of pneumolysin. The overall
difference between the two groups at this time point is observed in number of dead cells. In contrast
at 96 hours, there is almost 10% more apoptosis occurring when cells are stimulated in the presence
of pneumolysin than when cells are stimulated with ovalbumin alone.
It is clear that stimulated cultures increase in live cells over time whereas cells in unstimulated
cultures die. Furthermore, it is also clear that stimulating cells in the presence of pneumolysin
causes the induction of apoptosis.
5.2.3	 Pneumolysin co-localises to lipid rafts.
The work presented in this section on lipid rafts and in Figure 5-11 was carried out in collaboration with Graeme
Cowan, University of Glasgow. The work in this section is purely preliminary.
The data generated thus far pointed to the changes to the T cell upon activation as being crucial to
the inhibitory effects of pneumolysin. One of the key changes upon T cell activation is the forma-
tion of lipid rafts which preferentially sequester cholesterol into their structure (Garcia  eta!., 2003).
While the exact role of cholesterol within the binding of pneumolysin to cells remains unclear it is
obvious that cholesterol is vital to the binding activity (Giddings eta!., 2003). 1 therefore proposed
that the inhibitory effect I was observing of pneumolysin upon activated T cells may be the result of
accumulation of pneumolysin within the lipid rafts of activated cells. This would explain the differ-
ence in effect ofpneumolysin upon stimulated and resting T cells since resting cells would have far
5 - 29less lipid rafts. I therefore assessed the binding of pneumolysin to lipid rafts on resting and acti-
vated cells.
As observed in Figure 5-11, unstimulated cells (A) have a diffuse pattern of GM-i distribution
indicating the absence of lipid rafts while pneumolysin (B) is not localised to a particular region.
Furthermore no co-localisation of the cholera toxin and pneumolysin is observed in C. In compari-
son, stimulated cells (D) show a punctate pattern of GM-i distribution that is characteristic of lipid
raft accumulation in the cell surface membrane and co-localisation is observed of the lipid rafts
with pneumolysin in E. This data suggests that pneumolysin does indeed concentrate within the
lipid rafts of activated T cells.
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Pneumolysin co-localises to lipid rafts
We used lymph node preparations from DO 11.10 mice and where appropriate stimulated them
using ovalbumin. We compared the localisation of GFP-PLY6 with the raft marker CtxB- on acti-
vated and unactivated cells.
5 - 315 - 325.3 Discussion
In this chapter I demonstrated that pneumolysin acts directly upon the T cell, inducing apoptosis by
a mechanism potentially involving preferential binding to lipid rafts. By sequential examination of
the possible sites of pneumolysins action, I demonstrated that the mechanism of T cell inhibition
by pneumolysin does not involve inducing a secondary messenger from accessory cells within the
lymph node preparation. Furthermore I demonstrated that pneumolysin does not alter antigen process-
ing and presentation by dendritic cells and that pneumolysin acts directly upon the T cell. I demon-
strated that pneumolysin does not alter the upregulation of T cell activation markers nor does it
induce T cell anergy but that pneumolysin induces apoptosis of activated T cells.
To examine if pneumolysin was acting indirectly upon the I cell via accessory cells I was required
to use T cells purified from naive mice along with BMDC. Since studies using these cells were to
be compared to my earlier work using whole lymph node preparations, it was important to keep the
number of variables to a minimum. It has been shown that DC's are the primary APC responsible
for presenting antigen to naive T cells (Jenkins et a!., 2001) and so I wanted to use purified DC's as
APC within my proposed system. At the time of my studies it was impractical to use DC's isolated
directly from mice. I therefore used BMDC. Clearly the use of BMDC introduces a variable when
comparing this experiment to my earlier studies using the whole lymph node preparation. However
it has been shown that BMDC function similarly to splenic isolated DC in vitro (Garrigan et a!.,
1996). I was therefore confident that my results using BMDC would be a true representation of the
situation when using lymph node preparations. The work of Colino et a!. (Colino and Snapper,
2003a) demonstrated that pneumolysin is able to induce apoptosis of dendritic cells. I therefore
checked that at the concentration ofpneumolysin I was using dendritic cells were remaining viable
(data not shown). Colino et a!. had demonstrated this effect in experimental systems different to
ours particularly in the use of high concentrations of whole bacteria.
As I discussed in the introduction to this thesis, pneumolysin has many effects on different cell
types. One of those effects is inducing macrophage to release nitric oxide (Braun et a!., 1999).
However the results of Figure 5-2 show that accessory cells such as macrophages are not required
for the T cell inhibitory activity of pneumolysin. This means that despite the range of effects of
pneumolysin on cells none of these effects are critical to mediate the effect of inhibiting the T cell
5-33response. It should be noted however that the possibility of a synergistic effect between a released
factor and pneumolysins inhibitory action cannot be ruled out.
Despite these findings there remained the possibility that pneumolysin was causing the BMDC to
release a T cell inhibitory factor. Reports in the literature had suggested that BMDC may be able to
release nitric oxide to a greater extent than ex vivo DC (Powell et a!., 2003) and the inhibitory effect
of nitric oxide release by BMDC on T cell proliferation had been confirmed (Bonham eta!., 1996).
We demonstrated that the inhibitory effect was not dependent on BMDC by utilising APC inde-
pendent proliferation. This was a critical result to enable us to conclude that BMDC are not releas-
ing an inhibitory factor.
In order to examine the question of the effect of pneumolysin on antigen processing by APC I
chose to revert to using the whole lymph node system. This allowed me to make a direct compari-
son of the effect of pneumolysin upon antigen processing requirements for the inhibitory effect of
pneumolysin since the only variable between my earlier experiments and these experiments was
the change in using whole ovalbumin as antigen to using ovalbumin peptide. I found that pneumo-
lysin was still able to inhibit T cell proliferation even when peptide was used as antigen and there-
fore was able to conclude that pneumolysin did not act by inhibiting the processing of antigen by
the APC. My results are in contrast to the findings ofDarji et a!. (Darji et a!., 1 997),who found that
LLO inhibited T cells by altering antigen processing so that antigen was presented in a way that
induced T cell anergy. In further contrast to my results they demonstrated that peptide-induced T
cell activation is not affected at all by LLO since the inhibitory mechanism is by-passed.
For my studies on antigen presentation I used the GFP expressing T cell hybridoma. This system
has previously been used to measure the amount of antigen presented by dendritic cells (Sun eta!.,
2003) (Rush et a!., 2002). Similar systems using different reporter genes have also been used
(Storozynsky et a!., 1999) (Hartmann and McCoy, 1996; McCoy et a!., 1995) to measure antigen
presentation, however use of the DO11.10 GFP hybridoma is a rapid and quantitative measure of
antigen presentation (Underhill et a!., 1999). We found that pneumolysin appeared to inhibit the
expression of GFP in hybridoma T cells which suggests a decreased amount of antigen was being
presented to the cell. In hindsight the fact that I was examining the effect of a toxin upon T cells
makes the choice of a non-T cell readout more attractive since the potential complication is evi-
dent; i.e. it is equally reasonable to suppose that the toxin may affect the readout T cells as it does
5 - 34the normal T cells in my previous experiments. In recognition of this I suggest the detection of
antigen bound to the MHC of the APC would be a better method. At the time of experimenting such
a method was available (Kobets et al., 2003; Manickasingham and Reis e Sousa, 2000; Reis e
Sousa and Germain, 1999; Zhong et al., 1997) however this method does not yield particularly
clear data and so was not used. Subsequently a better method has been developed that could be
used (Itano et aL, 2003). Earlier it was noted that Vac A of Ilelicobacter pylon inhibits T cells by
preventing the translocation of NFAT (Gebert et a!., 2003). This work on Vac A meant that my
proposal, that pneumolysin may be interfering with the T cell and specifically with NFAT, was not
unprecedented.
I went on to measure the degree of T cell activation within the system in which I had observed
pneumolysin inhibiting the T cell response. I found that pneumolysin did not alter the expression
level of the activation markers that I measured. It is common practice to measure CD69 and CD25
when examining the effects of a potential immunomodulator upon T cells (e.g. (Holcombe eta!.,
2002)). CD25 is part of the IL-2 receptor while the function of CD69 is unknown but its expression
level on the T cell surface is observed to increase rapidly upon activation (Ziegler eta!., 1994). Not
only does CD25 inform about the activation state of the T cell but it also informs about the ability
of the T cell to utilise IL-2. Some toxins produced by pathogens have been shown to alter IL 2
receptor expression; either increasing it (Bone et a!., 2002) or decreasing it (Szamel et a!., 1997)
yet in our study pneumolysin did not alter expression level at. A previous study examined the effect
of radiation killed Streptococcus pneumoniae on the CD25 and CD69 expression levels on T cells
isolated from humans (Arva and Andersson, 1999a). The researcher found that incubating Strepto-
coccus pneumoniae with the T cells caused an increase in expression of CD69 and CD25 within the
first 24 hours when compared to unstimulated cells. However compared to T cells stimulated with
PHA this increase was significantly smaller. The study did not compare the effect of incubating the
pneumococcus with a bystander antigen and so the results are not directly relevant to my work.
Additionally, the use of the whole pneumococcus, as I saw earlier, introduces a range of variable
that were absent from my studies using the purified toxin.
The apparent incongruence in my results between measuring NFAT expression via the GFP
hybridoma cells and measuring activation markers on ex vivo T cells requires explanation. It may
be expected that these two experiments would yield the same result yet the GFP system suggested
pneumolysin was inhibiting presentation while the activation marker system suggested there was
5 - 35no difference in presentation. The difference in susceptibility of different cell types to pneumolysin
is my primary hypothesis for this incongruence since it is probable that the hybridoma will have a
different susceptibility compared to ex vivo T cells. However it has also been demonstrated that
hybridoma T cells and primary T cells have a different susceptibility to death due to different
biochemical features that make hybridoma T cells initially more prone to die after TcR stimulation
(Hildeman eta!., 2002).
Darji et a!. (Darji et al., 1997) had found that LLO inhibits T cell altering APC processing of
antigen in such a way that causes the presented antigen to induce T cell anergy. As I mentioned
above they had found that LLO was unable to inhibit T cells when using peptide antigen. My work
contrasts with this since I found that pneumolysin exerted no effect on the APC in terms of antigen
processing or presentation. None the less I recognised an important point from their work; that
despite the APC appearing to present antigen to the same degree, it may be the case that the antigen
is presented in a qualitatively different manner that causes the induction of T cell anergy. I there-
fore were concerned to use exogenous IL-2 to examine if anergy was being induced by pneumo-
lysin. I showed that anergy was not being induced since the addition of exogenous IL-2 did not
restore T cell proliferation and so concluded that pneumolysin was utilising a mechanism distinct
from that used by LLO in the reports by Darji eta!. of T cell inhibitory activity (Darji eta!., 1997).
My observation that addition of exogenous IL-2 to proliferation cultures did not alter the inhibitory
activity of pneumolysin and therefore was not inducing anergy in vitro (DeSilva eta!., 1996), led
me to measure apoptosis. The work of Li et al. (Li and Darzynkiewicz, 1995) helped me to inter-
pret my results from Laser Scanning Cytometry which initially indicated that cells treated with
pneumolysin had a rapid increase in the number of daughter cells. Li et a!. showed that this cell
population with the phenotype of daughter cells is in fact a pre apoptotic group that has condensed
chromatin not as the result of being newly divided but rather as the result of being apoptotic. My
data from the LSC (see Figure 5-8) showed that pneumolysin was inducing the formation of an
apoptotic group of cells by 72 hours. I subsequently measured apoptosis using the Annexin V / P1
method (see Figure 5-10). Overall my results from this method were consistent with those from the
LSC; that pneumolysin is causing increased death of activated cells, however the actual percent-
ages between the methods are not the same. Using the Annexin V method revealed that by 72
hours 75% of cells stimulated with ovalbumin and pneumolysin are dead or dying while using the
5 - 36LSC only 35% of cells are dead or dying. This discrepancy is more likely accounted for by the
difference in technique. Highly fragmented DNA is unlikely to be picked up by the LSC and so
cells that are already dead may not be recorded thereby giving an unusually low record when
compared to a method such as Annexin V  / PT which recorded dead cells. Additionally the Armexin
V / PT method measures cell permeability and phosphatidylserine exposure which are early indica-
tors of cell death, whereas the LSC technique measure DNA fragmentation which is later in the cell
death pathway. These difference in technique are likely to be responsible for the difference in
percentage between the experiments.
After establishing that the T cell inhibitory mechanism ofpneumolysin is the induction ofapoptosis
the natural progression was to examine the mechanism of inducing apoptosis. A number of find-
ings made me consider the role that lipid rafts may have in the mechanism of induction of apoptosis
by pneumolysin. Shimada eta!. (Shimada eta!., 2002) had previously demonstrated that the pneu-
molysin related toxin, perfringolysin, preferentially bound to the cholesterol in lipid rafts. In addi-
tion Tuosto et a!. (Tuosto eta!., 2001) had shown that activated T cells have more lipid rafts than
resting T cells. I had observed a difference in susceptibility to apoptosis between resting and acti-
vated T cells and I therefore postulated that this difference may be the result of pneumolysin inter-
acting differently with cells containing high numbers of lipid rafts.
My studies on the colocalisation ofpneumolysin to lipid rafts are preliminary. I found that pneumo-
lysin does co-localise to the lipid raft however I used a small group size and identified the cells as
being lymphocytes only by light morphological examination. Further investigations would need to
use a larger study group and identif' the cells examined as being activated Tg T cells. It would also
be informative to examine whether activated T cells bind more pneumolysin than unactivated T
cells. The answer to this possibility would help to determine whether pneumolysin causes apoptosis
of activated T cells as a result of increased toxin binding per cell, or because of unequal distribution
of toxin on the cell membrane. Finally it would be informative to examine the effect of the F433
pneumolysin mutant upon lipid rafts. The popularity of FRET analysis to examine colocalisation
more definitively would also be an advantage to further studies (Kenworthy  eta!., 2000; Willhite et
a!., 2002).
5-37My tentative findings that pneumolysin interacts with lipid rafts on activated T cells to induce
apoptosis are consistent with other studies on the mechanism of apoptosis induction by pathogen
toxins (Manes eta!., 2003; Nusrat eta!., 2001; Rohde eta!., 2003; Wu eta!., 2003). For example,
studies on shiga toxin have shown that one of the mechanisms the toxin uses to induce apoptosis of
it target cell is via preferential binding to its receptor located in lipid rafts (Cherla eta!., 2003). This
enhances the uptake of the toxin into the cell where it then stimulates an apoptotic signalling cas-
cade (Kovbasnjuk eta!., 2001). Tetanus toxin also requires the presence of lipid rafts to allow it to
bind to its GPI anchored protein receptor (Munro et a!., 2001). Williams et a!. (Nashar eta!., 1996)
demonstrated that the non-toxic B subunit oligomer (EtxB) of Escherichia co!i heat-labile entero-
toxin (Etx) induces apoptosis of CD8 T cells by cross linking the GM-I receptor on the T cell
surface. The signalling pathways involved have recently been elucidated (Salmond et a!., 2002).
Vac A of Helicobacter pylon has been shown to bind preferentially to lipid rafts (Kuo and Wang,
2003; Patel et a!., 2002; Ricci et a!., 2000; Schraw et a!., 2002). Finally the pore forming toxin,
aerolysin, has been shown to induce T cell apoptosis. There is some debate over whether aerolysin
preferentially binds to lipid rafts (Nelson and Buckley, 2000) but the evidence is in favour of it
doing so (Abrami and van Der Goot, 1999; Abrami et a!., 2000). This leads to selective
permeabilisation of the membrane which causes the cell to take on the characteristics of apoptotic
cells (Abrami eta!., 1998). The authors have subsequently shown that the preferential association
of the toxin with lipid rafts effectively results in areas of the membrane that have a high toxin
concentration. This allows the toxin to oligomenise and therefore form pores in the membrane
(Abrami and van Der Goot, 1999). Clearly the similarities between aerolysin and pneumolysin
make the theories proposed above for aerolysin a potential staring point for further examination of
the mechanism of pneumolysin.
During the writing of this thesis Zenewicz et a!. (Zenewicz eta!., 2004) published a seminal paper.
Previously it had been demonstrated that during listeria infection lymphocyte apoptosis occurs
(Merrick et a!., 1997). However Zenewicz et a!. (Zenewicz et a!., 2004) found that listeriolysin
induces the upregulation of Fas L on T cells yet does not alter the expression of CD2S or CD69 (or
CD44, CD28, CD 128). These findings regarding CD25 and CD69 are consistent with my data.
Shortly after the publication of the paper by Zenewicz et a!. (Zenewicz et a!., 2004), Carrero et a!.
(Carrero et a!., 2004) published data that demonstrated that in vitro LLO induces apoptosis of
activated T cells at a dose of 25ng/ml via a caspase dependent mechanism. Clearly the consistency
of all these findings with my data consolidates my finding that pneumolysin induces T cell apoptosis.
5 - 38One of the key issues to address after my findings was the type of apoptosis induced by pneumo-
lysin. The recent recognition of multiple apoptotic pathways not restricted to death receptor medi-
ated pathways (Davidson et a!., 2002; Jaattela and Tschopp, 2003; Proskuryakov et a!., 2003)
(Figure 1-5) and the different implications of each (Hildeman eta!., 2002) means that the elucida-
tion of the pathway induced is critical. However the work by Zenewicz  et a!. appears to give me a
starting place by implicating Fas in the mechanism of apoptosis. The work of Scheel-Toellner  eta!.
(Scheel-Toellner et a!., 2002) recently demonstrated the necessity of lipid rafts for the induction of
apoptosis by Fas while rafts have been proposed as central to the control of apoptosis due to their
ability to recruit signalling molecules, thereby allowing their interaction (Garcia et a!., 2003). In
addition to this resting T cells are generally resistant to Fas mediated death (Budd, 2001). All of
these studies seem to be consistent with my findings on the mechanism of inducing apoptosis by
pneumolysin. As a result of these I speculate that Fas mediated apoptosis is likely to be the mecha-
nism of apoptosis used by pneumolysin and that the preferential binding of pneumolysin to lipid
rafts will be an important part of this mechanism. Interestingly S. pneumoniae has been found to
induce apoptosis of dendritic cells by a pneumolysin dependent but caspase independent mecha-
nism (Colino and Snapper, 2003a) and in neuronal cells by a caspase independent mechanism
(Braun eta!., 2002). An examination of the caspase dependency and Fas involvement of the apoptosis
of T cells by pneumolysin would therefore be informative.
My studies here suggest that pneumolysin and thereby Streptococcus pneumoniae could join a
growing list of toxins / pathogens that induce apoptosis of T cells. I recognised that the importance
of pneumolysin's induction of apoptosis to the knowledge of pneumococcal infection was depend-
ent upon proving that pneumolysin induces T cell apoptosis in vivo during pneumococcal infec-
tion. Similarly the importance of pneumolysins induction of apoptosis to its usefulness as an
immunomodulator is also dependent on proving it functions in this way  in vivo.
I start to address these issues in the following chapter however it is pertinent at this point to men-
tion the work of Kemp et a!. (Kemp et a!., 2002) who studied T cells in human patients with
pneumococcal infections. In their studies they noticed that pneumococcal infections were associ-
ated with an increase in the number of apoptotic T cells and soluble Fas levels and a decrease in the
5-39number of activated T cells. The number of resting T cells remained constant. Furthermore they
they found that the CD4 T cell count returned to normal after infection and the decrease in CD4 T
cell numbers was found in the TH1 T cell compartment. These results are remarkably consistent
with the predictions that would be drawn from my data. The authors did not suggest a mechanism
for the decline in T cell numbers however I propose, as a result of my studies, that pneumolysin is
a likely cause of this finding.
5 - 406 Assessing the T cell inhibitory ability of
pneumolysin in vivo.
6-16.1 Introduction
The importance of my findings regarding the induction of T cell apoptosis by pneumolysin is
dependent on proving that pneumolysin functions in this way in  vivo. This is for two reasons;
firstly the relevance of pneumolysin inducing T cell apoptosis in vivo may contribute to the under-
standing of pneumococcal infection but only if this is actually what occurs during infection. Fur-
thermore, the potential usefulness of pneumolysin as a therapeutic molecule clearly depends on it
being able to function in vivo.
My studies on the interaction of pneumolysin and the T cell would, until recently, have been re-
garded as irrelevant since the T cell was regarded to have no role in pneumococcal infection
(Winkelstein and Swift, 1975). However, there has been renewed interest in the role of the T cell in
pneumococcal infection and this interest appears set to increase (Kadioglu and Andrew, 2004). As
seen in the introduction to this thesis, recent work suggests that the T cell may be involved in two
aspects ofpneumococcal infection. Some investigators have suggested a possible role for T cells as
part of the innate response to pneumococcal lung infection (Kadioglu et a!., 2000) while the work
of a number of groups have identified an essential role for CD4 T cells in the antibody response to
pneumococcal protein and polysaccharide antigens (Baxendale et a!., 2000; Hwang et aL, 2000;
Jeurissen eta!., 2002; Khan eta!., 2004). Despite these recent advances it remains unclear what the
role of pneumolysin is in relation to these findings.
My studies in this chapter represent initial investigations into the significance of pneumolysins
ability to induce T cell apoptosis. My work in vitro allowed me to orientate my in vivo investiga-
tion. I had demonstrated in vitro that pneumolysin inhibits the T cell response by acting directly on
the T cell and that this inhibitory mechanism is mediated by the induction of apoptosis. I therefore
wanted to begin my studies in vivo by examining the same parameters.
6-26.2 Results
6.2.1	 Optimising the pneumolysin dose in vivo
In vitro I had observed that pneumolysin was able to inhibit the proliferation of antigen-stimulated
CD4 T cells by inducing cell death after the cells became activated. Pneumolysin did not induce
death of unstimulated T cells. I wanted to be able to examine the same parameters in vivo as I had
examined in vitro. The DO 11.10 adoptive transfer system would allow me to examine the param-
eters such as T cell proliferation, T cell activation and T cell death (for review see (Adams et a!.,
2004b; Adams eta!., 2004c)). I therefore considered it a good system in which to begin my in vivo
studies.
6.2.1.1 Optimisation process
Throughout my in vitro studies both wild and F433 type pneumolysin purified using the His tag!
metal chelate column method had been used. Due to the large amounts of toxin required for the in
viva experiments, I used only the wild type toxin prepared using the HIC/Anion Exchange method.
I wanted first of all to assess the effect ofpneumolysin on in viva T cell proliferation. In order to do
so I had to determine the concentration ofpneumolysin that I could inject into the mice that did not
alter the resting T cell population. After obtaining this concentration I would then be able to
progress to examining the effects of pneumolysin upon antigen stimulated lymphocytes.
1 Oug Pneumolysin i.p. does not alter basal lymphocyte population
To establish a concentration of pneumolysin that could be administered without altering resting
lymphocytes I measured the percent of Tg T cells in mice that received various concentrations of
pneumolysin. Figure 6-1 shows that mice that received only PBS had a basal level of transgenic
cells of 0.8%. Mice that received 2Oug of pneumolysin had 0.4% Tg T cells which represent 50%
less transgenic T cells, compared to the PBS control and although this is not significantly different
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Figure 6-1
The effect of pneumolysin upon resting T cells in vivo
BALB/c mice were adoptively transferred with cells from DO 11.10 mice on day
-1. On day 0 and day 1 groups of three mice were injected with 20, 10, 5, or 1 ug
of pneumolysin or PBS i.p. On day 3 mice were sacrificed and the lymph nodes
(inguinal, brachial, cervical) removed and stained with CD4-PE and biotinylated
KJ1 .26/ streptavidin FITC to enable the determination of the percent of transgenic
T cells within the lymph nodes by flow cytometry. None of the results were
statistically significant to p( 0.05.
6-4it is considerable. In mice receiving bug or 5ug ofpneumolysin, transgenic cells represented 0.6%
of cells. Finally, mice receiving lug ofpneumolysin had 0.8% transgenic cells which is the same as
the control.
From this I concluded that 2Oug pneumolysin may potentially decrease the basal level of resting T
cells in transferred animals and thercfore was deemed unsuitable for further study. 10 and Sug,
despite causing a decrease in basal T cells, did not significantly alter this level and were therefore
considered for further study. lug pneumolysin did not alter the resting cell level and was a candi-
date dose for further study.
10, 5 and 1 mg pneumolysin do not alter T cell accumulation.
On the basis of the data from the above experiment I used 10, 5 and 1 mg pneumolysin to examine
the hypothesis that pneumolysin would cause apoptosis of T cells  in vivo. By adoptively transfer-
ring T cells Tg for ovalbumin and administering ovalbumin to transferred mice, I proposed that
pneumolysin would inhibit T cell accumulation within the lymph nodes of mice that received oval-
bumin but would not affect the resting T cell population in mice that did not receive ovalbumin.
In order to examine the effect of pneumolysin upon T cell accumulation I measured the accumula-
tion of Tg T cells in mice that received ovalbumin along with pneumolysin. In mice injected with
PBS i.p. and PBS s.c., the number of Tg cells was constant at  0.5% on days 3,5 and 7 (see Figure 6-
2) while in mice injected with PBS i.p. and OVA-CFA s.c. the percentage of transgenic T cells
found in the lymph nodes changed over the 7 day period examined; On day 3 transgenic cells
constituted 1.3% of the lymph node cells increasing to 2.5% by day 5 and then decreasing by day 7
to 0.9%.
Figure 6-2 (A) demonstrates that in mice that received lug pneumolysin i.p. and PBS s.c. the
percentage of transgenic cells was 0.6% over days 3, 5 and 7, which is slightly higher than the
control mice that received PBS only. However, the difference is not significant. In mice that re-
ceived lug pneumolysin i.p. and OVA-CFA s.c. the percentage of transgenic cells was 1.4% on day
3, 3% on day 5 and 1.8% on day 7. This is slightly greater than that for control mice receiving PBS
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Figure 6-2
The effect of 10,5, 1 ug pneumolysin upon T cell accumulation in vivo
We transferred DO 11.10 cells from transgenic donor mice into BALBIc recipients
on day —1. On day 0 groups of three mice were injected with PBS or lug (see A),
5ug (see B) or lOug (see C) of pneumolysin i.p, a few hours prior to receiving
either PBS or OVA-CFA subcutaneously. The following day (day 1) mice were
again injected with PBS or the same dose of pneumolysin as they had received the
previous day. Mice were sacrificed on day 3,5 and 7 and the percent of transgenic
T cells was measured in the lymph nodes (inguinal, brachial, cervical) by flow
cytometry using CD4 antibody and the clonotypic antibody KJ1.26. The graphs
A, B and C illustrate the positive control of PBS/OVA/PBS as a pink line. The
negative control of PBS/PBS/PBS is represented as a blue line. Mice that received
ovalbumin and were treated with pneumolysin (PLY/OVA/PLY) are represented
on each graph as a yellow line while mice treated with pneumolysin but received
no ovalbumin (PLY/PBS/PLY) are shown as turquoise line. On day 7 no statistical
difference was observed between any of the groups as judged by p<= 0.05.
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6-7and OVA-CFA. Again, as for the mice that did not receive ovalbumin, this difference was not
significant on day 7.
In mice that received 5ug of pneumolysin i.p. and PBS s.c. the percentage of transgenic T cells is
exactly the same as for the control mice that received PBS i.p. and PBS s.c. over the 7 day period
(see Figure 6-2 B). Mice that received Sug of pneumolysin i.p. and OVA-CFA s.c. have an unusu-
ally high percentage of transgenic cells on day 3 of 2.3% and this declines to 2% on day 5 and 1.6%
on day 7. This is an unexpected pattern of transgenic T cell distribution when compared to the
control mice that received PBS i.p. and OVA-CFA s.c., however the error bars on this data are large
and the difference is not significant on day 7.
Mice that received lOug of pneumolysin i.p. and PBS s.c. had the same percentage of transgenic
cells over the 7 day period examined as the control mice that received PBS i.p. and PBS s.c. as
shown in Figure 6-2 C. Mice that received 10mg pneumolysin i.p. and OVA-CFA s.c. had 1.6%,
3.2% and 2% transgenic cells on days 3,5 and 7 respectively. As can be seen in Figure 6-2 C, this
represents 0.2% more transgenic T cells at each time point relative to the PBS/OVA-CFA control
value at the same time points. This difference is not significant on day 7.
My conclusions were; As expected, mice that did not receive ovalbumin did not accumulate T cells
whereas mice that received OVAJCFA did. This peaks on day 5. 10, 5 and 1 ug pneumolysin did not
alter the number of T cells in mice that did not receive ovalbumin. None of these doses ofpneumo-
lysin caused an inhibition of T cell accumulation since pneumolysin treated mice that received
ovalbumin did not have significantly different levels of transgenic T cells compared to the control
mice that received only ovalbumin. I knew from Figure 6-1 that a 20mg dose was too high since it
altered the resting T cell population and from Figure 6-2 I knew that 10mg had no effect on antigen
stimulated T cells. In order to obtain a dose of pneumolysin that altered antigen stimulated T cells
but did not alter resting levels, I proposed to use a higher dose of pneumolysin of 15mg and also of
20mg as a positive control.
1 5ug and 2Oug pneumolysin inhibit T cell accumulation
I did not know if 1 Sug or 2Oug pneumolysin would inhibit T cell accumulation after antigen
stimulation. Therefore in order to assess the value of a full scale experiment using these doses, a
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Figure 6-3
The effect of l5ug or 2Oug pneumolysin upon T cell accumulation
BALB/c mice were transferred with DOli.iO cells on day—i and then injected on day
O with pneumolysin (l5ug or 2Oug) or PBS i.p then a few hours later with OVA-CFA
and finally injected with pneumolysin (l5ug or 2Oug) or PBS i.p on dayl. Three mice
were used in each group. On day 5 mice were sacrificed and the proportion oftransgenic
T cells measured in the lymph nodes (inguinal, brachial, cervical) using flow cytometly.
As this was a preliminary experiment there was no negative control group; all mice
received OVA-CFA s.c. Mice that received l5ug pneumolysin i.p. followed by
ovalbumin s.c. followed by l5ug pneumolysin i.p. are marked as PLY15/OVAJPLY15.
Mice that received 2Oug pneumolysin i.p. followed by ovalbumin s.c. followed by
2Oug pneumolysin i.p. are marked as PLY2O/OVAIPLY2O. The difference between
PLY2O/OVA/PLY2O and PBS/OVA/PBS is statistically significant to p<=  0.05.
6-9pilot experiment was first carried out. A full scale experiment would use many mice and take up
much time; a pilot experiment would ensure I was not wasting resources. I assessed, the effect of
15mg and 20mg of pneumolysin on T cell accumulation in mice that did not receive ovalbumin at
one time point.
Figure 6-3 demonstrates that 4.3% of cells in mice that received PBS i.p. and OVA-CFA s.c. were
transgenic on day 5. In comparison in mice that received 15 or 20mg ofpneumolysin i.p. and OVA-
CFA s.c. 2.8% of cells were transgenic on day 5 for 20mg This is a significantly lower value than
that of the control indicating that 20mg of pneumolysin is sufficient to inhibit the accumulation of
T cells in the lymph nodes of adoptively transferred mice that received ovalbumin. 15mg was not
quite statistically significant but the decrease was considerable.
Since both doses of pneumolysin had a very similar effect it was considered best to proceed with
15mg for further study since 20mg was known to alter resting T cell numbers.
6.2.2 Pneumolysin inhibits T cells in vivo
My previous work had established that 15mg of pneumolysin was a potentially suitable dose to use
for my in vivo studies since it had an observable inhibitory effect upon T cell accumulation after
administration of ovalbumin. I therefore wanted to determine that this dose had no adverse effect
on the basal lymphocyte population and then to further investigate the parameters of the inhibitory
effect.
6.2.2.1 Pneumolysin inhibits T cell accumulation
I measured the effect of pneumolysin upon T cells by adoptively transferring the Tg cells from
DO 11.10 mice and measuring the effect of pneumolysin upon the resting cell population and the
effect of pneumolysin upon mice that received ovalbumin (see Figure 6-4).
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Figure 6-4
The effect of lSug of pneumoiysin upon T cells in vivo
We transferred DO 11.10 cells from transgenic donor mice into BALB/c recipients
on day —1. On day 0 mice were injected with PBS or l5Dg of pneumolysin i.p a
few hours prior to receiving either PBS or OVA-CFA subcutaneously. The following
day (day 1) mice were again injected with PBS or the same dose of pneumolysin
as they had received the previous day. Mice were sacrificed on day 3,5 and 7 and
the percent of transgenic T cells was measured in the lymph nodes (inguinal,
brachial, cervical) by flow cytometry using CD4 antibody and the clonotypic
antibody KJ1.26. The group called PBS/PBS/PBS (blue line) received PBS i.p
and PBS s.c and had a total of three mice in the group. The group labelled PLY/
PBS/PLY (turquoise line) received l5ug pneumolysin i.p twice and PBS S.0 and
had three mice in total in the group. The group labelled PBS/OVA/PBS (pink line)
received PBS i.p twice and OVA/CFA s.c and had 9 mice in the group. The group
labelled PLY/OVA/PLY (yellow line) received l5ug pneumolysin i.p twice and
OVA/CFA s.c and had 9 mice in the group. The difference on day 7 between PLY!
OVA and PBS/OVA is statistically significant to p<= 0.05.
6-11Figure 6-4 demonstrates that in mice injected with PBS i.p. and PBS s.c. transgenic cells repre-
sented 0.35%. Similarly, mice that received PLY i.p. and PBS s.c. transgenic cells represented
0.3 5% throughout the 7 day period examined. Thus mice that did not receive ovalbumin showed no
difference in the proportion of KJ+ cells, nor was there any effect on the basal level of lymphocytes
attributable to pneumolysin throughout the period examined.
On day 3 mice that had received PBS i.p. and OVA-CFA s.c. had increased T cell percentage (see
Figure 6-4) compared to the control of mice that received PBS only so that transgenic cells repre-
sented 2.5% of cells in the lymph nodes. By day 5 this had increased to 4.1% and then decreased to
day 7 where 3.8% of cells were KJ+. At all three time points, mice that had received 15mg pneu-
molysin i.p. and OVA-CFA s.c., had a lower percentage of KJ+ cells than the control of PBS i.p.
and OVA-CFA. On day 3 the difference is minimal; pneumolysin treated mice have 2.1% KJ+ cells
compared to the control of 2.5%. On day 5 the difference is larger; pneumolysin treated mice have
3.5% KJ+ cells compared to the control of 4.1%. On day 7 the difference is largest; pneumolysin
treated mice have 2.7% KJ+ cells and the control has 3.8% KJ+ cells. This difference is significant
at this time point.
From the data presented in Figure 6-4, I was able to conclude two things. The fact that on day 7, in
mice that received ovalbumin, those treated with pneumolysin had less KJ+ cells than those that
did not receive pneumolysin led me to conclude that pneumolysin is able to inhibit T cell accumu-
lation in vivo. Furthermore the fact that, in mice that did not receive ovalbumin, those treated with
pneumolysin did not have any difference in the number of KJ+ cells compared to those mice that
did not receive ovalbumin led me to conclude that pneumolysin does not rely on the removal of a
percentage of the basal lymphocyte population to accomplish its T cell inhibitory effect in vivo.
6.2.2.2 Pneumolysin inhibits the number of KJ+ cells in the lymph nodes
Simultaneous to the measurements of Figure 6-4, I further assessed the proportion of transgenic T
cells within the groups. I measured the actual number of KJ+ cells isolated when the lymph nodes
of each mouse were pooled. Figure 6-5 illustrates that the mice injected with PBS i.p. and PBS s.c.
had 1.1 x 1 0 KJ+ transgenic cells while mice that received PLY i.p. and PBS s.c. had 1 .2x I O KJ+
transgenic cells throughout the 7 day period examined.
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Figure 6- 5
The effect of pneumolysin on the number of KJ^ CD4^ T cells in the lymph
nodes of mice that recieved ovalbumin
The experiment was set up as for figure 6-4. On each day the number of lymphocytes
was counted by trypan blue exclusion within the single cell suspensions made from
the lymph nodes of each mouse prior to flow cytometric analysis. Using the percent
KJ^ cells measured by flow cytometry the number of KJ+ cells was calculated and
the results presented above are the averages from each group. Lymphocytes from
mice that received PBS i.p and PBS s.c are represented as a blue line. Those from
mice that received PLY i.p and PBS s.c are shown as a turquoise line. Lymphocytes
from mice that received PBS i.p and OVA s.c are represented as a pink line. Those
from mice that received PLY i.p and OVA s.c are shown as a yellow line.
6-13On day 3 mice that had received PBS/OVA had 5.5x 10 KJ+ cells rising to 9.8x 10 cells on day 5
and finally 1.5x 106 KJ+ cells on day 7. Comparison of this with mice that had received ovalbumin
and had been treated with pneumolysin demonstrates that pneumolysin inhibits real number of KJ+
cells since the treated group has 4x 10 KJ+ cells on day 3, 7x l0 cells on day and 5 and 8.7x 10
cells on day 7.
This data confirms the observations of Figure 6-4; that there are less KJ+ T cells in mice that
received ovalbumin and were treated with pneumolysin.
6.2.2.3 Ex vivo stimulation of lymph node cells from pneumolysin treated
mice proliferate less than those from PBS treated mice.
In addition to measuring the percentage of KJ+ T cells and the actual number of KJ+ cells, I
utilised a further measure of T-cell proportion within the lymph nodes by re stimulating lymph
node preparations ex vivo using ovalbumin.
The proliferation data from each individual mouse was pooled to create a group data set (see Figure
6-6). Lymphocytes from the PBS/PBS group or the PLY/PBS group proliferated little over the 72
period examined. After 24 hours lymphocytes from the PBS/OVA group that had been stimulated
with ovalbumin had proliferated to 1.3 x 10 cpm. By 48 hours this had increased to 1 x l0 cpm
and by 72 hours 1.8 x 10 cpm. In comparison lymphocytes from the PLY/OVA group proliferated
after 24 hours to 7000 cpm rising to 6 x 10 cpm after 48 hours and 1.2 x 10 cpm after 72 hours.
Therefore PLY/OVA treated mice are shown to contain less cells that proliferate in response to
ovalbumin than PBS/OVA treated mice.
Since, in the data presented in Figure 6-6, the amount of thymidine incorporation is simply a reflec-
tion of the number of T cells present in each mouse, this data does not inform about the ability of
the I cells from each mouse to proliferate. However this data provided further evidence that the
KJ+ T-cells accumulated less in the pneumolysin treated mice.
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Figure 6-6
The effect of pneumolysin upon T cell accumulation as measured by the ex vivo proliferation
of transgenic cells.
On day 7 a proliferation assay was set up using lymph node single cell suspensions from each
mouse. The number of lymphocytes was equalised so that each well contained 2 x 10 lymphocytes.
Cultures were stimulated with lmg/ml ovalbumin and proliferation was measured by 3H thymidine
incorporation at 24,48 and 72 hours. Proliferation of lymphocytes from mice that received PBS i.p
and S.0 is shown as a blue line and represents a group of one mouse. Proliferation of lymphocytes
from mice that received PLY i.p and PBS S.0 is shown as a turquoise line and represents a group of
one mouse. Proliferation of lymphocytes from mice that received PBS i.p and OVA s.c is shown as
a pink line and represents a group of three mice. Proliferation of lymphocytes from mice that
received PLY i.p and OVA s.c is shown as a pink line and represents a group of three mice. For
groups of mice, the proliferation of each individual mouse was recorded and then an average calcu-
lated and plotted on the graph above.
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Figure 6-7
The effect of pneumolysin administration upon the activation of T cells.
In the experiment outlined in figure 6-4 we simultaneously measured the acti-
vation state of the T cells by measuring the amount of CD25 expressed on the
surface of the KJ^, CD4+ T cells using an antibody to CD25 and flow cytometry.
The group called PBS/PBS/PBS (blue line) received PBS i.p and PBS s.c. The
group labelled PLY/PBS/PLY (turquoise line) received pneumolysin i.p twice
and PBS s.c. The group labelled PBS/OVA/PBS (pink line) received PBS i.p
twice and OVA/CFA s.c. The group labelled PLY/OVA/PLY (yellow line) re-
ceived pneumolysin i.p twice and OVA/CFA s.c. Rat 1gM FITC was used as
the isotype control (data not shown).
6-166.2.2.4 Pneumolysin does not affect T cell activation
In vitro I had observed that pneumolysin did not alter the proportion of T cells to become activated
yet the subsequent proliferation of those T cells was altered by the presence of pneumolysin. I was
therefore interested to see if the same effect could be observed in vivo. Simultaneous to measuring
the proportion of KJ+ cells within the lymph node (see Figure 6-4) I also measured the activation
state of the T cells using an anti-CD25 antibody (see Figure 6-7). In mice that received either  PBS
i.p. and PBS s.c. or PLY i.p. and PBS s.c. the number of CD25+ cells remained constant at 3% of
transgenic T cells. Mice that received PBS i.p. and OVA-CFA s.c. or PLY i.p. and OVA-CFA S.C.
had the same percentage of activated cells at each time point. On day 3 this was 7%, day  5, 4% and
by day 7 it had decreased to 3%. No significant difference between mice receiving  PBS/OVA-CFA
and those receiving PLY/OVA-CFA was observed at any time point. The isotype control showed
no increase at any time point (data not shown). I concluded that in mice receiving ovalbumin and
treated with pneumolysin, T cells become activated to the same degree as those in mice receiving
ovalbumin and treated with PBS.
This data coincides with the data I obtained from my in vitro studies where T cells became acti-
vated to the same degree when pneumolysin was present but the subsequent expansion after activa-
tion differs.
6.2.2.5 Pneumolysin inhibits antibody production in vivo
CD4 T-cell function can be further assessed by measuring antigen-specific antibody levels 21 days
after ovalbumin administration. Ovalbumin specific anti IgGi was measured by antibody ELISA
using blood harvested from mice on day 21. As can be seen from Figure 6-8 no anti Ovalbumin
specific IgGI is produced in response to injections of PBS or pneumolysin alone. However groups
receiving PBS/OVA a titre of 10000 is achieved after day 21 yet a titre of only 3500 is achieved for
groups that received ovalbumin and were treated with pneumolysin. Mice that received PLY/OVA
therefore produce significantly less IgGi than mice that received PBS/OVA.
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Figure 6-8
The effect of in vivo pneumolysin administration upon antibody response to
ovalbumin
On day 21 of the experiment described in figure 6-4, mice were sacrificed and
blood collected from the portal vein and antibody ELISA's were performed for anti-
ova IgGi. The Pbs group and the Ply group had 1 mouse per group while the Pbs!
ova and the Ply/ova had three mice per group. Titres for each mouse were calculated
and averaged. The difference between pbs/ova and ply/ova is statistically significant
to 0.05.
6 - 186.2.2.6 Immunohistochemical anaylsis of the effect of pneumolysin in
vivo
Differences in the number of antigen-specific CD4 T-cells within a lymph node can sometimes be
more clearly evident using immunohistochemistry. While this method is not quantitative it can be
informative since decreased antibody production may be the result not only of less T cells being
present but also the result of a lack of T cell migration to the B cell follicles. I performed immuno-
histochemistry on lymph nodes frozen on day 7 by staining for B220 and KJ1 .26.
Figure 6-9 shows the images. Image A demonstrates the lack of KJ+ T cells within an animal that
did not receive ovalbumin. The high degree of blue staining in the next three images (B, C, D)
illustrates the increase in KJ+ T cells in animals that received ovalbumin. The final three images
(E, F, G) show that in animals that received ovalbumin and were treated with pneumolysin the
amount of KJ+ T cells noticeably decreases when compared to mice that have received ovalbumin
since in these images the amount of blue dots is noticeably less than in images B, C and D. This
data corresponds with the data from Figure 6-4 where the percentage of KJ+ T cells was shown to
be less in the lymph nodes of mice that had received ovalbumin and been treated with pneumolysin
compared to those of the mice that received ovalbumin but did not receive pneumolysin.
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Immunohistochemistry
On day 7 in the experiment outlined in figure 6-4 in addition to measuring %KJ and
%CD25+ T cells, one lymph node was frozen and later used for IHC where staining
for KJ1 .26 (blue) and B220 (brown) was carried out. Image A is from a mouse that
received PBS only. Images B, C and D are sections from mice treated with PBS!
OVA. Images E, F and G are from mice treated with pneumolysin!OVA.
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6 - 226.3 Discussion
In this chapter I have demonstrated that wild type pneumolysin is able to inhibit the accumulation
of transgenic T cells in mice that received ovalbumin. I have demonstrated this by direct flow
cytometric measurement and by ex vivo restimulation of lymph node cells. Furthermore the evi-
dence from antibody production and immunohistochemistry confirms this data. I have also shown
that the number of T cells that become activated by day 3 after receiving ovalbumin is not altered
by pneumolysin yet there are less T cells within the lymph nodes on day 7.
In 1994 Keamey et al. first used the DO 11.10 adoptive transfer system to track transgenic T cells in
vivo (Kearney et a!., 1994). Since then this system has been used to study a range of immune
responses in vivo including the activation and development of T cell phenotypes following the
induction of immunity, autoimmunity, allergy and tolerance and the trafficking ofeffector lymphocyte
populations (Chen and Jenkins, 1998; Garside et al., 1998; Iqbal eta!., 2002; Jenkins eta!., 2001;
Khoruts et a!., 1998; McSorley et a!., 2002; Pape et al., 1998; Rush et a!., 2002; Smith et a!.,
2004b). There have been few groups who have used this system to assess the effect of potential
immunomodulators on the T cell response despite it being ideally suited to this purpose. In 2000
Shepherd eta!. used the transfer system to assess the effects of TCDD on the activation of transgenic
T cells in vivo (Shepherd et al., 2000). However the work most closely related to my studies was
that of Boitelle eta!. (Boitelle et a!., 2003) and Plant eta!. (Plant et a!., 2003) who, used the system
to assess the effects of a pathogen produced molecule (Ascaris body fluid and EtxB, respectively)
on the T cell response. These studies confirm the validity of using the DO 11.10 system as I have
done while other work using the system has helped me with the design an interpretation of my
results.
The data I presented showing expansion of antigen specific T cells on day 3, peaking on dayS and
then declining to day 7 is consistent with other groups findings when using this system (Kearney  et
a!., 1994). While my data clearly shows that pneumolysin results in less transgenic T cells on day
7, the situation on day 5 is less evident. The decreased number of T cells observed on day 5 is not
significant which suggests two possible interpretations of the data. If the number of T cells on day
5 was essentially the same between untreated mice and mice treated with pneumolysin, yet the
number of T cells in treated mice was less on day 7, then I would interpret the data to show that
6 - 23pneumolysin does not inhibit T cell expansion but rather sensitises T cells to a more rapid death. If
however a difference in number of T cells was observed on day 5 then this would demonstrate that
pneumolysin does inhibit T cell expansion. Further work is necessary to decide between these two
alternatives although my in vitro data suggests that the latter is more likely.
The data presented in this chapter is remarkably consistent with the data I provided from my
studies in vitro. In vitro I demonstrated that pneumolysin inhibited antigen specific T cell expan-
sion and I have shown this in vivo. However it is essential to recognise the differences between the
in vitro and in vivo systems. The in vitro system is closed, whereas the lymph nodes in vivo are not.
T cell accumulation is measured in vivo as opposed to proliferation since when the percentage of
transgenic T cells is measured in vivo this is a product of proliferation in the lymph node but also of
recruitment of transgenic cells and other cell types, the migration of cells out of the lymph nodes
and cell death. It is possible therefore that a decrease in the percentage of transgenic T cells ob-
served in vivo could be the result of a migration of non transgenic T cells into the lymph node
which effectively dilutes the concentration of transgenic cells. Where this effect was occurring, the
percentage and number of transgenic cells would appear less as measured by flow cytometty, ex
vivo proliferation and lymphocyte counting. A functional measure of T cells, such as antibody
production, would be able to discriminate between a real decrease and a perceived decrease in T
cell numbers. My data measuring the antibody response to ovalbumin is therefore informative in
this regard as it gives some indication that a real decrease in T cell function is occurring in the
lymph nodes, although an effect of pneumolysin upon B cells cannot be excluded.
Direct injection of pneumolysin has been used to mimic a number of pneumococcal induced
pathologies (Feldman eta!., 1991; Harrison eta!., 1982) and immunisation with pneumolysin has
been used to induce protective antibody against pneumococcal infection (Alexander et a!., 1994;
Briles eta!., 2000; Kuo eta!., 1995), however using pneumolysin as I have done is, to my know!-
edge, unprecedented. I was therefore unsure about the initial dose of toxin to use and chose a dose
as had been used for immunisation. The distribution of pneumolysin after it has been injected has
never been examined. Given the propensity of pneumolysin to bind to cells it seems likely that
much toxin will have bound to cells at the injection site and whether any free toxin reached the site
of antigen presentation to T cells is unknown. What does seem likely is that the effective dose of
pneumolysin at the site of antigen presentation to T cells is likely to be significantly less than that
injected. The distribution of toxin and the concentration of free toxin along with the delivery of cell
6 - 24bound toxin to lymph nodes are all un-investigated parameters of this system that require further
examination. The fact that pneumolysin is immunogenic and requires no adjuvant means that it
seems likely that antibodies to pneumolysin would have formed and therefore repeated administra-
tion for therapeutic purposes may be problematic.
In vitro I had examined the early activation markers CD69 and CD25 on transgenic T cells and
found no decrease in their upregulation in the presence of pneumolysin. This demonstrated that T
cells were becoming activated as normal and that the inhibitory effect I observed was not the result
of a defect in T cell activation. In vivo I chose to examine CD25 only since CD69 peaks within the
first 24 hours of T cell activation and therefore would be an invalid measure on day 3. The in vivo
data was consistent with the in vitro data since no difference in T cell activation was observed in
the presence of pneumolysin which suggests that the same inhibitory mechanism functions  in vivo
as does in vitro.
I have mentioned the usefulness of my studies on antibody production to enable me to functionally
measure the effect of pneumolysin upon the T cell which helps me to interpret the questions that
arise as a result of the system being open. My examination of lymph node sections by
immunohistochemistry is also useful in this regard since they clearly display a real difference in the
number of T cells within the whole lymph node. One further area to investigate via
immunohistochemistry is whether the T cells migrate to the B cell follicles to the same degree in
mice treated with pneumolysin as in controls. This would allow us to observe if pneumolysin is
also inducing anergy in any T cells since these would be observed not to migrate. Consolidation of
the data obtained by IHC is required since while the images shown are representative of those
obtained, it would be good practice to obtain images from a larger sample group.
Overall my data in this chapter clearly demonstrates that pneumolysin can inhibit the T cell re-
sponse in vivo in the purified form. To further address this question it would be interesting to
further mimic my in vitro findings in vivo by using CFSE labelled T cells and transferring them to
examine cell division in this way. It would also be interesting to examine if T cell apoptosis is being
induced by administration of the purified toxin in vivo. The work I mentioned previously of Kemp
et al. (Kemp et a!., 2002) suggests that it may.
6 - 25I have demonstrated in this chapter that pneumolysin is able to inhibit the expansion of antigen
specific T cells in vivo and have proposed on the basis of my in vitro studies that pneumolysin
accomplishes this by inducing apoptosis although this has yet to be demonstrated in vivo. It is
important to set this work in the wider context of the pneumococcal infection.
I mentioned in the introduction to this chapter that the role of the T cell in the immune response to
the pneumococcus is still being elucidated. Initial work by Winkeistein (Winkeistein and Swift,
1975) has suggested that T cells were unimportant for the immune response to the pneumococcus.
These studies were based on the i.p. injection of lethal doses of pneumococci and resulted in the
conclusion that T cells have no role in defence against the pneumococcus since no difference in
lethal dose is observed in the presence or absence of T cells. The validity of these studies was
limited by two key points; the i.p. injection of pneumococci is not the standard route of host en-
counter with pneumococci, and secondly, since T cells are primarily mediators of adaptive immu-
nity, use of a challenge model does not examine the functional role of the T cell correctly.
In 1987 Sestini et a!. (Sestini eta!., 1987, 1988) found that T cells in the lung mediate an antibac-
terial effect against the pneumococcus. More recently Kadioglu et a!. (Kadioglu eta!., 2000) have
implicated the T cell in the immune response to the pneumococcus in the lung since they discov-
ered that the decline in pneumococcal numbers within the lung coincided with the influx of B and
T cells into certain parts of the lung tissue. They were careful to point out that this appears to be the
result of redistribution within the lung tissue as opposed to influx of cells from outside of the lung.
Recently the same group have communicated that CD4 deficient mice are more susceptible to
bronchopneumonia and septicaemia than mice with intact CD4 T cell functioning (Kadioglu and
Andrew, 2004) and they have demonstrated this using MHC II -I- mice (Kadioglu et a!., 2004).
Taken together this work suggests that T cells may have a role in the innate immune response to the
pneumococcus since the time period in these studies is too short for any adaptive response to be
involved.
In the introduction to this thesis I made extensive reference to the studies that have elucidated the
role of the T cell in the production of antibody to pneumococcal proteins and polysaccharides. The
studies of Wu et a!. (Wu et aL, 1999) have demonstrated the necessity of CD4 T cells for an
effective antibody response to protein antigens such as PspA to be generated. Investigations into
the T cell requirements for an antibody response to pneumococcal polysaccharide antigen remains
6 - 26controversial (Snapper, 2004) however the consensus of results suggest that an effective antibody
response to the phosphoryicholine (PC) determinant of the polysaccharide cell wall component,
techinoic acid, and capsular polysaccharide requires CD4 T cells to provide a CD4O and CD28
signal (Hwang et a!., 2000; Wu et a!., 1999) (Wu et a!., 2000). Wu also demonstrated that the
despite being T cell dependent, the anti-PC response is TcR independent (Wu  eta!., 2000). In 2004
Khan et a!. (Khan eta!., 2004) demonstrated that these findings for PC are consistent for capsular
polysaccharide however they discovered that capsular polysaccharide is TcR dependent.
To summarise the role of the T cell in the immune response to the pneumococcus Kadioglu et a!.
suggest that T cells may have some undefined role during the innate phase of the immune response
and that T cells have a defined role in enabling the production of antibody to protein and polysac-
charide antigens of the pneumococcus. My work on the induction of T cell apoptosis may be rel-
evant with respect to these two T cell activities since it implies that wherever the pneumococcus
encounters an activated T cell, apoptosis may be induced. This may occur during a range of pneu-
mococcal pathologies, however my work is only really of interest where a defined and important
role has been elucidated for the T cell since it is in then that the induction of T cell apoptosis may
have an effect on the outcome of pneumococcal infection.
I therefore hypothesise that pneumolysin may induce T cell apoptosis during the innate immune
response in the lung or during the formation of antibody during invasive disease or colonisation.
This hypothesis has a number of testable implications. As soon as these implications are consid-
ered however the complications imposed by the multifunctional nature of pneumolysin are imme-
diately clear. It has been repeatedly demonstrated that pneumolysin has a number of important
functions in vivo and therefore the study of pneumolysin deficient strains is complicated by the
way they differ from the wild type strain. None the less my hypothesis in relation to the lung
activities of T cells would be that if one of the functions ofpneumolysin is to induce apoptosis of T
cells in the lung then I would expect to see fewer T cells when pneumolysin sufficient pneumo-
cocci are present compared to a pneumolysin deficient strain. When using a pneumolysin deficient
strain the opposite is actually discovered (Kadioglu eta!., 2000) but this is because pneumolysin is
actually required for recruitment of the T cells. No other studies have attempted to examine this
question and so further insightful studies are required in this area.
6 - 27Studies have shown that carriage and invasive disease can result in antibody formation to pneumo-
coccal antigens including PspA, polysaccharide and pneumolysin (Rapola et a!., 2000) however
this is strain dependent for polysaccharide (Soininen et a!., 2001) and not always observed for
pneumolysin (McCool et a!., 2003). According to the summary of the role of the CD4 T cell in
antibody formation to the pneumococcus presented in the introduction to this thesis, this antibody
will be CD4 T cell dependent. If apoptosis of the CD4 T cells involved in the production of anti-
body to the pneumococcus is occurring then a number of hypothesises result;
I would predict that antibody formed during invasive disease would be greater in the absence of
pneumolysin. Studies using the pneumolysin deficient strain of pneumolysin have not examined
this issue. Once again these studies are complicated by the differing course of infection of pneumo-
lysin deficient strains. I would also predict that the formation of antibody as a result of carriage
would also be greater in the absence of pneumolysin. I suggest that pneumolysin functions during
colonisation not to enable current colonisation but rather to enable future colonisation by inhibiting
the development of antibodies to the pneumococcus during colonisation. Again no studies have
directly addressed this question however a number of studies have produced some interesting data
in this area.
While the development of antibodies during colonisation has been demonstrated this has been
found to vary between strains. Therefore it is possible that pneumolysin is the reason for this vari-
ation. Furthermore in 1998 Rubins et a!. (Rubins et al., 1998) studied the effect of pneumolysin
upon colonisation. They found that a pneumolysin deficient strain of S.  pneumoniae was able to
colonise and persist in the nasopharynx equally as well as the wild type strain. This data is in
contrast with other data that found that pneumolysin deficient strains did not colonise the nasopharynx
with the same success as pneumolysin sufficient strains (Kadioglu  et a!., 2002) although these
studies used different strains and so some strain variation seems to be a factor.
Neither study addressed the effect of pneumolysin upon antibody formation since the work of
McCool et a!. demonstrated that during colonisation antibody to PspA increased, yet it had very
little effect upon the carriage of the current strain but did inhibit re-colonisation (McCool el a!.,
2002). Therefore measuring current colonisation does not correlate with the development of anti-
body. Therefore since we are suggesting that during colonisation pneumolysin may be inducing
6 - 28apoptosis of CD4 T cells and thereby inhibiting antibody production, the effect of it doing this will
not be observed on current colonisation but only upon attempted recolonisation.
My survey of the current literature suggests that the hypothesis presented in this chapter remains
largely un-addressed and is worthy of a fuller examination. I made suggestions earlier in this
chapter of possible future directions of enquiry using the purified toxin and I now suggest that a
line of enquiry be pursued using a pneumolysin deficient strain of Streptococcus pneumoniae into
the effect of pneumolysin upon the T cell in the context of pneumococcal infection.
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7-17.1 Conclusion
In this thesis I have demonstrated that pneumolysin inhibits in vitro antigen specific murine CD4 T
cell proliferation and cytokine production. Furthermore, I have shown that this effect is not ob-
served with the non-hemolytic pneumolysin mutant F433. I have demonstrated that pneumolysin
accomplished this inhibitory activity by inducing apoptosis of activated CD4 T cells and suggest
that lipid rafts may be involved in this process since I also demonstrated that pneumolysin prefer-
entially binds to lipid rafts.
In order to further understand the mechanism of action of pneumolysin it would be interesting to
elucidate a more detailed description of the role lipid rafts, caspases, active cell death and anergy
have in the apoptosis induction process by pneumolysin. Furthermore given the role lipid rafts
have in controlling T cells and that lipid rafts have been identified as being potential therapeutic
targets (Van Laethem and Leo, 2002) it is possible that pneumolysin could be a highly functional
therapeutic molecule and therefore understanding its interaction with lipid rafts could prove criti-
cal. The studies conducted on listeriolysin which have demonstrated that listeriolysin induces
apoptosis of T cells by a Fas dependent mechanism (Zenewicz et a!., 2004) when considered along
with the work which demonstrated elevated Fas ligand levels during pneumococcal infection (Kemp
et al., 2002) suggests that further in vitro investigation into the role of Fas in the apoptosis inducing
process of pneumolysin would be worthwhile.
In this thesis I have also demonstrated that pneumolysin is able to inhibit the in vivo accumulation
of T cells and also inhibits in vivo antibody production. I have suggested that these results may be
important in terms ofpneumococcal pathogenesis whenever pneumolysin encounters CD4 T cells.
Some recent data has focused on the encounter between the pneumococcus and T cells during lung
infection (Kadioglu and Andrew, 2004) and has suggested that T cells are essential for pneumococ-
cal clearance. Furthermore pneumolysin sufficient strains have been demonstrated to persist for
longer within the host lung (Kadioglu et a!., 2002). While it has been shown that pneumolysin is
involved in T cell recruitment in the lung, there have been no studies that have examined whether
pneumolysin induces T cell apoptosis and whether this is responsible for the increased virulence
observed in pneumolysin sufficient strains of pneumococci. I specifically therefore suggest that
7-2pneumolysin may be involved in the pathogenesis of the pneumococcus by inducing apoptosis of
activated T cells in the lung.
In order to further elucidate the role of apoptosis in the pathogenesis of the pneumococcus, I sug-
gest that demonstration that purified pneumolysin induces apoptosis of T cells in vivo should be
followed up by the measurement of T cell apoptosis during pneumococcal infection. While meas-
uring the amount of apoptosis during pneumococcal infection such as was carried out in humans
(Kemp et a!., 2002) is relatively straightforward, demonstration of pneumolysin to be the causative
agent is more difficult. This is because pneumolysin deficient pneumococcal strains do not follow
the same course of infection and therefore differences are hard to measure. One possibility would
be to use a pneumococcal strain containing the F433 mutant since T cell recruitment into the lung
is the same for this mutant and yet according to our studies the pneumolysin would not induce
apoptosis.
Other studies have focused upon the T cell requirement of the antibody response to the pneumo-
coccus (Khan eta!., 2004; Snapper eta!., 2001; Wu et al., 2001; Wu et al., 2002) and have shown
a T cell dependency for antibody produced to pneumococcal protein and polysaccharide. I there-
fore also specifically have suggested that pneumolysins induction of T cell apoptosis may therefore
have an effect on antibody production to the pneumococcus.
Given the limited role antibody development has on the clearance of current infection (McCool  et
a!., 2002) the effect of pneumolysin upon antibody development is of interest with regard to future
infection since antibody developed during previous exposure to the pneumococcus would prevent
colonisation upon re-exposure. While it has been shown that pneumolysin deficient strains of the
pneumococcus are carried for the same length of time as pneumolysin sufficient strains it would be
interesting to measure the development of antibody in these situations.
Finally the use of pneumolysin as a potential therapeutic molecule is also of interest. In demon-
strating that pneumolysin is able to inhibit the in vivo function of CD4 T cells it would be interest-
ing to examine the effects administering the toxin (or some derivative of it) on CD4 T cell mediated
diseases such as rheumatoid arthritis. Experiments similar to those carried out using ES-62 on the
collagen induced arthritis model (Mclnnes et a!., 2003) would be ideal for examining this thera-
peutic potential.
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DNA loading buffer (6x)
0.25% Bromophenol blue
0.25% Xylene cyanol FF
40% (w/v) sucrose in water
Soc
Make SOB first;
950m1 dH2O
20g Bacto Tryptone
5g Bacto Yeast Extract
0.5gNaCl
lOmi 250nM KC1
5ml 2M MgC1
Then make into SOC by adding 20m1 of 1M glucose
PBS
2.4g KJ-12PO4
2gKCL
14.4g NaH2PO
SOg NaCL
in 1 litre water
7-51.SM Tris HCL
24.2g Tris base (trizma)
add to 50m1 dH2O
add HC1 to pH 8.8 or pH 6.8
make to lOOmI
Bromophenol Blue
100mg Bromophenol Blue in 10m1 water
Running buffer
3g Tris (25mM)
l4.4g glycine (192mM)
ig SDS (0.1%)
H20 to 1L
Sample buffer
Tris HC1 (pH 6.8) - 60mM
5m1 50% glycerol (25%)
2m1 10% SDS (2%)
0.5ml 2-ME (14.4mM)
imi Bromophenol blue (0.1%)
0.9m1 of dH2O
7-6Separating gel
4.05m1
pH 8.8 - 2.5m1
lOOuI
3.3m1
SOul
Sul
Stacking gel
3.05m1
pH 6.8— 1.25m1
50u1
665u1
25u1
5u1
Coomassie stain
ig coomassie blue (0.1%)
1L destain
Destain
40% methanol
10% acetic acid
50% dH2O
dH2O
1.SM Tris TIC!
10% SDS
30% Acyrilamide bis
10% APS
Temed
Transfer buffer
25mm Tris base 3.03g
192mM Glycine 14.4g
20%v/v methanol
	
200m1
Add dH2O to 1L,
Tris NaC1
Tris base I .2g	
7-7NaC1 8.7g
Conc HCI 800u1
Make toiL
Developer
30mg of 4-chloro-l-naphtol (freezer)
dissolve in lOmis of methanol
add to 5Omls Tris NaCI
also 30u1 H202 (30% v/v)
MACS Buffer
500ml PBS
2m1 0.5M EDTA
25m1 10% sterile BSA
FACS buffer
500m1 PBS
2%FCS
0.2% Na Azide
Fc block
anti-CD 16/32 hybridoma supernatant
10% mouse serum (Diagnostic Scotland, Edinburgh, UK)
0.1% sodium azide (Sigma)
7-8Complete RPMI
RPMI 1640 (Gibco BRL, Paisley, UK)
10% foetal calf serum
glutamine
perilstrep (100U/ml penicillin, 100mg/mi streptomycin)
50tM 2-mercaptoethanol (all Gibco BRL, Paisley, Scotland, UK).
Complete IMDM
Pen/Strep
2mM L-Glutamine
50tM 2-Mercaptoethanol
10%FCS
TNB
0.1M Tris-HCI pH7.5, O.15M NaCI, 0,5% blocking reagent (NEN Life Science)
TNT
0.1M Tris-IICI p117.5, 0.15M NaC1, 0.05% Tween
lonomycin - Ca2+ salt - Sigma
7-9PMA - Phorbol 12 Myristate 13-Acetate - Sigma
Recombinant murine IL-2 was purchased from R&D Systems.
FACS Antibodies
Biotinylated clonotypic anti-TcR antibody, KJ1 .26 (produced from the original hybridoma (Haskins
eta!., 1983))
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AMRESCO Inc.
30175 Solon Industrial Parkway
Solon, Ohio
Amico Millipore
Millipore (U.K.) Limited
Units 3&5 The Courtyards
Hatters Lane
Watford, WD18 8YH
England
Becton DickinsoniPharmingen
BD Biosciences
21 Between Towns Road
Cowley
Oxford, UK
Bibby Sterelin
Lindon House
Heeley Road
Birmingham
UK
Biorad Labs Ltd
Bio-Rad House
Maylands Ave
Hemel Hempstead
Hertfordshire
7 - 12UK
Biotek Instruments
via Fisher Scientific UK
Bishop Meadow Road
Loughhorough
Leicestershire LE1 1 5RG
United Kingdom
BioWhittaker Ltd
BioWhittaker House
I Ashville Way
Berkshire
UK
Cadisch Precision Meshes, London, UK
Costar, Corning, N.Y., USA
CompuCyte Corporation
12 Emily Street
Cambridge, MA 02139
Constant Systems Ltd
Cell Disrupting Equipment
Unit 3
Amherst Business Centre
Budbrooke Road
Warwick
Decon Labs Ltd
Conway Street, Hove, East Sussex, BN3 3LY UK
7-13Duchefa
P0 Box 2281
2002 CG Haarlem
Netherlands
Dynex Technologies, Vancouver, USA
Gibco/Invitrogen Ltd
3 Fountain Drive
Inchinnan Business Park
Paisley
UK
Harlan-Olac
Shaw's Farm
Blackthorn, Bicester
Oxon 0X25 1TP
England
Hawksley & Sons
Marlborough Road
Lancing Business Park
Lancing
Sussex
Helima
Heilma GmbH & Co KG
Klosterrunsstrasse 5
D-79371 MUliheim
Hybaid
Action Ct
7 - 14Ashford Rd
Middlesex
UK
Kirkegaard and Perry Laboratories, Gaithersburg, MD, USA
Melford Laboratories Ltd
Suffolk
UK
Menzel Glaser, Germany
Molecular Probes
Molecular Probes, Inc.
PU Box 22010
Eugene,
Miltenyi Biotec
Miltenyi Biotec Ltd.
Almac House
Church Lane, Bisley
Surrey GU24 9DR
New England Biolabs
32 Tozer Road
Beverly, MA 0 1915-5599
Novagen
Merck Biosciences Ltd.
Boulevard Industrial Park
Padge Road
Beeston
NOTTINGHAM
7- 15NG9 2JR
Nunc
Nalge Limited
Unit la, Thom Business Park
Hereford UK
Oxoid Ltd, Basingstoke, Hampshire, England
Perseptive Systems
850 Lincoln Centre Drive
Foster City, CA 94404 USA
Promega
Southampton
UK
QIAGEN Ltd.
QIAGEN House
Fleming Way
Crawley
West Sussex,
R&D Systems, Minneapolis, MN, USA
Rimmel
via Boots UK
Serotec Ltd, 22 Bankside, Station Approach, Kidlington, Oxford, 0X5 1JE
Sartorius Ltd.
Longmead Business Park
Blenheim Road
7 16Epsom Surrey
UK
Sakura
Hoge Rijndijk 48a
2382 AT Zoeterwoude
The Netherlands
Sigma-Aldrich Company Ltd
Second Avenue
Heatherhouse Industrial Estate
Irvine
KAl2 8NB
Scotland
Sigma-Genosys Ltd.
London Road, Pampisford
Cambridge CB2 4EF, UK
Stratagene
11011 N. Torrey Pines Road
La Jolla, CA 92037
ThermoShandon
Pittsburgh
PA, USA
Unicam
P0 l3ox 206
York Street
Cambridge
UK
7 - 17Vector Laboratories
Burlingame
CA, USA
Wallac/Perkin Elmer Life Science
549 Albany Street
Boston, MA USA
Zeiss
Woodfield Road
Weiwyn Garden City
Herts
UK
7-18References
7 - 19References
References
Abrami, L., Fivaz, M., Glauser, P.E., Parton, R.G., and van der Goot, F.G. (1998) A pore-forming
toxin interacts with a GPI-anchored protein and causes vacuolation of the endoplasmic
reticulum. JCellBiol 140: 525-540.
Abrami, L., and van Der Goot, F.G. (1999) Plasma membrane microdomains act as concentration
platforms to facilitate intoxication by aerolysin. J Cell Biol 147: 175-184.
Abrami, L., Fivaz, M., and van der Goot, F.G. (2000) Surface dynamics of aerolysin on the plasma
membrane of living cells. IntJMed Microbiol 290: 363-367.
Adams, C.L., Grierson, A.M., Mowat, A.M., Hamett, M.M., and Garside, P.  (2004a) Differences in
the kinetics, amplitude, and localization of ERK activation in anergy and priming revealed
at the level of individual primary T cells by laser scanning cytometry. J Immunol 173:
1579-1586.
Adams, C.L., Kobets, N., Meiklejohn, G.R., Millington, O.R., Morton, A.M., Rush, C.M., Smith,
K.M., and Garside, P. (2004b) Tracking lymphocytes in vivo. Arch Immunol TherExp (Warsz)
52: 173-187.
Adams, C.L., Rush, C.M., Smith, K.M., and Garside, P. (2004c) Tracking antigen-specific
lymphocytes in vivo. Methods Mo! Bio! 239: 133-146.
Akesson, P., Sjoholni, A.G., and Bjorck, L. (1996) Protein SIC, a novel extracellular protein of
Streptococcus pyogenes interfering with complement function. J Biol Chem 271: 1081-
1088.
Alexander, J.E., Lock, R.A., Peeters, C.C., Poolman, J.T., Andrew, P.W, Mitchell, T.J., Hansman,
D., and Paton, J.C. (1994) Immunization of mice with pneumolysin toxoid confers a
significant degree ofprotection against at least nine serotypes of Streptococcus pneumoniae.
InJèctI,nmun 62: 5683-5688.
Alexander, J.E., Berry, A.M., Paton, J.C., Rubins, J.B., Andrew, P.W., and Mitchell, T.J. (1998)
Amino acid changes affecting the activity ofpneumolysin alter the behaviour ofpneumococci
in pneumonia. Microb Pathog 24: 167-174.
7 - 20Au, F., Lee, M.E., lannelli, F., Pozzi, G., Mitchell, T.J., Read, R.C., and Dockrell, D.H. (2003)
Streptococcus pneumoniae-Associated Human Macrophage Apoptosis after Bacterial
Internalization via Complement and Fcgamma Receptors Correlates with Intracellular
Bacterial Load. JinfeciDis 188: 1119-1131.
Alonso, A., Bottini, N., Bruckner, S., Rahmouni, S., Williams, S., Schoenberger, S.P., and Mustelin,
T. (2004) Lck Dephosphorylation at Tyr-394 and Inhibition of T Cell Antigen Receptor
Signaling by Yersinia Phosphatase Yopil. J. Biol. Chem. 279: 4922-4928.
Alonso, M.A., and Millan, J. (2001) The role of lipid rafts in signalling and membrane trafficking
in T lymphocytes. JCellSci 114: 3957-3965.
Alving, C.R., Habig, W.H., Urban, K.A., and Hardegree, M.C. (1979) Cholesterol-dependent
tetanolysin damage to liposomes. Biochim Biophys Ada 551: 224-228.
Arva, E., and Andersson, B. (1999a) Kinetic of Cytokine Release and Expression of Lymphocyte
Cell-Surface Activation Markers After In Vitro Stimulation of Human Peripheral Blood
Mononuclear Cells with Streptococcus pneumoniae. Scandinavian Journal ofImmunology
49: 237-243.
Arva, E., and Andersson, B. (1999b) Induction of phagocyte-stimulating and Thi-promoting
cytokines by in vitro stimulation of human peripheral blood mononuclear cells with
Streptococcus pneumoniae. ScandJlmmunol 49: 417-423.
Ashwell, J.D., Cunningham, R.E., Noguchi, P.D., and Hernandez, D. (1987) Cell growth cycle
block of T cell hybridomas upon activation with antigen. JExp Med 165: 173-194.
Baba, H., Kawamura, I., Kohda, C., Nomura, T., Ito, Y., Kimoto, T., Watanabe, I., Ichiyama, S., and
Mitsuyama, M. (2001) Essential role of domain 4 of pneumolysin from Streptococcus
pneumoniae in cytolytic activity as determined by truncated proteins. Biochem Biophys Res
Commun 281: 37-44.
Baba, H., Kawamura, I., Kohda, C., Nomura, T., Ito, Y., Kimoto, T., Watanabe, I., Ichiyama, S., and
Mitsuyama, M. (2002) Induction of gamma interferon and nitric oxide by truncated
pneumolysin that lacks pore-forming activity. Infect Immun 70: 107-113.
Balachandran, P., Hollingshead, S.K., Paton, J.C., and Briles, D.E. (2001) The autolytic enzyme
LytA of Streptococcus pneumoniae is not responsible for releasing pneumolysin. JBacteriol
183: 3 108-3116.
Banks, T.A., and Rouse, B.T. (1992) Herpesviruses—immune escape artists? Gun Infect Dis 14:
933-941.
7-21Baxendale, HE., Davis, Z., White, H.N., Spellerberg, M.B., Stevenson, F.K., and Goldblatt, D.
(2000) In-imunogenetic analysis of the immune response to pneumococcal polysaccharide.
EurJlmmunol3O: 1214-1223.
Benton, K., Everson, M., and Briles, D. (1995) A pneumolysin-negative mutant of Streptococcus
pneumoniae causes chronic bacteremia rather than acute sepsis in mice.  Infect. Immun. 63:
448-455.
Benton, K.A., Paton, J.C., and Briles, D.E. (1997) The hemolytic and complement-activating
properties of pneumolysin do not contribute individually to virulence in a pneumococcal
bacteremia model. MicrobPathog23: 201-209.
Benton, K.A., VanCott, J.L., and J3riles, D.E. (1998) Role of tumor necrosis factor alpha in the host
response of mice to bacteremia caused by pneumolysin-deficient Streptococcus pneumoniae.
Infect Immun 66: 839-842.
Bergeron, Y., Ouellet, N., Deslauriers, A.M., Simard, M., Olivier, M., and Bergeron, M.G. (1998)
Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection
in mice. Infect Immun 66: 9 12-922.
Berry, A.M., Yother, 3., Briles, D.E., Hansman, D., and Paton, J.C. (1989) Reduced virulence of a
defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect Immun 57:2037-
2042.
Berry, A.M., Paton, J.C., and Hansman, D. (1992) Effect of insertional inactivation of the genes
encoding pneumolysin and autolysin on the virulence of Streptococcus pneumoniae type 3.
Microb Pathog 12: 87-93.
Beny, A.M., Alexander, J.E., Mitchell, T.J., Andrew, P.W., Hansman, D., and Paton, J.C. (1995)
Effect of defined point mutations in the pneumolysin gene on the virulence of Streptococcus
pneumoniae. Infect Immun 63: 1969-1974.
Berry, A.M., and Paton, J.C. (1996) Sequence heterogeneity of PsaA, a 37-kilodalton putative
adhesin essential for virulence of Streptococcus pneumoniae. Infect Immun 64: 5255-5262.
Berry, A.M., Ogunniyi, A.D., Miller, D.C., and Paton, J.C. (1999) Comparative virulence of
Streptococcus pneumoniae strains with insertion-duplication, point, and deletion mutations
in the pneumolysin gene. Infect Immun 67: 98 1-985.
Berry, A.M., and Paton, J.C. (2000) Additive attenuation of virulence of Streptococcus pneumoniae
by mutation of the genes encoding pneumolysin and other putative pneumococcal virulence
proteins. Infect Immun 68: 133-140.
7 - 22Bhakdi, S., and Tranum-Jensen, J. (1984) Mechanism of complement cytolysis and the concept of
channel-forming proteins. Philos Trans R Soc LondB BiolSci 306: 3 11-324.
Bhakdi, S., Tranum-Jensen, J., and Sziegoleit, A. (1985) Mechanism of membrane damage by
streptolysin-O. Infect linmun 47: 52-60.
Billington, S.J., Jost, B.H., and Songer, J,G. (2000) Thiol-activated cytolysins: structure, function
and role in pathogenesis. FEMS MicrobiolLeti 182: 197-205.
Boes, M., Prodeus, A.P., Schmidt, T., Carroll, M.C., and Chen, J. (1998) A critical role of natural
immunoglobulin M in immediate defense against systemic bacterial infection. JExp Med
188: 238 1-2386.
Boes, M. (2000) Role of natural and immune 1gM antibodies in immune responses. Mol Immunol
37: 1141-1149.
Bogaert, D., De Groot, R., and Hermans, P.W. (2004) Streptococcus pneumoniae colonisation: the
key to pneumococcal disease. Lancet Infect Dis 4: 144-154.
Boitelle, A., Scales, H.E., Di Lorenzo, C., Devaney, E., Kennedy, M.W., Garside, P., and Lawrence,
C.E. (2003) Investigating the impact of helminth products on immune responsiveness using
a TCR transgenic adoptive transfer system. Jlmmunol 171: 447-454.
Bone, H., Eckholdt, S., and Williams, N.A. (2002) Modulation of B lymphocyte signalling by the
B subunit of Escherichia coli heat-labile enterotoxin. mt Immunol 14: 647-658.
Bonham, C.A., Lu, L., Li, Y., Hoffman, R.A., Simmons, R.L., and Thomson, A.W. (1996) Nitric
oxide production by mouse bone marrow-derived dendritic cells: implications for the
regulation of allogeneic T cell responses. Transplantation 62: 1871-1877.
Boulnois, G., Mitchell, T., Saunders, F.K., Mendez, F., and Andrew, P.W. (1990) Structure and
function ofpneumolysin, the thiol activated toxin of Streptococcus pneumoniae. In  Bacterial
protein toxins. Alouf, J.E., Rappuoli, R. and Falmagne, P. (eds). Stuttgart: Fischer,  pp. 43-
51.
Boulton, I.C., and Gray-Owen, S.D. (2002) Neisserial binding to CEACAM1 arrests the activation
and proliferation of CD4+ T lymphocytes. Nat Immunol 3: 229-236.
Branger, J., Knapp, S., Weijei; S., Leemans, J.C., Pater, J.M., Speelman, P., Florquin, S., and van
der Poll, T. (2004) Role of Toll-like receptor 4 in gram-positive and gram-negative pneumonia
in mice. Infect Immun 72: 788-794.
Braun, J.S., Novak, R., Gao, G., Murray, P.J., and Shenep, J.L. (1999) Pneumolysin, a protein toxin
of Streptococcus pneumoniae, induces nitric oxide production from macrophages. Infect
Immun 67: 3750-3756.
7 - 23Braun, J.S., Sublett, J.E., Freyer, D., Mitchell, T.J., Cleveland, J.L., Tuomanen, E.I., and Weber,
JR. (2002) Pneumococcal pneumolysin and H(2)O(2) mediate brain cell apoptosis during
meningitis. JClin Invest 109: 19-27.
Bremm, K.D., Brom, H.J., Alouf, J.E., Konig, W., Spur, B., Crea, A., and Peters, W. (1984) Generation
of leukotrienes from human granulocytes by alveolysin from Bacillus alvei. Infect Immun
44: 188-193.
Bricker, A.L., Cywes, C., Ashbaugh, C.D., and Wessels, M.R. (2002) NAD+-glycohydrolase acts
as an intracellular toxin to enhance the extracellular survival of group A streptococci. Mo!
Micro biol 44: 257-269.
Briles, D.E, Nahm, M., Schroer, K., Davie, J., Baker, P., Kearney, J., and Barletta, R. (1981)
Antiphosphocholine Antibodies Found in Normal Mouse Serum are Protective Against
Intravenous Infection with Type 3 Streptococcus pneumoniae. Journal of Experimental
Medicine 153: 694-705.
Briles, D.E., Forman, C., Horowitz, J.C., Volanakis, J.E., Benjamin, WH., Jr, McDaniel, L.S.,
Eldridge, J., and Brooks, J. (1989) Antipneumococcal effects of C-reactive protein and
monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect. Immun. 57:
1457- 1464.
Briles, D.E., Hollingshead, S., Brooks-Walter, A., Nabors, G.S., Ferguson, L., Schilling, M.,
Gravenstein, S., Braun, P., King, J., and Swift, A. (2000) The potential to use PspA and
other pneumococcal proteins to elicit protection against pneumococcal infection.  Vaccine
18: 1707-1711.
Brown, J.S., Hussell, T., Gilliland, S.M., Holden, D.W., Paton, J.C., Ehrenstein, M.R., Walport,
M.J., and Botto, M. (2002) The classical pathway is the dominant complement pathway
required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Nat!
AcadSci USA 99: 16969-16974.
Budd, R.C. (2001) Activation-induced cell death. Curr Opin Immunol 13: 356-362.
Camara, M., Mitchell, T.J., Andrew, P.W., and Boulnois, G.J. (1991) Streptococcus pneumoniae
produces at least two distinct enzymes with neuraminidase activity: cloning and expression
of a second neuraminidase gene in Escherichia coli. Infect Imrnun 59: 2856-2858.
Canvin, J.R., Marvin, A.P., Sivakumaran, M., Paton, J.C., Boulnois, G.J., Andrew, P.W., and Mitchell,
T.J. (1995) The Role of Pneumolysin and Autolysin in the Pathology of Pneumonia and
Septicemia in Mice Infected With a Type-2 Pneumococcus.  Journal of Infectious Diseases
172: 119-123.
7 - 24Carrero, J.A., Calderon, B., and Unanue, E.R. (2004) Listeriolysin 0 from Listeria monocytogenes
is a lymphocyte apoptogenic molecule. Jlmmunol 172: 4866-4874.
Chen, Y., Smith, M.R., Thirumalai, K., and Zychlinsky, A. (1996) A bacterial invasin induces
macrophage apoptosis by binding directly to ICE. Embo J 15: 3853-3860.
Chen, Z.M., and Jenkins, M.K, (1998) Revealing the in vivo behaviour of CD4+ T cells specific for
an antigen expressed in Escherichia coli. J. Immunol. 160: 3462-3470.
Cherla, R.P., Lee, S.Y., and Tesh, V.L. (2003) Shiga toxins and apoptosis.  FEMS Microbiol Lett
228: 159-166.
Chikuma, S., Imboden, J.B., and Bluestone, J.A. (2003) Negative regulation of T cell receptor-
lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4. JExp Med 197: 129-
135.
Clatworthy, M.R., and Smith, K.G. (2004) Fc{gamma}RTIb Balances Efficient Pathogen Clearance
and the Cytokine-mediated Consequences of Sepsis. JExp Med 199: 717-723.
Cockeran, R., Steel, H.C., Mitchell, T.J., Feldman, C., and Anderson, R. (2001a) Pneumolysin
potentiates production of prostaglandin e(2) and leukotriene b(4) by human neutrophils.
Infect Immun 69: 3494-3496.
Cockeran, R., Theron, A.J., Steel, H.C., Matlola, N.M., Mitchell, T.J., Feldman, C., and Anderson,
R. (2001b) Proinflammatory interactions of pneumolysin with human neutrophils. Jlnfect
Dis 183: 604-611.
Cockeran, R., Anderson, R., and Feldman, C. (2002a) The role ofpneumolysin in the pathogenesis
of Streptococcus pneumoniae infection. Curr Opin Infect Dis 15: 235-239.
Cockeran, R., Durandt, C., Feldman, C., Mitchell, T.J., and Anderson, R. (2002b) Pneumolysin
activates the synthesis and release of interleukin-8 by human neutrophils in vitro.  J Infect
Dis 186: 562-565.
Coconnier, M.H., Lorrot, M., Barbat, A., Laboisse, C., and Servin, A.L. (2000) Listeriolysin 0-
induced stimulation of mucin exocytosis in polarized intestinal mucin-secreting cells:
evidence for toxin recognition of membrane-associated lipids and subsequent toxin
internalization through caveolae. Cell Micro biol 2: 487-504.
Colino, J., Shen, Y., and Snapper, C.M. (2002) Dendritic cells pulsed with intact Streptococcus
pneumoniae elicit both protein- and polysaccharide-specific immunoglobulin isotype
responses in vivo through distinct mechanisms. Journal of Experimental Medicine 195: 1-
13.
7 - 25Colino, J., and Snapper, C.M. (2003a) Two Distinct Mechanisms For Induction of Dendritic Cell
Apoptosis in Response to Intact Streptococcus pneumoniae. Jlmmunol 171: 2354-2365.
Colino, J., and Snapper, C.M. (2003b) Opposing signals from pathogen-associated molecular patterns
and IL- 10 are critical for optimal dendritic cell induction of in vivo humoral immunity to
Streptococcus pneumoniae. Jlmmunol 171: 3508-3519.
Cowell, J.L., Kim, K.S., and Bernheimer, A.W. (1978) Alteration by cereolysin of the structure of
cholesterol-containing membranes. Biochim Biophys Acta 507: 230-24 1.
Cram, M.J., II, W.D.W., Turner, J.S., Yother, J., Talkington, D.F., McDaniel, L.S., Gray, B.M., and
Briles, D.E. (1990) Pneumococcal surface protein A (PspA) is serologically highly variable
and is expressed by all clinically important capsular serotypes of  Streptococcus pneumoniae.
Infect Immun 58: 3293-3299.
Crotty, S., and Ahmed, R. (2004) Immunological memory in humans. Semin Iminunol 16: 197-203.
Darji, A., Beschin, A., Sileghem, M., Heremans, H., Brys, L., and De Baetselier, P. (1996) In vitro
simulation of immunosuppression caused by Trypanosoma brucei: active involvement of
gamma interferon and tumor necrosis factor in the pathway of suppression. Infect Immun
64: 1937-1943.
Darji, A., Stockinger, B., Wehiand, J., Chakraborty, T., and Weiss, S. (1997) T-cell anergy induced
by antigen presenting cells treated with the hemolysin of Listeria monocytogenes. Immunol
Lett 57: 33-37.
Dave, S., Carmicle, S., Hammerschmidt, S., Pangbum, M.K., and McDaniel, L.S. (2004) Dual
roles of PspC, a surface protein of Streptococcus pneumoniae, in binding human secretory
IgA and factor H. Jlmmunol 173: 471-477.
Davidson, W.F., Haudenschild, C., Kwon, J., and Williams, M.S. (2002) T cell receptor ligation
triggers novel nonapoptotic cell death pathways that are Fas-independent or Fas-dependent.
Jlmmunol 169: 62 18-6230.
Deehan, M.R., Harnett, M.M., and Harnett, W. (1997) A filarial nematode secreted product
differentially modulates expression and activation of protein kinase C isoforms in B
lymphocytes. Jlmmunol 159: 6105-6111.
DeLeo, F.R. (2004) Modulation of phagocyte apoptosis by bacterial pathogens.  Apoptosis 9: 399-
413.
DeSilva, DR., Feeser, W.S., Tancula, E.J., and Scherle, P.A. (1996) Anergic T cells are defective in
both jun NH2-terminal kinase and mitogen-activated protein kinase signaling pathways. J
Exp Med 183: 20 17-2023.
7-26Djaldetti, M., Salman, H., Bergman, M., Djaldetti, R., and Bessler, H. (2002) Phagocytosis—the
mighty weapon of the silent warriors. Microsc Res Tech 57: 421-431.
Dockrell, D.H., Lee, M., Lynch, D.H., and Read, R.C. (2001) Immune-mediated phagocytosis and
killing of Streptococcus pneumoniae are associated with direct and bystander macrophage
apoptosis. J Infect Dis 184: 713-722.
Donelson, J.E., Hill, K.L., and El-Sayed, N.M. (1998) Multiple mechanisms of immune evasion by
African trypanosomes. MolBiochem Parasitol9l: 5 1-66.
Dziarski, R. (2003) Recognition of bacterial peptidoglycan by the innate immune system. Cell Mo!
Life Sci 60: 1793-1804.
Eaton, A.D., Xu, D., and Garside, P. (2003) Administration of exogenous interleukin-18 and
interleukin-12 prevents the induction of oral tolerance. Immunology 108: 196-203.
Echchannaoui, H., Frei, K., Schnell, C., Leib, S.L., Zimmerli, W., and Landmann, R. (2002) Toll-
Like Receptor 2-Deficient Mice Are Highly Susceptible to Streptococcus pneumoniae
Meningitis because of Reduced Bacterial Clearing and Enhanced Inflammation.  J Infect
Dis 186: 798-806.
El-Sayed, N.M., and Donelson, J.E. (1997) African trypanosomes have differentially expressed
genes encoding homologues of the Leishmania GP63 surface protease. JBiol Chem 272:
26742-26748.
Else, K.J., Finkelman, F.D., Maliszewski, C.R., and Grencis, R.K. (1994) Cytokine-mediated
regulation of chronic intestinal helminth infection. JExp Med 179: 347-35 1.
Else, K.J., and Finkelman, F.D. (1998) Intestinal nematode parasites, cytokines and effector
mechanisms. liv' JParasitol 28: 1145-1158.
Estabrook, M.M., Jack, D.L., Klein, N.J., and Jarvis, G.A. (2004) Mannose-binding lectin binds to
two major outer membrane proteins, opacity protein and porin, ofNeisseria meningitidis.  J
Immunol 172: 3784-3792.
Fadok, V.A., and Chimini, G. (2001) The phagocytosis of apoptotic cells.  Semin Immunol 13: 365-
372.
Feldman, C., Munro, N.C., Jeffery, P.K., Mitchell, T.J., Andrew, P.W., Boulnois, G.J., Guerreiro,
D., Rohde, J.A., Todd, H.C., Cole, P.J., and et al. (1991) Pneumolysin induces the salient
histologic features of pneumococcal infection in the rat lung in vivo. Am JRespir Cell Mo!
Biol 5: 4 16-423.
7 - 27Feldman, C., Anderson, R., Cockeran, R., Mitchell, T., Cole, P., and Wilson, R. (2002) The effects
of pneumolysin and hydrogen peroxide, alone and in combination, on human ciliated
epithelium in vitro. Respir Med 96: 580-585.
Ferrante, A., Rowan-Kelly, B., and Paton, J.C. (1984) Inhibition of in vitro human lymphocyte
response by the pneumococcal toxin pneumolysin. Infection and Immunity 46: 585-589.
Figueroa, J.E., and Densen, P. (1991) Infectious diseases associated with complement deficiencies.
Clin Microbiol Rev 4: 359-395.
Firestein, G.S. (2003) Evolving concepts of rheumatoid arthritis. Nature 423: 356-36 1.
Firestein, G.S. (2004) The T cell cometh: interplay between adaptive immunity and cytokine networks
in rheumatoid arthritis. J. Clin. Invest. 114: 47 1-474.
Flak, T.A., and Goldman, W.E. (1999) Signalling and cellular specificity of airway nitric oxide
production inpertussis. Cell Microbiol 1:51-60.
Friedland, I.R., Paris, M.M., Hickey, S., Shelton, S., Olsen, K., Paton, J.C., and McCracken, G.H.
(1995) The limited role of pneumolysin in the pathogenesis of pneumococcal meningitis.  J
Infect Dis 172: 805-809.
Fujimoto, T., Hayashi, M., Iwamoto, M., and Obno-Iwashita, Y. (1997) Crosslinked plasmalemmal
cholesterol is sequestered to caveolae: analysis with a new cytochemical probe. JHistochem
Cytochem 45: 1197-1205.
Fussle, R., Bhakdi, S., Sziegoleit, A., Tranum-Jensen, J., Kranz, T., and Wellensiek, H.J. (1981) On
the mechanism of membrane damage by Staphylococcus aureus alpha-toxin.  JCellBiol9l:
83-94.
Gao, L., and Abu Kwaik, Y. (2000) Hijacking of apoptotic pathwaysby bacterial pathogens.  Microbes
Infect2: 1705-1719.
Garcia, A., Cayla, X., Fleischer, A., Guergnon, J., Alvarez-Franco Canas, F., Rebollo, M.P., Roncal,
F., and Rebollo, A. (2003) Rafts: a simple way to control apoptosis by subcellular
redistribution. Biochimie 85: 727-731.
Garrigan, K., Moroni-Rawson, P., McMurray, C., Hermans, I., Abernethy, N., Watson, J., and
Ronchese, F. (1996) Functional comparison of spleen dendritic cells and dendritic cells
cultured in vitro from bone marrow precursors. Blood 88: 3508-3512.
Garside, P., Steel, M., Liew, F.Y., and Mowat, A.M. (1995) CD4+ but not CD8+ T cells are required
for the induction of oral tolerance. Intlmmunol 7: 50 1-504.
7-28Garside, P., Ingulli, E., Merica, R.R., Johnson, J.G., Noelle, R.J., and Jenkins, M.K. (1998)
Visualisation of specific B and T lymphocyte interactions in the lymph node. Science 281:
96-99.
Gebert, B., Fischer, W., Weiss, E., Hoffmann, R., and Haas, R. (2003) Helicobacterpylori vacuolating
cytotoxin inhibits T lymphocyte activation. Science 301: 1099-1102.
Geelen, S., Bhattacharyya, C., and Tuomanen, E. (1993) The Cell Wall Mediates Pneumococcal
Attachment to and Cytopathology in Human Enpthelial Cells. Infection & Immunity 61:
153 8-1543.
Genestier, L., Bonnefoy-Berard, N., and Revillard, J.P. (1999) Apoptosis of activated peripheral T
cells. Transplant Proc 31: 33S-38S.
Gerber, A., Heimburg, A., Reisenauer, A., Wille, A., Welte, T., and Buhling, F. (2004) Proteasome
inhibitors modulate chemokine production in lung epithelial and monocytic cells. EurRespir
J24: 40-48.
Giacomini, B., Jona, E., Ferroni, L., Miettinen, M., Fattorini, L., Orefici, G., Julkunen, I., and
Coccia, E.M. (2001) Infection of human macrophages and dendritic cells with
Mycobacterium tuberculosis induces a differential cytokine gene expression that modulates
T cell response. Jlmmunol 166: 7033-7041.
Giddings, K.S., Johnson, A.E., and Tweten, R.K. (2003) Redefining cholesterol's role in the
mechanism of the cholesterol-dependent cytolysins. PNAS 100: 11315-11320.
Gilbert, R.J., Jimenez, J.L., Chen, S., Tickle, I.J., Rossjohn, J., Parker, M., Andrew, P.W, and
Saibil, H.R. (1999) Two structural transitions in membrane pore formation by pneumolysin,
the pore-forming toxin of Streptococcus pneumoniae. Cell 97: 647-655.
Gilbert, R.J.C., Rossjolm, J., Parker, M.W., Tweten, R.K., Morgan, P.J., Mitchell, T.J., Errington,
N., Rowe, A.J., Andrew, P.W., and Byron, 0. (1998) Self-interaction of pneumolysin, the
pore-forming protein toxin of Streptococcus pneumoniae. Journal of Molecular Biology
284: 1223-1237.
Gillespie, S.H. (1989) Aspects ofpneumococcal infection including bacterial virulence, host response
and vaccination. J. Med. Microbiol. 28: 237-248.
Gingles, N.A., Alexander J.E., Kadioglu, A., Andrew, P.W., Kerr, A., Mitchell, T.J., Hopes, E.,
Denny, P., Brown, S., Jones, H.B., Little, S., Booth, G.C., and McPheat, W.L. (2001) Role
of genetic resistance in invasive pneumococcal infection: identification and study of
susceptibility and resistance in inbred mouse strains. Infect Immun 69: 426-434.
7 - 29Gosink, K.K., Mann, E.R., Guglielmo, C., Tuomanen, E.I., and Masure, H.R. (2000) Role of novel
choline binding proteins in virulence of Streptococcus pneumoniae.  Infect Immun 68: 5690-
5695.
Goto, Y., Hogg, J.C., Whalen, B., Shih, C.-H., Ishii, FL, and van Eeden, S.F. (2004) Monocyte
Recruitment into the Lungs in Pneumococcal Pneumonia. Am. J. Respir Cell Mo!. Biol. 30:
620-626.
Granucci, F., and Ricciardi-Castagnoli, P. (2003) Interactions of bacterial pathogens with dendritic
cells during invasion of mucosal surfaces. Curr Opin Microbiol 6: 72-76.
Grencis, R.K., and Entwistle, G.M. (1997) Production of an interferon-gamma homologue by an
intestinal nematode: functionally significant or interesting artefact?  Parasitology 115: Sb!-
106.
Group, L.M.S. (1999) TNF neutralization in MS: results of a randomized, placebo-controlled
multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of
British Columbia MS/MRI Analysis Group. Neurology 53: 457-465.
Guo, L., Lim, K.B., Gunn, J.S., Bainbridge, B., Darveau, R.P., Hackett, M., and Miller, S.I. (1997)
Regulation of lipid A modifications by Salmonella typhimurium virulence genes phoP-
phoQ. Science 276: 250-253.
Guzman, C.A., Domann, E., Rohde, M., Bruder, D., Darji, A., Weiss, S., Wehiand, J., Chakraborty,
T., and Timmis, K.N. (1996) Apoptosis of mouse dendritic cells is triggered by listeriolysin,
the major virulence determinant of Listeria monocytogenes. Mo! Micro biol 20: 119-126.
Haas, K.M., Hasegawa, M., Steeber, D.A., Poe, J.C., Zabel, M.D., Bock, C.B., Karp, D.R., Briles,
D.B., Weis, J.H., and Tedder, T.F. (2002) Complement receptors CD21/35 link innate and
protective immunity during Streptococcus pneumoniae infection by regulating IgG3 antibody
responses. Immunity 17: 7 13-723.
Hammerschmidt, S., Talay, S.R., Brandtzaeg, P., and Chhatwal, G.S. (1997) SpsA, a novel
pneumococcal surface protein with specific binding to secretory immunoglobulin A and
secretory component. Mo! Microbiol 25: 1113-1124.
Hammerschmidt, S., Bethe, G., Remane, P.11., and Chhatwal, G.S. (1999) Identification of
pneumococcal surface protein A as a lactoferrin-binding protein of Streptococcus
pneumoniae. Infect Immun 67: 1683-1687.
Harnett, M.M., Deehan, M.R., Williams, D.M., and Hamett, W. (1998) Induction of signalling
anergy via the T-cell receptor in cultured Jurkat T cells by pre-exposure to a filarial nematode
secreted product. Parasite Immunol 20: 55 1-563.
7 - 30Hamett, W., and Hamett, M.M. (2001) Modulation of the host immune system by phosphoiylcholine-
containing glycoproteins secreted by parasitic filarial nematodes. Biochim Biophys Acta
1539: 7-15.
Harnett, W., Harnett, M.M., Leung, B.P., Gracie, J.A., and Mclnnes, lB. (2004) The Anti-
inflammatory Potential of the Filarial Nematode Secreted Product, ES-62. Curr Top Med
Chem 4: 553-559.
Harrison, J.C., Karcioglu, Z.A., and Johnson, M.K. (1982) Response of leukopenic rabbits to
pneumococcal toxin. Curr Eye Res 2: 705-710.
Hartmann, C.B., and McCoy, K.L. (1996) Gallium arsenide augments antigen processing by
peritoneal macrophages for CD4+ helper T cell stimulation.  Toxicol App! Pharmacol 141:
3 65-372.
Hasbold, J., Gett, A.V., Rush, J.S., Deenick, E., Avery, D., Jun, J., and Hodgkin, P.D. (1999)
Quantitative analysis of lymphocyte differentiation and proliferation in vitro using
carboxyfluorescein diacetate succinimidyl ester. Immunol Cell Biol 77: 516-522.
Haskins, K., Kubo, R., White, J., Pigeon, M., Kappler, J., and Marrack, P. (1983) The major
histocompatibility complex-restricted antigen receptor on T-cells. I .Isolation with a
monoclonal antibody. J. Exp. Med 157: 1149-1169.
Hava, D., and Camilli, A. (2002) Large-scale identificationof serotype 4 Streptococcus pneumoniae
virulence factors. Mo! Micro biol 45: 1389-1406.
Hava, D.L., LeMieux, J., and Camilli, A. (2003) From nose to lung: the regulation behind
Streptococcus pneumoniae virulence factors. Mo! Microbiol 50: 1103-1110.
Hayashi, F., Smith, K.D., Ozinsky, A., Hawn, T.R., Yi, E.C., Goodlett, D.R., Eng, J.K., Akira, S.,
Underhill, D.M., and Aderem, A. (2001) The innate immune response to bacterial flagellin
is mediated by Toll-like receptor 5. Nature 410: 1099-1103.
Hemmer, B., Archelos, J.J., and Hartung, H.P. (2002) New concepts in the immunopathogenesis of
multiple sclerosis. NatRevNeurosci 3:291-301.
Heuck, A.P., Tweten, R.K., and Johnson, A.E. (2003) Assembly and topography of the prepore
complex in cholesterol-dependent cytolysins. JBiol Chem 278: 3 1218-31225.
Ilildebrand, A., PohI, M., and Bhakdi, S. (1991) Staphylococcus aureus alpha-toxin. Dual mechanism
of binding to target cells. JBio! Chem 266: 17195-17200.
Hildeman, D.A., Zhu, Y., Mitchell, T.C., Kappler, J., and Marrack, P. (2002) Molecular mechanisms
of activated T cell death in vivo. Curr Opin Immunol 14: 354-359.
7 -31Hildeman, D.A., Mitchell, T., Kappler, J., and Marrack, P. (2003) T cell apoptosis and reactive
oxygen species. JClin Invest 111: 575-581.
Hill, A., Jugovic, P., York, I., Russ, G., Bennink, J., Yewdell, J., Ploegh, H., and Johnson, D. (1995)
Herpes simplex virus turns off the TAP to evade host immunity. Nature 375: 411-415.
Hill, J., Andrew, P.W., and Mitchell, T.J. (1994) Amino acids in pneumolysin important for hemolytic
activity identified by random mutagenesis. Infect Imniun 62: 757-758.
Hiltbold, E.M., Poloso, N.J., and Roche, P.A. (2003) MHC class Il-peptide complexes and APC
lipid rafts accumulate at the immunological synapse. Jlmmunol 170: 1329-133 8.
Hirst, R.A., Sikand, K.S., Rutman, A., Mitchell, T.J., Andrew, P.W., and O'Callaghan, C. (2000)
Relative roles of pneumolysin and hydrogen peroxide from Streptococcus pneumoniae in
inhibition of ependymal ciliary beat frequency. Infect Immun 68: 1557-1562.
Hirst, R.A., Yesilkaya, H., Clitheroe, E., Rutman, A., Dufty, N., Mitchell, T.J., O'Callaghan, C.,
and Andrew, P.W. (2002) Sensitivities of human monocytes and epithelial cells to
pneumolysin are different. Infect Immun 70: 1017-1022.
Holcombe, H., Mellman, I., Janeway, C.A., Jr., Bottomly, K., and Dittel, B.N. (2002) The
immunosuppressive agent 1 5-deoxyspergualin functions by inhibiting cell cycle progression
and cytokine production following naive T cell activation. Jlmmunol 169: 4982-4989.
Hornef, M.W., Wick, M.J., Rhen, M., and Normark, S. (2002) Bacterial strategies for overcoming
host innate and adaptive immune responses. Nat Immunol3: 1033-1040.
Hosea, S.W., Brown, E.J., and Frank, M.M. (1980) The critical role of complement in experimental
pneumococcal sepsis. Jinfect Dis 142: 903-909.
Houldsworth, S., Andrew, P.W, and Mitchell, T.J. (1994) Pneumolysin stimulates production of
tumor necrosis factor alpha and interleukin- 1 beta by human mononuclear phagocytes. Infect
Immun 62: 1501-1503.
Hsieh, C.S., Macatonia, S.E., Tripp, C.S., Wolf, S.F., O'Garra, A., and Murphy, K.M. (1993)
Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced
macrophages. Science 260: 547-549.
Hueck, C.J. (1998) Type III protein secretion systems in bacterial pathogens of animals and plants.
Microbiol MolBiol Rev 62: 379-433.
Hughes, R.A., Hadden, R.D., Gregson, N.A., and Smith, K.J. (1999) Pathogenesis of Guillain-
Bane syndrome. JNeuroimmunol 100: 74-97.
7 - 32Hwang, Y., Nahm, M.H., Briles, D.E., Thomas, D., and Purkerson, J.M. (2000) Acquired, but not
innate, immune responses to Streptococcus pneumoniae are compromised by neutralization
of CD4OL. Infect Immun 68: 511-5 17.
Hynes, W.L., and Walton, Si. (2000) Hyaluronidases of Gram-positive bacteria.  FEMS Micro biol
Lett 183: 20 1-207.
lannelli, F., Chiavolini, D., Ricci, S., Oggioni, M.R., and Pozzi, G. (2004) Pncumococcal Surface
Protein C Contributes to Sepsis Caused by Streptococcus pneumoniae in Mice. Infect. Immun.
72: 3077-3080.
Imaizumi, K., Matsunaga, K., Higuchi, H., Kaidoh, T., and Takeuchi, S. (2003) Effect of amino
acid substitutions in the epitope regions of pyolysin from Arcanobacterium pyogenes.  Vet
Microbiol 91: 205-2 13.
Iqbal, N., Oliver, J.R., Wagner, F.H., Lazenby, A.S., Elson, C.O., and Weaver, C.T. (2002) T helper
1 and T helper 2 cells are pathogenic in an antigen-specific model of colitis.  JExp Med 195:
71-84.
Itano, A.A., McSorley, S.J., Reinhardt, R.L., Ehst, B.D., Ingulli, B., Rudensky, A.Y, and Jenkins,
M.K. (2003) Distinct dendritic cell populations sequentially present antigen to CD4 T cells
and stimulate different aspects of cell-mediated immunity. Immunity 19: 47-57.
Ito, Y., Kawamura, I., Kohda, C., Baba, H., Nomura, T., Kimoto, T., Watanabe, I., and Mitsuyama,
M. (2003) Seeligeriolysin 0, a cholesterol-dependent cytolysin of Listeria seeligeri, induces
gamma interferon from spleen cells of mice. Infect Immun 71: 234-241.
Jaattela, M., and Tschopp, 3. (2003) Caspase-independent cell death in T lymphocytes. Nat Immunol
4: 416-423.
Jack, D.L., Klein, N.J., and Turner, M.W. (2001) Mannose-binding lectin: targeting the microbial
world for complement attack and opsonophagocytosis. Immunol Rev 180: 86-99.
Jacobs, T., Darji, A., Frahm, N., Rohde, M., Wehiand, J., Chakraborty, T., and Weiss, S. (1998)
Listeriolysin 0: cholesterol inhibits cytolysis but not binding to cellular membranes. Mo!
Microbiol 28: 1081-1089.
Janeway, C.A., Jr., and Medzhitov, R. (2002) Innate immune recognition. Annu Rev Immunol 20:
197-2 16.
Janoff, E.N., O'Brien, J., Thompson, P., Ehret, J., Meiklejohn, G., Duvall, G., and Douglas, J.M.,
Jr. (1993) Streptococcus pneumoniae colonization, bacteremia, and immune response among
persons with human immunodeficiency virus infection. Jlnfect Dis 167: 49-56.
7 - 33Jendro, M.C., Kohier, L., Kuipers, J.G., and Zeidler, H. (2002) Microbe-induced T cell apoptosis:
subversion of the host defense system? FEMS Micro biol Lett 207: 12 1-126.
Jenkins, M.K., Khoruts, A., Ingulli, E., Mueller, D.L., McSorley, S.J., Reinhardt, R.L., Itano, A.,
and Pape, K.A. (2001) In vivo activation of antigen-specific CD4 T cells. Annu Rev Immunol
19: 23-45.
Jenson, J.S., O'Connor, R., Osborne, J., and Devaney, E. (2002) Infection with Brugiamicrofilariae
induces apoptosis of CD4(+) T lymphocytes: a mechanism of immune unresponsiveness in
filariasis. EurJlmmunol32: 858-867.
Jeurissen, A., Wuyts, M., Kasran, A., Ramdien-Murli, S., Boon, L., Ceuppens, J.L., and Bossuyt,
X. (2002) Essential role for CD4O ligand interactions in T lymphocyte-mediated modulation
of the murine immune response to pneumococcal capsular polysaccharides. Jltnmunol 168:
2773-2781.
Johnson, M.K., Geoffroy, C., and Alouf, J.E. (1980) Binding of cholesterol by sulfhydryl-activated
cytolysins. Infect Immun 27: 97-101.
Johnson, M.K., Boese-Marrazzo, D., and Pierce, WA. (1981) Effects of pneumolysin on human
polymorphonuclear leukocytes and platelets. Infect Immun 34: 171-176.
Johnson, M.K., Hobden, J.A., O'Callaghan, R.J., and Hill, J.M. (1992) Confirmation of the role of
pneumolysin in ocular infections with Streptococcus pneumoniae. Curr Eye Res 11: 1221-
1225.
Jonas, D., Walev, I., Berger, T., Liebetrau, M., Palmer, M., and Bhakdi, S. (1994) Novel path to
apoptosis: small transmembrane pores created by staphylococcal alpha-toxin in T
lymphocytes evoke intemucleosomal DNA degradation. Infect Immun 62: 1304-1312.
Jonsson, S., Musher, D.M., Chapman, A., Goree, A., and Lawrence, E.C. (1985) Phagoocytosis
and Killing of Common Bacterial pathogens of the Lung by Human Alveolar Macrophages.
The Journal of Infectious Diseases 152: 4-13.
Jost, B.H., Songer, J.G., and Billington, S.J. (1999) An Arcanobacterium (Actinomyces) pyogenes
mutant deficient in production of the pore-forming cytolysin pyolysin has reduced virulence.
Infect Immun 67: 1723-1728.
Jounblat, R., Kadioglu, A., Mitchell, T.J., and Andrew, P.W. (2003) Pneumococcal behavior and
host responses during bronchopneumonia are affected differently by the cytolytic and
complement-activating activities of pneumolysin. Infect Immun 71: 1813-1819.
7 - 34Kadioglu, A., Gingles, N.A., Grattan, K., Kerr, A., Mitchell, T.J., and Andrew, P.W. (2000) Host
cellular immune response to pneumococcal lung infection in mice. Infect Immun 68: 492-
501.
Kadioglu, A., Taylor, S., lannelli, F., Pozzi, G., Mitchell, T.J., and Andrew, P.W. (2002) Upper and
lower respiratory tract infection by Streptococcus pneurnoniae is affected by pneumolysin
deficiency and differences in capsule type. Infect Immun 70: 2886-2890.
Kadioglu, A., and Andrew, P.W (2004) The innate immune response to pneumococcal lung infection:
the untold story. Trends in Immunology 25: 143 - 149.
Kadioglu, A., Coward, W, Colston, M.J., Hewitt, C.R., and Andrew, P.W. (2004) CD4-T-lymphocyte
interactions with pneumolysin and pneumococci suggest a crucial protective role in the
host response to pneumococcal infection. Infect Immun 72: 2689-2697.
Kanclerski, K., and Moilby, R. (1987) Production and purification of Streptococcus pneumoniae
hemolysin (pneumolysin). J Gun Micro biol 25: 222-225.
Kearney, E.R., Pape, K.A., Loh, D.Y., and Jenkins, M.K. (1994) Visualization ofpeptide-specific T
cell immunity and peripheral tolerance induction in vivo. Immunity 1: 327-3 39.
Kelly, R.T., Fanner, S., and Greiff, D. (1967) Neuraminidase activities of clinical isolates of
Diplococcus pneumoniae. JBacteriol 94: 272-273.
Kelly, S.J., and Jedrzejas, M.J. (2000) Crystallization and preliminary X-ray diffraction analysis of
a functional form of pneumolysin, a virulence factor from Streptococcus pneumoniae.  Ada
Crystallogr D Biol Crystallogr 56 (Pt 11): 1452-1455.
Kemp, K., Bruunsgaard, H., Skinhoj, P., and Kiarlund Pedersen, B. (2002) Pneumococcal Infections
in Humans Are Associated with Increased Apoptosis and Trafficking of Type 1 Cytokine-
Producing T Cells. Infect. Immun. 70: 5019-5025.
Kenworthy, AK., Petranova, N., and Edidin, M. (2000) High-resolution FRET microscopy of cholera
toxin B-subunit and GPI-anchored proteins in cell plasma membranes. Mo! Biol Cell 11:
1645-1655.
Kerr, A.R., Irvine, J.J., Search, J.J., Gingles, N.A., Kadioglu, A., Andrew, P.W, McPheat, W.L.,
Booth, C.G., and Mitchell, T.J. (2002) Role of inflammatory mediators in resistance and
susceptibility to pneumococcal infection. Infect Immun 70: 1547-1557.
Kerr, J.F. (1971) Shrinkage necrosis: a distinct mode of cellular death.  iPathol. 105: 13-20.
Khan, A.Q., Shen, Y., Wu, Z.Q., Wynn, T.A., and Snapper, C.M. (2002) Endogenous pro- and anti-
inflammatory cytokines differentially regulate an in vivo humoral response to Streptococcus
pneumoniae. Infect Immun 70: 749-761.
7 - 35Khan, A.Q., Lees, A., and Snapper, C.M. (2004) Differential regulation of IgG anti-capsular
polysaccharide and antiprotein responses to intact Streptococcus pneumoniae in the presence
of cognate CD4+ T cell help. Jlmmunol 172: 532-53 9.
Khoruts, A., Mondino, A., Pape, K.A., Reiner, S.L., and Jenkins, M.K. (1998) A natural
immunological adjuvant enhances T cell clonal expansion through a CD28-dependent,
interleukin (IL)-2-independent mechanism. JExp Med 187: 225-23 6.
Kimoto, T., Kawamura, I., Kohda, C., Nomura, T., Tsuchiya, K., Ito, Y., Watanabe, I., Kaku, T.,
Setianingrum, E., and Mitsuyama, M. (2003) Differences in gamma interferon production
induced by listeriolysin 0 and ivanolysin 0 result in different levels of protective immunity
in mice infected with Listeriamonocytogenes and Listeria ivanovii. Infect Immun 71: 2447-
2454.
Kluck, R.M., Bossy-Wetzel, E., Green, D .R., and Newmeyer, D.D. (1997) The release of cytochrome
c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275: 1132-
113 6.
Knapp, S., Leemans, J.C., Florquin, S., Branger, J., Mans, N.A., Pater, J., van Rooijen, N., and van
der Poll, T. (2003) Alveolar macrophages have a protective antiinflammatory role during
murine pneumococcal pneumonia. Am JRespir Grit Care Med 167: 171-179.
Knapp, S., Wieland, C.W., van 't Veer, C., Takeuchi, 0., Akira, S., Florquin, S., and van der Poll, T.
(2004) Toll-like receptor 2 plays a role in the early inflammatory response to murine
pneumococcal pneumonia but does not contribute to antibacterial defense.  Jlmmunol 172:
3 132-3 138.
Kobets, N., Kennedy, K., and Garside, P. (2003) An investigation of the distribution of antigen fed
in tolerogenic or immunogenic forms. Immunol Left 88: 147-155.
Kodama, T., Kuribayashi, K., Nakamura, H., Fujita, M., Fujita, T., Takeda, K., Dakhama, A., Gelfand,
E.W., Matsuyama, T., and Kitada, 0. (2003) Role of interleukin-12 in the regulation of
CD4+ T cell apoptosis in a mouse model of asthma. Gun Exp Immunol 131: 199-205.
Kohda, C., Kawamura, I., Baba, H., Nomura, T., Ito, Y., Kimoto, T., Watanabe, 1., and Mitsuyama,
M. (2002) Dissociated linkage of cytokine-inducing activity and cytotoxicity to different
domains of listeriolysin 0 from Listeria monocytogenes. Infect Immun 70: 1334-1341.
Kopp, E.B., and Medzhitov, R. (1999) The Toll-receptor Family and Control of Innate Immunity.
Current Opinion in Immunology 11: 13-18.
Korchev, Y.E., Bashford, C.L., Pederzolli, C., Pasternak, C.A., Morgan, P.J., Andrew, P.W., and
Mitchell, T.J. (1998) A conserved tryptophan in pneumolysin is a determinant of the
7-36characteristics of channels formed by pneumolysin in cells and planar lipid bilayers.  Biochem
J329(Pt3): 571-577.
Kovbasnjuk, 0., Edidin, M., and Donowitz, M. (2001) Role of lipid rafts in Shiga toxin 1 interaction
with the apical surface of Caco-2 cells. J Cell Sci 114: 4025-4031.
Kruetzmann, S., Rosado, M.M., Weber, H., Germing, U., Tournilhac, 0., Peter, H.H., Berner, R.,
Peters, A., Boehm, T., Plebani, A., Quinti, I., and Carsetti, R. (2003) Human immunoglobulin
M memory B cells controlling Streptococcus pneumoniae infections are generated in the
spleen. JExp Med 197: 93 9-945.
Kuo, C.H., and Wang, WC. (2003) Binding and internalization of Helicobacter pylon VacA via
cellular lipid rafts in epithelial cells. Biochem Biophys Res Commun 303: 640-644.
Kuo, J., Douglas, M., Ree, H.K., and Lindberg, A.A. (1995) Characterization of a recombinant
pneumolysin and its use as a protein carrier for pneumococcal type 1 8C conjugate vaccines.
Infect Immun 63: 2706-2713.
Kyaw, M.H., Clarke, S., Jones, 1G., and Campbell, H. (2002) Incidence of invasive pneumococcal
disease in Scotland, 1988-99. Epidemiol Infect 128: 139-147.
Lafleur, R.L., Mala.zdrewich, C., Jeyaseelan, S., Bleifield, E., Abrahamsen, M.S., and Maheswaran,
S.K. (2001) Lipopolysaccharide enhances cytolysis and inflammatory cytokine induction
in bovine alveolar macrophages exposed to Pasteurella (Mannheimia) haemolytica
leukotoxin. Microb Pathog 30: 347-357.
Lagrou, K., Peetermans, W.E., Jorissen, M., Verhaegen, J., Van Damme, J., and Van Eldere, J.
(2000) Subinhibitory concentrations of erythromycin reduce pneumococcal adherence to
respiratory epithelial cells in vitro. JAntimicrob Chemother 46: 7 17-723.
Lally, E.T., Kieba, I.R., Demuth, D.R., Rosenbloom, J., Golub, RE., Taichman, N.S., and Gibson,
C.W. (1989) Identification and expression of the Actinobacillus actinomycetemcomitans
leukotoxin gene. Biochem Biophys Res Commun 159: 256-262.
Lamping, N., Dettmer, R., Schroder, N.W., Pfeil, D., Hallatschek, W., Burger, R., and Schumann,
R.R. (1998) LPS-binding protein protects mice from septic shock caused by LPS or gram-
negative bacteria. JClin Invest 101: 2065-2071.
Langlct, C., Bernard, A.M., Drevot, P., and He, H.T. (2000) Membrane rafts and signaling by the
multichain immune recognition receptors. Curr Opin Irnnunol 12: 250-255.
Lassmann, H., and Ransohoff, R.M. (2004) The CD4-Thl model for multiple sclerosis: a crucial
re-appraisal. Trends Immunol 25: 132-137.
7 - 37Lauw, F.N., Branger, J., Florquin, S., Speelman, P., van Deventer, S.J., Akira, S., and van der Poll,
T. (2002) IL- 18 improves the early antimicrobial host response to pneumococcal pneumonia.
Jlmmunol 168: 372-378.
Lawrence, E., Van Eeden, S., English, D., and Hogg, J. (1996) Polymorphonuclear leukocyte (PMN)
migration in streptococcal pneumonia: comparison of older PMN with those recently released
from the marrow. Am. J. Respir Cell Mo!. Biol. 14: 2 17-224.
Lei, B., DeLeo, F.R., Hoe, N.P., Graham, M.R., Mackie, S.M., Cole, R.L., Liu, M., Hill, H.R., Low,
D.E., Federle, M.J., Scott, J.R., and Musser, J.M. (2001) Evasion of human innate and
acquired immunity by a bacterial homolog of CDI lb that inhibits opsonophagocytosis. Nat
Med7: 1298-1305.
Leite, F., O'Brien, S., Sylte, M.J., Page, T., Atapattu, D., and Czuprynski, C.J. (2002) Inflammatory
cytokines enhance the interaction of Mannheimia haemolytica leukotoxin with bovine
peripheral blood neutrophils in vitro. Infect Immun 70: 4336-4343.
Lenardo, M., Chan, K.M., Hornung, F., McFarland, H., Siegel, R., Wang, J., and Zheng, L. (1999)
Mature T lymphocyte apoptosis—inmiune regulation in a dynamic and unpredictable
antigenic environment. Annu Rev Immunol 17: 22 1-253.
Lens, S.M., den Drijver, B.F., Potgens, A.J., Tesselaar, K., van Oers, M.H., and van Lier, R.A.
(1998) Dissection of pathways leading to antigen receptor-induced and Fas/CD95-induced
apoptosis in human B cells. Jlmmunol 160: 6083-6092.
Levesque, M.C., and Haynes, B .F. (2001) Activated T lymphocytes regulate hyaluronan binding to
monocyte CD44 via production of IL-2 and IFN-gamma. Jlmmunol 166: 188-196.
Levitskaya, J., Sharipo, A., Leonchiks, A., Ciechanover, A., and Masucci, M.G. (1997) Inhibition
of ubiquitinlproteasome-dependent protein degradation by the Gly-Ala repeat domain of
the Epstein-Barr virus nuclear antigen 1. Proc NatlAcadSci USA 94: 12616-12621.
Li, X., and Darzynkiewicz, Z. (1995) Labelling DNA strand breaks with BrdUTP. Detection of
apoptosis and cell proliferation. Cell Prolf28: 571-579.
Limbago, B., Penumalli, V., Weinrick, B., and Scott, J.R. (2000) Role of Streptolysin 0 in a Mouse
Model of Invasive Group A Streptococcal Disease. Infect. Immun. 68: 6384-6390.
Liu, Y., and Jancway, C.A., Jr. (1992) Cells that present both specific ligand and costimulatory
activity are the most efficient inducers of clonal expansion of normal CD4 T cells.  Proc
NatlAcadSci USA 89: 3 845-3849.
7 - 38Lock, R.A., 1-lansman, D., and Paton, J.C. (1992) Comparative efficacy of autolysin and pneumolysin
as immunogens protecting mice against infection by Streptococcus pneumoniae. Microb
Pathog 12: 137-143.
Lutz, H.U. (1999) How pre-existing, germline-derived antibodies and complement may help induce
a primary immune response to nonseif. ScandJlmmunol 49: 224-228.
Lutz, M.B., Kukutsch, N., Ogilvie, A.L., Rossner, S., Koch, F., Romani, N., and Schuler, G. (1999)
An advanced culture method for generating large quantities of highly pure dendritic cells
from mouse bone marrow. Jlmmunol Methods 223: 77-92.
Lyons, A.B., and Parish, C.R. (1994) Determination of lymphocyte division by flow cytometty.  J
Immunol Methods 171: 13 1-137.
Lyons, A.B. (2000) Analysing cell division in vivo and in vitro using flow cytometric measurement
of CFSE dye dilution. Jlmmunol Methods 243: 147-154.
Mabbott, N.A., Coulson, P.S., Smythies, L.E., Wilson, R.A., and Sternberg, J.M. (1998) African
trypanosome infections in mice that lack the interferon-gamma receptor gene: nitric oxide-
dependent and -independent suppression of T-cell proliferative responses and the
development of anaemia. Immunology 94: 476-480.
Macey, M.G., Whiley, R.A., Miller, L., and Nagamune, H. (2001) Effect on polymorphonuclear
cell function of a human-specific cytotoxin, intermedilysin, expressed by Streptococcus
intermedius. Infect Immun 69: 6102-6109.
Madden, J.C., Ruiz, N., and Caparon, M. (2001) Cytolysin-mediated translocation (CMT): a
fltnctional equivalent of type III secretion in gram-positive bacteria. Cell 104: 143-152.
Madsen, M., Lebenthal, Y., Cheng, Q., Smith, B.L., and Hostetter, M.K. (2000) A pneumococcal
protein that elicits interleukin-8 from pulmonary epithelial cells. Journal of Infectious
Diseases 181: 1330-1336.
Male, C.J. (1979) Immunoglobulin Al protease production by Haemophilus influenzae and
Streptococcus pneumoniae. Infect Immun 26: 254-261.
Malley, R., Henneke, P., Morse, S.C., Cieslewicz, M.J., Lipsitch, M., Thompson, C.M., Kurt-Jones,
B., Paton, J.C., Wessels, M.R., and Golenbock, D.T. (2003) Recognition of pneumolysin by
Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Nail A cad Sci USA
100: 1966-1971.
Manes, S., del Real, G., and Martinez, A.C. (2003) Pathogens: raft hijackers. Nat Rev Immunol 3:
557-568.
7 - 39Mangan, D.F., Taichman, N.S., Lally, E.T., and Wahi, S.M. (1991) Lethal effects of Actinobacillus
actinomycetemcomitans leukotoxin on human T lymphocytes. Infect Immun 59: 3267-3272.
Manickasingham, S., and Reis e Sousa, C. (2000) Microbial and T cell-derived stimuli regulate
antigen presentation by deridritic cells in vivo. Jlmmunol 165: 5027-5034.
Mariano Andrade, R., Monteiro Almeida, G., Alexandre DosReis, G., and Alves Melo Bento, C.
(2003) Glucuronoxylomanrian of Cryptococcus neoformans exacerbates in vitro yeast cell
growth by interleukin 10-dependent inhibition of CD4+ T lymphocyte responses.  Cell
Immunol 222: 116-125.
Marsden, V.S., and Strasser, A. (2003) Control of apoptosis in the immune system: Bcl-2, BH3-
only proteins and more. Annu Rev Immunol 21: 7 1-105.
Matsue, H., Yang, C., Matsue, K., Edelbaum, D., Mummert, M., and Takashima, A. (2002)
Contrasting impacts of immunosuppressive agents (rapamycin, FK506, cyclosporin A, and
dexamethas one) on bidirectional dendritic cell-T cell interaction during antigen presentation.
Jlmmunol 169: 3555-3564.
McCool, T.L., Cate, T.R., Moy, G., and Weiser, J.N. (2002) The Immune Response to Pneumococcal
Proteins during Experimental Human Carriage. J. Exp. Med 195: 359-365.
McCooI, T.L., Cate, T.R., Tuomanen, E.I., Adrian, P., Mitchell, T.J., and Weiser, J.N. (2003) Serum
immunoglobulin G response to candidate vaccine antigens during experimental human
pneumococcal colonization. Infect Immun 71: 5724-5732.
McCoy, K.L., Gainey, D., and Cabral, G.A. (1995) delta 9-Tetrahydrocannabinol modulates antigen
processing by macrophages. JPharmacolExp Ther 273: 12 16-1223.
McDaniel, L.S., Sheffield, J.S., Delucchi, P., and Briles, D.E. (1991) PspA, a surface protein of
Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more
than one capsular type. Infect Immun 59: 222-22 8.
Mclnnes, I.B., Leung, B.P., Harnett, M., Gracie, J.A., Liew, F.Y., and Harnett, W. (2003) A novel
therapeutic approach targeting articular inflammation using the filarial nematode-derived
phosphoryicholine-containing glycoprotein ES-62. J Immunol 171: 2127-2133.
McNeil, P.L., Miyake, K., and Vogel, S.S. (2003) The endomembrane requirement for cell surface
repair. Proc NatlAcadSci USA 100: 4592-4597.
McSorley, S., Asch, S., Costalonga, M., Reinhardt, R., and Jenkins, M. (2002) Tracking Salmonella-
specific CD4 T-cells in vivo reveals a local mucosal response to a disseminated infection.
Immunity 16: 365-377.
7 - 40Medzhitov, R., and Janeway, C.A., Jr. (2002) Decoding the patterns of self and nonseif by the
innate immune system. Science 296: 298-300.
Meehi, M.A., and Caparon, M.G. (2004) Specificity of streptolysin 0 in cytolysin-mediated
translocation. Mo! Microbiol 52: 1665-1676.
Mengaud, J., Vicente, M.F., Chenevert, J., Geoffroy, C., Baquero, F., Perez-Diaz, J.C., and Cossart,
P. (1989) A genetic approach to demonstrate the role of listeriolysin 0 in the virulence of
Listeria monocytogenes. Acta Microbiol Hung 36: 177-182.
Merrick, J.C., Edelson, B.T., Bhardwaj, V., Swanson, P.E., and Unanue, E.R. (1997) Lymphocyte
apoptosis during early phase of Listeria infection in mice. Am iPathol 151: 785-792.
Mestas, J., and Hughes, C.C. (2004) Of mice and not men: differences between mouse and human
immunology. Jlmmunol 172: 2731-2738.
Michel, E., Reich, K.A., Favier, R., Berche, P., and Cossart, P. (1990) Attenuated mutants of the
intracellular bacterium Listeria monocyto genes obtained by single amino acid substitutions
in listeriolysin 0. Mo! Microbioi4: 2167-2178.
Mills, S.D., Boland, A., Sory, M.P., van der Smissen, P., Kerbourch, C., Finlay, B.B., and Comelis,
G.R. (1997) Yersinia enterocolitica induces apoptosis in macrophages by a process requiring
functional type III secretion and translocation mechanisms and involving YopP, presumably
acting as an effector protein. Proc NatlAcadSci USA 94: 12638-12643.
Mitchell, T.J., Walker, J.A., Saunders, F.K., Andrew, P.A., and Boulnois, G.J. (1989) Expression of
the pneumolysin gene in Escherichia coil : rapid purification and biological properties.
Biochim etBiophys. Acta. 1007: 67-72.
Mitchell, T.J., Andrew, P.W., Saunders, F.K., Smith, A.N., and Boulnois, G.J. (1991) Complement
activation and antibody binding by pneumolysin via a region of the toxin homologous to a
human acute-phase protein. Mo! Micro biol 5: 1883-188 8.
Mizrachi-Nebenzahl, Y., Lifshitz, S., Teitelbaum, R., Novick, S., Levi, A., Benharroch, D., Ling,
E., and Dagan, R. (2003) Differential activation of the immune system by virulent
Streptococcus pneumoniae strains determines recovery or death of the host. C/in Exp immunol
134: 23-31.
Mold, C., Rodic-Polic, B., and Du Cbs, T.W. (2002) Protection from Streptococcus pneurnoniae
Infection by C-Reactive Protein and Natural Antibody Requires Complement But Not
Fc{gamma} Receptors. Jlmmunol 168: 6375-6381.
Mond, J.J., Lees, A., and Snapper, C.M. (1995a) T-Cell-Independent Antigens Type-2. Annual
Review of Immunology 13: 65 5-692.
7-41Mond, J.J., Vos, Q., Lees, A., and Snapper, C.M. (1995b) T-Cell Independent Antigens. Current
Opinion in Immunology 7: 349-354.
Monton, C., and Tones, A. (1998) Lung inflammatory response in pneumonia. MonaldiArch Chest
Dis 53: 56-63.
Monton, C., Tones, A., El-Ebiary, M., Filella, X., Xaubet, A., and de La Bellacasa, J.P. (1999)
Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit Care Med
27: 1745-1753.
Moore, K.W., O'Garra, A., de Waal Ma1ef't, R., Vieira, P., and Mosmann, T.R. (1993) Interleukin-
l0.Annu Rev Immunol 11: 165-190.
Moore, L.J., Pridmore, A.C., Dower, S.K., and Read, R.C. (2003) Penicillin enhances the toll-like
receptor 2-mediated proinflammatory activity of Streptococcus pneumoniae.  J infect Dis
188: 1040-1048.
Moreland, L.W., Heck, L.W., Jr., and Koopman, W.J. (1997) Biologic agents for treating rheumatoid
arthritis. Concepts and progress. Arthritis Rheum 40: 3 97-409.
Morgan, P.J., Varley, P.G., Rowe, A.J., Andrew, P.W., and Mitchell, T.J. (1993) Characterization of
the solution properties and conformation of pneumolysin, the membrane-damaging toxin
of Streptococcus pneumoniae. Biochem J296 (Pt 3): 67 1-674.
Monison, L.A., Lukacher, A.E., Braciale, V.L., Fan, D.P., and Braciale, T.J. (1986) Differences in
antigen presentation to MHC class I-and class TI-restricted influenza virus-specific cytolytic
T lymphocyte clones. JExp Med 163: 903-92 1.
Mosser, D.M., and Edelson, P.J. (1985) The mouse macrophage receptor for C3bi (CR3) is a major
mechanism in the phagocytosis of Leishmania promastigotes. Jlmmunol 135: 2785-2789.
Mummert, M.E., Mummert, D., Edelbaum, D., Hui, F., Matsue, H., and Takashima, A. (2002)
Synthesis and surface expression of hyaluronan by dendritic cells and its potential role in
antigen presentation. Jlmmunol 169: 4322-433 1.
Munro, P., Kojima, H., Dupont, J.L., Bossu, J.L., Poulain, B., and Boquet, P. (2001) High sensitivity
of mouse neuronal cells to tetanus toxin requires a GPI-anchored protein. Biochem Biophys
Res Commun 289: 623-629.
Murphy, K.M., Heimberger, A.B., and Loh, D.Y. (1990) Induction by antigen of intrathymic apoptosis
of CD4+CD8+ TCRIo thymocytes in vivo. Science 250: 1718-1721.
7 - 42Nagamune, H., Ohnishi, C., Katsuura, A., Fushitani, K., Whiley, R.A., Tsuji, A., and Matsuda, Y.
(1996) Intermedilysin, a novel cytotoxin specific for human cells secreted by Streptococcus
intermedius UNS46 isolated from a human liver abscess.  Infect Immun 64: 3093-3 100.
Nagamune, H., Whiley, R.A., Goto, T., Inai, Y., Maeda, T., Hardie, J.M., and Kourai, H. (2000)
Distribution of the intermedilysin gene among the anginosus group streptococci and
correlation between intermedilysin production and deep-seated infection with Streptococcus
intermedius. Journal of Clinical Microbiology 38: 220-226.
Nakamura, M., Sekino, N., Iwamoto, M., and Ohno-Iwashita, Y. (1995) Interaction of theta-toxin
(perfringolysin 0), a cholesterol-binding cytolysin, with liposomal membranes: change in
the aromatic side chains upon binding and insertion. Biochemistry 34: 65 13-6520.
Nakao, H., and Takeda, T. (2000) Escherichia coli Shiga toxin. JNat Toxins 9: 299-3 13.
Nandoskar, M., Ferrante, A., Bates, E.J., Hurst, N., and Paton, J.C. (1986) Inhibition of human
monocyte respiratory burst, degranulation, phospholipid methylation and bactericidal activity
by pneumolysin. Immunology 59: 515-520.
Nashar, TO., Williams, N.A., Hirst, T.R., and Nahar, T.O. (1996) Cross-linking of cell surface
ganglioside GM1 induces the selective apoptosis of mature CD8+ T lymphocytes. mt
Immunol 8: 73 1-736.
Navarre, W.W., and Zychlinsky, A. (2000) Pathogen-induced apoptosis ofmacrophages: a common
end for different pathogenic strategies. Cell Microbiol 2: 265-273.
Nelson, K.L., Brodsky, R.A., and Buckley, J.T. (1999) Channels formed by subnanomolar
concentrations of the toxin aerolysin trigger apoptosis of T lymphomas. Cell Microbiol 1:
69-74.
Nelson, K.L., and Buckley, J.T. (2000) Channel formation by the glycosyiphosphatidylinositol-
anchored protein binding toxin aerolysin is not promoted by lipid rafts. JBiol Chem 275:
19839-19843.
Ng, E.W., Costa, J.R., Samiy, N., Ruoff, K.L., Connolly, E., Cousins, F.V., and D'Amico, D.J.
(2002) Contribution of pneumolysin and autolysin to the pathogenesis of experimental
pneumococcal endophthalmitis. Retina 22: 622-632.
Nusrat, A., von Eichel-Streiber, C., Turner, J.R., Verkade, P., Madara, J.L., and Parkos, C.A. (2001)
Clostridium difficile toxins disrupt epithelial barrier function by altering membrane
microdomain localization of tight junction proteins. Infect Immun 69: 1329-1336.
O'Brien, D.K., and Melville, S.B. (2004) Effects of Clostridium perfringens Alpha-Toxin (PLC)
and Perfringolysin 0 (PFO) on Cytotoxicity to Macrophages, on Escape from the Phagosomes
7-43of Macrophages, and on Persistence of C. perfringens in Host Tissues. Infect. Immun. 72:
5204-52 15.
Ochsenbein, A.F., Fehr, T., Lutz, C., Suter, M., Brombacher, F., Hengartner, H., and Zinkernagel,
R.M. (1999) Control of early viral and bacterial distribution and disease by natural antibodies.
Science 286: 2156-2159.
Ochsenbein, A.F., and Zinkernagel, R,M. (2000) Natural antibodies and complement link innate
and acquired immunity. Immunol Today 21: 624-630.
Ohno-Iwashita, Y., Iwamoto, M., Mitsui, K., Ando, S., and Nagai, Y. (1988) Protease-nicked theta-
toxin of Clostridium perfringens, a new membrane probe with no cytolytic effect, reveals
two classes of cholesterol as toxin-binding sites on sheep erythrocytes. EurfBiochem 176:
95-101.
Ohno-Iwashita, Y., Iwamoto, M., Ando, S., Mitsui, K., and Iwashita, S. (1990) A modified theta-
toxin produced by limited proteolysis and methylation: a probe for the functional study of
membrane cholesterol. Biochiin Biophys Acta 1023: 441-448.
Ohno-lwashita, Y, Iwamoto, M., Mitsui, K.-I., Ando, S., and Iwashita, S. (1991) A cytolysin, 0-
toxin, preferentially binds to membrane cholesterol surrounded by phospholipids with 18-
carbon hydrocarbon chains in cholesterol-rich region. J. Biochem 110: 369-375.
Olsson, T., Bakhiet, M., Edlund, C., Hojeberg, B., Van der Meide, P.H., and Kristensson, K. (1991)
Bidirectional activating signals between Trypanosoma brucei and CD8+ T cells: a
trypanosome-released factor triggers interferon-gamma production that stimulates parasite
growth. Eur Jlmmunol 21: 2447-2454.
O'Riordan, K., and Lee, J.C. (2004) Staphylococcus aureus capsular polysaccharides. Gun Microbiol
Rev 17: 218-234.
Palaniyar, N., Nadesalingam, J., and Reid, K.B. (2002) Pulmonary innate immune proteins and
receptors that interact with gram-positive bacterial ligands. Immunobiology 205: 575-594.
Palmer, M., Saweijew, P., Vulicevic, I., Valeva, A., Kehoe, M., and Bhakdi, S. (1996) Membrane-
penetrating domain of streptolysin 0 identified by cysteine scanning mutagenesis. Journal
of Biological Chemistry 271: 26664-26667.
Palmer, M., Harris, R., Freytag, C., Kehoe, M., Tranum-Jensen, J., and Bhakdi, S. (1998) Assembly
mechanism of the oligomeric streptolysin 0 pore: the early membrane lesion is lined by a
free edge of the lipid membrane and is extended gradually during oligomerization. Embo J
17: 1598-1605.
7 - 44Palmer, M. (2001) The family of thiol-activated, cholesterol-binding cytolysins.  Toxicon 39: 168 1-
1689.
Pape, K.A., Merica, R., Mondino, A., Khoruts, A., and Jenkins, M.K. (1998) Direct evidence that
functionally impaired CD4+ T cells persist in vivo following induction of peripheral
tolerance. Jlmmunol 160: 47 19-4729.
Parsons, H.K., and Dockrell, D.H. (2002) The burden of invasive pneumococcal disease and the
potential for reduction by immunisation. mt JAntimicrob Agents 19: 85-93.
Patel, H.K., Willhite, D.C., Pate!, R.M., Ye, D., Williams, C.L., Tones, E.M., Marty, K.B.,
MacDonald, R.A., and Blanke, S.R. (2002) Plasma membrane cholesterol modulates cellular
vacuolation induced by the Helicobacter pylon vacuolating cytotoxin.  Infect Immun 70:
4112-4123.
Paton, J.C., and Ferrante, A. (1983) Inhibition of human polymorphonuclear leukocyte respiratory
burst, bactericidal activity, and migration by pneumolysin. Infection and Immunity 41: 1212-
1216.
Paton, J.C., Rowan-Kelly, B., and Ferrante, A. (1984) Activation of human complement by the
pneumococcal toxin pneumolysin. Infection and Immunity 43: 1085-1087.
Paton, J.C., Berry, A.M., Lock, R.A., Hansman, D., and Manning, P.A. (1986) Cloning and expression
in Escherichia coli of the Streptococcus pneumoniae gene encoding pneumolysin.  Infect
Immun 54: 50-55.
Pericone, C.D., Overweg, K., Hermans, P.W.M., and Weiser, J.N. (2000) Inhibitory and Bactericidal
Effects of Hydrogen Peroxide Production by Streptococcus pneumoniae on Other Inhabitants
of the Upper Respiratory Tract. Infect. Immun. 68: 3990-3997.
Perticarari, S., Presani, G., Prodan, M., Granzotto, M., Murgia, R., and Cinco, M. (2003) Lymphocyte
apoptosis co-cultured with Borrelia burgdorferi. Microb Pat hog 35: 139-145.
Pinkney, M., Beachey, E., and Kehoe, M. (1989) The thiol-activated toxin streptolysin 0 does not
require a thiol group for cytolytic activity. Infect Immun 57: 2553-2558.
Plant, A., Williams, R., Jackson, M.E., and Williams, N.A. (2003) The B subunit of Escherichia
coli heat labile enterotoxin abrogates oral tolerance, promoting predominantly Th2-type
immune responses. Eur .1 Immunol 33: 3186-3195.
Polekhina, G., Giddings, K.S., Tweten, R.K., and Parker, M.W. (2004) Crystallization and preliminary
X-ray analysis of the human-specific toxin intermedilysin. Acta Crystallogr D Biol
Crystallogr 60: 347-349.
7 -45Powell, T.J., Jenkins, CD., Hattori, R., and MacPherson, G.G. (2003) Rat bone marrow-derived
dendritic cells, but not ex vivo dendritic cells, secrete nitric oxide and can inhibit T-cell
proliferation. Immunology 109: 197-208.
Proskuryakov, S.Y, Konoplyannikov, A.G., and Gabai, V.L. (2003) Necrosis: a specific form of
programmed cell death? Exp Cell Res 283: 1-16.
Rapola, S., Jantti, V., Haikala, R., Syrjanen, R., Carlone, G.M., Sampson, J.S., Briles, D.E., Paton,
J.C., Takala, A.K., Kilpi, T.M., and Kayhty, H. (2000) Natural development of antibodies to
pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in
relation to pneumococcal carriage and acute otitis media. Jlnfect Dis 182: 1146-1152.
Regev-Yochay, G., Raz, M., Dagan, R., Porat, N., Shainberg, B., Pinco, E., Keller, N., and Rubinstein,
E. (2004) Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in
community and family settings. Gun Infect Dis 38: 632-639.
Reina-San-Martin, B., Degrave, W., Rougeot, C., Cosson, A., Chamond, N., Cordeiro-Da-Silva,
A., Arala-Chaves, M., Coutinho, A., and Minoprio, P. (2000) A B-cell mitogen from a
pathogenic trypanosome is a eukaryotic proline racemase. Nat Med 6: 890-897.
Reinhardt, R.L., Bullard, D.C., Weaver, C.T., and Jenkins, M.K. (2003) Preferential accumulation
of antigen-specific effector CD4 T cells at an antigen injection site involves CD62E-
dependent migration but not local proliferation. JExp Med 197: 75 1-762.
Reis e Sousa, C., and Germain, R.N. (1999) Analysis of adjuvant function by direct visualization of
antigen presentation in vivo: endotoxin promotes accumulation of antigen-bearing dendritic
cells in the T cell areas of lymphoid tissue. Jlmmunol 162: 6552-6561.
Reis e Sousa, C. (2004) Toll-like receptors and dendritic cells: for whom the bug tolls. Semin
Immunol 16: 27-34.
Rhen, M., Eriksson, S., Clements, M., Bergstrom, S., and Normark, S.J. (2003) The basis of persistent
bacterial infections. Trends Microbiol 11: 80-86.
Ricci, V., Galmiche, A., Doye, A., Necchi, V., Solcia, E., and Boquet, P. (2000) High cell sensitivity
to Helicobacter pylon VacA toxin depends on a GPI-anchored protein and is not blocked by
inhibition of the clathrin-mediated pathway of endocytosis. MolBiol Cell 11: 3897-3909.
Rijneveld, A.W., Florquin, S., Branger, J., Speelman, P., Van Deventer, S.J., and van der Poll, T.
(2001) TNF-alpha compensates for the impaired host defense of IL-i type I receptor-deficient
mice during pneumococcal pneumonia. Jlmmunol 167: 5240-5246.
7 - 46Rijneveld, A.W., Lauw, F.N., Schultz, M.J., Florquin, S., Te Velde, A.A., Speelman, P., Van Deventer,
S.J., and Van Der Poll, T. (2002) The role of interferon-gamma in murine pneumococcal
pneumonia. Jinfect Dis 185: 9 1-97.
Rodriguez-Barradas, M.C., Tharapel, R.A., Groover, J.E., Giron, K.P., Lacke, C.E., Houston, E.D.,
Hamill, R.J., Steinhoff, M.C., and Musher D.M. (1997) Colonization by Streptococcus
pneumoniae among human immunodeficiency virus-infected adults: prevalence of antibiotic
resistance, impact of immunization, and characterization by polymerase chain reaction with
BOX primers of isolates from persistent S. pneumoniae carriers. JlnfectDis 175: 590-597.
Rohde, M., Muller, B., Chhatwal, G.S., and Talay, S.R. (2003) Host cell caveolae act as an entry-
port for group A streptococci. Cell Microbiol 5: 323-342.
Rosenow, C., Ryan, P., Weiser, J.N., Johnson, S., Fontan, P., Ortqvist, A., and Masure, H.R.  (1997)
Contribution of novel choline-binding proteins to adherence, colonization and
immunogenicity of Streptococcus pneumoniae. Mol Microbiol 25: 819-829.
Rossjohn, J., Feil, S.C., McKinstry, W.J., Tweten, R.K., and Parker, M.W. (1997) Structure of a
cholesterol-binding, thiol-activated cytolysin and a model of its membrane form.  Cell 89:
685-692.
Rossjohn, J., Gilbert, R.J.C., Crane, D., Morgan, P.J., Mitchell, T.J., Rowe, A.J., Andrew, P.W.,
Paton, J.C., Tweten, R.K., and Parker, M.W. (1998) The molecular mechanism of
pneumolysin, a virulence factor from Streptococcus pneumoniae. Journal of Molecular
Biology 284: 449-461.
Rubins, J.B., Duane, P.G., Charboneau, D., and Janoff, E.N. (1992) Toxicity of pneumolysin to
pulmonaiy endothelial cells in vitro. Infect Immun 60: 1740-1746.
Rubins, J.B., Duane, P.G., Clawson, D., Charboneau, D., Young, J., and Niewoehner, D.E. (1993)
Toxicity of pneumolysin to pulmonary aveo1ar epithelial cells.  Infect Immun 61: 1352-
1358.
Rubins, J.B., Charboneau, D., Paton, J.C., Mitchell, T.J., Andrew, P.W., and Janoff, E.N.  (1995)
Dual function of pneumolys in in the early pathogenesis ofmurine pneumococcal pneumonia.
J C/in Invest 95: 142-150.
Rubins, J.B., and Pomeroy, C. (1997) Role of Gamma Interferon In the Pathogenesis of Bacteremic
Pneumococcal Pneumonia. Infection and Immunity 65: 2975-2977.
Rubins, J.B., Paddock, A.H., Charboneau, D., Berry, A.M., Paton, J.C., and Janoff, E.N.  (1998)
Pneumolysin in pneumococcal adherence and colonization. Microb Pathog 25: 337-342.
7 - 47Ruiz, N., Wang, B., Pentland, A., and Caparon, M. (1998) Streptolysin 0 and adherence
synergistically modulate proinflammatory responses ofkeratinocytes to group A streptococci.
Mo! Microbiol 27: 337-346.
Rush, C., Mitchell, T., and Garside, P. (2002) Efficient priming of CD4+ and CD8+ T cells by DNA
vaccination depends on appropriate targeting of sufficient levels ofimniunologically relevant
antigen to appropriate processing pathways. Jlmmunol 169: 495 1-4960.
Saeland, E., Vidarsson, G., Leusen, J.H., Van Garderen, E., Nahm, M.H., Vile-Weekhout, H.,
Wairaven, V., Stemerding, A.M., Verbeek, J.S., Rijkers, G.T., Kuis, W., Sanders, E.A., and
Van De Winkel, J.G. (2003) Central role of complement in passive protection by human
IgGi and IgG2 anti-pneumococcal antibodies in mice. Jlmmunol 170: 6158-6164.
Salmond, R.J., Pitman, R.S., Jimi, E., Soriani, M., Hirst, T.R., Ghosh, S., Rincon, M., and Williams,
NA. (2002) CDS+ T cell apoptosis induced by Escherichia coli heat-labile enterotoxin B
subunit occurs via a novel pathway involving NF-kappaB-dependent caspase activation.
Eurflmmunol 32: 1737-1747.
Sampson, J.S., O'Connor, S.P., Stinson, A.R., Tharpe, J.A., and Russell, H. (1994) Cloning an
Nucleotide Sequence Analysis of psaA, the Streptococcus pneumoniae Gene Encoding a
37-kilodalton Protein Homologous to Previously Reported Streptococcus sp. adhesins.
Infection and Immunity 62: 3 19-324.
Sandgren, A., Sjostrom, K., Olsson-Liljequist, B., Christensson, B., Samuelsson, A., Kronvall, G.,
and Henriques Normark, B. (2004) Effect of clonal and serotype-specific properties on the
invasive capacity of Streptococcus pneumoniae. Jinfect Dis 189: 785-796.
Sangster, M.Y., Riberdy, J.M., Gonzalez, M., Topham, D.J., Baumgarth, N., and Doherty, P.C.
(2003) An early CD4+ T cell-dependent immunoglobulin A response to influenza infection
in the absence of key cognate T-B interactions. JExp Med 198: 1011-1021.
Sato, K., Quartey, M.K., Liebeler, C.L., Le, C.T., and Giebink, G.S. (1996) Roles of autolysin and
pneumolysin in middle ear inflammation caused by a type 3 Streptococcus pneumoniae
strain in the chinchilla otitis media model. Infect Immun 64: 1140-1145.
Saunders, F.K., Mitchell, T.J., Walker, J.A., Andrew, P.W., and Boulnois, G.J. (1989) Pneumolysin,
the thiol-activated toxin of Streptococcus pneumoniae, does not require a thiol group for in
vitro activity. Infect Imtnun 57: 2547-2552.
Savill, J., Fadok, V, Henson, P., and Haslett, C. (1993) Phagocyte recognition of cells undergoing
apoptosis. Immunol Today 14: 131-136.
7 - 48Scheel-Toellner, D., Wang, K., Singh, R., Majeed, S., Raza, K., Cumow, S.J., Salmon, M., and
Lord, J.M. (2002) The death-inducing signalling complex is recruited to lipid rafts in Fas-
induced apoptosis. Biochem Biophys Res Commun 297: 876-879.
Schleifer, K.W., Filutowicz, H., Schopf, L.R., and Mansfield, J.M. (1993) Characterization of T
helper cell responses to the trypanosome variant surface glycoprotein.  Jlmmunol 150: 2910-
2919.
Schneider, R.F., and Rosen, M.J. (1999) Pneumococcal infections in HIV-infected adults. Semin
Respir Infect 14: 237-242.
Schraw, W., Li, Y., McClain, M.S., van der Goot, F.G., and Cover, T.L. (2002) Association of
Helicobacter pylon vacuolating toxin (VacA) with lipid rafts.  J Biol Chem 277: 34642-
34650.
Sekino-Suzuki, N., Nakamura, M., Mitsui, K.I., and Ohno-Iwashita, Y. (1996) Contribution of
individual tryptophan residues to the structure and activity of theta-toxin (perfringolysin
0), a cholesterol-binding cytolysin. Eur JBiochem 241: 94 1-947.
Semnani, R.T., Liu, A.Y., Sabzevari, H., Kubofcik, J., Zhou, J., Gilden, J.K., and Nutman, T.B.
(2003) Brugia malayi microfilariae induce cell death in human dendritic cells, inhibit their
ability to make IL-12 and IL-iD, and reduce their capacity to activate CD4+ T cells.  J
Immunol 171: 1950-1960.
Sestini, P., Nencioni, L., Villa, L., Boraschi, D., and Tagliabue, A. (1987) Antibacterial Activity
Against Streptococcus pneumoniae by Mouse Lung Lymphocytes. Advances in Experimental
Medicine andBiology 216: 5 17-525.
Sestini, P., Nencioni, L., Villa, L., Boraschi, D., and Tagliabue, A. (1988) IgA-Driven Antibacterial
Activity Against Streptococcus pneumoniae by Mouse Lung Lymphocytes. Ameican Reviews
of Respiratory Disease 137: 138-143.
Shakhnovich, E.A., King, S.J., and Weiser, J.N. (2002) Neuraminidase Expressed by Streptococcus
pneumoniae Desialylates the Lipopolysacchanide ofNeissenia meningitidis and Haemophilus
influenzae: a Paradigm for Interbacterial Competition among Pathogens of the Human
Respiratory Tract. Infect. Immun. 70: 7161-7164.
Shatursky, 0., Heuck, A.P., Shepard, L.A., Rossjohn, J., Parker, M.W., Johnson, A.E., and Tweten,
R.K. (1999) The mechanism of membrane insertion for a cholesterol-dependent cytolysin:
a novel paradigm for pore-forming toxins. Cell 99: 293-299.
Shepard, L.A., Heuck, A.P., Harriman, 13.D., Rossjohn, J., Parker, M.W., Ryan, K.R., Johnson,
A.E., and Tweten, R.K. (1998) Identification of a membrane-spanning domain of the thiol-
7 - 49activated pore-forming toxin Clostridium perfringens perfringolysin 0: an alpha-helical to
beta-sheet transition identified by fluorescence spectroscopy. Biochemistry 37: 14563-14574.
Shepard, L.A., Shatursky, 0., Johnson, A.E., and Tweten, R.K. (2000) The mechanism of pore
assembly for a cholesterol-dependent cytolysin: formation of a large prepore complex
precedes the insertion of the transmembrane beta-hairpins. Biochemistry 39: 10284-10293.
Shepherd, D.M., Dearstyne, E.A., and Kerkvliet, N.J. (2000) The effects of TCDD on the activation
of ovalbumin (OVA)-specific DO 11.10 transgenic CD4(+) T cells in adoptively transferred
mice. ToxicoiSci 56: 340-350.
Shimada, Y., Maruya, M., Iwashita, S., and Ohno-Iwashita, Y. (2002) The C-terminal domain of
perfringolysin 0 is an essential cholesterol-binding unit targeting to cholesterol-rich
microdomains. EurJBiochem 269: 6 195-6203.
Shumway, C.N., and Kiebanoff, S.J. (1971) Purification ofpneumolysin. Infect Immun 4: 388-3 92.
Smith, K.M., Pottage, L., Thomas, E.R., Leishman, A.J., Doig, T.N., Xu, D., Liew, F.Y., and Garside,
P. (2000) Thi and Th2 CD4+ T cells provide help for B cell clonal expansion and antibody
synthesis in a similar manner in vivo. Jlmmunol 165: 3136-3 144.
Smith, K.M., Davidson, J.M., and Garside, P. (2002a) T-cell activation occurs simultaneously in
local and peripheral lymphoid tissue following oral administration of a range of doses of
immunogenic or tolerogenic antigen although tolerized T cells display a defect in cell division.
Immunology 106: 144-158.
Smith, K.M., McAskill, F., and Garside, P. (2002b) Orally tolerized T cells are only able to enter B
cell follicles following challenge with antigen in adjuvant, but they remain unable to provide
B cell help. Jlmmunol 168: 4318-4325.
Smith, K.M., Brewer, J.M., Mowat, A.M., Ron, Y., and Garside, P. (2004a) The influence of follicular
migration on T-celI differentiation. Immunology 111: 248-25 1.
Smith, K.M., Brewer, J.M., Rush, C.M., Riley, J., and Garside, P. (2004b) In vivo generated Thi
cells can migrate to B cell follicles to support B cell responses. Jlmmunol 173: 1640-1646.
Snapper, C.M., Shen, Y., Khan, A.Q., Colino, 3., Zelazowski, P., Mond, J.J., Gause, W.C., and Wu,
Z.Q. (2001) Distinct types of T-cell help for the induction of a humoral immune response to
Streptococcus pneumoniae. Trends in Immunology 22: 308-3 11.
Snapper, C.M. (2004) Letter to the Editor; T cell dependent and independent reposnes.  Journal of
Immunology 172: 2728.
Sohn, S.J., Rajpal, A., and Winoto, A. (2003) Apoptosis during lymphoid development. Curr Opin
Immunol 15: 209-216.
7 - 50Soininen, A., Pursiainen, H., Kilpi, T., and Kayhty, H. (2001) Natural development of antibodies to
pneumococcal capsular polysaccharides depends on the serotype: association with
pneumococcal carriage and acute otitis media in young children. Jlnfect Dis 184: 569-576.
Soriani, M., Williams, N.A., and Hirst, T.R. (2001) Escherichia coli enterotoxin B subunit triggers
apoptosis of CD8(+) T cells by activating transcription factor c-myc. Infect Immun 69:
4923-4930.
Spath, G.F., Epstein, L., Leader, B., Singer, S.M., Avila, H.A., Turco, S.J., and Beverley, S.M.
(2000) Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in
the protozoan parasite Leishmania major. Proc NatlAcadSci USA 97: 9258-9263.
Spreer, A., Lis, A., Gerber, J., Reinert, R.R., Eiffert, H., and Nau, R. (2004) Differences in clinical
manifestation of Streptococcus pneumoniae infection are not correlated with in vitro
production and release of the virulence factors pneumolysin and lipoteichoic and teichoic
acids. J Clin Microbiol 42: 3342-3345.
Spriggs, M.K. (1996) One step ahead of the game: viral immunomodulatory molecules. Annu Rev
Immunol 14: 101-130.
Stahl, W.L., and O'Toole, R.D. (1972) Pneumococcal neuraminidase: purification and properties.
Biochim Biophys Ada 268: 480-487.
Stassen, M., Muller, C., Richter, C., Neudorfi, C., Hultner, L., Bhakdi, S., Walev, I., and Schmitt, E.
(2003) The streptococcal exotoxin streptolysin 0 activates mast cells to produce tumor
necrosis factor alpha by p38 mitogen-activated protein kinase- and protein kinase C-
dependent pathways. Infect Immun 71: 6171-6 177.
Stevens, P.K., and Czuprynski, C.J. (1996) Pasteurella haemolytica leukotoxin induces bovine
leukocytes to undergo morphologic changes consistent with apoptosis in vitro.  Infect Immun
64: 2687-2694.
Storozynsky, E., Woodward, J.G., Frelinger, J.G., and Lord, E.M. (1999) Interleukin-3 and
granulocyte-macrophage colony-stimulating factor enhance the generation and function of
dendritic cells. Immunology 97: 13 8-149.
Stout, R.D., and Bottomly, K. (1989) Antigen-specific activation of effector macrophages by IFN-
gamma producing (TH1) T cell clones. Failure of IL-4-producing (TH2) T cell clones to
activate effector function in macrophages. J Immunol 142: 760-765.
Sun, H., Pollock, K.G., and Brewer, J.M. (2003) Analysis of the role of vaccine adjuvants in
modulating dendritic cell activation and antigen presentation in vitro. Vaccine 21: 849-855.
7 - 51Sutliff, W.D., and Zoffuto, A. (1968) Pneumolysin and antipneumolysin. Antimicrobial Agents
Chemother 8: 350-3 52.
Szamel, M., Ebel, U., Uciechowski, P., Kaever, V., and Resch, K. (1997) T cell antigen receptor
dependent signalling in human lymphocytes: cholera toxin inhibits interleukin-2 receptor
expression but not interleukin-2 synthesis by preventing activation of a protein kinase C
isotype, PKC-alpha. Biochim Biophys Ada 1356: 237-248.
Taichman, N.S., Dean, R.T., and Sanderson, C.J. (1980) Biochemical and morphological
characterization of the killing of human monocytes by a leukotoxin derived from
Actinobacillus actinomycetemcomitans. Infect Immun 28: 258-268.
Taira, S., Jalonen, E., Paton, J.C., Sarvas, M., and Runeberg-Nyman, K. (1989) Production of
pneumolysin, a pneumococcal toxin, in Bacillus subtilis. Gene 77: 2 11-218.
Takashima, K., Tateda, K., Matsumoto, T., Jizawa, Y., Nakao, M., and Yamaguchi, K. (1997) Role
of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect
Immun 65: 257-260.
Takazoe, M., Tanaka, T., Kondo, K., Ichimori, T., and Shinoda, T. (2002) The present status and the
recent development of the treatment for inflammatory bowel diseases: desirable effect of
extracorporeal immunomodulation. Ther Apher 6: 305-311.
Talkington, D.F., Brown, B.G., Tharpe, IA., Koenig, A., and Russell, H. (1996) Protection of mice
against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin
A (PsaA). Microb Pathog 21: 17-22.
ten Hove, T., van Montfrans, C., Peppelenbosch, M.P., and van Deventer, S.J. (2002) Infliximab
treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50:
206-2 11.
Termeer, C., Sleeman, J.P., and Simon, J.C. (2003) Hyaluronan—magic glue for the regulation of
the immune response? Trends Immunol 24: 112-114.
Thumbikat, P., Briggs, R.E., Kannan, M.S., and Maheswaran, S.K. (2003) Biological effects of two
genetically defined leukotoxin mutants of Mannheimia haemolytica.  Microb Pathog 34:
2 17-226.
Tiede, I., Fritz, G., Strand, S., Poppe, D., Dvorsky, R., Strand, D., Lehr, H.A., Wirtz, S., Becker, C.,
Atreya, R., Mudter, J., Hildner, K., Bartsch, B., Holtmann, M., Blumberg, R., Walczak, H.,
Iven, H., Galle, P.R., Ahmadian, M.R., and Neurath, M.F. (2003) CD28-dependent Raci
7 - 52activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes.
JClin Invest 111: 1133-1145.
Tong, H.H., Blue, L.E., James, M.A., and DeMaria, T.F. (2000) Evaluation of the virulence of a
Streptococcus pneumoniae neuraminidase-deficient mutant in nasopharyngeal colonization
and development of otitis media in the chinchilla model. Infect Immun 68: 92 1-924.
Tranum-Jensen, J., Bhakdi, S., Bhakdi-Lehnen, B., Bjernim, O.J., and Speth, V. (1978) Complement
lysis: the ultrastructure and orientation of the C5b-9 complex on target sheep erythrocyte
membranes. Scand J Immunol 7: 45-46.
Trapani, J.A., Jans, D.A., Jans, P.J., Smyth, M.J., Browne, K.A., and Sutton, V.R. (1998) Efficient
nuclear targeting of granzyme B and the nuclear consequences of apoptosis induced by
granzyme B and perform are caspase-dependent, but cell death is caspase-independent.  J
Biol Chem 273: 27934-2793 8.
Tsao, N., Chang, W.W, Liu, C.C., and Lei, H.Y. (2002) Development of hematogenous pneumococcal
meningitis in adult mice: the role of TNF-alpha. FEMS Immunol Med Microbiol 32: 133-
140.
Tu, A.T., Fulgham, R.L., McCrory, M.A., Briles, D.E., and Szalai, A.J. (1999) Pneumococcal Surface
Protein A Inhibits Complement Activation by Streptococcus pneumoniae. Infection and
Immunity 67: 4720-4724.
Tuosto, L., Parolini, I., Schroder, S., Sargiacomo, M., Lanzavecchia, A., and Viola, A. (2001)
Organization of plasma membrane functional rafts upon T cell activation. Eur Jlmmunol
31: 345-349.
Tweten, R.K. (1988) Nucleotide sequence of the gene for perfringolysin 0 (theta-toxin) from
Clostridium perfringens: significant homology with the genes for streptolysin 0 and
pneumolysin. Infect Immun 56: 323 5-3240.
Tweten, R.K., Parker, M.W., and Johnson, A.E. (2001) The cholesterol-dependent cytolysins.  Curr
Top Microbiol Immunol 257: 15-3 3.
Underhill, D.M., Bassetti, M., Rudensky, A., and Aderem, A. (1999) Dynamic interactions of
macrophages with T cells during antigen presentation.  JExp Med 190: 1909-19 14.
Usherwood, RJ., Crowther, G., and Woodland, D.L. (1999) Apoptotic cells are generated at every
division of in vitro cultured T ccli lines. Cell Imniunol 196: 131-137.
van der Poll, T., Marchant, A., Keogh, C.V., Goldman, M., and Lowry, S.F. (1996a) Interleukin-lO
Impairs Host Defense in Murine Pneumococcal Pneumonia. The Journal of Infectious
Diseases 174: 994-1000.
7 - 53van der Poll, T., Marchant, A., Keogh, C.V., Goldman, M., and Lowry, S.F. (1996b) Interleukin-lO
impairs host defense in murine pneumococcal pneumonia. Jlnfect Dis 174: 994-1000.
van der Poll, T., Keogh, C.V., Guirao, X., Buurman, W.A., Kopf, M., and Lowry, S.F. (1997)
Interleukin-6 gene-deficient mice show impaired defense against pneurnococcal pneumonia.
JlnfectDis 176: 439-444.
Van Deventer, S.J. (2000) Immunotherapy of Crohn's disease. ScandJlmmunol 51: 18-22.
Van Laethem, F., and Leo, 0. (2002) Membrane lipid rafts: new targets for immunoregulation.
CurrMolMed2: 557-570.
van Oosten, B.W., Lai, M., Hodgkinson, S., Barkhof, F., Miller, D.H., Moseley, I.F., Thompson,
A.J., Rudge, P., McDougall, A., McLeod, J.G., Ader, H.J., and Polman, C.H. (1997) Treatment
of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a
randomized, double-blind, placebo-controlled, MR-monitored phase II trial.  Neurology 49:
351-357.
VanHeyningen, T.K., Collins, H.L., and Russell, D.G. (1997) IL-6 produced by macrophages infected
with Mycobacterium species suppresses T cell responses. Jlmmunol 158: 330-337.
Vazquez-Boland, J.A., Dominguez, L., Rodriguez-Fern, E.F., Fernandez-Garayzabal, J.F., and
Suarez, G. (1989) Preliminary evidence that different domains are involved in cytolytic
activity and receptor (cholesterol) binding in listeriolysin 0, the Listeria monocytogenes
thiol-activated toxin. FEMS Microbiol Lett 53: 95-99.
Waheed, A.A., Shimada, Y., Heijnen, H.F., Nakamura, M., Inomata, M., Hayashi, M., Iwashita, S.,
Slot, J.W., and Ohno-Iwashita, Y. (2001) Selective binding of perfringolysin 0 derivative
to cholesterol-rich membrane microdomains (rafts). Proc Nat! Acad Sd US A 98: 4926-
4931.
Walev, I., Palmer, M., Valeva, A., Weller, U., and Bhakdi, S.  (1995) Binding, oligomerization, and
pore formation by streptolysin 0 in erythrocytes and fibroblast membranes: detection of
nonlytie polymers. Infect Immun 63: 1188-1194.
Walev, I., Bhakdi, S.C., Hofmann, F., Djonder, N., Valeva, A., Aktories, K., and Bhakdi, S. (2001)
Delivery of proteins into living cells by reversible membrane permeabilization with
streptolysin-O. Proc Nat! Acad Sci USA 98: 3185-3190.
Walcv, I., Hombach, M., Bobkiewicz, W., Fenske, D., Bhakdi, S., and Husmann, M. (2002) Resealing
of large transmembrane pores produced by streptolysin 0 in nucleated cells is accompanied
by NF-kappaB activation and downstream events. Faseb J 16: 237-239.
7 - 54Walker, J.A., Allen, R.L., Falmagne, P., Johnson, M.K., and Boulnois, G.J. (1987) Molecular cloning,
characterization, and complete nucleotide sequence of the gene for pneumolysin, the
sulfhydryl-activated toxin of Streptococcus pneumoniae. Infect immun 55: 1184-1189.
Wang, J., Brooks, E.G., Bamford, K.B., Denning, T.L., Pappo, 3., and Ernst, P.B. (2001) Negative
selection of T cells by Helicobacter pylon as a model for bacterial strain selection by immune
evasion. Jlmmunol 167: 926-934.
Watanabe-Ohnishi, R., Low, D.E., McGeer, A., Stevens, D.L., Schlievert, P.M., Newton, D.,
Schwartz, B., Kreiswirth, B., and Kotb, M. (1995) Selective depletion of V beta-bearing I
cells in patients with severe invasive group A streptococcal infections and streptococcal
toxic shock syndrome. Ontario Streptococcal Study Project. Jinfect Dis 171: 74-84.
Waterhouse, N.J., and Trapani, J.A. (2002) CTL: Caspases Terminate Life, but that's not the whole
story. Tissue Antigens 59: 175-183.
Weinrauch, Y., and Zychlinsky, A. (1999) THE INDUCTION OF APOPTOSIS BY BACTERIAL
PATHOGENS. Annual Review of Micro biology 53: 155-187.
Weiser, J.N., Bae, D., Fasching, C., Scamuna, R.W., Rather, A.J., and Janoff, E.N. (2003) Antibody-
enhanced pneumococcal adherence requires IgAl protease. Proc NatlAcadSci USA 100:
4215-4220.
We1Imer A., Zysk, G., Gerber, J., Kunst, T., Von Mering, M., Bunkowski, S., Eiffert, H., and Nau,
R. (2002) Decreased virulence of a pneumolysin-deficient strain of Streptococcus
pneumoniae in murine meningitis. Infect Immun 70: 6504-6508.
Wilihite, D.C., Ye, D., and Blanke, S.R. (2002) Fluorescence resonance energy transfer microscopy
of the Helicobacter pylon vacuolating cytotoxin within mammalian cells. Infect Immun 70:
3824-3832.
Williams, N.A., Stasiuk, L.M., Nashar, TO., Richards, C.M., Lang, A.K., Day, M.J., and Hirst,
T.R. (1997) Prevention of autoimmune disease due to lymphocyte modulation by the B-
subunit of Escherichia coli heat-labile enterotoxin. Proc Nat! Acad Sci U S A 94: 5290-
5295.
Winkeistein, J.A., and Swift, A.J. (1975) Host Defense Against the Pneumococcus in T-Lymphocyte-
Deficient, Nude Mice. Infection and Immunity 12: 1222-1223.
Winkeistein, J.A., and Tomasz, A. (1977) Activation of the Alternative Complement Pathway by
Pneumococcal Cell Walls. The Journal of Immunology 118: 45 1-454.
Winkeistein, J.A. (1981) The role of Complement in the Host's Defense Against  Streptococcus
pneumoniae. Reviews of Infectious Disease 3: 289-298.
7 - 55Wu, A.G., Alibek, D., Li, Y.L., Bradburne, C., Bailey, C.L., and Alibek, K. (2003) Anthrax toxin
induces hemolysis: an indirect effect through polymorphonuclear cells. J Infect Dis 188:
1138-1141.
Wu, Z.Q., Vos, Q., Shen, Y., Lees, A., Wilson, S.R., Briles, D.E., Gause, W.C., Mond, J.J., and
Snapper, C.M. (1999) In vivo polysaccharide-specific IgU isotype responses to intact
Streptococcus pneumoniae are T cell dependent and require CD4O- and B7-ligand
interactions. Jlmmunol 163: 659-667.
Wu, Z.Q., Khan, A.Q., Shen, Y., Schartman, J., Peach, R., Lees, A., Mond, J.J., Gause, W.C., and
Snapper, C.M. (2000) B7 requirements for primary and secondary protein- and
polysaccharide-specific IG isotype responses to Streptococcus pneumoniae. Journal of
Immunology 165: 6840-6848.
Wu, Z.Q., Khan, A., Shen, Y., Schartman, J., Peach, R., Lees, A., Mond, J.L., Gause, W.C., and
Snapper, C.M. (2001) B7 requirements for primary and secondary protein-and
polysaccharide-specific Ig isotype responses to Streptococcus pneumoniae.  Faseb Journal
15: A310-A310.
Wu, Z.-Q., Shen, Y., Khan, A.Q., Chu, C.-L., Riese, R., Chapman, H.A., Kanagawa, 0., and Snapper,
C.M. (2002) The Mechanism Underlying T Cell Help for Induction of an Antigen-Specific
In Vivo Humoral Immune Response to Intact Streptococcus pneumoniae Is Dependent on
the Type of Antigen. Jlmmunol 168: 555 1-5557.
Wyllie, A.H., Morris, R.G., Smith, A.L., and Dunlop, D. (1984) Chromatin cleavage in apoptosis:
association with condensed chromatin morphology and dependence on macromolecular
synthesis. JPathol 142: 67-77.
Xu, G.L., Zhu, X.H., Guo, B., and Wu, Y.Z. (2004) Involvement of CTLA-4 in T-cell anergy
induced by staphylococcal enterotoxin A in vitro. Mol Immunol 41: 1-8.
Yamaguchi, N., Kubo, C., Masuhiro, Y., Lally, E.T., Koga, T., and Hanazawa, S. (2004) Tumor
Necrosis Factor Alpha Enhances Actinobacillus actinomycetemcomitans Leukotoxin-
Induced HL-60 Cell Apoptosis by Stimulating Lymphocyte Function-Associated Antigen
1 Expression {dagger}. Infect. Immun. 72: 269-276.
Yankelevich, B., Soldatenkov, V.A., Hodgson, J., Polotsky, A.J., Creswell, K., and Mazumder, A.
(1996) Differential induction of programmed cell death in CD8+ and CD4+ T cells by the B
subunit of cholera toxin. Cell Immunol 168: 229-234.
7 - 56Yao, T., Mecsas, J., Healy, J.I., Falkow, S., and Chien, Y. (1999) Suppression of T and B lymphocyte
activation by a Yersinia pseudotuberculosis virulence factor, yopH. JExp Med 190: 1343-
1350.
York, l.A., Roop, C., Andrews, D.W., Riddell, S.R., Graham, F.L., and Johnson, D.C. (1994) A
cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes.
Cell 77: 525-535.
Yoshimura, A., Lien, E., Ingalls, R.R., Tuomanen, E., Dziarski, R., and Golenbock, D. (1999)
Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate
immune system occurs via Toll-like receptor 2. Jlmmunol 163: 1-5.
Zamze, S., Martinez-Pomares, L., Jones, H., Taylor, P.R., Stillion, R.J., Gordon, S., and Wong, S.Y.
(2002) Recognition of bacterial capsular polysaccharides and lipopolysaccharides by the
macrophage mannose receptor. JBiol Chem 277: 416 13-41623.
Zenewicz, L.A., Skinner, J.A., Goldfine, H., and Shen, H. (2004) Listeria monocytogenes virulence
proteins induce surface expression of Fas ligand on T lymphocytes. Mo! Microbiol 51:
1483- 1492.
Zhong, G., Reis e Sousa, C., and Germain, R.N. (1997) Production, specificity, and functionality of
monoclonal antibodies to specific peptide-major histocompatibility complex class II
complexes formed by processing of exogenous protein. Proc NatlAcadSci USA 94: 13 856-
13861.
Zhu, Y., Bao, L., Zhu, S., Chen, Z., van der Meide, P., Nennesmo, I., Winbiad, B., Ljunggren, H.G.,
and Zhu, J. (2002) CD4 and CD8 T cells, but not B cells, are critical to the control of murine
experimental autoimmune neuritis. Exp Neurol 177: 314-320.
Ziegler, S.F., Ramsdell, F., and Alderson, M.R. (1994) The activation antigen CD69.  Stem Cells
12: 456-465.
Zwijnenburg, P.J., van der Poll, T., Florquin, S., Akira, S., Takeda, K., Roord, J.J., and van Furth,
A.M. (2003a) Interleukin-18 gene-deficient mice show enhanced defense and reduced
inflammation during pneumococcal meningitis. JNeuroimmunol 138: 3 1-37.
Zwijnenburg, P.J., van der Poll, T., Florquin, S., Roord, J.J., and Van Furth, A.M. (2003b) IL-i
receptor type 1 gene-deficient mice demonstrate an impaired host defense against
pneumococcal meningitis. Jlmmunol 170: 4724-473 0.
Zwijnenburg, P.J., van der Poll, T., Florquin, S., Roord, J.J., and van Furth, A.M. (2003c) Interleukin-
10 negatively regulates local cytokine and chemokine production but does not influence
7 - 57antibacterial host defense during murine pneumococcal meningitis. Infect Immun 71: 2276-
2279.
Zychlinsky, A., Prevost, M.C., and Sansonetti, P.J. (1992) Shigella flexneri induces apoptosis in
infected macrophages. Nature 358: 167-169.
Zychlinsky, A., Thirumalai, K., Arondel, J., Cantey, J.R., Aliprantis, A.O., and Sansonetti, P.J.
(1996) In vivo apoptosis in Shigella flexneri infections. Infect Immun 64: 5357-5365.
Zysk, G., Bejo, L., Schneider-Wald, B.K., Nau, R., and Heinz, H. (2000) Induction of necrosis and
apoptosis of neutrophil granulocytes by Streptococcus pneumoniae.  Gun Exp Immunol 122:
6 1-66.
Zysk, G., Schneider-Wald, B.K., Hwang, J.H., Bejo, L., Kim, K.S., Mitchell, T.J., Hakenbeck, R.,
and Heinz, H.P. (2001) Pneumolysin is the main inducer of cytotoxicity to brain microvascular
endothelial cells caused by Streptococcus pneumoniae. Infect Immun 69: 845-852.
7 - 58